]> Alexander D. Diehl Thomas Todd Rebecca Racz Ryan R. Brinkman Alan Ruttenburg Barry Smith Bjoern Peters Febuary 2, 2012 Samantha G. Sayers (SGS) en Richard H. Scheuermann Melanie Courtot Chris Mungall An ontology for the annotation of the vaccine domain. Draft version Lindsay Cowell OWL-DL The Vaccine Ontology (VO) is a biomedical ontology in the domain of vaccine. VO aims to standardize vaccine annotation, integrate various vaccine data, and support computer-assisted reasoning. VO supports basic vaccine R&D and clincal vaccine usage. VO is primarily developed by Dr. Yongqun "Oliver" He at the University of Michigan Medical School. VO is being developed as a community-based ontology with support and collaborations from the vaccine and bio-ontology communities. Vaccine Ontology Vision Release; 1.0.562 Yongqun "Oliver" He (YH) Yu Lin (YL) Zuoshuang "Allen" Xiang definition editor note has curation status definition source definition editor alternative term editor preferred term example of usage has_dose_specification YH, XZ has_dose_specification is a relation that specifies the dose of a vaccine used for a specific vaccination process. has_vaccine_contraindication has_vaccine_contraindication is a relation that specifies contraindication of a vaccine. YH This relation may be replaced by has_vaccine_allergen. We need to determine if any vaccine contraindicator is not a vaccine allergen. has_adverse_event_disposition YH, XZ has_adverse_event_disposition is a relation that specifies some adverse event disposition that a vaccine may have. infection_of The relation 'infection_of' is introduced to represent an infection caused by an infectious pathogen. A pathogen infection is a disorder. Since the number of pathogens is large, there are numerous infections. To make the description of a specific infection simple, the shortcut term 'infection_of' is defined: infection_of X = infection and has_part some (organism X and has_disposition some infectious disposition) YH, XZ, MC, BP, AR infection_of is a relation between a disorder and an infectious pathogen. disease_caused_by YH vaccinates "A vaccinates B" means that the vaccine A is used for vaccinating the host B (e.g., human). A relationship between a vaccine instance and an organism type such that if the vaccine instance is given to an instance of the organism by the process vaccination, then it changes the organism's disposition to have an immune response against a disease. YH, AR, ZX, MC has_route_specification YH has_vaccination_route is a relation that specifies the route of a vaccine. has_vaccine_allergen has_vaccine_allegen is a relation that specifies an allegen to a vaccine. YH has_gene_mutation_of YH is_distributed_by YH, ZX is_distributed_by is a relation that specifies a company that distributes a product (e.g., vaccine). The company is very likely not the manufacturer of the product. has_vaccine_target YL is a short relation: 'vaccine' has_vaccine_target 'Y' equal to: 'vaccine' is_output_of ('vaccine preparation and (realizes some ('vaccine target specification' and is_about some 'Y'))) Y is the union of organism and disease. participates_in influenza Feline herpesvirus 1 VEE virus Birds chicken horse pig independent variable specification dependent variable specification live part of pathogen organism in vaccine YH 'part of organism in vaccine' is a pathogen component in vaccine that contains only a part of the pathogen organism instead of the whole organism. vaccine Many vaccines are developed to protect against infectious pathogens. Many vaccines are also being developed against some diseases such as cancer and autoimmune diseases. Vaccine is developed against a disease. Allergy. YH, BP, BS, MC, LC, XZ, RS A vaccine is a processed material with the function that when administered, it prevents or ameliorates a disorder in a target organism by inducing or modifying adaptive immune responses specific to the antigens in the vaccine. MeSH: D014612 vaccination YH, BP Vaccination is: an 'administering substance in vivo' that involves in adding vaccine into a host (e.g., human, mouse) in vivo with the intent to invoke a protective immune response. vaccine administration ACAM2000 Smallpox (Vaccinia) Vaccine, Live CVX: 75 YH Trade Name: ACAM2000 ActHIB Product Name: Haemophilus b Conjugate Vaccine (Tetanus Toxoid Conjugate) YH PMID: 1517908 CVX: 48 PMID: 1735812 Trade Name: ActHIB PMID: Preparation: The vaccine consists of the Haemophilus b capsular polysaccharide (polyribosyl-ribitol-phosphate, PRP), a high molecular weight polymer prepared from the Haemophilus influenzae type b (HiB) strain 1482 grown in a semi-synthetic medium, covalently bound to tetanus toxoid. The tetanus toxoid is prepared by extraction, ammonium sulfate purification, and formalin inactivation of the toxin from cultures of Clostridium tetani (Harvard strain) grown in a modified Mueller and Miller medium. The toxoid is filter sterilized prior to the conjugation process. When ActHIB vaccine is reconstituted with saline diluent, each single dose of 0.5 mL is formulated to contain 10 mu g of purified capsular polysaccharide conjugated to 24 mu g of inactivated tetanus toxoid, and 8.5% of sucrose (ActHIB 2005). Reference: http://www.violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=157&keywords= Adacel Product Name: Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine, Adsorbed Trade Name: Adacel YH CVX: 115 CVX: 20 Afluria Product Name: Influenza Virus Vaccine YH Trade Name: Afluria CVX: 141 CVX: 140 Attenuvax Product Name: Measles Virus Vaccine, Live Trade Name: Attenuvax YH vaccine-induced lymphocyte activation YH vaccine-induced B cell antigen processing and presentation YH vaccine-induced B cell cytokine production YH B cell epitope in vaccine YH vaccine-induced B cell mediated immunity YH Bacillus anthracis vaccine anthrax vaccine A vaccine that protects against Bacillus anthrax that causes anthrax. MeSH: D022122 YH Biothrax Product Name: Anthrax Vaccine Adsorbed Trade Name: Biothrax YH CVX: 24 Boostrix Product Name: Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine, Adsorbed CVX: 20 YH Trade Name: Boostrix CVX: 115 AE: fever YH, SS AE: pyrexia Fever is a frequent medical sign that describes an increase in internal body temperature to levels above normal. Fever is characterized as a temporary elevation in the body's thermoregulatory set-point, usually by about 1-2 degree C (1.8-3.6 degree F). febrile response AE: body temperature increased AE: rash AE:rash is a vaccine induced skin adverse event. A rash is a change of the skin which affects its color, appearance, or texture. A rash may be localized in one part of the body, or affect all the skin. Rashes may cause the skin to change color, itch, become warm, bumpy, dry, cracked or blistered, swell and may be painful. This term is a COSTART term but not a MP term (3/17/2009). YH Brucella abortus DNA vaccine pcDNA-SOD PMID: 15039330 YH A Brucella abortus vaccine that expresses Cu/Zn SOD with DNA plasmid pcDNA. PMID: 15039330. AE: infection This term is a COSTART term but not a MP term (3/17/2009). YH Brucella abortus strain RB51 as vaccine vector YH Brucella abortus RB51 Brucella abortus vaccine RB51 is a Brucella abortus vaccine that is licensed in the USA since 1992. Brucella abortus vaccine RB51 is a live attenuated cattle vaccine against brucellosis that is currently used in the USA and many other coutries. PMID: 11504226 PMID: 12438380 B. abortus RB51 PMID: 12704101 Brucella RB51 PMID: 8890203 PMID: 12119140 Brucella RB-51 PMID: 7806364 PMID: 10534009 YH SRB51 PMID: 11768128 PMID: 17894637 WEB: http://rb51.com PMID: 11504238 PMID: 19362381 PMID: 8740701 PMID: 7622248 PMID: 1439207 PMID: 11500423 PMID: 16713034 PMID: 17653832 PMID: 11193615 PMID: 18836016 PMID: 11553603 PMID: 8039890 PMID: 1908158 PMID: 19439382 PMID: 7927779 Brucella abortus strain 19 Brucella strain-19 Brucella S19 YH PMID: 8039890 PMID: 11058778 A live attenuated Brucella abortus vaccine that is licensed and used in many countries. AE: syndrome YH This term is a COSTART term but not a MP term (3/17/2009). syndrome is the association of several clinically recognizable features, signs (observed by a physician), symptoms (reported by the patient), phenomena or characteristics that often occur together, so that the presence of one feature alerts the physician to the presence of the others. AE: agitation YH emotional state of excitement or restlessness This term is a COSTART term but not a MP term (3/17/2009). Brucella vaccine YH MeSH: D002004 brucellosis vaccine A vaccine that protects against Brucella that causes brucellosis in animals and humans. injection-site AE This term is a COSTART term but not a MP term (3/17/2009). injection-site reaction YH AE: injection-site hypersensitivity This term is a COSTART term but not a MP term (3/17/2009). YH Comvax Product Name: Haemophilus b Conjugate Vaccine (Meningococcal Protein Conjugate) & Hepatitis B Vaccine (Recombinant) PMID: CVX: 51 Trade Name: Comvax YH DAPTACEL Product Name: Diphtheria & Tetanus Toxoids & Acellular Pertussis Vaccine Adsorbed Trade Name: DAPTACEL CVX: 106 YH CVX: 20 DECAVAC Product Name: Tetanus & Diphtheria Toxoids Adsorbed for Adult Use CVX: 113 Trade Name: DECAVAC YH DNA of pathogen organism as vaccine component YH DNA from protective protein that is used as vaccine component. This is usually used for preparation of DNA vaccine. DNA vaccine synonym: naked DNA vaccine genetic vaccine nucleic acid vaccine DNA vaccine is a vaccine that is composed of a plasmid vaccine vector (a circular double stranded DNA molecule) containing genes encoding one or more proteins of a pathogen. YH naked DNA vaccine Diphtheria and Tetanus Toxoids Adsorbed by Sanofi Pasteur Inc Product Name: Diphtheria & Tetanus Toxoids Adsorbed YH CVX: 28 Diphtheria and Tetanus Toxoids Adsorbed by Sanofi Pasteur Ltd Product Name: Diphtheria & Tetanus Toxoids Adsorbed YH Dryvax Product Name: Smallpox Vaccine, Dried, Calf Lymph Type YH CVX: 75 Trade Name: Dryvax http://en.wikipedia.org/wiki/Dryvax Dryvax is a freeze-dried calf lymph smallpox vaccine. It is the world's oldest smallpox vaccine, created in the late 19th century by American Home Products, a predecessor of Wyeth. By the 1940s, Wyeth was the leading US manufacturer of the vaccine and the only manufacturer by the 1960s. After world health authorities declared smallpox had been eradicated from nature in 1980, Wyeth stopped making the vaccine. ETEC vaccine ACAM2010 YH PMID: 17566016 ACAM2007 is a vaccine candidate expressing CFA/II. Adenovirus vaccine A viral vaccine that protects against infection of an adenovirus. YH, SGS vaccine persistence assay YH An assay that measures the persistent survival of live vaccine in a host in vivo. AE: injection-site edema YH AE: injection-site oedema This term is a COSTART term but not a MP term (3/17/2009). AE: injection-site pain YH This term is a COSTART term but not a MP term (3/17/2009). Escherichia coli vaccine A bacterial vaccine that prevents against Escherichia coli infection. E. coli vaccine YH MeSH: D022361 AE: injection-site inflammation YH This term is a COSTART term but not a MP term (3/17/2009). FluLaval Product Name: Influenza Virus Vaccine, Trivalent, Types A and B Trade Name: FluLaval CVX: 141 YH FluMist Product Name: Influenza Virus Vaccine, Live, Intranasal Trade Name: FluMist CVX: 111 YH Fluarix Product Name: Influenza Virus Vaccine, Trivalent, Types A and B YH CVX: 140 Trade Name: Fluarix Fluvirin Product Name: Influenza Virus Vaccine, Trivalent, Types A and B Trade Name: Fluvirin YH CVX: 140 CVX: 141 Fluzone Product Name: Influenza Virus Vaccine, Trivalent, Types A and B CVX: 144 CVX: 140 CVX: 141 Trade Name: Fluzone YH virmugen a gene that once deleted, would make an attenuated microbe that can be used as a live attenuated vaccine against virulent pathogen. YH, YL, ZX Gardasil Product Name: Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine Gardasil is a quadrivalent vaccine meaning it protects against 4 strains of virus (types 6, 11, 16, and 18). The vaccine was made using genetic engineering techniques. The genes that encode a specific protein from each of these strains are expressed in yeast in large-scale fermentation cultures. Protein purification methods are then used to isolate the proteins and make the vaccine. Cited from: http://biotech.about.com/b/2008/09/03/gardasil-safety-of-genetically-engineered-hpv-vaccine-still-in-question.htm Trade Name: Gardasil CVX: 62 YH HIV based lentivirus vaccine vector YH Balb/c mouse YH Havrix Product Name: Hepatitis A Vaccine, Inactivated YH Trade Name: Havrix CVX: 83 CVX: 52 Neisseria meningitidis vaccine MeSH: D022401 YH A bacterial vaccine that prevents Neisseria meningitidis infection. Meningococcal vaccine IPOL Product Name: Poliovirus Vaccine Inactivated (Monkey Kidney Cell) Trade Name: IPOL CVX: 10 YH PMID: vaccine related journal article YL The jourmal article that mentions a vaccine, which was retrieved from PubMed and annotated using VO-SciMinner.(Hur J, Xiang Z, Feldman EL, He Y. Ontology-based Brucella vaccine literature indexing and systematic analysis of gene-vaccine association network. BMC Immunology. 12(1):49 2011 Aug 26. PMID: 21871085.) United Vaccines, Inc Heska Corporation Texas Vet lab, Inc SolidTech Animal Health, Inc MVP Laboratories, Inc Addison Biological Laboratory, Inc Neotech, LLC neotechvaccines.com/ Imovax Rabies Product Name: Rabies Vaccine CVX: 18 Trade Name: Imovax YH Infanrix Product Name: Diphtheria & Tetanus Toxoids & Acellular Pertussis Vaccine Adsorbed CVX: 20 YH Trade Name: Infanrix Influenza Virus Vaccine H5N1 by Sanofi Pasteur Inc Product Name: Influenza Virus Vaccine, H5N1 (for National Stockpile) WEB: http://atomicnewsreview.org/2009/10/22/approval-for-the-arepanrix%E2%84%A2-gsk-vaccine-in-canada/ YH JE-Vax Product Name: Japanese Encephalitis Virus Vaccine Inactivated CVX: 39 YH Trade Name: JE-Vax KINRIX Product Name: Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed and Inactivated Poliovirus Vaccine CVX: 130 YH Trade Name: KINRIX Listeria monocytogenes as vaccine vector YH M-M-R II Product Name: Measles, Mumps, and Rubella Virus Vaccine, Live CVX: 03 Trade Name: M-M-R II YH M-M-Vax Product Name: Measles and Mumps Virus Vaccine, Live Trade Name: M-M-Vax YH Menactra Product Name: Meningococcal Polysaccharide (Serogroups A, C, Y and W-135) Diphtheria Toxoid Conjugate Vaccine WEB: http://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm176044.htm CVX: 114 Trade Name: Menactra Meningococcal Polysaccharide (Serogroups A, C, Y and W-135) Diphtheria Toxoid Conjugate Vaccine YH Menomune A C Y W135 Product Name: Meningococcal Polysaccharide Vaccine, Groups A, C, Y and W-135 Combined CVX: 32 YH Trade Name: Menomune-A/C/Y/W-135 Meruvax II Product Name: Rubella Virus Vaccine Live YH Trade Name: Meruvax II CVX: 06 Mumpsvax Product Name: Mumps Virus Vaccine Live CVX: 07 Trade Name: Mumpsvax YH AE: injection-site hemorrhage This term is a COSTART term but not a MP term (3/17/2009). YH AE: injection-site mass This term is a COSTART term but not a MP term (3/17/2009). Not sure where to put "mass", which requires more discussion. AE: injection-site mass is a mass at physical injection site YH, SS Mycobacterium tuberculosis vaccine YH MeSH: D032581 tuberculosis vaccine A vaccine that protects against Mycobacterium tuberculosis. Mycobax Mycobax is a BCG vaccine that is made by Sanofi Pasteur, Ltd. Ref: http://www.biopharma.com/cgi/full6.lasso?Key=412.65916 Product Name: BCG Vaccine CVX: 19 Trade Name: Mycobax YH O antigen of pathogen organism as vaccine compent YH AE: pruritus itch AE: pruritus generalised Itch (Latin: pruritus) is an unpleasant sensation that evokes the desire or reflex to scratch. itching This term is a COSTART term but not a MP term (3/17/2009). YH, SS WEB: http://www.ncbi.nlm.nih.gov/sites/entrez?db=mesh&cmd=DetailsSearch&term=pruritus+generalised&log$=activity Influenza A (H1N1) 2009 Monovalent Vaccine by Novartis Pediarix Product Name: Diphtheria & Tetanus Toxoids & Acellular Pertussis Vaccine Adsorbed, Hepatitis B (recombinant) and Inactivated Poliovirus Vaccine Combined YH Trade Name: Pediarix CVX: 110 PedvaxHIB Product Name: Haemophilus b Conjugate Vaccine (Meningococcal Protein Conjugate) CVX: 49 YH PMID: Trade Name: PedvaxHIB PMID: 2791073 Pentacel Product Name: Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed, Inactivated Poliovirus and Haemophilus b Conjugate (Tetanus Toxoid Conjugate) Vaccine CVX: 120 YH Trade Name: Pentacel Plague Vaccine by Greer Laboratories Inc Product Name: Plague Vaccine CVX: 23 YH AE: pain This term is a COSTART term but not a MP term (3/17/2009). YH Plasmodium falciparum vaccine a malaria vaccine that protects against malaria caused by Plasmodium falciparum. YH Pneumovax 23 Product Name: Pneumococcal Vaccine, Polyvalent CVX: 33 Trade Name: Pneumovax 23 YH Poliovax Product Name: Poliovirus Vaccine Inactivated (Human Diploid Cell) Trade Name: Poliovax YH Prevnar Product Name: Pneumococcal 7-valent Conjugate Vaccine (Diphtheria CRM197 Protein) Trade Name: Prevnar CVX: 100 YH ProQuad Product Name: Measles, Mumps, Rubella and Varicella Virus Vaccine Live Trade Name: ProQuad YH CVX: 94 RNA of pathogen organism as vaccine component YH RNA from protective protein that is used as vaccine component. This is usually used for preparation of RNA vaccine. mineral salt vaccine adjuvant CVX: 119 SGS, YH a vaccine adjuvant that is formed as a mineral salt. RabAvert Product Name: Rabies Vaccine CVX: 18 YH Trade Name: RabAvert Rabies Vaccine Adsorbed by BioPort Corp Product Name: Rabies Vaccine Adsorbed YH Adenovirus Type 4 and Type 7 Vaccine, Live, Oral CVX: 143 YH, SGS RotaTeq Product Name: Rotavirus Vaccine, Live, Oral, Pentavalent Trade Name: RotaTeq YH CVX: 116 SIV based lentivirus vaccine vector YH AE: myalgia This term is a COSTART term but not a MP term (3/17/2009). YH Myalgia means "muscle pain" and is a symptom of many diseases and disorders. muscle pain vaccine-induced T-helper 1 type immune response YH vaccine-induced T-helper 2 type immune response YH TENIVAC Product Name: Tetanus & Diphtheria Toxoids Adsorbed for Adult Use YH Trade Name: TENIVAC TICE BCG Intravesical TICE BCG has been used as a therapy for, and to prevent recurrence of, tumors in patients with carcinoma in situ (CIS) of the urinary bladder, and to prevent recurrence of Stage Ta T1 papillary tumors of the bladder at high risk of recurrence. Refernce URL: http://www.ticebcg.com/Consumer/aboutTice/index.asp Product Name: BCG Vaccine CVX: 19 Trade Name: TICE BCG YH TYPHIM Vi Product Name: Typhoid Vi Polysaccharide Vaccine CVX: 101 Trade Name: TYPHIM Vi YH T cell epitope in vaccine YH vaccine-induced T cell mediated immunity YH T cell vaccine antigen processing and presentation YH Brucella abortus vaccine YH Tetanus Toxoid Adsorbed by Sanofi Pasteur Inc Product Name: Tetanus Toxoid Adsorbed YH CVX: 35 E. coli O157:H7 intimin vaccine PMID: 11500434 YH E. coli Int280a has been found to be a protective antigen. This subunit vaccine uses E. coli Int280a combined with adjuvant. This antigen can be used for development of type-specific EPEC or EHEC vaccine. Tetanus and Diphtheria Toxoids Adsorbed for Adult Use by Massachusetts Public Health Biologic Lab Product Name: Tetanus & Diphtheria Toxoids Adsorbed for Adult Use YH Tripedia Product Name: Diphtheria & Tetanus Toxoids & Acellular Pertussis Vaccine Adsorbed CVX: 20 YH Trade Name: Tripedia Twinrix Product Name: Hepatitis A Inactivated and Hepatitis B (Recombinant) Vaccine YH Trade Name: Twinrix CVX: 104 AE: urticaria This term is a COSTART term but not a MP term (3/17/2009). Urticaria is a kind of skin rash notable for dark red, raised, itchy bumps. YH hives vaccine-induced T cell activation AE: headache This term is a COSTART term but not a MP term (3/17/2009). YH respiratory system AE YH I created this term and make it to be an umbrella term for different disorder terms related to respiratory system. --Oliver He microbial derivative vaccine adjuvant CVX: 52 a vaccine adjuvant that contains microbial derived material. YH, SGS CVX: 83 Varivax Product Name: Varicella Virus Vaccine Live CVX: 21 YH Trade Name: Varivax Vivotif Product Name: Typhoid Vaccine Live Oral Ty21a Trade Name: Vivotif CVX: 25 YH YF-Vax Product Name: Yellow Fever Vaccine YH CVX: 37 Trade Name: YF-Vax Yellow fever 17D as vaccine vector YH Yellow fever virus vaccine A viral vaccine that protects against infection with Yellow fever virus. YH MeSH: D022341 Zostavax Product Name: Zoster Vaccine, Live, (Oka/Merck) YH CVX: 121 Trade Name: Zostavax licensed turkey vaccine YH live attenuated pathogen as vaccine component YH aluminum hydroxide vaccine adjuvant an aluminum vaccine adjuvant that contains aluminum hydroxide. alum YH aluminum phosphate vaccine adjuvant Al(PO)4 Adju-Phos® an aluminum vaccine adjuvant that is aluminum phosphate. YH, SGS vaccination frequency YH Vaccination frequency is a qualitative term that represents how many times vaccination has occurred. AE: increased leukocyte cell number SS, YH MP: MP_0000218 According to the Vaccine Adverse Event Reporting System (VAERS), 'leukocytosis' is an adverse event that was mentioned in 1,021 VAERS reports (0.8%) during1991-2001 (Reference: PMID: 12825543). AE: white blood cell count increased greater than normal number of nucleated cells of the myeloid or lymphoid lineages, found in blood or other tissue calcium phosphate vaccine adjuvant YH, SGS a mineral salt vaccine adjuvant composed of calcium phosphate. CaHPO4 AE: decreased leukocyte cell number According to the Vaccine Adverse Event Reporting System (VAERS), 'leukopenia' is an adverse event that was mentioned in 417 VAERS reports (0.3%) during1991-2001 (Reference: PMID: 12825543). MP: MP_0000221 reduction in the number of nucleated cells of the myeloid or lymphoid lineages, found in blood or other tissue Freund's emulsified oil adjuvant YH, SGS an emulsion vaccine adjuvant that consists of a water-in-oil emulsion of aqueous antigen in paraffin (mineral) oil of low specific gravity and low viscosity. It is named after Jules T. Freund (1890-1960), Hungarian-born American immunologist. It is a water in oil emulsion. vaccine-induced T cell proliferation vaccine-induced adaptive immune response YH adenovirus vaccine vector YH adjuvant role YH live virulent pathogen as vaccine component YH complete Freund's adjuvant is a Freund's emulsfied oil adjuvant that contains inactivated and dried mycobacteria, usually Mycobacterium tuberculosis (the pathogenic agent of tuberculosis). YH agglutinating antibody role YH virulence factor YH incomplete Freund's adjuvant a Freud's adjuvant that does not contain the mycobacterial components. YH cholera toxin CT A microbial derivative vaccine adjuvant consisting of cholera toxin (CT) from Vibrio cholerae. YH, SGS alphavirus vaccine vector YH vaccine vector role YH Corynebacterium-derived P40 vaccine adjuvant A microbial derivative vaccine adjuvant that is the P40 particulate fraction isolated from Corynebacterium. YH, SGS PMID: 8447157 vaccine adjuvant role YH antibody role YH Aceto Pharma Corp antibody titer Antibody titer is a titer of antibody that shows how much antibody an organism has produced that recognizes a particular epitope, expressed as the greatest dilution ratio (or its reciprocal) that still gives a positive result. ELISA is a common means of determining antibody titers. YH WEB: http://en.wikipedia.org/wiki/Antibody_titer immunized an organismal quality that indicates an organism (e.g., human) is immunized against a disease. To assign the state of ‘immunized’, we will need to do some assay to measure indicators of immunity, e.g., antibody titers in serum samples. YH, YL Francisella tularensis vaccine YH preparation of toxoid vaccine YH A vaccine preparation that results in the generation of a toxoid vaccine Brucella abortus sodC YH bacterial gene YH viral gene YH HIV gene YH AE: abnormal blood pressure MP: MP_0000230 altered tension of the blood within the systemic arteries preparation of live attenuated vaccine by serial passages in vitro Brucella abortus cattle vaccine RB51 was developed by serial passages of virulent B. abortus strain 2308 in vitro in rifampin agar plates (Reference: PMID: 1908158). A live attenuated vaccine prepraration process that is performed by serial passages in vitro for pathogen attenuation. YH Influenza A (H1N1) 2009 Monovalent Vaccine by Sanofi Pasteur Escherichia coli gene E. coli gene YH avirulent YH Mycobacterium tuberculosis gene YH bacterial vaccine YH A vaccine that protects against some bacterial disease. MeSH: D001428 bacterial vaccine vector YH AE: asthenia YH This term is a COSTART term but not a MP term (3/17/2009). Asthenia is a medical term denoting symptoms of physical weakness and loss of strength. Asthenia is a side effect of vaccines such as the HPV vaccine Gardasil. Salmonella gene YH Shigella gene YH protozoan gene YH Plasmodium gene YH Plasmodium falciparum gene YH attenuated YH Leishmania gene YH AE: muscle ache muscle pain YH vaccine-induced T cell differentiation cancer vaccine neoplasm vaccine tumor vaccine A vaccine that prevents or treats cancer. It is produced using the patient's own whole tumor cells as the source of antigens, or using tumor-specific antigens, often recombinantly produced. MeSH: D019496 YH inactivated vaccine preparation A vaccine preparation that results in the generation of a inactivated vaccine YH part of vaccine YH cardinal part of vaccine vaccine component A 'part of vaccine' is a material entity that is a part or component of a vaccine. vaccine-induced cell activation YH lipopolysaccharide vaccine adjuvant LPS vaccine adjuvant A microbial derivative vaccine adjuvant made from bacterial lipopolysaccharide (LPS) of gram-negative bacteria. YH, SGS vaccine-induced antibacterial agglutination antibody response YH Japanese encephalitis virus gene YH Ebola virus gene YH Influenza virus gene YH RNA vaccine Using RNA may eliminate the problem of having to tailor a vaccine for each individual patient with their specific immunity. The advantage of RNA is that it can be used for all immunity types and can be taken from a single cell. DNA vaccines need to produce RNA which then prompts the manufacture of proteins. However, RNA vaccine eliminates the step from DNA to RNA. A vaccine that uses RNA(s) derived from a pathogen organism. YH muramyl dipeptide a synthetic vaccine adjuvant formulated to correspond to a component found in a water-soluble extract of cell walls of mycobacteria used in complete Freund's adjuvant (CFA). YH, SGS PMID: 344799 MDP Dengue virus gene YH colony forming unit CFU YH WEB: http://en.wikipedia.org/wiki/Colony-forming_unit Colony-forming unit (CFU) is a titer measurement of viable bacterial or fungal numbers. Unlike in direct microscopic counts where all cells, dead and living, are counted, CFU measures viable cells. By convenience the results are given as CFU/mL (colony-forming units per milliliter) for water, and CFU/g (colony-forming units per gram) for soil or other porous material. squalene YH, SGS an emulsion vaccine adjuvant that contains an organic polymer with some antigenic epitopes which might be shared with other organic polymers acting as immunostimulators. arlacel A a synthetic vaccine adjuvant that is an emulsifier called Arlacel A. PMID: 2042393 YH, SGS Montanide 103 YH a montanide vaccine adjuvant that is Montanide 103. Bordetella pertussis component vaccine adjuvant a microbial derivitive vaccine adjuvant that contains components from killed Bordetella pertussis. The killed B. pertussis has a strong adjuvant effect on the diphtheria and tetanus toxoids in the DPT vaccines. YH PCV2 vaccine YH conjugate vaccine Conjugate vaccine is vaccine that conjugates/links antigens to the molecules that form the outer coat of disease-causing bacteria to promote an immune response. Conjugate vaccines are designed primarily for very young children because their immune systems can not recognize the outer coats of certain bacteria. YH preparation of recombinant vector vaccine YH A vaccine preparation that results in the generation of a recombinant vector vaccine West Nile virus gene YH chickenpox virus gene YH Rubella virus gene YH Hepatitis B virus gene YH Porcilis-PCV2 YH Characteristics: Inactivated baculovirus expressed PCV2 ORF2 protein; adjuvanted Hepatitis A virus gene YH Suvaxyn PCV2 Characteristics: Inactivated PCD1-2 chimera; adjuvanted YH Intervet YH http://www.intervet.com/ Fort Dodge YH http://www.wyeth.com/divisions/fort_dodge.asp licensed pig vaccine YH contraindication YH a contraindication is a condition or factor that increases the risks involved in using a particular drug, carrying out a medical procedure, or engaging in a particular activity. vaccine in research role YH vaccine in research role is a 'regulation-assigned roleof a vaccine that is not licensed or in clinical trial; instead, it is currently in laboratory research. AE: maculopapular rash A maculopapular rash is a rash with flat, red area on the skin that is covered with small confluent bumps. YH This term is a COSTART term but not a MP term (3/17/2009). hemagglutination-inhibition assay an immune response detection assay that detects specific antiviral antibodies in a test serum. The serum, usually a twofold dilution series, is mixed with a standard number, usually 4 to 8 HA units, of virus and incubated prior to the addition of a standard suspension of erythrocytes. The highest dilution of serum that inhibits hemagglutination is the HI titer of the serum. For example, influenza (AI) viruses agglutinate erythrocytes through the interaction of the virus surface glycoprotein, the hemagglutinin (HA), with receptors on the surface of the erythrocyte. Inhibition of the agglutination reaction by HA subtype-specific antisera is the basis of the hemagglutination-inhibition (HI) assay. YH HI assay inactivated YH behavioural inactive (PATO:0001706) AE: arthralgia This term is a COSTART term but not a MP term (3/17/2009). Arthralgia means joint pain. It is a symptom of injury, infection, illnesses (in particular arthritis) or an allergic reaction to medication. According to MeSH, the term "arthralgia" should only be used when the condition is non-inflammatory, and the term "arthritis" should be used when the condition is inflammatory. YH hypersensitivity to chicken product YH AE: vesiculobullous rash This term is a COSTART term but not a MP term (3/17/2009). vesiculobullous rash is a blistering rash characterized by serous-fluid-filled vesicles (blisters) YH AE: screaming syndrome YH This term is a COSTART term but not a MP term (3/17/2009). AE: dizziness YH, SS This term is a COSTART term but not a MP term (3/17/2009). Dizziness describes a number of subjective symptoms, which the patient may describe as feelings of lightheadedness, floating, wooziness, giddiness, confusion, disorientation or loss of balance. Medical terms include vertigo, disequilibrium, pre-syncope or syncoptic episode. Causes may stem from a variety of failures of equilibrioception, hypotension, cerebral hypoxia or a reaction to environmental chemicals or drugs. AE: peripheral edema AE: oedema peripheral AE: peripheral edema is an edema thatresults in swelling of tissues, usually in the lower limbs, due to the accumulation of fluids This term is a COSTART term but not a MP term (3/17/2009). WEB: http://en.wikipedia.org/wiki/Peripheral_edema YH, SS AE: edema peripheral hypersensitivity to chicken egg YH vaccine solvent solution A vaccine solvent solution is a vaccine additive that helps to dissolve all vaccine components in liquid. YH malaise This term is a COSTART term but not a MP term (3/17/2009). YH Malaise is a feeling of general discomfort or uneasiness, an "out of sorts" feeling. Malaise is often the first indication of an infection or other disease. Vaccination may induce malaise. AE: somnolence This term is a COSTART term but not a MP term (3/17/2009). drowsiness YH, SS Somnolence (or "drowsiness") is a state of near-sleep, a strong desire for sleep, or sleeping for unusually long periods (c.f. hypersomnia). AE: paresthesia Paresthesia is a sensation of tingling, pricking, or numbness of a person's skin with no apparent long-term physical effect. It is more generally known as the feeling of "pins and needles" or of a limb being "asleep" (although this is not directly related to the phenomenon of sleep). The manifestation of paresthesia may be transient or chronic. YH This term is a COSTART term but not a MP term (3/17/2009). AE: paraesthesia AE: crying abnormal This term is a COSTART term but not a MP term (3/17/2009). YH hypersensitivity to antibiotic YH hypersensitivity to neomycin YH hypersensitivity to polymyxin YH reaction to previous vaccination YH parasite vaccine YH, ZX bacterial vaccine preparation A vaccine preparation that results in the generation of a bacterial vaccine YH, ZX chills YH Chills refers to feeling cold after an exposure to a cold environment. The word can also refer to an episode of shivering, accompanied by paleness and feeling cold. This term is a COSTART term but not a MP term (3/17/2009). AE: stupor This term is a COSTART term but not a MP term (3/17/2009). Stupor is the lack of critical cognitive function and level of consciousness wherein a sufferer is almost entirely unresponsive and only responds to base stimuli such as pain. The word derives from the Latin stupure, meaning insensible. Being characterised by impairments of reactions to external stimuli, in this case, vaccine immunization. YH AE: anorexia AE: decreased appetite This term is a COSTART term but not a MP term (3/17/2009). Anorexia is the decreased sensation of appetite. anorexia nervosa YH life-threatening reaction to previous vaccination YH AE: face edema AE: face oedema WEB:http://www.nlm.nih.gov/medlineplus/ency/article/003105.htm This term is a COSTART term but not a MP term (3/17/2009). AE: face edema is an edema that results in facial swelling, the build-up of fluid in the tissues of the face. Swelling may also affect the neck and upper arms YH, SS life-threatening reaction to previous influenza vaccination YH AE: cough increased WEB: http://www.nlm.nih.gov/medlineplus/cough.html This term is a COSTART term but not a MP term (3/17/2009). AE: cough increased is an abnormal respiration that results in a reflex that keeps your throat and airways clear cough YH, SS hypersensitivity to gentamicin YH dominant epitope in vaccine YH vaccine-induced down-regulated gene expression YH hypersensitity to gelatin YH preparation of vaccine using heat inactivation YH A vaccine prepraration process that is performed by heat inactivation of virulent pathogen. CFU reduction assay CFU reduction assay is an assay that measures the reduction of the colony forming units of infected pathogens in vaccine-vaccinated animals compared to nonvaccinated animals. YH assay of CFU reduction in spleen YH assay of CFU reduction in spleen is a CFU reduction assay that is measured using the extracted spleen as the tissue for isolation of infected pathogens. hypersensitity to arginine Arginine is a conditionally essential amino acid, meaning most of the time it can be manufactured by the human body, and does not need to be obtained directly through the diet. The biosynthetic pathway however does not produce sufficient arginine, and some must still be consumed through diet. Individuals who have poor nutrition or certain physical conditions may be advised to increase their intake of foods containing arginine. Infants are unable to meet their requirements and thus arginine is nutritionally essential for infants. YH edibility YH, MC Melanie has submitted this term and its two subclasses to obo: http://sourceforge.net/tracker/?func=detail&aid=2873643&group_id=76834&atid=595654 A physical quality inhering in a bearer by virtue of the bearer being fit to be eaten. edible This term may be submitted to PATO. A quality of edibility that inheres in a bearer by virtue of the bearer being suitable for oral ingestion as food, drug, or vaccine. YH vaccine efficacy Vaccine efficacy is an efficacy of a vaccine in induction of protective immune response in vivo or protection against infection of a virulent pathogen. Specifically, vaccine efficacy (VE) is the percentage reduction in disease incidence attributable to vaccination, calculated by means of the following equation: VE(%) = (U - V)/U x 100 where U = the incidence in unvaccinated people and V = the incidence in vaccinated people. Ref: Hadler TC, et al. Immunization in developing countries. In: Vaccines. Editors: Plotkin S, et al. 2008. p1542-71. YH history of asthma YH vaccine-induced antiviral neutralizing antibody response YH AE: flu syndrome This term is a COSTART term but not a MP term (3/17/2009). YH peptide of pathogen organism as vaccine component YH peptide of pathogen that is used as vaccine component. This peptide may function as epitope to stimulate protective immunity. AE: syncope This term is a COSTART term but not a MP term (3/17/2009). Syncope is the medical term for fainting, a sudden, usually temporary, loss of consciousness. YH, SS AE: syncope is a sensory capability AE that results in loss of consciousness, fainting fainting WEB: http://en.wikipedia.org/wiki/Syncope_%28medicine%29 AE: sweating According to the Vaccine Adverse Event Reporting System (VAERS), 'sweating' is an adverse event that was mentioned in 2,301 VAERS reports (1.8%) during1991-2001 (Reference: PMID: 12825543). YH vaccination with a licensed cattle vaccine YH usage of bronchodilator YH AE: abdominal pain According to the Vaccine Adverse Event Reporting System (VAERS), 'abdominal pain' is an adverse event that was mentioned in 2,254 VAERS reports (1.8%) during1991-2001 (Reference: PMID: 12825543). YH, SS AE: abdominal pain is a pain in abdominal cavity, stomach ache WEB: http://en.wikipedia.org/wiki/Abdominal_pain This term is a COSTART term but not a MP term (3/17/2009). AE: hypertension According to the Vaccine Adverse Event Reporting System (VAERS), 'hypertension' is an adverse event that was mentioned in 1,038 VAERS reports (0.8%) during1991-2001 (Reference: PMID: 12825543). blood pressure increased YH, SS MP: MP_0000231 hypertension sustained high blood pressure at a level that is likely to result in cardiovascular disease and/or other pathological states AE: lab test abnormal YH According to the Vaccine Adverse Event Reporting System (VAERS), 'sweating' is an adverse event that was mentioned in 2,056 VAERS reports (1.6%) during1991-2001 (Reference: PMID: 12825543). Intially, 'adverse event' and (is_specified_output_of some 'laboratory test') However, it cannot be inferred right. The reason appears that the is_specified_output_of cannot be another process (here, the AE is defined as a process.) We will think it over. This term is a COSTART term but not a MP term (3/17/2009). AE: myasthenia myasthenia gravis This term is a COSTART term but not a MP term (3/17/2009). Myasthenia represenats myasthenia gravis, a neuromuscular disease leading to fluctuating muscle weakness and fatiguability. YH According to the Vaccine Adverse Event Reporting System (VAERS), 'myasthenia' is an adverse event that was mentioned in 1,812 VAERS reports (1.4%) during1991-2001 (Reference: PMID: 12825543). vaccine-induced follicular dendritic cell activation YH usage of steroid YH AE: chest pain This term is a COSTART term but not a MP term (3/17/2009). YH According to the Vaccine Adverse Event Reporting System (VAERS), 'chest pain' is an adverse event that was mentioned in 1,752 VAERS reports (1.4%) during1991-2001 (Reference: PMID: 12825543). sodB(Ft) PMID: 16923916 sodBFt is a live vaccine strain mutant of Francisella tularensis with reduced Fe-superoxide dismutase gene expression. Ref: PMID: 18692537. YH PMID: 18692537 ProtaTek International, Inc www.protatek.com/ Arko Laboratories Ltd www.arkolabs.com/ fungal disease YH fungal vaccine MeSH: D005657 A vaccine that protects against infection with some fungus. YH Newport Laboratories, Inc www.newportlabs.com Texas Agricultural Experiment Station F. tularensis vaccine LVS PMID: 16912944 YH A live attenuated Francisella tularensis vaccine. It is available in American Type Culture Collection with ATCC ID: 29684. PMID: 8757866 AE: exacerbation of underlying condition According to the Vaccine Adverse Event Reporting System (VAERS), 'exacerbation of underlying condition' is an adverse event that was mentioned in 1,606 VAERS reports (1.2%) during1991-2001 (Reference: PMID: 12825543). This term is a COSTART term but not a MP term (3/17/2009). YH AE: insomnia Insomnia is a symptom of a sleeping disorder characterized by persistent difficulty falling asleep or staying asleep despite the opportunity. Insomnia is a symptom, not a stand-alone diagnosis or a disease. YH According to the Vaccine Adverse Event Reporting System (VAERS), 'insomnia' is an adverse event that was mentioned in 1,526 VAERS reports (1.2%) during1991-2001 (Reference: PMID: 12825543). This term is a COSTART term but not a MP term (3/17/2009). AE: twitching Involuntary sudden movement of part of the body. According to the Vaccine Adverse Event Reporting System (VAERS), 'twitching' is an adverse event that was mentioned in 1,511 VAERS reports (1.2%) during1991-2001 (Reference: PMID: 12825543). YH This term is a COSTART term but not a MP term (3/17/2009). AE: febrile seizure This term is a COSTART term but not a MP term (3/17/2009). According to the Vaccine Adverse Event Reporting System (VAERS), 'febrile seizure' is an adverse event that was mentioned in 1,490 VAERS reports (1.2%) during1991-2001 (Reference: PMID: 12825543). YH AE: asthma According to the Vaccine Adverse Event Reporting System (VAERS), 'asthma' is an adverse event that was mentioned in 1,373 VAERS reports (1.1%) during1991-2001 (Reference: PMID: 12825543). Asthma is a common chronic lung disease. It has been defined by the National Heart, Lung and Blood Institute as a common chronic disorder of the airways that is complex and characterized by variable and recurring symptoms, airflow obstruction, bronchial hyperresponsiveness (bronchospasm), and an underlying inflammation. This term is a COSTART term but not a MP term (3/17/2009). YH vaccine function YH, MC, XZ, and AR PERSPN: Oliver He: There has been hot discussion about whether we use 'vaccine function' or 'vaccine role'. Vaccine role may not be the good term to use. Vaccine is designed to be 'vaccine', so it should be vaccine function. One special case is cowpox virus. The cowpox virus can be mixed with some liquid like water and used as a smallpox vaccine. In this case, people often say: the cowpox virus has a 'vaccine role'. However, the cowpox virus vaccine is a processed material of a mix of the virus with water. The virus is a virus, it is not a vaccine per se. Therefore, vaccine role may not be an accurate term. vaccine function is a function that inheres in a vaccine that induces protective immune response against a disease. It is realized in the immunization process in the host. AE: neck pain This term is a COSTART term but not a MP term (3/17/2009). YH According to the Vaccine Adverse Event Reporting System (VAERS), 'neck pain' is an adverse event that was mentioned in 1,323 VAERS reports (1.0%) during1991-2001 (Reference: PMID: 12825543). AE: positive rechallenge In contrast, positive dechallenge occurs when the adverse reaction disappears once the drug is stopped. Positive rechallenge occurs when the adverse reaction re-emerges once a drug (e.g., vaccine) is restrarted. This term is a COSTART term but not a MP term (3/17/2009). According to the Vaccine Adverse Event Reporting System (VAERS), 'positive rechallenge' is an adverse event that was mentioned in 1,292 VAERS reports (1.0%) during1991-2001 (Reference: PMID: 12825543). YH heat killed pathogen in vaccine YH AE: back pain YH According to the Vaccine Adverse Event Reporting System (VAERS), 'back pain' is an adverse event that was mentioned in 1,277 VAERS reports (1.0%) during1991-2001 (Reference: PMID: 12825543). This term is a COSTART term but not a MP term (3/17/2009). herpesvirus vaccine vector YH AE: alopecia MP: MP_0000414 VAE According to the Vaccine Adverse Event Reporting System (VAERS), 'alopecia'; is an adverse event that was mentioned in 260 VAERS reports (0.2%) during1991-2001 (Reference: PMID: 12825543). absence of hair or loss of hair; not usually in reference to primary genetic hairlessness but may be due to dietary, stress, secondary to immune condition alopecia AE: gastrointestinal hemorrhage According to the Vaccine Adverse Event Reporting System (VAERS), 'gastrointestinal hemorrhage'; is an adverse event that was mentioned in 183 VAERS reports (0.1%) during1991-2001 (Reference: PMID: 12825543). MP: MP_0000465 bleeding in the stomach and/or the intestines vaccine-induced host gene response YH vaccine-induced host immune response YH vaccine-induced host response a processual entity that specifies host response to a vaccine. YH host response to vaccine adjuvant a process that specifies host response to a vaccine adjuvant. YH host response to vaccine component a processual entity that specifies host response to a vaccine component. YH host response to vaccine antigen a process that specifies host response to a vaccine antigen. YH host response to vaccine vaccine vector a process that specifies host response to a vaccine vector. YH AE: eyes gaze upward According to the Vaccine Adverse Event Reporting System (VAERS), 'eyes gaze upward' is an adverse event that was mentioned in 1,249 VAERS reports (1.0%) during1991-2001 (Reference: PMID: 12825543). YH AE: neuropathy This term is a COSTART term but not a MP term (3/17/2009). peripheral neuropathy Neuropathy is a medical term describing disorders of the nerves of the peripheral nervous system (specifically excluding encephalopathy and myelopathy, which refer to the central nervous system.) It is usually considered equivalent to peripheral neuropathy. YH According to the Vaccine Adverse Event Reporting System (VAERS), 'neuropathy' is an adverse event that was mentioned in 1,154 VAERS reports (0.9%) during1991-2001 (Reference: PMID: 12825543). human immunodeficiency virus vaccine AIDS vaccine YH MeSH: D016915 HIV vaccine A viral vaccine that protects against infection with human immunodeficiency virus that causes AIDS. Brinton Laboratories Inc AE: skin nodule According to the Vaccine Adverse Event Reporting System (VAERS), 'skin nodule' is an adverse event that was mentioned in 1,134 VAERS reports (0.9%) during1991-2001 (Reference: PMID: 12825543). YH This term is a COSTART term but not a MP term (3/17/2009). AE: arthrosis According to the Vaccine Adverse Event Reporting System (VAERS), 'arthrosis' is an adverse event that was mentioned in 1,129 VAERS reports (0.9%) during1991-2001 (Reference: PMID: 12825543). This term is a COSTART term but not a MP term (3/17/2009). YH A degenerative disease of a joint. Arthrosis is an articular illness that produces fibrosis or degeneration of the cartilage. company YH Brucella melitensis strain VTRM1 YH AE: hypokinesia YH Hypokinesia refers to slow or diminished movement of body musculature. AE: muscle twitching muscle contraction muscle fasciculation YH Brucella suis strain VTRS1 YH PMID: 17428946 B. suis VTRS1 AE: skin discoloration AE: skin discoloration is a skin adverse event that results in change in color of skin or mucus membranes According to the Vaccine Adverse Event Reporting System (VAERS), 'skin discoloration' is an adverse event that was mentioned in 909 VAERS reports (0.7%) during1991-2001 (Reference: PMID: 12825543). AE: skin discolouration YH, SS AE: herpes zoster This term is a COSTART term but not a MP term (3/17/2009). zoster Herpes zoster is a viral disease characterized by a painful skin rash with blisters in a limited area on one side of the body, often in a stripe. The initial infection with varicella zoster virus (VZV) causes the acute (short-lived) illness chickenpox, and generally occurs in children and young people. Once an episode of chickenpox has resolved, the virus is not eliminated from the body but can go on to cause shingles (an illness with very different symptoms) often many years after the initial infection. shingles According to the Vaccine Adverse Event Reporting System (VAERS), 'herpes zoster' is an adverse event that was mentioned in 892 VAERS reports (0.7%) during1991-2001 (Reference: PMID: 12825543). YH AE: laryngismus This term is a COSTART term but not a MP term (3/17/2009). YH sudden laryngeal spasm with crowing inhalation and cyanosis. It is an uncontrolled/involuntary muscular contraction (spasm) of the laryngeal cords. laryngospasm According to the Vaccine Adverse Event Reporting System (VAERS), 'laryngismus' is an adverse event that was mentioned in 881 VAERS reports (0.7%) during1991-2001 (Reference: PMID: 12825543). KKF24 YH PMID: 16552035 KKF24 is a recombinant strain of Francisella novicida U112 with iglC mutation (F. novicida delta-iglC::ermC). PMID: 14680699. F. tularensis vaccine LVS LPS YH F. tularensis vaccine LVS lipopolysaccharide PMID: 10722593 vaccine-induced antibody mediated immune response immunoglobulin mediated immune response to vaccine YH immunologic adjuvant YH B. melitensis lipopolysaccharide vaccine YH B. melitensis LPS-GBOMP noncovalent complex vaccine PMID: 8723881 B. melitensis LPS-GBOMP subunit vaccine YH AE: speech disorder According to the Vaccine Adverse Event Reporting System (VAERS), 'speech disorder' is an adverse event that was mentioned in 848 VAERS reports (0.7%) during1991-2001 (Reference: PMID: 12825543). This term is a COSTART term but not a MP term (3/17/2009). YH AE: hemorrhage MP: MP_0001914 According to the Vaccine Adverse Event Reporting System (VAERS), 'hemorrhage' is an adverse event that was mentioned in 338 VAERS reports (0.3%) during1991-2001 (Reference: PMID: 12825543). hemorrhage loss of blood from the vascular compartment to the exterior or into nonvascular body space as a result of rupture or severance of the blood vessels inactivated vaccine killed vaccine YH A vaccine that is made from whole viruses or bacteria that have been inactivated with chemicals or heat. inactivated organism vaccine AE: neck rigidity YH This term is a COSTART term but not a MP term (3/17/2009). According to the Vaccine Adverse Event Reporting System (VAERS), 'Neck rigidity' is an adverse event that was mentioned in 829 VAERS reports (0.6%) during1991-2001 (Reference: PMID: 12825543). AE: Guillain-Barre syndrome AE: GBS YH, SS This term is a COSTART term but not a MP term (3/17/2009). Guillain-Barre syndrome is a disorder in which the body's immune system attacks part of the peripheral nervous system. The first symptoms of this disorder include varying degrees of weakness or tingling sensations in the legs. In many instances, the weakness and abnormal sensations spread to the arms and upper body. These symptoms can increase in intensity until the muscles cannot be used at all and the patient is almost totally paralyzed. In these cases, the disorder is life-threatening and is considered a medical emergency. Usually Guillain-Barre occurs a few days or weeks after the patient has had symptoms of a respiratory or gastrointestinal viral infection. Occasionally, surgery or vaccinations will trigger the syndrome. Reference: http://www.ninds.nih.gov/disorders/gbs/gbs.htm. According to the Vaccine Adverse Event Reporting System (VAERS), Guillain-Barre yndrome is an adverse event that was mentioned in 820 VAERS reports (0.6%) during1991-2001 (Reference: PMID: 12825543). AE: nausea and vomiting This term will most likely removed since it is just a combination of nausea and vomiting. YH According to the Vaccine Adverse Event Reporting System (VAERS), 'nausea and vomiting' is an adverse event that was mentioned in 812 VAERS reports (0.6%) during1991-2001 (Reference: PMID: 12825543). This term is a COSTART term but not a MP term (3/17/2009). AE: sudden infant death This term is a COSTART term but not a MP term (3/17/2009). YH According to the Vaccine Adverse Event Reporting System (VAERS), 'sudden infant death' is an adverse event that was mentioned in 808 VAERS reports (0.6%) during1991-2001 (Reference: PMID: 12825543). AE: fever with chills This term is a COSTART term but not a MP term (3/17/2009). AE: chills and fever successive stages of chills and fever. This is a symptom of malaria. YH According to the Vaccine Adverse Event Reporting System (VAERS), 'chills and fever' is an adverse event that was mentioned in 722 VAERS reports (0.6%) during1991-2001 (Reference: PMID: 12825543). Brucella abortus DNA vaccine encoding BCSP31, SOD and L7/L12 YH B. abortus DNA vaccine expressing BCSP31, SOD and L7/L12 PMID: 17570767 AE: personality disorder YH This term is a COSTART term but not a MP term (3/17/2009). According to the Vaccine Adverse Event Reporting System (VAERS), 'personality disorder' is an adverse event that was mentioned in 678 VAERS reports (0.5%) during1991-2001 (Reference: PMID: 12825543). Brucella abortus subunit vaccine using L7/L12 YH PMID: 8873388 recombinant B. abortus L7/L12 vaccine AE: lung disorder YH According to the Vaccine Adverse Event Reporting System (VAERS), 'lung disorder' is an adverse event that was mentioned in 614 VAERS reports (0.5%) during1991-2001 (Reference: PMID: 12825543). This term is a COSTART term but not a MP term (3/17/2009). B. melitensis DNA vaccine encoding Omp31 PMID: 17428946 YH muscle adverse event YH AE: liver/biliary system disorder YH AE: enlarged liver MP: MP_0000599 According to the Vaccine Adverse Event Reporting System (VAERS), 'hepatomegaly'; is an adverse event that was mentioned in 106 VAERS reports (<0.1%) during1991-2001 (Reference: PMID: 12825543). enlarged liver larger than average size of the liver Mycoplasma hyopneumoniae vaccine YL bacterial vaccine that protect against Mycoplasma hyopneumoniae infection inedible YH, MC A quality of edibility that inheres in a bearer by virtue of the bearer being not suitable for oral ingestion. AE: meningitis Meningitis is a medical condition caused by inflammation of the protective membranes covering the brain and spinal cord, known collectively as the meninges. The inflammation is caused by infection with viruses, bacteria, or other microorganisms, and less commonly by certain drugs or diseases. According to the Vaccine Adverse Event Reporting System (VAERS), 'meningitis' is an adverse event that was mentioned in 592 VAERS reports (0.5%) during1991-2001 (Reference: PMID: 12825543). This term is a COSTART term but not a MP term (3/17/2009). YH tertiary vaccination YH, Thom Todd tertiary vaccination is a vaccination that is performed at the third time in a row. Protozoa YL Protozoa are a diverse group of unicellular eukaryotic organisms,[1] many of which are motile. Originally, protozoa had been defined as unicellular protists with animal-like behavior, e.g., movement. Protozoa were regarded as the partner group of protists to protophyta, which have plant-like behaviour, e.g., photosynthesis.(http://en.wikipedia.org/wiki/Protozoa) digestive system AE YH vaccine injection site YH AE: facial paralysis YH According to the Vaccine Adverse Event Reporting System (VAERS), 'facial paralysis' is an adverse event that was mentioned in 580 VAERS reports (0.5%) during1991-2001 (Reference: PMID: 12825543). AE: confusion According to the Vaccine Adverse Event Reporting System (VAERS), 'confusion' is an adverse event that was mentioned in 579 VAERS reports (0.4%) during1991-2001 (Reference: PMID: 12825543). This term is a COSTART term but not a MP term (3/17/2009). YH Brucella melitensis bp26 deletion vaccine Brucella CGV26 PMID: 16519974 CGV26 YH A B. melitensis vaccine that is recombinant B. melitensis Rev. 1 vaccine with the bp26 deletion. It has similar vaccien efficacy to Rev. 1. Its advantage compared to Rev. 1 is that this feature of bp26 deletion promotes diagnosis. PMID: 17070627. F. tularensis vaccine FSC043 A spontaneous mutant of the SCHU S4 strain that protects against virulent F. tularensis infection. PMID: 16299332. PMID: 16299332 YH intramuscular route YH intranasal route YH intranasal route by drop YH intranasal route by spray YH intraperitoneal route YH Brucella melitensis WR201 YH AE: joint disorder According to the Vaccine Adverse Event Reporting System (VAERS), 'joint disorder' is an adverse event that was mentioned in 562 VAERS reports (0.4%) during1991-2001 (Reference: PMID: 12825543). YH This term is a COSTART term but not a MP term (3/17/2009). Brucella abortus bacA mutant YH PMID: 17196866 B. abortus bacA mutant Influenza A (H1N1) 2009 Monovalent Vaccine by CSL Limited Influenza A (H1N1) 2009 Monovalent Vaccine from MedImmune LLC Arepanrix MC, YH Adjumer PCPP salt SGS A synthetic vaccine adjuvant that is PCPP salt. polyidi (carboxylatophenoxy) lphosphazene PMID: 75551218 polyphosphazene Megan Egg WEB: http://www.fda.gov/ohrms/dockets/dockets/00n0504/00N-0504_emc-001650-02.pdf Megan Egg is a Salmonella vaccine that that consists of a double gene-deleted S. enterica serovar Typhimurium strain and is formulated fro immunization of pullets. Megan Egg contains the same Megan Vac1 organism but Megan Vac1 is used for younger birds (broilers). YH AE: eye disorder YH This term is a COSTART term but not a MP term (3/17/2009). According to the Vaccine Adverse Event Reporting System (VAERS), 'eye disorder' is an adverse event that was mentioned in 543 VAERS reports (0.4%) during1991-2001 (Reference: PMID: 12825543). B. ovis microparticle subunit vaccine PMID: 16481077 YH AE: autism This term is a COSTART term but not a MP term (3/17/2009). According to the Vaccine Adverse Event Reporting System (VAERS), 'autism' is an adverse event that was mentioned in 530 VAERS reports (0.4%) during1991-2001 (Reference: PMID: 12825543). YH Autism is a brain development disorder characterized by impaired social interaction and communication, and by restricted and repetitive behavior. AE: sedimentation rate increased ESR erythrocyte sedimentation rate Sedimentation rate is a diagnostic test for inflammation. The test measures the rate at which red blood cells fall to the bottom of a tube over time. An increased sedimentation rate corresponds to increased non-specific inflammation in the body. It is often called "sedrate" for short. YH This term should be inferred to lab test abnormal. sedrate According to the Vaccine Adverse Event Reporting System (VAERS), 'sedimentation rate increased' is an adverse event that was mentioned in 530 VAERS reports (0.4%) during1991-2001 (Reference: PMID: 12825543). AE: red blood cell sedimentation rate increased AE: red blood cell sedimentation rate increased is an AE: sedimentation rate increased that has an increase in rate at which red blood cells precipitate in a period of 1 hour. This term is a COSTART term but not a MP term (3/17/2009). AE: accidental injury According to the Vaccine Adverse Event Reporting System (VAERS), 'accidental injury' is an adverse event that was mentioned in 530 VAERS reports (0.4%) during1991-2001 (Reference: PMID: 12825543). This term is a COSTART term but not a MP term (3/17/2009). YH an injury that occurs accidentally. Brucella recombinant SurA protein vaccine Brucella rSurA protein vaccine Brucella recombinant SurA protein YH PMID: 17686554 lentivirus vaccine vector YH AE: amblyopia According to the Vaccine Adverse Event Reporting System (VAERS), 'amblyopia' is an adverse event that was mentioned in 507 VAERS reports (0.4%) during1991-2001 (Reference: PMID: 12825543). YH vaccine-induced leukocyte activation YH USA licensed human vaccine YH a human vaccine with license that is commercially used in the USA. licensed vaccine A vaccine that is licensed for commercial use. YH AE: mental retardation YH According to the Vaccine Adverse Event Reporting System (VAERS), 'mental retardation' is an adverse event that was mentioned in 498 VAERS reports (0.4%) during1991-2001 (Reference: PMID: 12825543). This term is a COSTART term but not a MP term (3/17/2009). lipopolysaccharide of pathogen organism as vaccine component YH liposome-based vaccine adjuvant YH a vaccine adjuvant that contains particles made up of concentric lipid membranes containing phospholipids and other lipids in a bilayer configuration separated by aqueous compartments. It is a relatively stable but non-covalently-bound complex of saponin adjuvant Quil-A, cholesterol and amphipathic antigen in a molar ratio of approximately 1:1:1. The spectrum of viral capsid antigens and non-viral amphipathic antigens of relevance for human vaccination, incorporated into ISCOMs, comprises influenza, measles, rabies, gp340 from EB-virus, gp120 from HIV, Plasmodium falciparum and Trypanosoma cruzi. Ref: http://www.vaccination.inoz.com/adjuvants.html. live attenuated vaccine A live vaccine that is made from microbes that have been attenuated (weakened) in the laboratory so that they can't cause disease. attenuated vaccine YH live pathogen organism as vaccine component YH live vaccine YH A vaccine that is made of live whole organism. live virulent vaccine YH quaternary vaccination quaternary vaccination is a vaccination that is performed at the fourth time in a row. YH, Thom Todd AE: erythema multiforme YH brain inflammation local accumulation of fluid, plasma proteins, and leukocytes in the brain According to the Vaccine Adverse Event Reporting System (VAERS), 'erythema multiforme' is an adverse event that was mentioned in 483 VAERS reports (0.4%) during1991-2001 (Reference: PMID: 12825543). This term is a COSTART term but not a MP term (3/17/2009). Brucella recombinant DnaK protein vaccine YH PMID: 17686554 divalent DNA B. abortus vaccine using L7/L12 and Omp16 PMID: 16622210 YH AE: SGOT increased According to the Vaccine Adverse Event Reporting System (VAERS), 'SGOT increased' is an adverse event that was mentioned in 477 VAERS reports (0.4%) during1991-2001 (Reference: PMID: 12825543). YH This term is a COSTART term but not a MP term (3/17/2009). Increased level of SGOT. SGOT respresents serum glutamic oxaloacetic transaminase, an enzyme that is normally present in liver and heart cells. SGOT is released into blood when the liver or heart is damaged. The blood SGOT levels are thus elevated with liver damage (for example, from viral hepatitis) or with an insult to the heart (for example, from a heart attack). Some medications can also raise SGOT levels. SGOT is also called aspartate aminotransferase (AST). AE: SGPT increased According to the Vaccine Adverse Event Reporting System (VAERS), 'SGPT increased' is an adverse event that was mentioned in 459 VAERS reports (0.4%) during1991-2001 (Reference: PMID: 12825543). This term is a COSTART term but not a MP term (3/17/2009). YH Increased level of SGPT. SGPT represents serum glutamic pyruvic transaminase, an enzyme that is normally present in liver and heart cells. SGPT is released into blood when the liver or heart are damaged. The blood SGPT levels are thus elevated with liver damage (for example, from viral hepatitis) or with an insult to the heart (for example, from a heart attack). Some medications can also raise SGPT levels. SGPT is also called alanine aminotransferase (ALT). AE: thinking abnormality YH This term is a COSTART term but not a MP term (3/17/2009). According to the Vaccine Adverse Event Reporting System (VAERS), 'thinking abnormality' is an adverse event that was mentioned in 457 VAERS reports (0.4%) during1991-2001 (Reference: PMID: 12825543). AE: dyspepsia This term is a COSTART term but not a MP term (3/17/2009). YH Dyspepsia is popularly known as indigestion, meaning hard or difficult digestion. It is a medical condition characterized by chronic or recurrent pain in the upper abdomen, upper abdominal fullness and feeling full earlier than expected when eating. According to the Vaccine Adverse Event Reporting System (VAERS), 'dyspepsia' is an adverse event that was mentioned in 454 VAERS reports (0.4%) during1991-2001 (Reference: PMID: 12825543). AE: anaphylactoid reaction This term is a COSTART term but not a MP term (3/17/2009). YH According to the Vaccine Adverse Event Reporting System (VAERS), 'anaphylactoid reaction' is an adverse event that was mentioned in 452 VAERS reports (0.4%) during1991-2001 (Reference: PMID: 12825543). is an acute systemic (multi-system) and very severe Type I Hypersensitivity allergic reaction in humans and other mammals. Minute amounts of allergens may cause a life-threatening anaphylactic reaction. AE: gastrointestinal disorder YH According to the Vaccine Adverse Event Reporting System (VAERS), 'gastrointestinal disorder' is an adverse event that was mentioned in 449 VAERS reports (0.3%) during1991-2001 (Reference: PMID: 12825543). This term is a COSTART term but not a MP term (3/17/2009). AE: previous reaction This term is a COSTART term but not a MP term (3/17/2009). According to the Vaccine Adverse Event Reporting System (VAERS), 'previous reaction' is an adverse event that was mentioned in 442 VAERS reports (0.3%) during1991-2001 (Reference: PMID: 12825543). YH AE: serum sickness Serum sickness is a reaction to proteins in antiserum derived from an animal source. It is a type of hypersensitivity, specifically immune complex hypersensitivity (type III). This term is a COSTART term but not a MP term (3/17/2009). YH According to the Vaccine Adverse Event Reporting System (VAERS), 'serum sickness' is an adverse event that was mentioned in 428 VAERS reports (0.3%) during1991-2001 (Reference: PMID: 12825543). AE: injection-site abscess YH According to the Vaccine Adverse Event Reporting System (VAERS), 'injection-site abscess' is an adverse event that was mentioned in 426 VAERS reports (0.3%) during1991-2001 (Reference: PMID: 12825543). This term is a COSTART term but not a MP term (3/17/2009). AE: abnormal electroencephalogram YH According to the Vaccine Adverse Event Reporting System (VAERS), 'abnormal electroencephalogram' is an adverse event that was mentioned in 420 VAERS reports (0.3%) during1991-2001 (Reference: PMID: 12825543). This term is a COSTART term but not a MP term (3/17/2009). Abnormal results of electroencephalography (EEG). EEG is the recording of electrical activity along the scalp produced by the firing of neurons within the brain. In clinical contexts, EEG refers to the recording of the brain's spontaneous electrical activity over a short period of time, usually 20-40 minutes, as recorded from multiple electrodes placed on the scalp. In neurology, the main diagnostic application of EEG is in the case of epilepsy, as epileptic activity can create clear abnormalities on a standard EEG study. A secondary clinical use of EEG is in the diagnosis of coma and encephalopathies. EEG used to be a first-line method for the diagnosis of tumors, stroke and other focal brain disorders, but this use has decreased with the advent of anatomical imaging techniques such as MRI and CT. Brucella abortus DNA vaccine encoding L7/L12 and P39 PMID: 16537031 B. abortus DNA vaccine encoding L7/L12 and P39 YH attenuated Brucella abortus with deletion of znuA PMID: 16790759 YH mucosal immune response to vaccine YH E. coli LT toxin derived vaccine adjuvant a microbial derivative vaccine adjuvant that is derived from E. coli heat labile toxin LT. YH, SGS Feline panleukopenia virus vaccine generated using OntoRat YL viral vaccine that is used to protect against Feline panleukopenia virus infection birds vaccine Vaccine that used for immunizing birds. YL Leptospira spp. vaccine bacterial vaccine that is used to protect against Leptospira spp. infection YL generated using OntoRat Campylobacter fetus vaccine bacterial vaccine that is used to protect against Campylobacter fetus infection generated using OntoRat YL Pseudomonas aeruginosa vaccine bacterial vaccine that is used to protect against Pseudomonas aeruginosa infection YL generated using OntoRat Bordetella bronchiseptica vaccine bacterial vaccine that is used to protect against Bordetella bronchiseptica infection generated using OntoRat YL inactive or killed pathogen organism in vaccine licensed rabbit vaccine neutralizing antibody role YH microencapsulated B. melitensis mutant vaccine YH A B. melitensis vaccine that is composed of live Brucella melitensis attenuated mutant vjbR::Tn5 (BMEII1116) delivered using alginate microspheres that is coated with a protein of the parasite Fasciola hepatica (vitelline protein B [VpB]). PMID: 18362129. A B. melitensis vaccine that is composed of live Brucella melitensis attenuated mutant delivered using a microsphere delivery system. PMID: 18362129 AE: vertigo Vertigo is a specific type of dizziness, a major symptom of a balance disorder. It is the sensation of spinning or swaying while the body is actually stationary with respect to the surroundings. The effects of vertigo may be slight. It can cause nausea and vomiting and, in severe cases, it may give rise to difficulties with standing and walking. This term is a COSTART term but not a MP term (3/17/2009). YH According to the Vaccine Adverse Event Reporting System (VAERS), 'vertigo' is an adverse event that was mentioned in 412 VAERS reports (0.3%) during1991-2001 (Reference: PMID: 12825543). AE: heart arrest According to the Vaccine Adverse Event Reporting System (VAERS), 'heart arrest' is an adverse event that was mentioned in 410 VAERS reports (0.3%) during1991-2001 (Reference: PMID: 12825543). cardiac arrest cardiopulmonary arrest asystole This term is a COSTART term but not a MP term (3/17/2009). heart arrest is the abrupt cessation of normal circulation of the blood due to failure of the heart to contract effectively during systole. circulatory arrest YH AE: bronchitis Bronchitis is an inflammation of the air passages within the lungs. It occurs when the trachea (windpipe) and the large and small bronchi (airways) within the lungs become inflamed because of infection or other causes. YH According to the Vaccine Adverse Event Reporting System (VAERS), 'bronchitis' is an adverse event that was mentioned in 407 VAERS reports 0.3%) during1991-2001 (Reference: PMID: 12825543). This term is a COSTART term but not a MP term (3/17/2009). AE: grand malconvulsion According to the Vaccine Adverse Event Reporting System (VAERS), 'grand malconvulsion' is an adverse event that was mentioned in 402 VAERS reports (0.3%) during1991-2001 (Reference: PMID: 12825543). YH A generalized seizure disorder characterized by recurrent major motor seizures. The initial brief tonic phase is marked by trunk flexion followed by diffuse extension of the trunk and extremities. The clonic phase features rhythmic flexor contractions of the trunk and limbs, pupillary dilation, elevations of blood pressure and pulse, urinary incontinence, and tongue biting. This is followed by a profound state of depressed consciousness (post-ictal state) which gradually improves over minutes to hours. The disorder may be cryptogenic, familial, or symptomatic (caused by an identified disease process). This term is a COSTART term but not a MP term (3/17/2009). porin-S-LPS from B. abortus strain 2308 YH complex of porin and S-LPS from B. abortus strain 2308 PMID: 2844673 Brucella abortus RB51WboA PMID: 15327798 B. abortus RB51WboA YH AE: liver function tests abnormal According to the Vaccine Adverse Event Reporting System (VAERS), 'liver function tests abnormal' is an adverse event that was mentioned in 717 VAERS reports (0.6%) during1991-2001 (Reference: PMID: 12825543). MP: MP_0000609 aberrant function of this bile-secreting exocrine gland, which is important for detoxification; for fat, carbohydrate, and protein metabolism; and for glycogen storage AE: ear disorder This term is a COSTART term but not a MP term (3/17/2009). According to the Vaccine Adverse Event Reporting System (VAERS), 'ear disorder' is an adverse event that was mentioned in 362 VAERS reports (0.3%) during1991-2001 (Reference: PMID: 12825543). YH recombinant O. anthropi 49237SOD YH PMID: 11953393 organ or tissue specific immune response to vaccine YH licensed horse vaccine YH AE: infect viral According to the Vaccine Adverse Event Reporting System (VAERS), 'infect viral' is an adverse event that was mentioned in 358 VAERS reports (0.3%) during1991-2001 (Reference: PMID: 12825543). This term is a COSTART term but not a MP term (3/17/2009). viral infection YH, SS WEB: http://en.wikipedia.org/wiki/Viral_infection AE: infect viral is an infection that results in detrimental colonization of a host organism by virus B. melitensis Bp26 and Tf protein vaccine YH PMID: 17239499 B. melitensis Bp26 and trigger factor B. melitensis P39 recombinant protein vaccine PMID: 11447155 YH A Brucella subunit vaccine that uses recombinant Brucella melitensis 16M P39, a putative periplasmic binding protein. PMID: 11447155. recombinant chimera BLSOmp31 YH PMID: 17442465 rBLSOmp31 Panvax Panvax is an H1N1 unadjuvanted monovalent vaccine. MC, YH WEB: http://www.infowars.com/h1n1-panvax-training-powerpoint-received-by-health-care-workers-in-australia/ parasite YH intravenous route YH, Thom Todd protozoan vaccine A vaccine that protects against some protozoan disease. parasitic vaccine MeSH: D016052 YH AE: lacrimation disorder According to the Vaccine Adverse Event Reporting System (VAERS), 'lacrimation disorder' is an adverse event that was mentioned in 334 VAERS reports (0.3%) during1991-2001 (Reference: PMID: 12825543). Disorder of lacrimation. Lacrimation is the production, secretion, and shedding of tears. YH This term is a COSTART term but not a MP term (3/17/2009). AE: jaundice MP: MP_0000611 AE: icterus SS, YH WEB: http://en.wikipedia.org/wiki/Jaundice According to the Vaccine Adverse Event Reporting System (VAERS), 'jaundice' is an adverse event that was mentioned in 317 VAERS reports (0.2%) during1991-2001 (Reference: PMID: 12825543). clinical manifestation of hyperbilirubinemia, with deposition of bile pigments in the skin, resulting in yellowish staining of the skin and mucous membranes jaundice pathogen organism component in vaccine a part of vaccine that originates from an organism such as a pathogen or an attenuated organism. YH Brucella abortus pcDNA-BLS B. abortus pcDNA-BLS YH AE: abscess An abscess is a collection of pus (dead neutrophils) that has accumulated in a cavity formed by the tissue on the basis of an infectious process (usually caused by bacteria or parasites) or other foreign materials (e.g. splinters, bullet wounds, or injecting needles). It is a defensive reaction of the tissue to prevent the spread of infectious materials to other parts of the body. YH This term is a COSTART term but not a MP term (3/17/2009). abscessus According to the Vaccine Adverse Event Reporting System (VAERS), 'abscess' is an adverse event that was mentioned in 318 VAERS reports (0.2%) during1991-2001 (Reference: PMID: 12825543). escheriosome-mediated delivery of B. abortus L7/L12 escheriosome-encapsulated B. abortus L7/L12 YH PMID: 17931756 AE: eye pain This term is a COSTART term but not a MP term (3/17/2009). YH According to the Vaccine Adverse Event Reporting System (VAERS), 'eye pain' is an adverse event that was mentioned in 316 VAERS reports (0.2%) during1991-2001 (Reference: PMID: 12825543). palpitation YH A palpitation is an abnormal awareness of the beating of the heart, whether it is too slow, too fast, irregular, or at its normal frequency. According to the Vaccine Adverse Event Reporting System (VAERS), 'palpitations' is an adverse event that was mentioned in 313 VAERS reports (0.2%) during1991-2001 (Reference: PMID: 12825543). This term is a COSTART term but not a MP term (3/17/2009). period of persistence of vaccine induced immune response period of persistence of vaccine induced immune response is a temporal interval during which a vaccine-induced immune response continuously exists. This term is related to the process 'persistence of vaccine induced immune response'. YH, MC phase 1 vaccine trial YH A vaccine clinical trial that investigates the safety profile of a vaccine in a small group (10-50) of healthy volunteers. phase 2 vaccine trial YH A vaccine clinical trial that studies vaccine efficacy with a target population (numbering 50-100). Different dosage levels will also be explored at this stage to determine the optimum dose. phase 3 vaccine trial YH A vaccine clinical trial that takes the trial to a large-scale safety and efficacy study in a relevant patient population, usually in excess of 3,000. phase 4 vaccine trial YH The final stage of vaccine clinical evaluation. Phase IV occurs after a vaccine or therapy is licensed and is being used by large numbers of people. These studies are not always required or completed. rLm/iglC Seven F. tularensis proteins including IglC (rLm/iglC) were expressed in recombinant L. monocytogenes (rLm) vaccines. These 7 F. tularensis proteins are: AcpA, Bfr, DnaK, GroEL, IglC, Pld and KatG from SchuS4 strain. YH nontypeable H. influenzae Hap Protein Vaccine PMID: 15557618 YH A subunit nontypeable H. influenzae vaccine that uses Hap protein. AE: tongue edema AE: tongue oedema According to the Vaccine Adverse Event Reporting System (VAERS), 'tongue edema'; is an adverse event that was mentioned in 310 VAERS reports (0.2%) during1991-2001 (Reference: PMID: 12825543). YH This term is a COSTART term but not a MP term (3/17/2009). AE: ear pain According to the Vaccine Adverse Event Reporting System (VAERS), 'ear pain'; is an adverse event that was mentioned in 302 VAERS reports (0.2%) during1991-2001 (Reference: PMID: 12825543). YH This term is a COSTART term but not a MP term (3/17/2009). plasmid vaccine vector YH B. melitensis DNA vaccine encoding Omp31 boosted with Omp31 pCIBLSOmp31 YH AE: angioedema This term is a COSTART term but not a MP term (3/17/2009). YH According to the Vaccine Adverse Event Reporting System (VAERS), 'angioedema'; is an adverse event that was mentioned in 296 VAERS reports (0.2%) during1991-2001 (Reference: PMID: 12825543). Angioedema is the rapid swelling (edema) of the dermis, subcutaneous tissue, mucosa and submucosal tissues. It is very similar to urticaria, but urticaria, commonly known as hives, occurs in the upper dermis. AE: rheumatoid arthritis According to the Vaccine Adverse Event Reporting System (VAERS), 'rheumatoid arthritis'; is an adverse event that was mentioned in 295 VAERS reports (0.2%) during1991-2001 (Reference: PMID: 12825543). an autoimmune disease that causes chronic inflammation of the joints and may also cause inflammation of the tissue around the joints, as well as other organs in the body YH Salmonella spp. vaccine generated using OntoRat YL bacterial vaccine that is used to protect against Salmonella spp. infection vaccine approval process WEB: http://www.examiner.com/x-7707-Infectious-Disease-Examiner~y2009m9d15-News-Release-H1N1-vaccines-get-FDA-approval-expected-to-be-available-in-4-weeks @2009/10/06. H1N1 vaccines get FDA approval. Food and Drug Administration announced today that it has approved four vaccines against the 2009 H1N1 influenza virus. Obtaining FDA licensure of this vaccine for A (H1N1) pandemic response is a key milestone that will enable Sanofi Pasteur to provide a licensed vaccine to the U.S. government to support pandemic immunization efforts YH, ZX, AR, and MC vaccine product approval process WEB: http://energycommerce.house.gov/images/stories/Documents/PDF/publications/109_health.pdf @2009/10/06. This is the US Health Law which includes a section about vaccine. WEB: http://news.prnewswire.com/ViewContent.aspx?ACCT=109&STORY=/www/story/09-15-2009/0005094621&EDATE @2009/10/06 vaccine approval process is a processual entity that involves approval of a vaccine. WEB: http://www.hhs.gov/nvpo/factsheets/fs_tableII_doc2.htm @2009/10/06 #Following the FDA's review of a license application, the sponsor and the FDA may present their findings to the FDA's Vaccines and Related Biological Products Advisory Committee (VRBPAC). This non-FDA expert committee (scientists, physicians, biostatisticians, and a consumer representative) provides advice to the Agency regarding the safety and efficacy of the vaccine for the proposed indication. vaccine candidate role BP, YH This role should be a subclass of 'test substance role', which will be mireoted from OBI by OntoFox. vaccine candidate role is the role of a material entity in an investigation, which is tested for its capability to serve as a vaccine. CFU measurement assay CFU measurement assay is an assay that measures the colony forming unit (CFU) of a bacterium in a specific location (e.g., spleen of a mouse). YH, MC vaccine effectiveness rate vaccine effectiveness rate is a measurement datum that measues the vaccine effectiveness. It is assessed with respect to prevention of the disease against which the vaccine is given. One simple method to estimate vaccine effectiveness is to use routine data on notifications of disease cases in vaccinated and unvaccinatted children and to compare the porportion of cases vaccinated with the vaccine covervage among the same age group in the general population. If p is the proportion vaccinated in the population and c is the proportion of cases reported to be vaccinated, then VE = (p-c)/p(1-c) x 100%. Hadler TC, et al. Immunization in developing countries. In: Vaccines. Editors: Plotkin S, et al. 2008. p1542-71. YH, MC WEB: http://en.wikipedia.org/wiki/Influenza_vaccine vaccine licensing YH, ZX vaccine licensing is a vaccine approval process that involves in licensing a vaccine. licensed chicken vaccine YH, XZ poxvirus vaccine vector YH AE: immune system disorder YH This term is a COSTART term but not a MP term (3/17/2009). According to the Vaccine Adverse Event Reporting System (VAERS), 'immune system disorder'; is an adverse event that was mentioned in 292 VAERS reports (0.2%) during1991-2001 (Reference: PMID: 12825543). AE: antinuclear antibody present This term is a COSTART term but not a MP term (3/17/2009). anti-nuclear factor present YH The presence of anti-nuclear antibodies (ANAs) that are antibodies directed against contents of the cell nucleus. ANAs are present in higher than normal numbers in autoimmune disease. The ANA test measures the pattern and amount of autoantibody which can attack the body's tissues as if they were foreign material. Autoantibodies are present in low titers in the general population, but in about 5% of the population, their concentration is increased, and about half of this 5% have an autoimmune disease. According to the Vaccine Adverse Event Reporting System (VAERS), 'antinuclear antibody present'; is an adverse event that was mentioned in 288 VAERS reports (0.2%) during1991-2001 (Reference: PMID: 12825543). NPAP Brucella vaccine Brucella vaccine using nonpathogenic alphaproteobacteria PMID: 17715332 YH AE: myelitis This term is a COSTART term but not a MP term (3/17/2009). According to the Vaccine Adverse Event Reporting System (VAERS), 'myelitis'; is an adverse event that was mentioned in 280 VAERS reports (0.2%) during1991-2001 (Reference: PMID: 12825543). Myelitis is a disease involving inflammation of the spinal cord, which disrupts central nervous system functions linking the brain and limbs. YH preventive vaccine function preventive vaccine function is a vaccine function realized by the process of vaccination and leading to induction of an adaptive immune response to the antigens in a vaccine, which protects against a specific disorder. YH prophylactic vaccine function prime boost regimen YH APEC vaccine using GST-Iss fusion protein YH Colibacillosis, caused by avian pathogenic Escherichia coli (APEC), is a major problem for the poultry industry in the world. prophylactic vaccine a vaccine that is used for prevention against a disease. YH protection efficacy Protection efficacy is an efficiency that is associated with protection by a biological product (e.g., vaccine) against a disease. YH protective antigen role YH Protective antigen is an antigen that stimulates protective immunity when used in vivo. E. coli LB-T vaccine E. coli heat-labile enterotoxin B-subunit (LB-T) vaccine PMID: 11500434 YH E. coli O157:H7 subunit vaccine expressing Esps and Tir PMID: 14670317 YH AE: migraine A migraine is a very painful type of headache. People who get migraines often describe the pain as pulsing or throbbing in one area of the head. During migraines, people are very sensitive to light and sound. They may also become nauseated and vomit. migraine headache This term is a COSTART term but not a MP term (3/17/2009). According to the Vaccine Adverse Event Reporting System (VAERS), 'migraine'; is an adverse event that was mentioned in 267 VAERS reports (0.2%) during1991-2001 (Reference: PMID: 12825543). YH AE: thrombocytopenic purpura Thrombocytopenic purpura are purpura associated with a reduction in circulating blood platelets which can result from a variety of causes. YH This term is a COSTART term but not a MP term (3/17/2009). According to the Vaccine Adverse Event Reporting System (VAERS), 'thrombocytopenic purpura'; is an adverse event that was mentioned in 267 VAERS reports (0.2%) during1991-2001 (Reference: PMID: 12825543). AE: multiple sclerosis YH Multiple sclerosis is an autoimmune condition in which the immune system attacks the central nervous system, leading to demyelination. MS This term is a COSTART term but not a MP term (3/17/2009). encephalomyelitis disseminata disseminated sclerosis According to the Vaccine Adverse Event Reporting System (VAERS), 'multiple sclerosis'; is an adverse event that was mentioned in 264 VAERS reports (0.2%) during1991-2001 (Reference: PMID: 12825543). AE: amnesia Amnesia is a short term memory condition in which memory is disturbed. In simple terms it is the loss of memory. According to the Vaccine Adverse Event Reporting System (VAERS), 'amnesia'; is an adverse event that was mentioned in 262 VAERS reports (0.2%) during1991-2001 (Reference: PMID: 12825543). This term is a COSTART term but not a MP term (3/17/2009). YH protein of pathogen organism as vaccine component YH AE: incoordination YH a lack of normal adjustment of muscular action so that the intended movement of the limb or other part is not made smoothly and harmoniously, and does not accurately achieve its objective. If the abnormality is hypermetric, the condition is referred to as ataxia. If it is inclined to weakness, e.g. knuckling at the turn, stumbling, failure to flex limbs properly, or to misdirection as in a proprioceptive deficit, it is called incoordination. This term is a COSTART term but not a MP term (3/17/2009). According to the Vaccine Adverse Event Reporting System (VAERS), 'incoordination'; is an adverse event that was mentioned in 261 VAERS reports (0.2%) during1991-2001 (Reference: PMID: 12825543). soybean-expressed E. coli LTB vaccine YH PMID: 17188785 AE: voice alteration This term is a COSTART term but not a MP term (3/17/2009). According to the Vaccine Adverse Event Reporting System (VAERS), 'voice alteration'; is an adverse event that was mentioned in 259 VAERS reports (0.2%) during1991-2001 (Reference: PMID: 12825543). YH AE: abortion WEB: http://en.wikipedia.org/wiki/Abortion This term is a COSTART term but not a MP term (3/17/2009). AE: abortion is a reproductive system AE that is the termination of a pregnancyby the removal or expulsion from the uterus of a fetus or embryo, resulting in or caused by its death. YH, SS According to the Vaccine Adverse Event Reporting System (VAERS), 'abortion'; is an adverse event that was mentioned in 257 VAERS reports (0.2%) during1991-2001 (Reference: PMID: 12825543). AE: shock According to the Vaccine Adverse Event Reporting System (VAERS), 'shock'; is an adverse event that was mentioned in 253 VAERS reports (0.2%) during1991-2001 (Reference: PMID: 12825543). mental shock acute stress reaction psychological shock Mental shock (or shock) is a psychological condition arising in response to a terrifying event. It should not be confused with the unrelated circulatory condition of shock. This term is a COSTART term but not a MP term (3/17/2009). acute stress disorder YH AE: purpura YH Purpura is the appearance of red or purple discolorations on the skin that do not blanch on applying pressure. They are caused by bleeding underneath the skin. This is common with typhus and can be present with meningitis caused by meningococcal meningitis or septicaemia. Reference: http://en.wikipedia.org/wiki/Purpura. This term is a COSTART term but not a MP term (3/17/2009). According to the Vaccine Adverse Event Reporting System (VAERS), 'purpura'; is an adverse event that was mentioned in 251 VAERS reports (0.2%) during1991-2001 (Reference: PMID: 12825543). nontypeable H. influenzae vaccine YH nontypeable Haemophilus influenzae NTHi Nontypeable Haemophilus influenzae (NTHi) is a nonencapsulated Haemophilus influenzae (a gram-negative bacterium). It is the cause of a number of human respiratory tract diseases, such as otitis media, sinusitis, bronchitis, and pneumonia. YH non-typeable H. influenzae rLP4/rLP6 and Moraxella catarrhalis UspA2 protein vaccine YH rLP4/rLP6/UspA2 PMID: 15308371 killed nontypeable H. influenzae whole-cell vaccine PMID: 1953532 PMID: 2867396 YH PMID: 2184330 PMID: 1859055 AE: bacterial infection event AE: bacterial infection event is an infection that results in detrimental colonization of a host organism by bacteria AE: bacterial infection This term is a COSTART term but not a MP term (3/17/2009). WEB: http://en.wikipedia.org/wiki/Bacterial_infection According to the Vaccine Adverse Event Reporting System (VAERS), 'bacterial infection'; is an adverse event that was mentioned in 250 VAERS reports (0.2%) during1991-2001 (Reference: PMID: 12825543). YH, SS radiated pathogen as vaccine component YH AE: skin striae Skin striae are irregular areas of skin that look like bands, stripes, or lines. Striae are seen when a person grows or gains weight rapidly or has certain diseases or conditions. striae distensae YH According to the Vaccine Adverse Event Reporting System (VAERS), 'skin striae'; is an adverse event that was mentioned in 247 VAERS reports (0.2%) during1991-2001 (Reference: PMID: 12825543). stretch marks E. coli vaccine using intimin polypeptide YH PMID: 14688094 PMID: 17258324 nontypeable H. influenzae cell membrane vaccine (CM-Hi) YH PMID: 10353870 nontypeable H. influenzae LOS-TT conjugate vaccine YH PMID: 12706701 Nontypeable H. influenzae lipooligosaccharide-tetanus toxoid conjugate vaccine PMID: 9353024 E. coli subunit vaccine using IroN PMID: 17145948 YH preparation of recombinant protein vaccine YH A vaccine preparation process that uses recombinant molecular technology to prepare recombinant protein. protein subunit vaccine A subunit vaccine that is made using recombinant DNA technology to engineer the antigen molecules of the particular microbe. YH recombinant vector vaccine A vaccine that uses a modified virus or bacterium to deliver genes that code for microbial antigens to cells of the body. YH E. coli subunit vaccine using CO393 YH PMID: 17145948 vaccination with a licensed pig vaccine YH AE: acute brain syndrome According to the Vaccine Adverse Event Reporting System (VAERS), 'acute brain syndrome'; is an adverse event that was mentioned in 240 VAERS reports (0.2%) during1991-2001 (Reference: PMID: 12825543). YH This term is a COSTART term but not a MP term (3/17/2009). E. coli subunit vaccine using FyuA PMID: 17258324 YH PMID: 14688094 vaccination with a licensed horse vaccine YH immunization WEB: http://en.wikipedia.org/wiki/Immunization immunization is a processual entity that primes or modifies an adaptivie immune response to some antigens. YH, XZ, BP active immunization WEB: http://en.wikipedia.org/wiki/Immunization Active immunization entails the introduction of a foreign molecule into the body, which causes the body itself to generate immunity against the target. This immunity comes from the T cells and the B cells with their antibodies. Active immunization can occur naturally when a person comes in contact with, for example, a microbe. If the person has not yet come into contact with the microbe and has no pre-made antibodies for defense (like in passive immunization), the person becomes immunized. The immune system will eventually create antibodies and other defenses against the microbe. The next time, the immune response against this microbe can be very efficient; this is the case in many of the childhood infections that a person only contracts once, but then is immune. Artificial active immunization is where the microbe, or parts of it, are injected into the person before they are able to take it in naturally. If whole microbes are used, they are pre-treated, Attenuated vaccine. (Wikipedia) Active immunization is an immunization process that entails the introduction of a foreign molecule into the body, which causes the body itself to generate adaptive immunity against the target. YH, XZ passive immunization WEB: http://en.wikipedia.org/wiki/Immunization YH, XZ Currently, antibodies can be used for passive immunization. This method of immunization works very quickly. However, it is short lasting. The antibodies are naturally broken down. If there are no B cells to produce more antibodies, they will disappear. Passive immunization is an immunization process where pre-synthesized elements of the immune system are transferred to an organism so that the body does not need to produce these elements itself. natural active immunization YH, XZ WEB: http://en.wikipedia.org/wiki/Immunization natural active immunization is an active immunization that occur naturally when a person or animal comes in contact with antigens includeing microbes. vaccine immunization YH, XZ WEB: http://en.wikipedia.org/wiki/Immunization artificial active immunization artificial active immunization is an active immunization that occurs when a person or animal is vaccinated with a specific vaccine. induction of adaptive immune response to antigen induction of adaptive immune response to antigen is an active immunization process that results in induction of adaptive immune response to some antigens, for example, in a vaccine. YH, XZ disorder prevention disorder prevention is a processual entity that prevents a disorder that is the physical basis of a disease. YH, XZ disorder treatment disorder treatment is a processual entity that leads to treat a disorder that is the physical basis of a disease. YH, XZ modification of adaptive immune response to antigen modification of adaptive immune response to antigen is an active immunization process that results in modification of an adaptive immune response to some antigens, for example, in a therapeutic vaccine. YH, XZ preventive infectious disease vaccine function YH, XZ infection disorder prevention YH, XZ infection disorder prevention is a process that prevents a disorder that is the physical basis of an infectious disease. E. coli vaccine using verocytotoxin toxoid PMID: 17145948 YH Inactivated ETEC expressing expressing CFA/I and CFA/II PMID: 1612730 YH coma YH Coma is a profound state of unconsciousness. A comatose person cannot be awakened, fails to respond normally to pain or light, does not have sleep-wake cycles, and does not take voluntary actions. This term is a COSTART term but not a MP term (3/17/2009). According to the Vaccine Adverse Event Reporting System (VAERS), 'coma'; is an adverse event that was mentioned in 230 VAERS reports (0.2%) during1991-2001 (Reference: PMID: 12825543). AE: hyperkinesia YH Hyperkinesia is an abnormal increase in muscular activity. According to the Vaccine Adverse Event Reporting System (VAERS), 'hyperkinesia'; is an adverse event that was mentioned in 227 VAERS reports (0.2%) during1991-2001 (Reference: PMID: 12825543). This term is a COSTART term but not a MP term (3/17/2009). EHEC O157 subunit vaccine using his-tagged N-terminal intimin YH PMID: 1612730 AE: cardiovascular disorder According to the Vaccine Adverse Event Reporting System (VAERS), 'cardiovascular disorder'; is an adverse event that was mentioned in 225 VAERS reports (0.2%) during1991-2001 (Reference: PMID: 12825543). YH This term is a COSTART term but not a MP term (3/17/2009). AE: encephalopathy According to the Vaccine Adverse Event Reporting System (VAERS), 'encephalopathy'; is an adverse event that was mentioned in 224 VAERS reports (0.2%) during1991-2001 (Reference: PMID: 12825543). Encephalopathy is disorder or disease of the brain. YH This term is a COSTART term but not a MP term (3/17/2009). AE: urine abnormality This term is a COSTART term but not a MP term (3/17/2009). According to the Vaccine Adverse Event Reporting System (VAERS), 'urine abnormality'; is an adverse event that was mentioned in 223 VAERS reports (0.2%) during1991-2001 (Reference: PMID: 12825543). YH nontypeable H. influenzae P5 peptide MVF/H3 vaccine YH PMID: 10603411 nontypeable H. influenzae rTbpB vaccine YH PMID: 10225866 ETEC vaccine ACAM2007 ACAM2007 is a vaccine candidate expressing CFA/II. YH AE: gastroenteritis YH This term is a COSTART term but not a MP term (3/17/2009). According to the Vaccine Adverse Event Reporting System (VAERS), 'gastroenteritis'; is an adverse event that was mentioned in 218 VAERS reports (0.2%) during1991-2001 (Reference: PMID: 12825543). AE: peripheral vascular disorder According to the Vaccine Adverse Event Reporting System (VAERS), 'peripheral vascular disorder'; is an adverse event that was mentioned in 215 VAERS reports (0.2%) during1991-2001 (Reference: PMID: 12825543). YH This term is a COSTART term but not a MP term (3/17/2009). AE: urinary tract infection According to the Vaccine Adverse Event Reporting System (VAERS), 'urinary tract infection'; is an adverse event that was mentioned in 213 VAERS reports (0.2%) during1991-2001 (Reference: PMID: 12825543). YH This term is a COSTART term but not a MP term (3/17/2009). rough phenotype YH AE: increased salivation According to the Vaccine Adverse Event Reporting System (VAERS), 'increased salivation' is an adverse event that was mentioned in 336 VAERS reports (0.3%) during1991-2001 (Reference: PMID: 12825543). MP: MP_0000622 greater than normal amounts of flowing saliva ETEC vaccine ACAM2017 ACAM2017 was derived from ACAM2007. Genes aroC, ompC, and ompF were deleted, while CS1 and pStrep were added. YH PMID: 17566016 B. anthracis DNA vaccine encoding PA63 YH This DNA vaccine contains the gene fragment encoding AAs 173-764 of PA. PMID: 9987172 depression This term is a COSTART term but not a MP term (3/17/2009). According to the Vaccine Adverse Event Reporting System (VAERS), 'depression'; is an adverse event that was mentioned in 196 VAERS reports (0.2%) during1991-2001 (Reference: PMID: 12825543). YH AE: diabetes mellitus Diabetes mellitus, often referred to simply as diabetes, is a syndrome of disordered metabolism, usually due to a combination of hereditary and environmental causes, resulting in abnormally high blood sugar levels (hyperglycemia). YH According to the Vaccine Adverse Event Reporting System (VAERS), 'diabetes mellitus'; is an adverse event that was mentioned in 196 VAERS reports (0.2%) during1991-2001 (Reference: PMID: 12825543). This term is a COSTART term but not a MP term (3/17/2009). diabetes B. anthracis DNA vaccine encoding PA83 and LF YH PMID: 15342913 DAAV using PA and PGA PMID: 12960361 YH smooth phenotype YH AE: laryngitis Laryngitis is an inflammation of the larynx. It causes hoarse voice or the complete loss of the voice because of irritation to the vocal folds (vocal cords). This term is a COSTART term but not a MP term (3/17/2009). YH According to the Vaccine Adverse Event Reporting System (VAERS), 'laryngitis'; is an adverse event that was mentioned in 190 VAERS reports (0.1%) during1991-2001 (Reference: PMID: 12825543). AE: generalized spasm YH This term is a COSTART term but not a MP term (3/17/2009). According to the Vaccine Adverse Event Reporting System (VAERS), 'generalized spasm'; is an adverse event that was mentioned in 186 VAERS reports (0.1%) during1991-2001 (Reference: PMID: 12825543). An involuntary contraction of a muscle or group of muscles. Spasms may involve skeletal muscle (MUSCLE, SKELETAL) or smooth muscle (MUSCLE, SMOOTH). rPA with adjuvant Nanoemulsion YH PMID: 17502384 AE: reflexes decreased According to the Vaccine Adverse Event Reporting System (VAERS), 'reflexes decreased'; is an adverse event that was mentioned in 178 VAERS reports (0.1%) during1991-2001 (Reference: PMID: 12825543). This term is a COSTART term but not a MP term (3/17/2009). YH reflexes decreased is an abnormal movement that showed decrease in an involuntary response to a peripheral stimulus M. tuberculosis arabinomannan-protein conjugate PMID: 12922145 Xref: VIOLIN vaccine ID: 223. YH AE: dry mouth YH dryness of the mouth resulting from reduced salivary secretion According to the Vaccine Adverse Event Reporting System (VAERS), 'dry mouth'; is an adverse event that was mentioned in 171 VAERS reports (0.1%) during1991-2001 (Reference: PMID: 12825543). xerostomia AE: optic neuritis This term is a COSTART term but not a MP term (3/17/2009). YH According to the Vaccine Adverse Event Reporting System (VAERS), 'optic neuritis'; is an adverse event that was mentioned in 171 VAERS reports (0.1%) during1991-2001 (Reference: PMID: 12825543). AE: thrombocythemia According to the Vaccine Adverse Event Reporting System (VAERS), 'thrombocythemia'; is an adverse event that was mentioned in 171 VAERS reports (0.1%) during1991-2001 (Reference: PMID: 12825543). YH Thrombocythemia (primary thrombocythemia) is a disorder in which excess platelets are produced, leading to abnormal blood clotting or bleeding. This term is a COSTART term but not a MP term (3/17/2009). subcutaneous route YH subdominant epitope in vaccine YH subunit vaccine A vaccine that is composed of a purified protein(s) or other antigenic determinant(s) from a disease-causing organism. A subunit vaccine does not include pathogen nucleic acids. The subunits have less risk of causing adverse reactions. YH recombinant S. typhimurium secreting M. tuberculosis ESAT-6 Xref: VIOLIN vaccineID: 176. PMID: 11427279 YH Ag85B and ESAT-6 fusion protein PMID: YH AE: epistaxis nosebleed This term is a COSTART term but not a MP term (3/17/2009). According to the Vaccine Adverse Event Reporting System (VAERS), 'epistaxis'; is an adverse event that was mentioned in 163 VAERS reports (0.1%) during1991-2001 (Reference: PMID: 12825543). Epistaxis is the relatively common occurrence of hemorrhage from the nose, usually noticed when the blood drains out through the nostrils. YH AE: lupus syndrome YH According to the Vaccine Adverse Event Reporting System (VAERS), 'lupus syndrome'; is an adverse event that was mentioned in 163 VAERS reports (0.1%) during1991-2001 (Reference: PMID: 12825543). This term is a COSTART term but not a MP term (3/17/2009). AE: photophobia YH Photophobia is a symptom of excessive sensitivity to light and the aversion to sunlight or well-lit places. In medical terms it is not fear, but an experience of discomfort or pain to the eyes due to light exposure. According to the Vaccine Adverse Event Reporting System (VAERS), 'photophobia'; is an adverse event that was mentioned in 163 VAERS reports (0.1%) during1991-2001 (Reference: PMID: 12825543). This term is a COSTART term but not a MP term (3/17/2009). time of survival of live vaccine inside host YH, MC time of survival of live vaccine inside host is a temporal interval during which a live vaccine survives inside a host organism. This entity is related to the process survival of live vaccine inside host. AE: abnormal salivary gland physiology MP: MP_0005310 any functional anomaly of any of the glands in the mouth that secrete saliva hallucination This term is a COSTART term but not a MP term (3/17/2009). YH According to the Vaccine Adverse Event Reporting System (VAERS), 'hallucinations'; is an adverse event that was mentioned in 157 VAERS reports (0.1%) during1991-2001 (Reference: PMID: 12825543). A hallucination, in the broadest sense, is a perception in the absence of a stimulus. In a stricter sense, hallucinations are defined as perceptions in a conscious and awake state in the absence of external stimuli which have qualities of real perception, in that they are vivid, substantial, and located in external objective space. attenuated M. bovis strain WAg539 PMID: 15784584 YH tongue disorder YH According to the Vaccine Adverse Event Reporting System (VAERS), 'tongue disorder'; is an adverse event that was mentioned in 156 VAERS reports (0.1%) during1991-2001 (Reference: PMID: 12825543). This term is a COSTART term but not a MP term (3/17/2009). AE: neuralgia Neuralgia or neuropathic pain can be defined most simply as non-nociceptive pain. Neuralgia is pain produced by a change in neurological structure or function. Unlike nociceptive pain, Neuralgia exists with no continuous nociceptive input. Neuralgia falls into two categories: central Neuralgia and peripheral Neuralgia. YH This term is a COSTART term but not a MP term (3/17/2009). According to the Vaccine Adverse Event Reporting System (VAERS), 'neuralgia'; is an adverse event that was mentioned in 155 VAERS reports (0.1%) during1991-2001 (Reference: PMID: 12825543). target YH AE: lung edema This term is a COSTART term but not a MP term (3/17/2009). YH According to the Vaccine Adverse Event Reporting System (VAERS), 'lung edema'; is an adverse event that was mentioned in 152 VAERS reports (0.1%) during1991-2001 (Reference: PMID: 12825543). AE: circumoral paresthesia This term is a COSTART term but not a MP term (3/17/2009). numbness around the mouth. According to the Vaccine Adverse Event Reporting System (VAERS), 'circumoral paresthesia'; is an adverse event that was mentioned in 152 VAERS reports (0.1%) during1991-2001 (Reference: PMID: 12825543). YH bacterial phenotype YH therapeutic vaccine A vaccine that is used for treatment for a disease. YH vaccination with a licensed vaccine YH, BP, XZ licensed use of vaccine is a vaccination process that follows a protocol for a licensed vaccine. attenuated M. bovis strain WAg520 PMID: 10225931 YH AE: thirst YH Thirst is the craving for liquids, resulting in the basic instinct of humans or animals to drink. It is an essential mechanism involved in fluid balance. According to the Vaccine Adverse Event Reporting System (VAERS), 'thirst'; is an adverse event that was mentioned in 148 VAERS reports (0.1%) during1991-2001 (Reference: PMID: 12825543). This term is a COSTART term but not a MP term (3/17/2009). AE: bone disorder YH This term is a COSTART term but not a MP term (3/17/2009). According to the Vaccine Adverse Event Reporting System (VAERS), 'bone disorder'; is an adverse event that was mentioned in 145 VAERS reports (0.1%) during1991-2001 (Reference: PMID: 12825543). titer WEB:http://en.wikipedia.org/wiki/Titer A titer (or titre) is a measure of concentration. Titer testing employs serial dilution to obtain approximate quantitative information from an analytical procedure that inherently only evaluates as positive or negative. The titer corresponds to the highest dilution factor that still yields a positive reading; for example, positive readings in the first 8 serial twofold dilutions translate into a titer of 1:256. YH vaccination with a licensed human vaccine licensed use of vaccine is a vaccination process that involves the vaccination of a licensed human vaccine. YH, XZ attenuated M. bovis strain WAg522 PMID: 10225931 YH recombinant nontypeable H. influenzae protein P6 with AdDP YH PMID: 15031801 adamantylamide dipeptide vaccine adjuvant a synthetic vaccine adjuvant, adamantylamide dipeptide (AdDP) is the desmuramyl analog of MDP. PMID: 8375945 YH, SGS AdDP toxin YH toxoid vaccine A vaccine containing a toxoid, used to protect against toxins produced by certain bacteria. A toxoid (also called inactivated toxin) is a processed toxin that has been treated by chemical means, heat, or irradiation and is no longer capable of causing disease. YH therapeutic vaccine function YH The therapeutic vaccine function is a function realized by the process of vaccination and leading to induction of an adaptive immune response to the antigens in a vaccine, which ameliorates a specific disorder. AE: fetal disorder YH According to the Vaccine Adverse Event Reporting System (VAERS), 'fetal disorder'; is an adverse event that was mentioned in 142 VAERS reports (0.1%) during1991-2001 (Reference: PMID: 12825543). This term is a COSTART term but not a MP term (3/17/2009). M. tuberculosis secA2 mutant PMID: 17671656 YH rBCG-Ag85A[Tokyo] YH PMID: 17720625 emotional liability This term is a COSTART term but not a MP term (3/17/2009). According to the Vaccine Adverse Event Reporting System (VAERS), 'emotional liability'; is an adverse event that was mentioned in 138 VAERS reports (0.1%) during1991-2001 (Reference: PMID: 12825543). YH DNA vaccine Rv1806-1807 YH PMID: 16520093 AE: muscle spasm SS, YH MP: MP_0000743 WEB: http://en.wikipedia.org/wiki/Spasm an involuntary and often painful muscle contraction or cramps having a number of causes ranging from nutritional deficiency to serious nervous system conditions muscle spasm vaccine-induced up-regulated gene expression YH AAV vaccine vector YH vaccination protocol vaccination protocol is the protocol of a vaccination procedure. YH vaccination schedule AE: tendon disorder According to the Vaccine Adverse Event Reporting System (VAERS), 'tendon disorder'; is an adverse event that was mentioned in 137 VAERS reports (0.1%) during1991-2001 (Reference: PMID: 12825543). A tendon (or sinew) is a tough band of fibrous connective tissue that usually connects muscle to bone and is capable of withstanding tension. This term is a COSTART term but not a MP term (3/17/2009). YH Tendon disorder is a medical condition that results in a tendon not functioning normally. route of administration YH vaccine candidate During our call, we decided not to say vaccine candidate is an output of vaccine preparation, which may be reserved for vaccine alone. -- Aug 4, 2009. YH, AR, BP, LC, MC, and ZX vaccine candidate is a processed material that is designed to prevent or ameliorate a disorder in a target organism by modulating adaptive immune responses in that organism by administrating the vaccine. thimerosal vaccine preservative YH Thimerosal vaccine preservative is a vaccine preservative that contains the chemical thimerosal. peptide vaccine Peptide vaccine is a subunit vaccine that uses small peptide(s) as immunoepitopes. YH H1N1 Influenza vaccine YH H1N1 Influenza vaccine is an Influenza virus vaccine that is used to vaccinate against H1N1 Influenza subtype vaccine. Haemophilus somnus vaccine YL generated using OntoRat bacterial vaccine that is used to protect against Haemophilus somnus infection vaccine adjuvant YH a vaccine component that is chemical substance added to vaccine and enhance and direct immune response to protective antigen. Many of vaccine adjuvants cause a range of serious side-effects. H. influenzae gene YH vaccine license application A vaccine regulatory process that is for vaccine producer to apply for vaccine license. YH nontypeable H. influenzae gene hel (encoding P4) YH Encodes for protein P4 immune response detection assay An assay that is used to detect the immune response of a host to vaccination of a vaccine. YH immunization objective WEB: http://en.wikipedia.org/wiki/Immunization YH, XZ immunization objective is the specification of an objective to achieve immunization. vaccination with a licensed dog vaccine YH AE: hostility This term is a COSTART term but not a MP term (3/17/2009). YH According to the Vaccine Adverse Event Reporting System (VAERS), 'hostility'; is an adverse event that was mentioned in 136 VAERS reports (0.1%) during1991-2001 (Reference: PMID: 12825543). M. tuberculosis phoP mutant SO2 YH PMID: 16564606 PMID: 17084814 AE: visual field defect According to the Vaccine Adverse Event Reporting System (VAERS), 'visual field defect'; is an adverse event that was mentioned in 131 VAERS reports (0.1%) during1991-2001 (Reference: PMID: 12825543). AE: visual impairment SS, YH This term is a COSTART term but not a MP term (3/17/2009). vaccine preparation vaccine production YH, BP vaccine preparation is a manufacturing process to produce a vaccine. vaccine generation vaccine protection assay An assay that is used to detect if a vaccine protects a host against infection of virulent pathogen after vaccine immunization. YH vaccine challenge experiment AE: myopathy According to the Vaccine Adverse Event Reporting System (VAERS), 'myopathy'; is an adverse event that was mentioned in 199 VAERS reports (0.2%) during1991-2001 (Reference: PMID: 12825543). MP: MP_0000751 any abnormal condition or disease of the skeletal muscle myopathy vaccine specific T cell cytokine production YH vaccine specific T cell mediated cytotoxicity YH vaccine dose YH, MC vaccine dose is a dose of vaccine specified by the vaccine manufacturer, distributor, or a regulatory agent. vaccine clinical trial A processual entity by which a vaccine is tested clinically for safety and effectiveness. Clinical trials are conducted in phases. Classically, clinical trials unfold in three phases in order to gather data and information about a vaccine and its performance. This will form the basis of a dossier submitted to regulatory authorities by way of an application for licensure. After a vaccine is licensed and is being used by large numbers of people, a Phase IV study may or may not be taken for vaccine clinical evaluation. Most vaccines against a pathogen (e.g., HIV) are not tested by vaccinating people and then deliberately exposing them to virulent pathogen (e.g., HIV). This strategy is never for a vaccine against a disease as serious as HIV. The best way to determine if a vaccine is effective is to test it in a randomized, controlled, double-blind clinical trial. This type of trial is often referred to as the gold standard in medical research and provides the strongest evidence for the efficacy of a vaccine. YH vaccine using part of organism A vaccine that uses part of pathogen organism. YH whole organism vaccine WEB: http://onlinelibrary.wiley.com/doi/10.1038/npg.els.0000491/full A vaccine t that uses whole organism as its component YH vaccine vector a vaccine component that functions as a vector that carries an inserted antigen (protein recognized by the body as foreign) from a disease causing agent to the vaccinee. YH vaccinia virus vector YH AE: apathy impassivity Apathy is a state of indifference, or the suppression of emotions such as concern, excitement, motivation and passion. An apathetic individual has an absence of interest or concern to emotional, social, or physical life. They may also exhibit an insensibility or sluggishness. According to the Vaccine Adverse Event Reporting System (VAERS), 'apathy'; is an adverse event that was mentioned in 129 VAERS reports (0.1%) during1991-2001 (Reference: PMID: 12825543). This term is a COSTART term but not a MP term (3/17/2009). perfunctoriness YH AE: hemiplegia YH Hemiplegia is total paralysis of the arm, leg, and trunk on the same side of the body. Hemiplegia is more severe than hemiparesis, wherein one half of the body is weakened but not paralysed. According to the Vaccine Adverse Event Reporting System (VAERS), 'hemiplegia'; is an adverse event that was mentioned in 129 VAERS reports (0.1%) during1991-2001 (Reference: PMID: 12825543). This term is a COSTART term but not a MP term (3/17/2009). BCG mutant secreting listeriolysin YH AE: pustular rash YH This term is a COSTART term but not a MP term (3/17/2009). Pastular rash is a rash that is composed of pustular lesions. According to the Vaccine Adverse Event Reporting System (VAERS), 'pustular rash'; is an adverse event that was mentioned in 128 VAERS reports (<0.1%) during1991-2001 (Reference: PMID: 12825543). AE: creatine phosphokinase increased An abnormal lab test that has increased creatine phosphokinase. Creatine kinase (CK), also known as creatine phosphokinase (CPK) or phosphocreatine kinase, is an enzyme (EC 2.7.3.2) expressed by various tissue types. It catalyses the conversion of creatine and consumes adenosine triphosphate (ATP) to create phosphocreatine and adenosine diphosphate (ADP). According to the Vaccine Adverse Event Reporting System (VAERS), 'creatine phosphokinase increased'; is an adverse event that was mentioned in 127 VAERS reports (<0.1%) during1991-2001 (Reference: PMID: 12825543). This term is a COSTART term but not a MP term (3/17/2009). YH delta ureC hly+ rBCG YH PMID: 16110326 Hiberix AE: intracranial hypertension YH According to the Vaccine Adverse Event Reporting System (VAERS), 'intracranial hypertension'; is an adverse event that was mentioned in 118 VAERS reports (<0.1%) during1991-2001 (Reference: PMID: 12825543). viral vaccine A vaccine that protects against some viral disease. YH MeSH: D014765 viral vaccine vector YH Haemophilus parasuis vaccine YL generated using OntoRat bacterial vaccine that is used to protect against Haemophilus parasuis infection virulent YH AE: gamma glutamyl transpeptidase increased According to the Vaccine Adverse Event Reporting System (VAERS), 'gamma glutamyl transpeptidase increased'; is an adverse event that was mentioned in 117 VAERS reports (<0.1%) during1991-2001 (Reference: PMID: 12825543). Gamma-GT increased GGTP increased GGT increased This term is a COSTART term but not a MP term (3/17/2009). YH An abnormal lab test that has increased gamma glutamyl transpeptidase (GGT). GGT is involved in the transfer of amino acids across the cellular membrane. Nontypeable H. influenzae protein P6 with cholera toxin PMID: 15297063 YH AE: abnormal stool This term is a COSTART term but not a MP term (3/17/2009). YH According to the Vaccine Adverse Event Reporting System (VAERS), 'abnormal stools'; is an adverse event that was mentioned in 111 VAERS reports (<0.1%) during1991-2001 (Reference: PMID: 12825543). animal model of vaccine research YH Animal model of vaccine research is a role played by some organism (e.g., mouse) that is used for vaccine research. AE: bone pain YH This term is a COSTART term but not a MP term (3/17/2009). According to the Vaccine Adverse Event Reporting System (VAERS), 'bone pain'; is an adverse event that was mentioned in 109 VAERS reports (<0.1%) during1991-2001 (Reference: PMID: 12825543). AE: cerebrovascular accident Cerebrovascular accident: The sudden death of some brain cells due to lack of oxygen when the blood flow to the brain is impaired by blockage or rupture of an artery to the brain. A CVA is also referred to as a stroke. YH According to the Vaccine Adverse Event Reporting System (VAERS), 'cerebrovascular accident'; is an adverse event that was mentioned in 106 VAERS reports (<0.1%) during1991-2001 (Reference: PMID: 12825543). stroke This term is a COSTART term but not a MP term (3/17/2009). vaccination with a licensed turkey vaccine YH Pasteurella multocida vaccine generated using OntoRat bacterial vaccine that is used to protect against Pasteurella multocida infection YL laboratory animal model of vaccine research Animal model of vaccine research is a role played by some organism (e.g., mouse) that is used for vaccine research in the laboratory. YH AE: parotid gland enlargement According to the Vaccine Adverse Event Reporting System (VAERS), 'parotid gland enlargement'; is an adverse event that was mentioned in 103 VAERS reports (<0.1%) during1991-2001 (Reference: PMID: 12825543). YH AE: flatulence Flatulence is the production of a mixture of gases in the digestive tract of mammals or other animals that are byproducts of the digestion process. Such a mixture of gases is known as flatus, and is expelled from the rectum in a process colloquially referred to as "passing gas" or "farting". According to the Vaccine Adverse Event Reporting System (VAERS), 'flatulence'; is an adverse event that was mentioned in 102 VAERS reports (<0.1%) during1991-2001 (Reference: PMID: 12825543). This term is a COSTART term but not a MP term (3/17/2009). YH whole pathogen organism in vaccine whole organism in vaccine is a organism component in vaccine that includes the whole organism such as a whole live attenuated organism. YH AE: liver damage According to the Vaccine Adverse Event Reporting System (VAERS), 'liver damage'; is an adverse event that was mentioned in 102 VAERS reports (<0.1%) during1991-2001 (Reference: PMID: 12825543). YH This term is a COSTART term but not a MP term (3/17/2009). survival assessment Need to point out more specifically that survival / death is measured. Survival assessment is an assay that measures the occurence of death events in one or more organisms that are monitored over time. YH H. influenzae Type b capsular polysaccharide vaccine PMID: 335348 YH PMID: 6387614 vaccination with a licensed rabbit vaccine YH B. anthracis recombinant vaccine using PA domain 4 YH PMID: 11854261 PMID: 15935874 licensed vaccine role YH licensed vaccine role is a regulation-assigned role that indicates that a vaccine obtains official approval for commercial production and selling on the market. vaccine in clinical trial role In medical research, clinical trials are conducted to allow safety and efficacy data to be collected for new drugs or devices. YH vaccine in clinical trial role is a regulation-assigned role that inheres in a vaccine that is currently in clinical trial. Imovax Polio Brucella melitensis Rev. 1 with P39 deletion YH PMID: 9784574 A B. melitensis vaccine that is recombinant B. melitensis Rev. 1 vaccine with the p39 gene deletion. B. melitensis Rev. 1 P39 deletion mutant licensed human vaccine YH a vaccine with license that is for human use. AE: sore throat YH Flavobacterium columnare vaccine bacterial vaccine that is used to protect against Flavobacterium columnare infection generated using OntoRat YL Clostridium vaccine A bacterial vaccine that protects against infection with Clostridium spp. YH Clostridium tetani vaccine tetanus vaccine YH a Clostridium vaccine that protects against infection with Clostridium tetani that causes tenanus. combination vaccine 2 Combination vaccine is a vaccine that induces protection against multiple infectious diseases or several different serotypes of the same organism. The anitgens contained in combination vaccines are either formulated together by the manufacturer or physically mixed by a health care provider just prior to administration. Both approaches require licensure. Ref: Baylor NW and Midthum K. Regulation and testing of vaccines. In: Vaccines (Editors: Plotkin S, Orenstein W, and Offit P). 2008. p1624. combo vaccine YH MeSH: D017778 Influenza virus vaccine A viral vaccine that protects against infection with influenza virus. YH MeSH: D007252 Influenza vaccine licensed cattle vaccine a vaccine with license that is used for cattle. YH Hepatitis B virus vaccine A viral vaccine that protects against infection with Hepatitis B virus. YH MeSH: D017325 licensed fish vaccine YH Hepatitis A virus vaccine A viral vaccine that protects against infection with Hepatitis A virus. YH MeSH: D022362 licensed goat and sheep vaccine YH Yersinia pestis vaccine A bacteria vaccine that prevents against Yersinia pestis infection that causes plague. MeSH: D010931 YH Plague vaccine licensed dog vaccine YH Rabies virus vaccine MeSH: D011819 A viral vaccine that protects against infection with Rabies virus. YH Smallpox virus vaccine YH MeSH: D012900 A viral vaccine that protects against infection with Smallpox virus. licensed cat vaccine YH licensed ferret vaccine YH Measles virus vaccine A viral vaccine that protects against infection with Measles virus. MeSH: D008458 Measles vaccine YH licensed deer vaccine YH Mumps virus vaccine A viral vaccine that protects against infection with Mumps virus. YH MeSH: D009108 licensed bird vaccine YH Rotavirus vaccine MeSH: D022243 A viral vaccine that protects against infection with Rotavirus. YH HIBTITER PMID: In most cases HibTITER was administered concomitantly with other vaccines including DTP, DTaP, hepatitis B vaccine, IPV, OPV, pneumococcal 7-valent conjugate vaccine, MMR, and/or meningococcal group C conjugate vaccine (not licensed in the US). YH PMID: 9353019 PMID: 2057256 ProHIBiT PMID: 2057256 Ref: http://www.rxlist.com/prohibit-drug.htm YH Haemophilus vaccine YH A bacterial vaccine that protects against infection with Haemophilus. MeSH: D018073 Haemophilus influenzae serotype b vaccine Haemophilus b vaccine YH SC602 A live attenuated Shigella flexneri 2a vaccine that carries deletions of the plasmid-borne virulence gene icsA (mediating intra- and intercellular spread) and the chromosomal locus iuc (encoding aerobactin). PMID: 10377124. YH PMID: 10377124 Poliovirus vaccine A viral vaccine that protects against infection with Poliovirus. MeSH: D023321 YH Japanese encephalitis virus vaccine A viral vaccine that protects against infection with Japanese encephalitis virus. YH MeSH: D022321 Japanese encephalitis vaccine CVD 1208 CVD 1208 is derived from wild type Shigella flexneri 2a strain 2457T and has defined deletions in four genes: (1) the guaBA chromosomal operon that encodes two enzymes (inositol 5'-monophosphate dehydrogenase and guanosine 5'synthase) essential for de novo purine biosynthesis; (2) set, a locus in a chromosomal pathogenicity island that encodes Shigella enterotoxin (ShET); (3) Pic, an autotransporter mucinase encoded on the opposite strand from set; and (4) sen, an invasiveness plasmid gene encoding ShET. PMID: 15499528 YH human papillomavirus vaccine YH CVD 1208S PMID: 17938573 YH CVD 1208S is the same thing as CVD 1208, but CVD 1208S was prepared using animal-free media. PMID: 17938573. Varicella-zoster virus vaccine YH EcSf2a-2 YH PMID: 1587589 This vaccine is an aro-D mutant derivative of EcSf2a-1. PMID: 1587589. Salmonella typhi vaccine YH heat-killed virulent Shigella flexneri 2a PMID: 10102148 YH Shigella Sfl 124 vaccine PMID: 1937767 YH Recombinant SFL124-27 expressing S. dysenteriae type 1 O antigen YH PMID: 9169740 Streptococcus pneumoniae vaccine YH S. dysenteriae 1 strain WRSd1 PMID: 12010984 YH S. flexneri 2a strain CVD 1207 A live attenuated Shigella flexneri 2a vaccine with specific deletion mutations in virG, sen, set, and guaBA. YH PMID: 10678904 S. sonnei strain WRSS1 PMID: 9712824 A stable attenuated Shigella sonnei strain with virG mutation. PMID: 9712824. YH PMID: 11895966 Shigella sonnei vaccine YH Shigella flexneri vaccine YH Shigella dysenteriae vaccine YH S. flexneri 2a LPS vaccine complexed with N. meningitidis proteosomes YH PMID: 8500877 vaccine regulation A processual entity that regulates vaccine-related processes, such as vaccine trial, vaccine license application. YH vaccine transportation A processual entity of transporting vaccine from one place to another place. YH AE: paralysis According to the Vaccine Adverse Event Reporting System (VAERS), 'paralysis' is an adverse event that was mentioned in 574 VAERS reports (0.4%) during1991-2001 (Reference: PMID: 12825543). SS, YH hemiplegia, palsy, paraplegia, quadiplegia MP: MP_0000753 loss of power of voluntary movement in a muscle through injury or disease of its nerve supply paralysis Acambis, Inc YH http://www.acambis.com/ Berna Biotech, Ltd YH http://www.crucell.com/ BioPort Corp http://www.bioport.com/ YH CSL Limited YH http://www.csl.com.au/ GlaxoSmithKline Biologicals YH http://www.gsk-bio.com/english/index.html Greer Laboratories Inc http://www.greerlabs.com/ YH ID Biomedical Corp of Quebec http://www.ctidirectory.com/search/company.cfm?company=129584 YH Massachusetts Public Health Biologic Lab YH MedImmune Vaccines, Inc YH http://www.medimmune.com/ Merck & Co, Inc http://www.merck.com/ YH Novartis Vaccines and Diagnostics YH http://www.novartis.com/about-novartis/our-businesses/vaccines-diagnostic.shtml Organon Teknika Corp YH Research Foundation for Microbial Diseases of Osaka University YH http://read.jst.go.jp/public/cs_kkn_004EventAction.do?action5=event&lang_act5=E&kcd1_act5=9535000000&judge_act5=2 Sanofi Pasteur Limited http://www.sanofipasteur.com YH Sanofi Pasteur, Inc YH http://www.sanofipasteur.us Wyeth Pharmaceuticals Inc YH http://www.wyeth.com/ Inactivated Poliomyelitis Vaccine - IPV Sanofi Pasteur, SA http://www.sanofipasteur.co.za/ YH vaccine specific antibody test YH vaccine trial regulation A vaccine regulation process for vaccine clinical trials. YH primary vaccination A vaccination process that occurs at the first time. prime vaccination YH boost vaccination A vaccination process that occurs after the primer vaccination with a purpose to boost host immune response to vaccine antigen. YH Brucella melitensis vaccine YH Brucella melitensis strain Rev. 1 YH Brucella melitensis Rev. 1 PMID: 13416171 Brucella melitensis Rev 1 inactivated viral vaccine killed viral vaccine vaccine allergen disposition YH Canada licensed human vaccine preparation of DNA vaccine YH A vaccine preparation that results in the generation of a DNA vaccine preparation of conjugate vaccine A vaccine preparation that results in the generation of a conjugate vaccine YH subunit vaccine preparation A vaccine preparation that results in the generation of a subunit vaccine YH live attenuated vaccine preparation YH A vaccine preparation that results in the generation of a live attenuated vaccine preparation of RNA vaccine YH A vaccine preparation that results in the generation of a RNA vaccine Brucella abortus strain RB51SOD PMID: 10816475 YH B. abortus strain RB51SOD Brucella suis vaccine YH Brucella suis strain 2 Brucella suis S2 YH An orally administrable brucellosis vaccine that was was developed in China. It is effective for oral vaccination of sheep, goats, cattle and pigsPMID: 3541425. Brucella abortus strain 45/20 B. abortus strain 45/20 YH PMID: 8236802 cytomegalovirus vaccine YH Dengue virus vaccine A viral vaccine that protects against infection with Dengue virus. MeSH: D053059 Dengue vaccine YH Ebola virus vaccine YH A viral vaccine that protects against infection with Ebola virus. MeSH: D046129 Ebola vaccine Herpesvirus vaccine A viral vaccine that protects against infection with Herpesvirus. MeSH: D022283 YH chickenpox virus vaccine YH Herpes simplex virus vaccine YH Marek disease vaccine YH Measles-Mumps-Rubella vaccine YH Diphtheria-Tetanus vaccine YH A combination vaccine that is used to vaccinate against infections with both Clostridium tetani and Corynebacterium diphtheriae. CVD 1204(pGA1-CS2) PMID: 11292735 YH CVD 1204(pGA1-CS3) YH PMID: 11292735 Corynebacterium diphtheriae vaccine A bacterial vaccine that protects against infection with Corynebacterium diphtheriae that causes Diphtheria. YH diphtheria vaccine Measles-Mumps vaccine YH Measles-Mumps-Rubella-Vericella vaccine YH Diphtheria-Tetanus-Pertussis vaccine YH Shigella ribosome-based Vaccine (SRB) YH PMID: 17507120 P. falciparum vaccine Combination B YH A malaria vaccine that comprises recombinant Plasmodium falciparum (P. falciparum) blood-stage proteins MSP1, MSP2 and RESA, formulated with the adjuvant Montanide ISA 720. PMID: 14604568. PMID: 14604568 Haemophilus influenzae serotype b YH Diphtheria-Tetanus-Pertussis-Poliovirus vaccine YH Diphtheria-Tetanus-Pertussis-Poliovirus-Hepatitis B vaccine YH Diphtheria-Tetanus-Pertussis-Poliovirus-Haemophilus b vaccine YH Hepatitis A&B vaccine YH Haemophilus b and Hepatitis B vaccine YH DNA and MVA encoding ME-TRAP YH A vaccine that contains DNA and modified vaccinia virus Ankara (MVA) encoding thrombospondin-related adhesion protein (TRAP) with a multiple-epitope string ME (ME-TRAP). This vaccine is used with a prime-boost regime by DNA priming and MVA boosting. PMID: 16988273. PMID: 16988273 Papillomavirus vaccine A viral vaccine that protects against infection with Papillomavirus. MeSH: D053918 YH Parainfluenza virus vaccine parainfluenza vaccine A viral vaccine that protects against infection with Parainfluenza virus. MeSH: D022241 YH Pseudorabies virus vaccine MeSH: D022421 pseudorabies vaccine A viral vaccine that protects against infection with Pseudorabies virus. YH Simian immunodeficiency virus vaccine SAIDS vaccine MeSH: D018449 A viral vaccine that prevents against infection with Simian immunodeficiency virus. YH West Nile virus vaccine A viral vaccine that protects against West Nile virus infection. MeSH: D053060 YH Respiratory syncytial virus vaccine YH A viral vaccine that prevents infection with Respiratory syncytial virus. MeSH: D022261 marker vaccine A vaccine that is used in conjunction with diagnostic tests to differentiate vaccinated animals from carrier animals. It can be a subunit or a gene-deleted vaccine. MeSH: D022581 YH edible vaccine YH MeSH: D022462 A vaccine that is edible and derived from an edible plant. The transgenic plant is used as recombinant protein production system. The edible plant tissue functions as an oral vaccine. acellular vaccine YH acellular vaccine is a subunit vaccine that is produced by using only the antigenic part of the disease causing organism. It often requires a "booster" every few years to maintain their effectiveness. MeSH term: D20.215.894.860.900. ISCOM The immunostimulating complex YH A particulate antigen delivery system, ISCOM is a vaccine adjuvant that consists of an assembly of antigens in multimeric form and presents an antigen to induce specific immunologic responses. The assembly is attached to a matrix with a built-in adjuvant, saponin. ISCOMs induce strong serum antibody responses, and are used as highly immunogenic forms of subunit vaccines. MeSH term: D20.215.894.860.449. Plasmodium vivax vaccine YH contraceptive vaccine antifertility vaccine MeSH: D022642 YH A vaccine that is used to prevent conception. Alzheimer vaccine A vaccine that prevents or treats Alzheimer disease. MeSH: D023582 YH malaria vaccine Plasmodium vaccine MeSH: D017780 Plasmodium vaccine is a vaccine that prevents against Plasmodium species causing malaria. It is made from antigens arising from any of the four strains of Plasmodium which cause malaria in humans, or from P. berghei which causes malaria in rodents. malarial Vaccine YH Leishmania vaccine YH Leishmaniasis vaccine MeSH: D054332 a protozoan vaccine that prevents against infection with Leishmania. Vibrio cholerae vaccine YH A bacterial vaccine that prevents infection with Vibrio cholera. MeSH: D022121 Lyme disease vaccine YH MeSH: D022123 A vaccine that prevents Lyme disease caused by Borrelia burgdorferi. Borrelia burgdorferi vaccine Bordetella pertussis vaccine A bacterial vaccine that prevents against Bordetella pertussis infection that causes pertussis or whooping cough. MeSH: D010567 YH Pertussis vaccine Pseudomonas vaccine MeSH: D054406 A bacterial vaccine that protects against infection with Pseudomonas. YH Rickettsial vaccine YH A bacterial vaccine that protects against diseases caused by various species of Rickettsia. MeSH: D012290 Salmonella vaccine A bacterial vaccine that protects against infections by various Salmonella species. MeSH: D022562 YH Shigella vaccine A bacterial vaccine that protects against infections with Shigella species. YH MeSH: D022281 Staphylococcal vaccine A bacterial vaccine that protects against infection with Staphylococcus. YH Staphylococcus vaccine MeSH: D013209 Staph vaccine BCG vaccine YH CVX: 19 Bacillus Calmette Guerin BCG Vaccine is a Mycobacterium tuberculosis vaccine that is a live attenuated strain of Mycobacterium bovis (Bacillus Calmette Guerin; BCG). Streptococcal vaccine A bacterial vaccine that prevents streptococcal infections. Streptococcus vaccine YH MeSH: D022541 MSP3-LSP with aluminium hydroxide PMID: 17280744 YH RTS,S/AS02A PMID: 15488216 YH RTS,S/AS02A is a pre-erythrocytic vaccine candidate based on Plasmodium falciparum circumsporozoite surface antigen. PMID: 15488216. P. falciparum MSP1 from transgenic mice with Freund's adjuvant YH PMID: 11752405 P. vivax PVS25 with Montanide ISA-720 YH PMID: 16291764 FMP1/AS02A FMP2.1/AS02A is a recombinant E. coli-expressed protein based upon the apical membrane antigen-1 (AMA-1) of the 3D7 clone formulated with the AS02A adjuvant. PMID: 17442466. YH PMID: 17442466 recombinant ABRA protein vaccine PMID: 11489167 YH PMID: 9400530 NP-VRP YH An Ebola virus vaccine that is composed of VEE replicon particle (VRP) encoding Ebola virus NP protein. GP-VRP An Ebola virus vaccine that is composed of VEE replicon particle (VRP) encoding Ebola virus GP protein. YH VRP expressing VP24 PMID: 11485406 YH An Ebola virus vaccine that is composed of VEE replicon particle (VRP) encoding Ebola virus VP24 protein. alphavirus replicon expressing VP24 VRP expressing VP30 PMID: 11485406 YH alphavirus replicon expressing VP30 An Ebola virus vaccine that is composed of VEE replicon particle (VRP) encoding Ebola virus VP30 protein. VRP expressing VP35 alphavirus replicon expressing VP35 YH PMID: 11485406 An Ebola virus vaccine that is composed of VEE replicon particle (VRP) encoding Ebola virus VP35 protein. VRP expressing VP40 PMID: 11485406 alphavirus replicon expressing VP40 An Ebola virus vaccine that is composed of VEE replicon particle (VRP) encoding Ebola virus VP40 protein. YH DNA vaccine expressing sGP PMID: 9427604 A DNA vaccine that encodes for a secreted form of Ebola virus GP protein. YH DNA and adenoviral vector Ad5 expressing SIV gag protein A vaccine combination that includes a DNA vaccine and a recombinant adenovirus Ad5 expressing the same codon-optimized SIV gag gene. The DNA vaccine is used for priming, and the Ad5 vaccine is used for boosting. PMID: 11797011. PMID: 11797011 YH gene YH A gene that is a pathogen gene used for vaccine preparation or a host gene encoding for an immune factor important in induction of protective immunity. a vaccine-associated gene that exists in a pathogen and has been engineered for vaccine develoment. This gene can encode for protective antigen that is overexpressed for vaccine development. This gene can also be a virulence factor that is mutated to attenuate a virulent pathogen with the purpose of making attenuated vaccine. The term 'gene' has appears in several ontologies, such as Sequence Ontology (SO) and Protein Ontology (PRO). We may choose to use a 'gene' term from other ontologies. The 'gene' term in SO has ID: SO:0000704. adenoviral vector Ad5 expressing SIV gag protein PMID: 11797011 A recombinant adenovirus (Ad5) expressing the codon-optimized SIV gag gene. PMID: 11797011. YH DNA and Ad5/35 vector expressing HIV gp160 protein PMID: 16079886 A vaccine combination that includes a DNA vaccine and a replication-defective chimeric Ad5 vector with the Ad35 fiber (Ad5/35) that express the same codon-optimized SIV gag gene. The DNA vaccine is used for priming, and the Ad5/35 vaccine is used for boosting. PMID: 16079886. YH Brucella gene YH human gene YH mouse gene YH Brucella abortus gene YH A Brucella gene that is from B. abortus. Brucella abortus wboA YH Brucella abortus gene wboA is interrupted in Brucella abortus cattle vaccine RB51. mouse Ifng YH Interferon-gamma (IFN-g) is an indicative of Th1 immune response. It is produced in host immunized by vaccines such as Brucella abortus cattle vaccine RB51. human ifng YH Interferon-gamma (IFN-g) is an indicative of Th1 immune response. cattle gene YH cattle Ifng YH Interferon-gamma (IFN-g) is an indicative of Th1 immune response. It is produced in host immunized by vaccines such as Brucella abortus cattle vaccine RB51. vaccine storage YH a storage process that is specifically for vaccine. vaccine storage at room temperature a vaccine storage that is execuated at room temperature. Room temperature is also referred to as ambient temperature. Room temperature denotes a certain temperature within enclosed space at which humans are accustomed. Room temperature is usually indicated by general human comfort, with the common range of 10 degree C (50 degree F) to 28 degree C (82.4 degree F). YH vaccine storage in refrigerator vaccine storage that is executed in refrigerator, usually 0-10^C. YH vaccine storage in freezer YH vaccine storage that is executed in freezer under 0^C. effectiveness YH Effectiveness is physical quality that represents the capability of a single physical entity (e.g., vaccine) producing an effect (e.g, protection against a disease). effective YH ineffective YH adverse event YH, MC An adverse event is an unexpected or dangerous reaction to a medical product, such as a chemical drug or a vaccine. A vaccine adverse event is associated with the use of medical intervention (e.g., an intervivaccine, regardless of whether it is considered vaccine-related, and includes any side effect, injury, toxicity, or sensitivity reaction or significant failure of pharmacologic action. Ref: Baylor NW and Midthum K. Regulation and testing of vaccines. In: Vaccines (Editors: Plotkin S, Orenstein W, and Offit P). 2008. p1623. WEB: http://www.fda.gov/Safety/MedWatch/HowToReport/ucm053087.htm WEB: http://en.wikipedia.org/wiki/Adverse_event AE side effect rapid vaccination A vaccination process that is implemented fast. vaccine rapid implementation YH vaccination coverage YH, MC WEB: http://www.who.int/immunization_monitoring/routine/immunization_coverage/en/ WEB: http://www.sanofipasteur.com/sanofi-pasteur2/front/index.jsp?siteCode=SP_CORP&codeRubrique=19 A measure datum that measures the coverage of vaccination in a specific area during a specific time period. immunization coverage DNA/MVA prime-boost HIV vaccine YH PMID: 17328232 An HIVA.DNA/modified vaccinia Ankara (MVA) prime-boost vaccine for the potential prevention of infection with HIV subtype A. The vaccination strategy consists of priming with a DNA vaccine made from HIV-1 clade A gag p24/p17 consensus sequence (pTHr.HIVA) then boosting with a MVA virus expressing HIVA (MVA.HIVA). PMID: 2152500. epitope YH USA licensed vaccine role YH a licensed vaccine role that indicates the vaccine occurs in USA. USA licensed cattle vaccine YH a cattle vaccine with license that is used in USA. vaccination dose vaccination dose is a dose of vaccine that is used in a vaccination. Vaccination dose may be and may be not the same as the vaccine dose. YH monthly YH biweekly YH DNA vaccine expressing multiple HIV epitopes YH A HIV vaccine that is composed of a DNA vaccine expressing conserved, multiple HIV epitopes. PMID: 16359234. PMID: 16359234 AE: weight loss MP: MP_0001263 According to the Vaccine Adverse Event Reporting System (VAERS), 'weight loss' is an adverse event that was mentioned in 415 VAERS reports (0.3%) during1991-2001 (Reference: PMID: 12825543). progressive reduction of body weight below normal average for age weight loss recombinant HIV gp120 with adjuvant NanoEmulsion PMID: 18260780 YH A HIV vaccine that is made of recombinant HIV gp120 protein adjuvanted with the adjuvant NanoEmulsion. PMID: 18260780. Aeromonas salmonicida vaccine YH bacterial vaccine that is used to protect against Aeromonas salmonicida infection Vetech Labs http://www.vetechinc.com/ YH Gag-VRPs Gag-VRPs is a cocktail vaccine of V3014-packaged VRPs expressing the SIVsm H-4i nonmyristylated matrix-capsid region, full-length gp160, and a secreted form of gp160 (gp140). PMID: 12120997. YH PMID: 10462249 PMID: 12120997 Vibrio anguillarum vaccine YH MVA expressing HIV Gag, Pol and Env proteins A recombinant modified vaccinia Ankara (MVA) expressing HIV Gag, Pol, and Env proteins. PMID: 16472543. PMID: 16472543 YH DNA and poxvirus priming-boosting SIV vaccine A SIV vaccine that is composed of a DNA vaccine and a poxvirus vector expressing the same SIV antigens. PMID: 15258286. PMID: 15258286 YH Brucella abortus S19 with P39 deletion A B. abortus vaccine that is recombinant B. abortus strain 19 vaccine with the p39 gene deletion. B. abortus S19 P39 deletion mutant PMID: 9784574 YH AdsecV PMID: 17041851 A Yersinia pestis vaccine that uses a recombinant Ad5-based vector (E1a, partial E1b, and partial E3 deletion) to express Y. pestis V antigen. YH Yersinia EV76 YH PMID: 4988692 A Yersinia pestis vaccine that is a pigmentation negative mutant of Y. pestis derived from a fully virulent strain. Yersinia EV-76 PMID: 8578841 Y. pestis F1 protein vaccine A Yersinia pestis subunit vaccine that uses Y. pestis F1 protein as antigen. PMID: 8675324 YH PMID: 312163 rF1 + rV vaccine PMID: 10930691 YH PMID: 15908389 A Y. pestis subunit vaccine that uses recombinant F1 and V antigens. PMID: 312163. PMID: 12922126 Recombinant Y. pestis V antigen vaccine PMID: 7622205 YH A Y. pestis subunit vaccine that uses recombinant Y. pestis V antigen. PMID: 7622205. modified Y. pestis with TLR4-stimulating LPS PMID: 16980981 YH Yersinia PAV YH A Yersinia pestis subunit vaccine that contains staphylococcal protein A-V antigen fusion peptide (PAV). PMID: 7622225. PMID: 7622225 recombinant Y. pestis YopD protein vaccine PMID: 10024607 PMID: 8890210 YH Epm vaccine In vitro-cultured merozoites, chemically inactivated YH Y. pestis YscF subunit vaccine YH A Y. pestis subunit vaccine that uses Y. pestis YscF protein as antigen. PMID: 15978133. PMID: 15978133 microencapsulated Caf1 and LcrV vaccine YH PMID: 16546306 Ovilis Enzovax Live temperature-sensitive mutant strain for subcutaneous or intramuscular injection YH Trovac AI H5 YH Fowlpox virus-vectored H5 recombinant Yersinia rV10 vaccine YH PMID: 16861680 A Y. pestis vaccine that uses the recombinant V10 (rV10), a variant (lacking residues 271 to 300) of Yersinia pestis LcrV. PMID: 16861680. Pfizer Animal Health http://www.pfizerah.com/ YH AquaVac ERM YH Killed oral vaccine Feline leukemia virus vaccine YH Art Vax YH Live temperature-sensitive mutant strain; spray inhalation or drinking water VSV vector expressing Y. pestis lcrV YH PMID: 16959385 BIOPHARM YH Plague vaccine USP A formalin-inactivated preparation that was manufactured by Cutter Biologicals (a division of Miles Laboratories, Inc.). It is now available only from Greer Laboratories, Inc. The killed or inactivated plague vaccine is prepared from Y. pestis organisms grown in artificial media and then inactivated in formaldehyde. URL: http://www.cdc.gov/mmwr/preview/mmwrhtml/00044836.htm YH PMID: 8578841 Cutter Biological YH Improvac YH Peptide-protein conjugate and water-miscible adjuvant; control of boar taint vaccine additive vaccine additive is a material that is added to the immunogen by the vaccine manfacturer for a specific purpose. Additives include adjuvants, preservatives and stablizers, as well as materials that are added to affect pH and isotonicity. Ref: Finn TM and Egan W, in Vaccines fifth edition, 2008. Page 73. YH vaccine preservative antimicrobial agent in vaccine vaccine preservative is an vaccine additive that is added to a vaccine formulation to prevent the growth of bacteria or fungi that inadvertently may be introduced into the vaccine during use. Ref: Finn TM and Egan W, in Vaccines fifth edition, 2008. Page 73. YH Periovac YH Killed vaccine against periodontitis vaccine stabilizer YH vaccine stabilizer is a vaccine additive that helps to protect the vaccine from adverse conditions such as the freeze-drying process (for those vaccines that are freeze-dried) or heat. Ref: Finn TM and Egan W, in Vaccines fifth edition, 2008. Page 75. vaccine residual Although no all manufacturing residuals may be identified and quantified, their presence and quantity is assumed to be constant because of the constancy of the manufacturing process. A vaccine residual is a part of vaccine that remains from the vaccine manufacturing process. Ref: Finn TM and Egan W, in Vaccines fifth edition, 2008. Page 73. YH inactivation residual in vaccine YH An inactivation residual in vaccine is a vaccine residual that is used to inactivate bacteria and viruses or to detoxify bacterial toxins. For example, formaldehyde is a frequently used inactivation agent in vaccine preparation. Ref: Finn TM and Egan W, in Vaccines fifth edition, 2008. Page 78. cell culture residual in vaccine YH A cell culture residual in vaccine is a vaccine residual that is generatead from cell culture for vaccine preparation. Examples include: antibiotics, sensitizing substances, bacterial and cellular residuals, and adventitious agents. Ref: Finn TM and Egan W, in Vaccines fifth edition, 2008. Page 78-81. vaccine-induced immune correlate of protection Immune correlate of protection is a host immune response to vaccine that correlates with protective induced by the vaccine. YH serologic correlate of protection YH Serological correlate of protection is an immune correlate of protection that is reflected by serologic antibody levels. cell mediated immune correlate of protection YH A cell mediated immune correlate of protection is an immune correlate of protection that is reflected by a cell mediated immune response. vaccine effectiveness YH Hadler TC, et al. Immunization in developing countries. In: Vaccines. Editors: Plotkin S, et al. 2008. p1542-71. Vaccine effectiveness is an effectiveness associated with a vaccine. Bioproperties YH http://www.bioproperties.com.au/ Canada Canada is a country that exists in north America. YH Pirodog YH In vitro-cultured supernatant antigens, reduce clinical disease Canada licensed vaccine role a licensed status that occurs in Canada. YH Porphyromonas gulae vaccine YH Fluviral S/F YH Influvac Influvac is an Influenza virus vaccine that is manufactured by Solvay Pharma. YH Vaxigrip Vaxigrip is an Influenza virus vaccine that is manufactured by 'Sanofi Pasteur Limited. YH, Melanie Solvay Pharmaceuticals YH Babesia bigemina vaccine by local veterinary institutes YH Purevax Feline Rabies Canarypox virus-vectored vaccine YH Babesia bovis vaccine by local veterinary institutes YH PGA/ME YH pGPA-incorporated microemulsion PMID: 16730934 Anthrax Spore Vaccine Anthrax Spore Vaccine is a B. anthracis vaccine that is prepared with a relatively nonpathogenic, noncapsulated variant strain of B. anthracis, originally developed at the Onderstepoort Laboratory, Pretoria, South Africa. Further work was conducted in England, India and in many other countries. Vaccine Strain is Sterne 34F2. The vaccine is a suspension of viable Bacillus anthracis spores in saponin. YH B. anthracis Sterne strain spore vaccine PMID: 3084385 pSecTag-PA83 YH PMID: 15293452 pCMV/ER-PA83 PMID: 15293452 YH Websters Animal Health https://www.webstervet.com/app.aspx YH RECOMBITEKEquine WNV Canarypox virus-vectored vaccine YH Porphyromonas denticanis YH pCLF4 YH PMID: 11401993 PMID: 15068841 pCLF4 is a Bacillus anthracis vaccine that contains the N-terminal region (amino acids [aa] 10-254) of Bacillus anthracis LF cloned into the pCI expression plasmid. Equity YH Peptide-protein conjugate and proprietary adjuvant (immunostimulating complex); control of estrus and estrus-related behavior single-dose Vaxigrip multi-dose Vaxigrip YH, Melanie, and Allen We still have not made it defined class since we still need to figure out how to represent multi-dose vs. single dose. The previous method discussed brief needs vetting. --YH The difference between single-dose and multi-dose Vaxigrip is that multi-dose Vaxigrip contains preservative thimoseral. aluminum vaccine adjuvant a mineral salt vaccine adjuvant that is composed of aluminum salt. Aluminum vaccine adjuvant is a vaccine adjuvant that is composed of some aluminum compound. YH vaccine preservative role Vaccine preservative role is a role realized by a material which is added into vaccine as a preservative to protect the vaccine. YH oral route YH Oral route is a route of administration of a material entity such as vaccine. interdermal route interdermal route is a route of administration of material entity such as vaccine. YH phenol vaccine preservative YH PleuroStar APP YH Recombinant ApxII, TbpB, CysL, OmlA(1), and OmlA(2) proteins Colorado Serum Company CZ Veterinaria http://www.colorado-serum.com/ YH phenoxy ethanol vaccine preservative YH Biken YH, ZX Schering-Plough http://www.schering-plough.com/ YH BHV-1 vaccine YH Baxter Healthcare Corporation YH, ZX http://www.baxter.com/ Merck Frosst YH, ZX http://www.merckfrosst.ca/ age at vaccination YH Age at vaccination is the age of an experiment animal at the time of vaccination. Theileria annulata vaccine by local veterinary institutes Culture-derived schizonts YH dose dose is a measurement data that measures the quantity of something that may be eaten by or administered to an organism, or that an organism may be exposed to. Quantities of nutrients, drugs, vaccines and toxins are referred to as doses. WEB: http://en.wikipedia.org/wiki/Dose_%28biochemistry%29 YH, MC challenge dose challenge dose is a dose of a virulent pathogen used for a vaccine challenge process. YH Boehringer-Ingelheim Vetmedica http://www.bi-vetmedica.com/ YH PROTEQ-FLU (European Union) Recombitek (United States) YH Canarypox virus-vectored vaccine secondary vaccination YH, Thom Todd Secondary vaccination is a vaccination that is performed immediately after the primary or the first vaccination. SBL Vaccine YH, ZX Wyeth Canada http://www.wyeth.ca/ YH, ZX Eimeria vaccine YH surface antigens from the zona pellucida YH Theileria annulata vaccine YH vaccine allergen YH, ZX vaccine allergen is a material entity that is capable of stimulating a type-I hypersensitivity reaction in atopic individuals who has been vaccinated with a vaccine. passive immunization using natural maternal antibody 09-26-2011 YL http://pathmicro.med.sc.edu/ghaffar/immunization-ver2.htm passive immunization that Immunity is transferred from mother to fetus through placental transfer of IgG or colostral transfer of IgA. chicken egg protein allergen YH, ZX, MC Eegg protein may come from NCIS thesaurus egg - poultry, combination of minimal anatomy terminology and NCBI taxonomy... Eventually, this term chicken egg protein allergen may become a cross product of sevreal ontology terms. chicken egg protein allergen is a vaccine allergen that is composed of chicken egg protein. latex vaccine allergen YH, ZX Virbac YH http://www.virbac.com/ gelatin vaccine allergen YH, ZX protamine sulfate vaccine allergen YH, ZX polymyxin B vaccine allergen YH, ZX EURIFEL FeLV YH Canarypox virus-vectored vaccine other addictive bovine albumin YH, ZX bovine serum glutamate RECOMBITEK Corona MLV YH Modified live virus glutaraldehyde Babesia bovis vaccine YH Infected blood from splenectomized calves human albumin human serum Raboral Vaccinia virus recombinant YH Reference: http://www.raboral.com/ polysorbate 20 polysorbate 80 residual protein from cell culture Canine coronavirus vaccine YH saccharin sorbitol Sarcocystis neurona vaccine YH Suvaxyn Aujeszky YH gE- and thymidine kinase-deleted marker vaccine A vaccine that is made of a TK-negative (TK -) and gI/gE-negative (gI/gE -) pseudorabies virus (PRV) mutant to protect pigs against Aujeszky's disease. Aujeszky's disease is also known as pseudorabies. It is a disease primarily of pigs and is caused by porcine herpesvirus 1. This disease is characterized by respiratory, reproductive and nervous signs. sucrose albumin xanthan gum yeast extract yeast protein Apex-IHN YH DNA vaccine Diphtheria-Tetanus-Pertussis-Haemophilus b vaccine Diphtheria-Tetanus-Poliovirus vaccine Vibro-E.coli vaccine Measles-Rubella vaccine Diphtheria-Tetanus-Pertussis-Poliovirus-Haemophilus b-Hepatitis B vaccine PreveNile Live flavivirus chimera vaccine YH Streptococcus equi vaccine YH Mycoplasma gallisepticum vaccine YH Salmonella typhi-Hepatitis A vaccine Bayovac CSF E2 YH Baculovirus recombinant E2 protein without emulsion Dhori virus vaccine Tick-borne virus vaccine pharyngeal mucosal route Pharyngeal mucosal route is an oral route of administration. TT, YH Intervet Avian Influenza virus vaccine YH Chimera virus on NDV backbone; field trials in 2007 host survival to pathogen challenge after vaccination AE: ataxia MP: MP_0001393 According to the Vaccine Adverse Event Reporting System (VAERS), 'ataxia' is an adverse event that was mentioned in 555 VAERS reports (0.4%) during1991-2001 (Reference: PMID: 12825543). ataxia inability to coordinate voluntary muscular movements skin adverse event AE: abnormal gait MP: MP_0001406 AE: gait disturbance According to the Vaccine Adverse Event Reporting System (VAERS), 'abnormal gait' is an adverse event that was mentioned in 998 VAERS reports (0.8%) during1991-2001 (Reference: PMID: 12825543). SS, YH abnormal gait unusual or distinctive way of walking Embrex http://www.embrex.com/ YH AE: dehydration hypohydration MP: MP_0001429 According to the Vaccine Adverse Event Reporting System (VAERS), 'dehydration' is an adverse event that was mentioned in 603 VAERS reports (0.5%) during1991-2001 (Reference: PMID: 12825543). YH, SS dehydration excessive water loss from the body or from an organ or bodily part AE: abnormal fluid regulation MP: MP_0001784 any anomaly in the control of intracellular and/or extracellular fluid AE: hyperglycemia MP: MP_0001559 According to the Vaccine Adverse Event Reporting System (VAERS), 'hyperglycemia'; is an adverse event that was mentioned in 268 VAERS reports (0.2%) during1991-2001 (Reference: PMID: 12825543). abnormally high concentration of glucose in the blood; generally refers to a pathological state hyperglycemia Canine gonadotropinreleasing factor immunotherapeutic Peptide-protein conjugate and water-miscible adjuvant; treatment of benign prostatic hyperplasia YH Novartis Animal Health YH http://www.ah.novartis.com/ AE: abnormal circulating bilirubin level MP: MP_0001569 According to the Vaccine Adverse Event Reporting System (VAERS), 'bilirubinemia'; is an adverse event that was mentioned in 221 VAERS reports (0.2%) during1991-2001 (Reference: PMID: 12825543). aberrant concentration in the blood of this yellow heme breakdown product AE: cyanosis According to the Vaccine Adverse Event Reporting System (VAERS), 'cyanosis' is an adverse event that was mentioned in 1,804 VAERS reports (1.4%) during1991-2001 (Reference: PMID: 12825543). MP: MP_0001575 a dark bluish or purple skin discoloration resulting from deficient oxygenation of the blood cyanosis AE: anemia According to the Vaccine Adverse Event Reporting System (VAERS), 'anemia' is an adverse event that was mentioned in 482 VAERS reports (0.4%) during1991-2001 (Reference: PMID: 12825543). MP: MP_0001577 anemia less than normal levels of red blood cells and/or hemoglobin within red blood cells, or volume of packed red blood cells in the bloodstream, resulting in insufficient oxygenation of tissues and organs AE: hypotension MP: MP_0001596 According to the Vaccine Adverse Event Reporting System (VAERS), 'hypotension' is an adverse event that was mentioned in 1,021 VAERS reports (0.8%) during1991-2001 (Reference: PMID: 12825543). blood pressure decreased, low blood pressure hypotension sustained low blood pressure at a level that is likely to result in cardiovascular disease and/or other pathological states AE: irregular heartbeat MP: MP_0001636 According to the Vaccine Adverse Event Reporting System (VAERS), 'arrhythmia'; is an adverse event that was mentioned in 164 VAERS reports (0.1%) during1991-2001 (Reference: PMID: 12825543). uneven timing of heart contraction AE: abnormal heartbeat MP: MP_0004085 AE: arrhythmia SS, YH WEB: http://www.nlm.nih.gov/medlineplus/arrhythmia.html anomaly in the appearance of regularly spaced contractions of the heart Novartis http://www.novartis.com/ YH Aqua Health LHRH YH luteinizing hormone-releasing hormone AE: abnormal digestion MP: MP_0001664 altered ability of the mechanical, chemical, and enzymatic processes of the body to convert ingested food into material suitable for assimilation for synthesis of tissues or liberation of energy homeostasis AE MP: MP_0001764 anomaly in the processes involved in the maintenance of an internal equilibrium of various functions and chemical or protein composition of the fluids and tissues AE: edema oedema, swelling, dropsy MP: MP_0001785 an accumulation of an excessive amount of watery fluid in cells or intercellular tissues edema AE: inflammation SS, YH WEB: http://en.wikipedia.org/wiki/Inflammation MP: MP_0001846 AE: inflammation is an immune system disorder that results in complex biological response of vascular tissues to harmful stimuli, such as pathogens, damaged cells, or irritants. Inflammation is a protective attempt by the organism to remove the injurious stimuli as well as initiate the healing process for the tissue greater than expected response to injury, infection, or insult AE: brain inflammation According to the Vaccine Adverse Event Reporting System (VAERS), 'encephalitis' is an adverse event that was mentioned in 480 VAERS reports (0.4%) during1991-2001 (Reference: PMID: 12825543). MP: MP_0001847 local accumulation of fluid, plasma proteins, and leukocytes in the brain AE: increased susceptibility to otitis media According to the Vaccine Adverse Event Reporting System (VAERS), 'otitis media' is an adverse event that was mentioned in 1,538 VAERS reports (1.2%) during1991-2001 (Reference: PMID: 12825543). MP: MP_0001850 greater likelihood of middle ear inflammation, with an accumulation of a thick, mucous-like fluid; usually associated with a viral or bacterial respiratory infection Bovilis IBR Marker Live or inactivated gE-deleted marker vaccine YH AE: eye inflammation MP: MP_0001851 local accumulation of fluid, plasma proteins, and leukocytes in the eye Porcilis Pesti YH Baculovirus recombinant E2 protein without emulsion AE: conjunctivitis MP: MP_0001852 According to the Vaccine Adverse Event Reporting System (VAERS), 'Conjunctivitis' is an adverse event that was mentioned in 860 VAERS reports (0.7%) during1991-2001 (Reference: PMID: 12825543). conjunctivitis inflammation of the mucous membrane that lines the inner surface of the eyelids and the front of the eyeball AE: liver inflammation MP: MP_0001860 According to the Vaccine Adverse Event Reporting System (VAERS), 'hepatitis' is an adverse event that was mentioned in 387 VAERS reports (0.3%) during1991-2001 (Reference: PMID: 12825543). local accumulation of fluid, plasma proteins, and leukocytes in the liver AE: lung inflammation MP: MP_0001861 According to the Vaccine Adverse Event Reporting System (VAERS), 'pneumonia' is an adverse event that was mentioned in 879 VAERS reports (0.7%) during1991-2001 (Reference: PMID: 12825543). local accumulation of fluid, plasma proteins, and leukocytes in the lung AE: respiratory system inflammation MP: MP_0002405 local accumulation of fluid, plasma proteins, and leukocytes in the respiratory system AE: vasculitis It's an inflammation. MP: MP_0001864 According to the Vaccine Adverse Event Reporting System (VAERS), 'vasculitis' is an adverse event that was mentioned in 353 VAERS reports (0.3%) during1991-2001 (Reference: PMID: 12825543). inflammation of a blood or lymph vessel vasculitis AE: salivary gland inflammation MP: MP_0001870 According to the Vaccine Adverse Event Reporting System (VAERS), 'staladenitis'; is an adverse event that was mentioned in 226 VAERS reports (0.2%) during1991-2001 (Reference: PMID: 12825543). local accumulation of fluid, plasma proteins, and leukocytes in the salivary gland Theileria parva vaccine by local veterinary institutes YH Infection followed by drug treatment Novus International http://www.novusint.com/ YH AE: sinus inflammation SS, YH MP: MP_0001872 sinusitis According to the Vaccine Adverse Event Reporting System (VAERS), 'sinusitis'; is an adverse event that was mentioned in 298 VAERS reports (0.2%) during1991-2001 (Reference: PMID: 12825543). increase in susceptibility of the hollow cavities in bone (usually but not exclusively those in the skull) to allergens and/or pathogens AE: allergic response MP: MP_0001878 hypersensitivity caused by exposure to a specific antigen (allergen) resulting in a marked increase in reactivity to that antigen upon subsequent exposure AE: abnormal cerebrospinal fluid production MP: MP_0001911 According to the Vaccine Adverse Event Reporting System (VAERS), 'Cerebrospinal fluid abnormal' is an adverse event that was mentioned in 600 VAERS reports (0.5%) during1991-2001 (Reference: PMID: 12825543). anomaly in the normal output of the fluid that fills the ventricles and other cavities of the brain and spinal cord nervous system AE MP: MP_0003633 Toxoplasma gondii vaccine YH AE: abnormal respiration Not sure if it is same as respiratory system disorder or abnormal respiration. --Oliver He MP: MP_0001943 According to the Vaccine Adverse Event Reporting System (VAERS), 'respiratory disorder' is an adverse event that was mentioned in 556 VAERS reports (0.4%) during1991-2001 (Reference: PMID: 12825543). anomaly in the movement of gases into and out of the lung SpayVac SpayVac is a contraceptive vaccine that has proven highly effective in deer and can be used to control populations. Refernce: http://terramar.bc.ca/. YH no longer available Crude ZPA preparation; supplied to research groups only AE: apnea MP: MP_0001957 According to the Vaccine Adverse Event Reporting System (VAERS), 'apnea' is an adverse event that was mentioned in 1,618 VAERS reports (1.3%) during1991-2001 (Reference: PMID: 12825543). apnea temporary cessation of breathing; sometimes episodic AE: deafness According to the Vaccine Adverse Event Reporting System (VAERS), 'deafness'; is an adverse event that was mentioned in 287 VAERS reports (0.2%) during1991-2001 (Reference: PMID: 12825543). MP: MP_0001967 deafness inability to hear gustatory system AE MP: MP_0001985 any anomaly in the perception of taste AE: taste sensitivity MP: MP_0001986 According to the Vaccine Adverse Event Reporting System (VAERS), 'taste perversion'; is an adverse event that was mentioned in 191 VAERS reports (0.1%) during1991-2001 (Reference: PMID: 12825543). changes in the ability to perceive a particular flavor or suggestion of something imparting a flavor by the chemoreceptors of the gustatory system Biomune http://www.biomunecompany.com/ YH AE: photosensitivity According to the Vaccine Adverse Event Reporting System (VAERS), 'photosensitivity reaction'; is an adverse event that was mentioned in 131 VAERS reports (0.1%) during1991-2001 (Reference: PMID: 12825543). MP: MP_0001999 alterations in the response to sunlight or UV irradiation, especially sensitivity of the eyes AE: blindness MP: MP_0002001 According to the Vaccine Adverse Event Reporting System (VAERS), 'blindness'; is an adverse event that was mentioned in 137 VAERS reports (0.1%) during1991-2001 (Reference: PMID: 12825543). blindness loss of the sense of sight AE: abnormal vision According to the Vaccine Adverse Event Reporting System (VAERS), 'abnormal vision' is an adverse event that was mentioned in 609 VAERS reports (0.5%) during1991-2001 (Reference: PMID: 12825543). MP: MP_0002090 abnormal vision inability or decreased ability to see AE: seizures This term has another path from 'abnormal nervous system physiology' in MP. MP: MP_0002064 seizures sudden and often acute manifestation of epileptic attack, sometimes convulsive behavior/neurological AE MP: MP_0004924 any anomaly in the actions, reactions, or performance of an organism in response to external or internal stimuli compared to controls AE: movement disorder MP: MP_0002066 According to the Vaccine Adverse Event Reporting System (VAERS), 'movement disorder'; is an adverse event that was mentioned in 237 VAERS reports (0.2%) during1991-2001 (Reference: PMID: 12825543). altered ability to coordinate voluntary movement or repetitive, compulsive movements Giardiavax Cultured trophozoites, reduces disease and cyst shedding YH plant-based Newcastle disease virus vaccine The plant-based Newcastle disease virus vaccine is a Newcastle disease virus vaccine that is developed by Dow AgroSciences LLC. It uses technology discovered at Washington University. It is the first plant-made animal vaccine approved for sale in the United States. HN recombinant produced in plant cell lines (registered but not on market) YH sensory capability AE MP: MP_0002067 inability or altered ability to respond to a sensory stimulus glucose homeostasis AE MP: MP_0002078 anomaly in the processes involved in the maintenance of an internal equilibrium of glucose in the fluids and tissues Classical swine fever virus vaccine YH AE: hypersensitivity MP: MP_0002148 immune response that results in tissue injury AE: muscular atrophy MP: MP_0002269 According to the Vaccine Adverse Event Reporting System (VAERS), 'muscle atrophy'; is an adverse event that was mentioned in 140 VAERS reports (0.1%) during1991-2001 (Reference: PMID: 12825543). a wasting of muscle tissue resulting in a derangement of the muscle fibers; occurs with age, immobilization, weightlessness, malnutrition or denervation AE: hyperventilation According to the Vaccine Adverse Event Reporting System (VAERS), 'Petechiae' is an adverse event that was mentioned in 510 VAERS reports (0.4%) during1991-2001 (Reference: PMID: 12825543). MP: MP_0002320 increased alveolar ventilation relative to metabolic carbon dioxide production; results in carbon dioxide pressure decreasing below normal Vectormune FP-ND YH Fowlpox virus vectored AE: hypoventilation MP: MP_0002321 According to the Vaccine Adverse Event Reporting System (VAERS), 'hypoventilation' is an adverse event that was mentioned in 321 VAERS reports (0.2%) during1991-2001 (Reference: PMID: 12825543). hypoventilation reduced alveolar ventilation relative to metabolic carbon dioxide production; results in alveolar carbon dioxide pressure increasing above normal hematopoietic system AE MP: MP_0002396 any structural or developmental anomaly of the blood cells or the organs associated with the development and formation of blood cells AE: mydriasis MP: MP_0002546 According to the Vaccine Adverse Event Reporting System (VAERS), 'mydriasis'; is an adverse event that was mentioned in 139 VAERS reports (0.1%) during1991-2001 (Reference: PMID: 12825543). dilation of one or both pupils regardless of light conditions mydriasis Immucox Paracox Coccivac Advent Nobilis Cox ATM YH Sporulated oocysts of several or all of the avian species AE: increased heart rate MP: MP_0002626 tachycardia WEB: http://en.wikipedia.org/wiki/Tachycardia According to the Vaccine Adverse Event Reporting System (VAERS), 'tachycardia' is an adverse event that was mentioned in 1,269 VAERS reports (1.0%) during1991-2001 (Reference: PMID: 12825543). greater than average resting heart beats per minute, usually measured by the number of times the heart ventricles contract per unit of time, usually per minute Megan Vac1 WEB: http://www.fda.gov/ohrms/dockets/dockets/00n0504/00N-0504_emc-001650-02.pdf YH Megan Vac1 is a Salmoneela vaccine that consists of a double gene-deleted S. enterica serovar Typhimurium strain and is designed for protection of broilers to reduce Salmonella contamination. AE: hyperresponsive to tactile stimuli According to the Vaccine Adverse Event Reporting System (VAERS), 'hypesthesia'; is an adverse event that was mentioned in 238 VAERS reports (0.2%) during1991-2001 (Reference: PMID: 12825543). MP: MP_0002738 exaggerated reflex action normally induced by touch or pain AE: opisthotonus According to the Vaccine Adverse Event Reporting System (VAERS), 'opisthotonos'; is an adverse event that was mentioned in 173 VAERS reports (0.1%) during1991-2001 (Reference: PMID: 12825543). MP: MP_0002880 a form of tetanic spasm in which the head, neck and spine are bent backward and the body is bowed forward opisthotonus AE: joint inflammation MP: MP_0002933 local accumulation of fluid, plasma proteins, and leukocytes in the joints AquaVac Furuvac Killed oral vaccine YH Lohman Animal Health International YH http://www.lahinternational.com/ AE: increased lactate dehydrogenase level MP: MP_0002944 According to the Vaccine Adverse Event Reporting System (VAERS), 'lactic dehydrogenase increased'; is an adverse event that was mentioned in 167 VAERS reports (0.1%) during1991-2001 (Reference: PMID: 12825543). greater than the normal concentration of this enzyme, which catalyzes the interconversion of lactate and pyruvate AE: increased circulating alkaline phosphatase level MP: MP_0002968 According to the Vaccine Adverse Event Reporting System (VAERS), 'alkaline phosphatase increased'; is an adverse event that was mentioned in 199 VAERS reports (0.2%) during1991-2001 (Reference: PMID: 12825543). elevated activity of this enzyme, which hydrolyzes orthophosphoric monoesters, found in the blood AE: arthritis According to the Vaccine Adverse Event Reporting System (VAERS), 'arthritis' is an adverse event that was mentioned in 972 VAERS reports (0.8%) during1991-2001 (Reference: PMID: 12825543). MP: MP_0002993 arthritis joint inflammation, marked by changes in the synovial membranes and thickening of articular structures, widespread degeneration of the collagen fibers in connective tissues, and by atrophy and rarefaction of bony structures AE: dysphagia According to the Vaccine Adverse Event Reporting System (VAERS), 'dysphagia' is an adverse event that was mentioned in 603 VAERS reports (0.5%) during1991-2001 (Reference: PMID: 12825543). MP: MP_0003158 difficulty in swallowing food or liquid dysphagia AE: decreased lateral semicircular canal size According to the Vaccine Adverse Event Reporting System (VAERS), 'anxiety' is an adverse event that was mentioned in 391 VAERS reports (0.3%) during1991-2001 (Reference: PMID: 12825543). MP: MP_0003162 small size of the lateral long bony tube of the labyrinth that is involved in the sense of balance Babesia bigemina vaccine YH AE: decreased platelet cell number MP: MP_0003179 platelet count decreased SS, YH According to the Vaccine Adverse Event Reporting System (VAERS), 'thrombocytopenia' is an adverse event that was mentioned in 640 VAERS reports (0.5%) during1991-2001 (Reference: PMID: 12825543). fewer than the normal numbers of the non-nucleated cells found in the blood and involved in blood coagulation Yersinia ruckeri vaccine YH AE: nausea MP: MP_0003259 gastric discomfort associated with the inclination to vomit nausea AE: vomiting MP: MP_0003260 the retrograde expulsion of gastric contents through the oral cavity vomiting AE: constipation According to the Vaccine Adverse Event Reporting System (VAERS), 'constipation'; is an adverse event that was mentioned in 242 VAERS reports (0.2%) during1991-2001 (Reference: PMID: 12825543). MP: MP_0003267 constipation incomplete, infrequent or difficult evacuation of fecal matter AE: abnormal defecation MP: MP_0003866 anomaly in the production and excretion of feces AE: urinary incontinence MP: MP_0003280 According to the Vaccine Adverse Event Reporting System (VAERS), 'urinary incontinence'; is an adverse event that was mentioned in 237 VAERS reports (0.2%) during1991-2001 (Reference: PMID: 12825543). inability to control the urinary excretory functions AE: intussusception According to the Vaccine Adverse Event Reporting System (VAERS), 'intussusception'; is an adverse event that was mentioned in 143 VAERS reports (0.1%) during1991-2001 (Reference: PMID: 12825543). MP: MP_0003294 intussusception telescoping of the intestine, or the prolapse of one part of the bowel to another; usually results in obstruction AE: pallor MP: MP_0003717 an unnatural paleness to the skin, generally attributable to anemia pallor AE: tinnitus According to the Vaccine Adverse Event Reporting System (VAERS), 'tinnitus'; is an adverse event that was mentioned in 268 VAERS reports (0.2%) during1991-2001 (Reference: PMID: 12825543). MP: MP_0003741 persistent sensation of buzzing, ringing, clicking, or other noises in the ear tinnitus AE: stomatitis MP: MP_0003746 According to the Vaccine Adverse Event Reporting System (VAERS), 'stomatitis'; is an adverse event that was mentioned in 121 VAERS reports (<0.1%) during1991-2001 (Reference: PMID: 12825543). This is a type of inflammation. inflammation of the mucous lining of the mouth stomatitis AE: mouth mucosal ulceration According to the Vaccine Adverse Event Reporting System (VAERS), 'mouth ulceration'; is an adverse event that was mentioned in 246 VAERS reports (0.2%) during1991-2001 (Reference: PMID: 12825543). MP: MP_0003747 lesions through the mucous membrane of the mouth, usually associated with loss of tissue AE: abnormal muscle tone MP: MP_0004142 anomaly in the resting tautness or laxity of a muscle, normally somewhere in the middle of the range between total contraction and total relaxation AE: hypertonia MP: MP_0004143 hypertonia increased muscle tension resulting in stiffness of the muscles in the resting state AE: hypotonia MP: MP_0004144 decreased muscle tension resulting in limpness of the muscles in the resting state, not to be confused with weakness hypotonia Vaxsafe MS YH Live temperature-sensitive mutant strain; eye drop administration AE: myositis MP: MP_0004510 According to the Vaccine Adverse Event Reporting System (VAERS), 'myositis'; is an adverse event that was mentioned in 103 VAERS reports (<0.1%) during1991-2001 (Reference: PMID: 12825543). inflammation of skeletal muscle; local accumulation of fluid, plasma proteins, and leukocytes in the striated muscle myositis AE: muscle inflammation MP: MP_0004511 local accumulation of fluid, plasma proteins, and leukocytes in muscle AE: increased lymphocyte cell number MP: MP_0005013 According to the Vaccine Adverse Event Reporting System (VAERS), 'lymphocytosis'; is an adverse event that was mentioned in 129 VAERS reports (0.1%) during1991-2001 (Reference: PMID: 12825543). greater than normal number of the cells involved in adaptive immune reactions of the body in most inflammatory and autoimmune diseases, including B cells, T cells and natural killer cells Nobivac Piro YH In vitro-cultured supernatant antigens, reduce clinical disease Equilis StrepE YH Live submucosal vaccine; deletions in aroA gene AE: diarrhea AE: diarrhoea MP: MP_0005036 abnormally frequent discharge of semi-solid or fluid fecal matter from the bowel diarrhea AE: hypoxia According to the Vaccine Adverse Event Reporting System (VAERS), 'hypoxia' is an adverse event that was mentioned in 566 VAERS reports (0.4%) during1991-2001 (Reference: PMID: 12825543). MP: MP_0005039 hypoxia reduced concentration of O2 in the blood, alveoli or other tissues resulting in the decreased pressure of this component of body gases AE: sepsis According to the Vaccine Adverse Event Reporting System (VAERS), 'sepsis' is an adverse event that was mentioned in 416 VAERS reports (0.3%) during1991-2001 (Reference: PMID: 12825543). MP: MP_0005044 presence of various pathogenic organisms, or their toxins, in the blood or tissues sepsis Centre for Ticks and Tickborne Disease, Malawi YH AE: hematuria MP: MP_0005161 According to the Vaccine Adverse Event Reporting System (VAERS), 'hematuria'; is an adverse event that was mentioned in 156 VAERS reports (0.1%) during1991-2001 (Reference: PMID: 12825543). hematuria presence of blood in the urine AE: abnormal enzyme level MP: MP_0005319 altered level of any enzyme or their cofactors, that act as catalysts to induce chemical changes in other substances Theileria parva vaccine YH AE: decreased heart rate WEB: http://en.wikipedia.org/wiki/Bradycardia bradycardia According to the Vaccine Adverse Event Reporting System (VAERS), 'bradycardia' is an adverse event that was mentioned in 359 VAERS reports (0.3%) during1991-2001 (Reference: PMID: 12825543). MP: MP_0005333 fewer than average resting heart beats per minute, usually measured by the number of times the heart ventricles contract per unit of time, usually per minute urinary system AE MP: MP_0005502 functional anomaly of any of the organs involved in the production or excretion of urine AE: decreased body temperature MP: MP_0005534 According to the Vaccine Adverse Event Reporting System (VAERS), 'hypothermia'; is an adverse event that was mentioned in 275 VAERS reports (0.2%) during1991-2001 (Reference: PMID: 12825543). less than the level of heat natural to a living being Neospora caninum vaccine YH AE: abnormal body temperature MP: MP_0005535 deviation in the level of heat natural to a living being AE: neuritis MP: MP_0006082 According to the Vaccine Adverse Event Reporting System (VAERS), 'neuritis'; is an adverse event that was mentioned in 195 VAERS reports (0.2%) during1991-2001 (Reference: PMID: 12825543). local accumulation of fluid, plasma proteins, and leukocytes in the brain and/or spinal cord AE: double vision MP: MP_0006150 According to the Vaccine Adverse Event Reporting System (VAERS), 'diplopia'; is an adverse event that was mentioned in 150 VAERS reports (0.1%) during1991-2001 (Reference: PMID: 12825543). double vision two images are perceived when only a single object is present ImmunoVaccine Technologies, Canada http://www.immunovaccine.com YH AE: hypochromic anemia MP: MP_0008387 According to the Vaccine Adverse Event Reporting System (VAERS), 'hypochromic anemia'; is an adverse event that was mentioned in 109 VAERS reports (<0.1%) during1991-2001 (Reference: PMID: 12825543). hemoglobin deficiency resulting from a reduction in the concentration of hemoglobin in red cells, resulting in insufficient oxygenation of tissues and organs AquaVac Vibrio YH Killed oral vaccine Reference: http://www.spaquaculture.com/default.aspx?pageid=553 AE: petechiae According to the Vaccine Adverse Event Reporting System (VAERS), 'hyperventilation' is an adverse event that was mentioned in 539 VAERS reports (0.4%) during1991-2001 (Reference: PMID: 12825543). MP: MP_0008816 petechiae very small blood spots or splotches that appear especially in skin as a result of localized hemorrhage AE: nervous According to the Vaccine Adverse Event Reporting System (VAERS), 'nervousness' is an adverse event that was mentioned in 583 VAERS reports (0.5%) during1991-2001 (Reference: PMID: 12825543). MP: MP_0008912 increased, skittish, behavior induced by stimulation such as handling, touching or noise nervous Babesia canis vaccine YH AE: ecchymosis MP: MP_0009276 According to the Vaccine Adverse Event Reporting System (VAERS), 'ecchymosis' is an adverse event that was mentioned in 1,347 VAERS reports (1.0%) during1991-2001 (Reference: PMID: 12825543). an ecchymosis is a spot caused by loss of blood from a vessel; it implies a larger size than a petechiae, and has a more diffuse border than purpura; an ecchymosis can be caused by a bruise (which implies trauma), but can also be caused by bleeding diathesis ecchymosis vaccination with a licensed goat and sheep vaccine YH Mycoplasma synoviae vaccine YH vaccination with a licensed fish vaccine YH Local veterinary institutes YH Androstenedione YH vaccination with a licensed cat vaccine YH vaccination with a licensed ferret vaccine YH Giardia duodenalis vaccine protozoan vaccine that is used to protect against Giardia intestinalis infection YH vaccination with a licensed bird vaccine YH Chlamydophila abortus vaccine YH vaccination with a licensed deer vaccine YH vaccination with a licensed chicken vaccine YH 2009 H1N1 vaccine protocol YH CDC recommendation of the use of Influenza A (h1N1) 2009 vaccine YH, XZ WEB: http://www.cdc.gov/mmwr/preview/mmwrhtml/rr58e0821a1.htm vaccination target group vaccination target group is a population group that have priority for vaccination when a vaccine is first available. YH, XZ Poulvac FluFend I AI H5N3 RG YH Chimera H5N3 virus, inactivated in oil-based adjuvant USDA YH 2009 H1N1 Influenza A vaccine target group YH, XZ WEB: http://www.cdc.gov/mmwr/preview/mmwrhtml/rr58e0821a1.htm a vaccination target group for 2009 H1N1 Influenza monovalent vaccine. pregnant women XY, XZ WEB: http://www.cdc.gov/mmwr/preview/mmwrhtml/rr58e0821a1.htm passive immunization by injecting pre-made immune element 09-26-2011 YL passive immunization by injecting a recipient with pre-made antibody, antitoxin, epitope, etc. Ovastim YH Increased ovulation/twinning RECOMBITEK rDistemper YH Canarypox virus-vectored vaccine (HA and F antigens) persons living with or providing care for infants aged <6 months WEB: http://www.cdc.gov/mmwr/preview/mmwrhtml/rr58e0821a1.htm XY, XZ health-care and emergency medical services personnel WEB: http://www.cdc.gov/mmwr/preview/mmwrhtml/rr58e0821a1.htm XY, XZ persons aged 6 months--24 years XY, XZ WEB: http://www.cdc.gov/mmwr/preview/mmwrhtml/rr58e0821a1.htm persons aged 25--64 years with medical conditions at higher risk for influenza-related complications WEB: http://www.cdc.gov/mmwr/preview/mmwrhtml/rr58e0821a1.htm XY, XZ vaccination target role vaccination target role is a regulation-assigned role to a group of population with priority of getting some vaccination (e.g., 2009 H1N1 Influenza vaccine). YH inactivation YH, MC, and XZ inactivation is a processual entity that produces inactive material. serious adverse event WEB: http://www.google.ca/url?sa=t&source=web&ct=res&cd=1&ved=0CA4QFjAA&url=http%3A%2F%2Fwww.irrd.ca%2Fethics%2Fimages%2FAdverse-event-definition.doc&ei=eqFMS-yFNZSoswOt6siKAQ&usg=AFQjCNGnQcwI8OXH7dqxwo4RgZEEn8X6lg&sig2=UNngkCdO5ZTFvbIB1pKuaA WEB: http://en.wikipedia.org/wiki/Serious_adverse_event YH, MC serious adverse event is an adverse event that requires in-patient hospitalization, or prolongation of existing hospitalization, or that causes congenital malformation, or that results in persistent or significant disability or incapacity, or that is life threatening or results in death. WEB: http://www.fda.gov/Safety/MedWatch/HowToReport/ucm053087.htm Lawsonia intracellularis vaccine YH adverse event with outcome of death a serious adverse event with a direct outcome of the patient's death. YH WEB: http://www.fda.gov/Safety/MedWatch/HowToReport/ucm053087.htm life-threating adverse event YH WEB: http://www.fda.gov/Safety/MedWatch/HowToReport/ucm053087.htm a serious adverse event during which a patient was at substantial risk of dying or it is suspected that the use or continued use of the product would result in the patient's death. adverse event leading to hospitalization a serious adverse event that results in admission to the hospital or prolongation of a hospital stay. YH WEB: http://www.fda.gov/Safety/MedWatch/HowToReport/ucm053087.htm adverse event leading to disability a serious adverse event that resulted in a significant, persistent, or permanent change, impairment, damage or disruption in the patient's body function/structure, physical activities or quality of life. WEB: http://www.fda.gov/Safety/MedWatch/HowToReport/ucm053087.htm YH Fecundin Linked to human serum albumin; increased ovulation/twinning YH withdrawn adverse event leading to congenital anomaly WEB: http://www.fda.gov/Safety/MedWatch/HowToReport/ucm053087.htm YH a serious adverse event that leads to suspicions that exposure to a medical product prior to conception or during pregnancy resulted in an adverse outcome in the child. adverse event that requires intervention to prevent permanent impairment or damage a serious adverse event that leads to suspicions that the use of a medical product may result in a condition which required medical or surgical intervention to preclude permanent impairment or damage to a patient. YH WEB: http://www.fda.gov/Safety/MedWatch/HowToReport/ucm053087.htm CoxAbic YH Gametocyte antigen(s); transmission blocking through maternal antibody transfer Bordetella avium vaccine YH non-serious adverse event WEB: http://www.google.ca/url?sa=t&source=web&ct=res&cd=1&ved=0CA4QFjAA&url=http%3A%2F%2Fwww.irrd.ca%2Fethics%2Fimages%2FAdverse-event-definition.doc&ei=eqFMS-yFNZSoswOt6siKAQ&usg=AFQjCNGnQcwI8OXH7dqxwo4RgZEEn8X6lg&sig2=UNngkCdO5ZTFvbIB1pKuaA YH, MC an adverse event that is considered not serious. survival of live vaccine inside host YH survival of live vaccine inside host is a processual entity that represents the survival of a live vaccine inside its host. The time of the survival is often important for the success of the live vaccine. persistence of vaccine induced immune response YH persistence of vaccine induced immune response is a processual entity that indicates the persistence of an immune reponse induced by a vaccine in a vaccinated host. AE: low-grade fever YH AE: low-grade fever is a fever adverse event with a temperature usually less than 38.5 C. Merial http://www.merial.com/ YH Bovilis Neoguard YH Killed tachyzoites, reduces abortion AE: moderate-grade fever AE: moderate-grade fever is a fever adverse event with a temperature usually in between 38.6 - 40 C. YH AE: high-grade fever YH AE: high-grade fever is a fever adverse event with a temperature usually in between 40 and 41.1 C. RECOMBITEK Canine Parvo Modified live virus YH AE: hyperpyrexia YH WEB: http://en.wikipedia.org/wiki/Hyperpyrexia AE: hyperpyrexia is a fever adverse event that shows an excessive and unusual elevation of set body temperature greater than or equal to 41 degree C (105.8 degree F). It is an extremely high fever. Such a high temperature is considered a medical emergency as it may indicate a serious underlying condition such as sepsis. Eimeria maxima vaccine YH Agriflu YH CVX: 140 live attenuated Brucella vaccine CVX: 135 live attenuated Brucella vaccine is a live attenuated vaccine that protects against a Brucella infection. YH AE: musculoskeletal pain SS, YH WEB: http://www.webmd.com/pain-management/guide/musculoskeletal-pain Musculoskeletal pain is pain that affects the muscles, ligaments and tendons, along with the bones. AE: injection-site erythema SS, YH WEB: http://en.wikipedia.org/wiki/Erythema AE: injection-site erythema is an injection-site AE that results in redness of skin, caused by hyperermia of the capillaries in the lower layers of the skin at the physical area of injection Actinobacillus pleuropneumoniae vaccine YH AE: erythema WEB: http://en.wikipedia.org/wiki/Erythema MP:0001190 Erythema AE is a skin adverse event that showns redness of the skin caused by hyperemia of the capillaries in the lower layers of the skin. SS, YH reddish skin assay of CFU reduction in liver assay of CFU reduction in liver is a CFU reduction assay that is measured using the extracted liver as the tissue for isolation of infected pathogens. YH assay of CFU reduction in lung YH assay of CFU reduction in lung is a CFU reduction assay that is measured using the extracted lung as the tissue for isolation of infected pathogens. live attenuated Brucella abortus vaccine live attenuated Brucella vaccine is a live attenuated vaccine that protects against a Brucella abortus infection. YH live attenuated Brucella melitensis vaccine YH live attenuated Brucella vaccine is a live attenuated vaccine that protects against a Brucella melitensis infection. live attenuated Brucella suis vaccine live attenuated Brucella vaccine is a live attenuated vaccine that protects against a Brucella melitensis infection. YH Eimeria tenella vaccine YH Ovilis Toxovax S48 strain with a lost ability to form cysts after passages in mice YH vaccine viability YH, ZX vaccine viability is a viability of a vaccine. West Nile-Innovator DNA YH DNA vaccine Brucella DNA vaccine Brucella DNA vaccine is a DNA vaccine that protects against a Brucella infection. YH Leishmania donovani vaccine YH DNA encoding pathogen protein as vaccine component YH Brucella DNA vaccine encoding chimera BLSOmp31 pCIBLSOmp31 PMID: 17600596 YH vaccine being viable vaccine being viable is a vaccine viability that indicates a vaccine uses live organism. YH, ZX vaccine being dead vaccine being dead is a vaccine viability that indicates a vaccine uses dead or killed organism. YH, ZX IL-12 vacince adjuvant a cytokine vaccine adjuvant that includes IL-12. IL-12 vaccine adjuvant is a vaccine adjuvant that contains IL-12. YH, ZX no vaccine protection YH, ZX significant vaccine protection YH, ZX enhanced significant protection YH, ZX Piscirickettsia salmonis vaccine YL bacterial vaccine that is used to protect against Piscirickettsia salmonis infection generated using OntoRat AE: sinus headache YH, SS AE: sinus headache is a headache located over the sinuses, (forehead, corners of the eye, and cheek areas). On occasion, the pain will be felt behind the eyes, in the back of the neck, or may extend into the upper teeth. WEB: http://american-rhinologic.org/patientinfo.headache.phtml Androvax Increased ovulation/twinning YH B. abortus HSA-L7/L12 YH Brucella abortus Human serum albumin (HAS)-L7/L12 B. abortus L7/L12 is a B. abortus subunit vaccine using L7/L12 that is formed by recombinant Human Serum Albumin (HAS)-L7/L12 fusion protein. PMID: 19293473 AE: pneumonia AE: pneumonia is a respiratory system AE that results in an abnormal inflammatory condition of the lung. It is often characterized as including inflammation of the parenchyma of the lung (that is, the alveoli) and abnormal alveolar filling with fluid (consolidation and exudation). WEB: http://en.wikipedia.org/wiki/Pneumonia SS, YH AE: lobar pneumonia AE: lobar pneumonia is a form of pneumonia that affects a large and continuous area of the lobe of a lung WEB: http://en.wikipedia.org/wiki/Lobar_pneumonia SS, YH AE: axillary pain AE: axillary pain is an AE: pain that occurs in the underarm (the area on the human body directly under the join where the arm connects to the shoulder). SS, YH Porcilis APP Extracted ApxI, ApxII, ApxIII, and outer membrane proteins YH PUREVAX Ferret Distemper Canarypox virus-vectored vaccine YH PUREVAX Ferret Distemper is a lyophilized ferret vaccine of a recombinant canarypox vector expressing the HA and F glycoproteins of canine distemper virus. Reference: http://www.drugs.com/vet/purevax-ferret-distemper.html. vaccination dose sepcification YH, ZX challenge dose specification YH, ZX specification of vaccination-challenge interval YH, ZX specification of time interval after vaccination for challenge is a plan specification that specifies the time interval after vacciation for challenge pathogen challenge protocol YH, ZX pathogen challenge protocol is a protocol that is used for a pathogen challenge process. reduction of colony forming unit reduction of colony-forming unit (CFU) is a titer measurement of viable bacterial or fungal numbers. It equals to a reduction of a CFU count from another CFU count. This term is often used as a measurement of a vaccine protection study. YH, ZX intraperitoneal pathogen challenge YH, ZX intraperitoneal pathogen challenge is a pathogen challenge process that occurs in the intraperitoneal site of a host. intraperitoneal vaccination YH, ZX intraperitoneal vaccination is a vaccination process that occurs in the intraperitoneal area of a host. AE: haematoma AE: haematoma is an cardiovascular adverse event that is a collection of blood outside the blood vessels, generally the result of hemorrhage, or more specifically, internal bleeding. It is commonly called a bruise. SS, YH AE: hematoma, bruise, ecchymoses WEB: http://en.wikipedia.org/wiki/Hematoma reproductive system AE reproductive system AE is an AE that occurs in the reproductive system. YH, SS E. coli DNA vaccine E. coli DNA vaccine is a DNA vaccine that protects against an E. coli infection. YH Brucella subunit vaccine YH Brucella subunit vaccine is a subunit vaccine that protects against a Brucella infection. B. melitensis Rev. 1 with bp26 and omp31 deletions PMID: 17070627 YH CGV2631 B. melitensis bp26 and omp31 deletion vaccine is a Brucella melitensis vaccine that has double deletions of bp26 and omp31. pCIOmp31 YH pCIOmp31 is a B. melitensis DNA vaccine expressing Omp31 that uses the pCI plasmid. PMID: 16177328 pTargeTomp31 YH PMID: 17014873 pTargeTomp31 is a B. melitensis DNA vaccine expressing Omp31 that uses the pTargeT mammalian expression system vector (Promega, USA). Schering-Plough Animal Health YH http://www.intervet.com/ B. abortus L7/L12 fused to MBP B. abortus L7/L12 fused to MBP is a B. abortus subunit vaccine using L7/L12 that uses recombinant L7/L12 fused on maltose binding protein MBP. PMID: 8873388 YH inactivated influenza vaccine YH inactivated influenza vaccine is an inactivated viral vaccine that targets at influenza viral infections. Livacox YH Precocious and egg-passaged lines live attenuated influenza vaccine live attenuated influenza vaccine is a live attenuated vaccine that protects against influenza viral infection. YH Bayer Leverkusen http://www.bayer.com/ YH laboratory test Vaxsafe MG YH Live temperature-sensitive mutant strain; eye drop administration ANOVA Oliver: It's temporary. We will get this term from OBI eventually. GonaCon YH registration reported to be in progress Peptide conjugated to keyhole limpet hemocyanin in mycobacterium-oil adjuvant (AdjuVac); contraceptive vaccine to control wildlife vaccine protection ANOVA Inovocox YH In ovo delivery using proprietary platform injection system vaccine protection data set YH intramuscular vaccination YH, YL a vaccination that occurs in the intramuscular route. vaccine strain data set YH vaccine viability data set YH IL-12 vaccine adjuvant data set YH vaccine protective antigen data set YH mutated gene in vaccine strain data set YH vaccination mouse strain data set YH biological sex data set YH vaccination route data set YH vaccination dose data set YH animal age at vaccination data set YH pathogen strain for challenge data set YH pathogen challenge data set YH Leishmune Native fucose-mannose-ligand antigen complex YH Enterisol Ileitis Live oral vaccine YH challenge dose data set YH vaccination-challenge interval data set YH CFU per volume data set YH CFU reduction data set YH vaccine protection efficacy data set YH p-value data set B. abortus BLS-L7/L12 YH B. abortus BLS-L7/L12 is a B. abortus subunit vaccine using L7/L12 that is made as a recombinant BLS-L7/L12 fusion protein vaccine. recombinant Brucella BLS-L7/L12 fusion protein vaccine PMID: 19596411 recombinant Brucella lumazine synthase and L7/L12 fusion protein vaccine vaccine protection efficacy measurement YH vaccine protection efficacy measurement is an assay that measures the protection efficayc of a vaccine. lipopolysaccharide subunit vaccine YH recombinant bacterial vector vaccine YH, XZ Coopers Animal Health YH http://www.coopersanimalhealth.com.au/ recombinant viral vector vaccine YH, ZX inactivated bacterial vaccine YH Vaxstrate LHRH peptide conjugated to ovalbumin; oil emulsion adjuvant withdrawn in 1996 YH inactivated Brucella vaccine YH live attenuated bacterial vaccine YH veterinary vaccine YH Veterinary vaccine is a vaccine that is used for animals (excluding humans), for example, pet, domestic, wildlife, and livestock animals. Dow AgroSciences YH http://www.dowagro.com/homepage/index.htm?DCSext.das=dowagro.com live attenuated viral vaccine YH Brucella abortus subunit vaccine YH Newcastle disease virus vaccine YH Brucella melitensis subunit vaccine YH Brucella suis subunit vaccine YH Brucella abortus DNA vaccine YH Brucella melitensis DNA vaccine YH Brucella suis DNA vaccine YH inactivated Brucella abortus vaccine recombinant bacterial vector vaccine for Brucella recombinant bacterial vector vaccine for Brucella abortus human vaccine Human vaccine is a vaccine that is used for human. YH protective antigen YH, ZX viral vaccine preparation A vaccine preparation that results in the generation of a viral vaccine YH, ZX parasite vaccine preparation YH, ZX A vaccine preparation that results in the generation of a parasite vaccine fungal vaccine preparation A vaccine preparation that results in the generation of a fungal vaccine YH, ZX preparation of cancer vaccine A vaccine preparation that results in the generation of a cancer vaccine CpG DNA vaccine adjuvant YH A microbial derivative vaccine adjuvant compsed of CpG DNA. PMID: 12899580 Ribi vaccine adjuvant Ribi vaccine adjuvant is an emulsion vaccine adjuvant that is a stable oil-in-water emulsion. http://www.sigmaaldrich.com/catalog/ProductDetail.do?D7=0&N5=SEARCH_CONCAT_PNO%7CBRAND_KEY&N4=M6661%7CSIGMA&N25=0&QS=ON&F=SPEC SGS RC529 vaccine adjuvant a synthetic vaccine adjuvant named RC529 that is a lipid A mimetic. PMID: 16204643 SGS aluminum potassium sulfate adjuvant An aluminum vaccine adjuvant that is aluminum potassium sulfate (AlK(SO4)2). ZX, SGS Alhydrogel ZX, SGS An aluminum hydroxide vaccine adjuvant that is a gel that is made by precipitation of aluminum hydroxide Al(OH)3 under alkaline conditions. PMID: 7551218 cholera toxin B subunit CTB SGS A microbial derivative vaccine adjuvant made of the B subunit of the cholera toxin from Vibrio cholerae. Streptococcus pneumoniae vaccine ZX Prevnar 13 ZX VIOLIN Vaccine ID: 1114 CVX: 133 Synflorix ZX VIOLIN Vaccine ID: 1115 Menveo VIOLIN Vaccine ID: 1113 CVX: 136 AREPANRIX H1N1 VIOLIN Vaccine ID: 1116 Intanza VIOLIN Vaccine ID: 1117 RC529-AF vaccine adjuvant RC529-AF can be obtained from Corixa Corporation (Seattle, WA). Reference: PMID: 15308371 RC529 vaccine adjuvant in an aqueour formulation an aqueous formula of the synthetic vaccine adjuvant RC529. MPL vaccine adjuvant PMID: 7551218 SGS 3D-MLA PMID: 10768940 A microbial derivative vaccine adjuvant derived from the lipopolysaccharide (LPS) of Salmonella minnesota R595. 3-O-deacylated monophosphoryl lipid A vaccine adjuvant LTK63 vaccine mutant PMID: 10790422; PMID: 17920733 A microbial derivative vaccine adjuvant that is a mutant form of LT containing a Ser-Lys substitution in position 63 which has been shown to be totally devoid of toxicity stable to protease treatment and able to act as mucosal adjuvant. PMID: 9607006 LTK63 is an enzymatically inactive mutant of the heat-labile enterotoxin of Escherichia coli. It can be used as a potent mucosal adjuvant. SGS toxoid YH WEB: http://en.wikipedia.org/wiki/Toxoid is a bacterial toxin (usually an exotoxin) whose toxicity has been weakened or suppressed either by chemical (formalin) or heat treatment, while other properties, typically immunogenicity, are maintained. capsular polysaccharide subunit vaccine YH capsular polysaccharide of pathogen organism as vaccine component YH polysaccharide subunit vaccine YH polysaccharide of pathogen organism as vaccine component YH prevention of disorder objective YH is the specification of an objective to prevent a disorder. amelioration of disorder objective is the specification of an objective to ameliorate a disorder. YH killed Corynebacterium parvum vaccine adjuvant SGS PMID: 4596278; PMID: 7591056 PMID: 5483667 A microbial derivative vaccine adjuvant derived from heat-killed Corynebacterium parvum. Titermax Gold URL: http://www.titermax.com/i_gold4.htm Titermax Gold is an emulsion vaccine adjuvant which is a water-in-oil adjuvant with CRL-8300 (a block copolymer), squalene, and sorbitan monooleate. SGS It's a water-in-oil emulsion adjuvant. Reference: http://www.titermax.com/i_gold4.htm. DDA vaccine adjuvant PMID: 1439129 a synthetic vaccine adjuvant that is dimethyldioctadecylammonium bromide (DDA), a lipophilic quaternary ammonium salt known as a good adjuvant when co-administered systemically or nasally with an antigen. SGS Dimethyl dioctadecyl ammonium bromide cationic liposomal vaccine adjuvant DDA:TDB SGS A liposome-based vaccine adjuvant that have a positive surface charge. PMID: 19874860 QuilA vaccine adjuvant a tenosactive compound vaccine adjuvant that contains purified extract from the bark of the South American tree Quillaja saponaria Molina. SGS PMID: 7551218 AS02 monophosphoryl lipid A (MPL), QS21 and an oil in water emulsion. PMID: 15780441; PMID: 15187142 SGS A combination vaccine adjuvant comprised of monophosphoryl lipid A (MPL), QS21 and an oil in water emulsion. AS04 AS04 is a combination vaccine adjuvant that is a combination of 50 μg of the immunoenhancer MPL (3-O-desacyl-4′-monophosphoryl lipid A) with 500 μg of aluminium salt. SGS PMID: 21527299 VSA-3 VSA-3 is an emulsion vaccine adjuvant which is an emulsion plus DDA. PMID:16187717 Emulsigen D SGS saponin vaccine adjuvant a tensoactive compound vaccine adjuvant that is derived from saponin, a compound that is an immunostimulator found in the plant P. senega. Montanide ISA 720 PMID: 15752840 A Montanide vaccine adjuvant that is formulated as water-in-oil emulsions and induces high antibody titers in several animal species. It is a vaccine adjuvant composed of metabolizable oil and a surfactant system designed to make a water-in-oil emulsion. It has been used since 1992 in more than 50 clinical trials related to therapeutic vaccines against various diseases such as cancer and malaria. WEB: http://www.seppic.com/human-health/vaccine-adjuvant/montanide-isa-720-@/view-1044-seproduit.html?menuid=,979,&lang=en YH, SGS Montanide ISA 720 VG Montanide incomplete Seppic adjuvant a montanide vaccine adjuvant that is a mineral oil adjuvant. Montanide ISA51 A montanide vaccine adjuvant that is a vaccine adjuvant composed of a light mineral oil and a surfactant system designed to make a water-in-oil emulsion. WEB: http://www.seppic.com/human-health/vaccine-adjuvant/montanide-isa-51-@/view-1042-seproduit.html?menuid=,979,&lang=en SGS Montanide vaccine adjuvant An emulsion vaccine adjuvant developed by Montanide (http://www.montanide.com/). YH, SS EtxB vaccine adjuvant B subunit of E. coli heat-labile enterotoxin YH, SS A microbial derivative vaccine adjuvant composed of the B subunit of E. coli heat-labile toxin. Polygen vaccine adjuvant A synthetic vaccine adjuvant with the tradename Polygen. YH, SS URL: http://www.mvp-technologies.com/adjuvants/Polygen%20Final%20Technical%20Bulletin.pdf vaccine host role YH, ZX a role of host that contains vaccine. It is a role that inheres in an organism that is the target of a vaccine administration (vaccination process). immunization target role a role that represents a target (i.e., some disorder) of immunization. YH, ZX bacterial vaccine immunization YH, ZX viral vaccine immunization YH, ZX cancer vaccine immunization YH, ZX parasite vaccine immunization YH, ZX immunization target role of pathogen immunization target role of bacterial pathogen YH, ZX immunization target role of viral pathogen YH, ZX immunization target role of parasite pathogen YH, ZX immunization target role of fungal pathogen YH, ZX Algal Glucan SGS A nonantigenic carbohydrate adjuvant, which enhances both humoral and cell-mediated immunity to oligopeptides in experimental animal models. PMID: 7551218 Algammulin PMID:1887671 SGS A suspension of 1-2μm ovoids of immune stimulant gamma inulin (g-IN) in which alum is embedded as a carrier for protein or other anionic antigens. BAY R1005 a synthetic vaccine adjuvant that is Bay R1005 (N-(2-Deoxy-2-L-leucylamino β-D-glucopyranosyl)-N-octadecyldodecanoylamide hydroacetate ). N-( 2-Deoxy-2-L-leucylamino-β-D-glucopyranosyl)-N-octadecyldodecanoylamide hydroacetate SGS PMID: 7551218 Avridine SGS N, N-dioctadecyl-N′, N′-bis( 2-hydroxyethyl) propanediamine CP20,96 PMID:7551218 A synthetic vaccine adjuvant that is N, N-dioctadecyl-N′, N′-bis( 2-hydroxyethyl) propanediamine (Avridine). calcium phosphate gel SGS PMID: 7551218 a calcium phosphate vaccine adjuvant that is a gel prepared by precipitating soluable calcium and phosphate salts. Cholera toxin A1-subunit-ProteinA D-fragment fusion protein SGS CTA1-DD gene fusion protein PMID: 7551218 A microbial derivative vaccine adjuvant composed of the CTA1-DD fusion protein. DOC/Alum Complex SGS A mineral salt vaccine adjuvant that is composed of Deoxycholic acid sodium salt (DOC) complexed with aluminum hydroxide. PMID:7551218 gamma Inulin PMID: 3265692; PMID: 7551218 SGS gamma inulin is a carbohydrate adjuvant that is a highly specific activator of the alternative pathway of complement in vitro and in vivo, and is composed of linear (unbranched) b-D-(2-1) polyfructofuranosyl-a-D-glucose. Gerbu Adjuvant Gerbu adjuvant is a combination vaccine adjuvant that is comprised of a mixture of GMDP, DDA, and Zinc L-proline salt complex (ZnPro8). SGS PMID: 7551218 PMID: 15953835 GM-CSF a cytokine vaccine adjuvant that includes GM-CSF. YH, SGS GMDP N-acetylglucosaminyl-(b1-4)-N-acetylmuramyl-L-alanyl-D-isoglutamine PMID: 7551218 SGS A synthetic vaccine adjuvant containing GMDP, a higly effective primary adjuvant. recombinant hIFN-gamma/Interferon-g an IFN-gamma vaccine adjuvant that is composed of recombinant hIFN-gamma. YH, SGS interleukin-1b a cytokine vaccine adjuvant that includes IL-1b. YH, SGS interleukin-2 YH, SGS a cytokine vaccine adjuvant that includes IL-2. interleukin-7 YH, SGS a cytokine vaccine adjuvant that includes IL-7. Loxoribine 7-allyl-8-oxoguanosine SGS a synthetic vaccine adjuvant loxoribine is a guanosine analog derivatized at position N7 and C8, and activates TLR-7. PMID: 7551218 MF59 PMID: 20488726 An emulsion vaccine adjuvant consisting of an oil (squalene)-in-water nano emulsion. SGS MTP-PE Liposomes MTP-PE liposomes are a liposome-based vaccine adjuvant that consists of liposomes containing the synthetic lipophilic analog of muramyl dipeptide, muramyl tripeptide phosphatidylethanolamine (MTP-PE). PMID: 1431559 SGS MTP-PE Murametide SGS PMID: 7551218 a synthetic vaccine adjuvant made of murametide that has adjuvant activity similar to MDP. Nac-Mur-L-Ala-D-Gln-OCH3 Murapalmitine PMID: 7551218 Nac-Mur-L-Thr-D-isoGIn-sn-glyceroI dipalmitoyl SGS a synthetic vaccine adjuvant called murapalmitine. D-Murapalmitine Nac-Mur-D-Ala-D-isoGln-sn-glycerol dipalmitoyl PMID: 7551218 SGS a synthetic adjuvant that is an MDP analog called D-Murapalmitine. NAGO SGS PMID: 7551218 a synthetic vaccine adjuvant that is composed of neuraminidase-galactose oxidase (NAGO) a mixture of mixture of the two enzymes-neuraminidase and galactose oxidase. Neuraminidase-galactose oxidase non-ionic surfactant vesicles a synthetic vaccine adjuvant consisting of multi-lamellar vesicles comprising a mixture of non-ionic surfactant (e.g., 1-monopalmitoyl-rac-glycerol), cholesterol and dicetyl phosphate used as a primary vaccine adjuvant for entrapped antigen. SGS PMID: 7551218 NISV PMMA PMID: 7551218 a synthetic vaccine adjuvant made from the emulsion polymerization of methyl methacrylate. Polymethyl methacrylate SGS protein cochleates PMID: 7551218 SGS a synthetic vaccine adjuvant synthesized from stable protein phospholipid-calcium precipitates. QS-21 SGS a tensoactive compound vaccine adjuvant that is composed of extracts from the bark of the Quillaja saponaria Molina tree. PMID: 7551218 Stimulon™ QS-21 Adjuvant Rehydragel HPA PMID: 7551218 SGS An aluminum vaccine adjuvant that is a synthetic oxyhydroxide of aluminum (aluminum hydroxide) prepared by acid-base precipitation. Rehydragel LV An aluminum hydroxide vaccine adjuvant that is a low visosity aluminum hydroxide gel. PMID: 7551218 SGS Sclavo peptide IL-1β 163-171 peptide YH, SGS a cytokine vaccine adjuvant that contains the 163-171 peptide of IL-1β. Specol SGS PMID: 1439130 Specon is an emulsion vaccine adjuvant that is a water-in-oil emulsion that is used as an adjuvant and has immunostimulating properties similar to Freund's complete adjuvant (FCA). SPT (Antigen Formulation) SPT is an emulsion vaccine adjuvant that is an emulsion of squalane (5%), Tween 80( 0.2%), Pluronic L121( 1.25%), phosphate-buffered saline pH 7.4, and antigen. PMID: 7551218 SGS stearyl tyrosine a synthetic vaccine adjuvant stearyl tyrosine is considered an "organic equivelant" of aluminum hydroxide. SGS PMID: 7551218 Theramide PMID: 7551218 a synthetic vaccine adjuvant called Theramide that is composed of N-acetylglucosaminyl-N-acetylinuramyl-L-Ala-D-isoGlu-L-Ala-dipalmitoxy propylamide (DTP-DPP). SGS CRL1005 PMID: 10717336 a synthetic vaccine adjuvant that is a copolymer (CRL1005), based on a 12 kDa polyoxypropylene (POP) core with 5% POE. SGS nanoemulsion vaccine adjuvant SGS Nanoemulsion vaccine adjuvant is an emulsion vaccine adjuvant and is made from non-toxic lipid droplets a few hundred nanometers in diameter and made from surfactants approved for human consumption and common food substances that are 'Generally Recognized as Safe' (GRAS) by the FDA. http://nano.med.umich.edu/platforms/Nanoemulsions.html AS03 PMID: 21256188 SGS AS03 is an emusion vaccine adjuvant that contains α-tocopherol and squalene, two biodegradable polyprenyls, in an oil-in-water emulsion. LTR192G PMID: 11803061 A microbial deriviative vaccine adjuvant that is a mutant form of E.coli heat-labile toxin. SGS E. coli heat-labile toxin, LT LT Oral Adjuvant A microbial derivative vaccine adjuvant containing E. coli heat-labile toxin. PMID: 7551218 SGS LT-OA amorphous aluminum hydroxyphosphate sulfate adjuvant (AAHSA) AAHSA Merck Aluminum Adjuvant PMID: 17581283 An aluminum vaccine adjuvant that is a a proprietary aluminum hydroxyphosphate sulfate formulation that is both physically and functionally distinct from traditional aluminum phosphate and aluminum hydroxide adjuvants. SGS Matrix-S Brucella abortus subunit vaccine using Bfr PMID: 11447155 recombinant Brucella abortus Bfr protein vaccine Brucella BFR antigen vaccine Brucella abortus subunit vaccine using Omp16 PMID: 18981242 Brucella abortus Omp16 vaccine B. melitensis DNA vaccine encoding Bp26 and Tf imiquimod vaccine adjuvant S26308 a synthetic vaccine adjuvant contiaing imiquimod a imidazoquinoline. 1-(2-methypropyl)-IH-imidazo[4,5-c]quinolin-4-amine R-837 SGS Aldara™ PMID: 7551218, PMID: 18566444 resiquimod vaccine adjuvant a synthetic vaccine adjuvant, resiquimod is a chemical analog of imiquimod. SGS PMID: 15068862 AF03 vaccine adjuvant SGS PMID:20193791 An emulsion vaccine adjuvant containing 2.5% squalene. Flagellin vaccine adjuvant PMID: 16428759, PMID: 21048152 FliC SGS A microbial derivative vaccine adjuvant composed of flagellin from gram-negative bacteria. poly(I:C) vaccine adjuvant SGS a synthetic vaccine adjuvant containing Poly(I:C), a synthetic double stranded analog of RNA. WEB: http://en.wikipedia.org/wiki/Polyinosinic:polycytidylic_acid polyriboinosinic-polyribocytidylic acid ISCOMATRIX vaccine adjuvant ISCOMATRIX is identical to ISCOMs except that it does not contain antigen. Ref: PMID: 17336431. a particulate antigen delivery system that is a vaccine adjuvant comprising cholesterol, phospholipid and saponin but without antigen. SGS PMID: 19450632 Abisco-100 vaccine adjuvant SGS, YH WEB: http://www.isconova.com/products/abisco-research-reagent/abisco-100.aspx a tensoactive compound vaccine adjuvant that is made from highly purified saponins. albumin-heparin microparticles vaccine adjuvant a particulate antigen delivery system that is albumin-heparin microparticles vaccine adjuvant that is prepared from albumin and heparin stabilized by cross-linking reaction with EDC. PMID: 16734558 SGS AS-2 vaccine adjuvant http://www.pasteur.fr/applications/euroconf/vaccins/vaccins-abs.html SGS SmithKline Beecham adjuvant system 2 (AS-2) is a combination vaccine adjuvant and is based on the combination of Monophosphoryl Lipid A(MPL), QS21 (a purified fraction of Saponin extracted from Quillarja Saponaria), and a proprietary oil in water emulsion. B7-2 vaccine adjuvant a cytokine vaccine adjuvant that includes B7-2. YH, SGS Bupivacaine vaccine adjuvant a synthetic vaccine adjuvant that is a local anaesthetic drug belonging to the amino amide group, and is used as a vaccine adjuvant in DNA vaccines. PMID: 15246629, WEB: http://en.wikipedia.org/wiki/Bupivacaine SGS cationic liposome-DNA complex JVRS-100 PMID: 19285425 SGS A liposome-based vaccine adjuvant that is composed of virus sized liposomes that contain a DNA plasmid. DHEA vaccine adjuvant prasterone a synthetic vaccine adjuvant that is DHEA, which is relatively stable and can be directly incorporated into vaccine formulations. SGS transdehydroandrosterone DHA androstenolone 5-androsten-3β-ol-17-one Dehydroepiandrosterone PMID: 7551218 DL-PGL (Polyester poly (DL-lactide-co-glycolide)) vaccine adjuvant PLGA a synthetic vaccine adjuvant that is PLGA, which has been used in the controlled delivery of peptide drugs. PMID: 15560948 PLGA microspheres SGS Polyester poly (DL-lactide-co-glycolide) IL-15 vaccine adjuvant a cytokine vaccine adjuvant that includes IL-15. YH, SGS immunoliposomes containing antibodies to costimulatory molecules SGS immunoliposomes containing antibodies to costimulatory molecules is a liposome-based vaccine adjuvant which is prepared from dehydration-rehydration vesicles (DRVs). PMID: 7551218 LTK72 vaccine adjuvant SGS A microbial derivative vaccine adjuvant that is a mutant form of heat-labile Escherichia coli enterotoxin (LT) that contains a substitution Ala → Arg in position 72 of the A subunit. PMID: 9529328 MPL-SE vaccine adjuvant SGS A microbial derivative vaccine adjuvant containing MPL and squalene. PMID: 12213399 formaldehyde vaccine preservative WEB: http://www.mja.com.au/public/issues/184_04_200206/eld10500_fm.pdf a vaccine preservative that contains formaldehyde. YH, SGS non-toxic mutant E112K of Cholera Toxin mCT-E112K A microbial derived vaccine adjuvant made of E112K mC, a mutated CT created by substituting a single amino acid in the ADP-ribosyltransferase active centre, glutamate to lysine at position 112. SGS mCT PMID: 11251876: cholera toxin derived vaccine adjuvant YH, SGS a microbial derivative vaccine adjuvant that is derived from cholera toxin. SAF-1 vaccine adjuvant PMID: 7551218 SAF-1 is a combination vaccine adjuvant that is composed of threonyl-MDP (0.05-1%) in an emulsion vehicle [5% squalane, 2.5% Pluronic® L121, 0.2% Polysorbate 80 and phosphate buffered saline (pH 7.4)]. SGS Sendai Proteoliposomes, Sendai-containing Lipid Matrices A liposome-based vaccine adjuvant that includes the glycoproteins of Sendai virus. SGS PMID: 7551218 threonyl muramyl dipeptide (TMDP) vaccine adjuvant [thr1 ]-MDP a synthetic vaccine adjuvant that is threonyl muramyl dipeptide (TMDP). Termurtide™ PMID: 7551218 N-acetyl muramyl-L-threonyl-D-isoglutamine SGS ty particles vaccine adjuvant PMID: 7551218 A microbial derivative vaccine adjuvant made of virus like particles (VLPS) containing the yeast retrotransposon Ty which has the amino acids 1-381 of the pI protein encoded. SGS Ty-VLPs cytokine vaccine adjuvant YH, SGS a vaccine adjuvant that contains active cytokine compound. combination vaccine adjuvant YH, SGS a vaccine adjuvant that is composed of differnt compounds under more than one category. emusion vaccine adjuvant particulate antigen delivery system a vaccine adjuvant that serves as a particulate antigen delivery system. YH, SGS synthetic vaccine adjuvant YH, SGS A vaccine aduvant that contains synthetic material. tensoactive compound vaccine adjuvant a vaccine adjuvant that includes tensioactive material. Tensioactive materials, surfactants or active surface agents are chemical substances with a polar-non polar structure. These substances have a tendency to locate themselves at the surface creating an adsorbed monomolecular layer on the interface. WEB: http://www.citt.ufl.edu/team/sepulveda/html/en_tensioactivos.htm tensioactive compound vaccine adjuvant YH, SGS carbohydrate adjuvant YH, SGS a vaccine adjuvant that is primarily composed of carbohydrates. IFN-gamma vaccine adjuvant YH, SGS a cytokine vaccine adjuvant that includes IFN-gamma. virmugen role YH, YL a role that is inherenced in a gene that can be mutated in a virulent pathogen, leading to an attenuated strain serving as a live attenuated vaccine strain. allergy vaccine YL, YH YL,YH a vaccine that targets for allergy. Clostridium perfringens vaccine bacterial vaccine that is used to protect against Clostridium perfringens infection YL generated using OntoRat human immunization objective bacterial vaccine function YH, YL a vaccine function against bacterial disease vaccine target role heat-inactivated vaccine an inactivation vaccine that is prepared by heat inactivation. YH, YL irradiation-inactivated vaccine an inactivation vaccine that is prepared by irradiation inactivation. YH, YL H2O2-inactivated vaccine YH, YL an inactivation vaccine that is prepared by H2O2 inactivation. formalin-inactivated vaccine an inactivation vaccine that is prepared by formalin inactivation. YH, YL preparation of vaccine using H2O2 inactivation YH A vaccine prepraration process that is performed by H2O2 inactivation of virulent pathogen. unimmunized an organismal quality that indicates an organism (e.g., human) is not yet immunized against a disease. YH immunized by vaccination with a licensed vaccine YH an organismal quality that indicates an organism (e.g., human) is immunized against a disease through vaccination with a licensed vaccine. vaccinated organism Vaccinee an organism that is vaccinated with a vaccine YH, YL, MC organism vaccinated with a licensed vaccine a vaccinated organism that is vaccinated with a licensed vaccine vaccinee YH, YL, MC vaccinated an organismal quality that indicates an organism (e.g., human) is vaccinated with a vaccine. YH unvaccinated YH an organismal quality that indicates an organism (e.g., human) is unvaccinated with any vaccine. vaccinated with a licensed vaccine a vaccinated quality that indicates an organism is vaccinated with a licensed vaccine. YH unvaccinated with a licensed vaccine YH a unvaccinated quality that indicates an organism has not been vaccinated with a licensed vaccine. B16 vaccine adjuvanted by loxoribine a cancer vaccine that protects mice against tumor growth following challenge with live B16 cells. YH PMID: 8306370 immunized organism an organism that is immunized for a disease YH, YL, MC organism immunized with a licensed vaccine YH, YL, MC an immunized organism that is immunized by vaccination with a licensed vaccine unvaccinated organism an organism that is unvaccinated with a vaccine YH, YL, MC Actinobacillus pleuropneumoniae gene a bacterial gene from Actinobacillus pleuropneumoniae. YH, RR Trypanosoma cruzi vaccine YH T. cruzi vaccine A vaccine that protects against Trypanosoma cruzi. T. cruzi DNA vaccine encoding CRP-10 YH A T. cruzi DNA vaccine that uses a DNA plasmid pGFP expressing T. cruzi CRP-10 protein. VIOLIN Vaccine ID: 803 T. cruzi DNA vaccine encoding G2 A T. cruzi DNA vaccine that uses a DNA plasmid pGFP expressing T. cruzi G2 protein. YH VIOLIN Vaccine ID: 807 T. cruzi DNA vaccine encoding G4 YH VIOLIN Vaccine ID: 809 A T. cruzi DNA vaccine that uses a DNA plasmid pGFP expressing T. cruzi G4 protein. T. cruzi DNA vaccine encoding TSA-1 A T. cruzi DNA vaccine that uses a DNA plasmid expressing T. cruzi TSA-1 protein. VIOLIN Vaccine ID: 812 YH T. cruzi DNA vaccine pGFP-TSA1 YH A T. cruzi DNA vaccine that uses a DNA plasmid pGFP expressing T. cruzi TSA-1 protein. VIOLIN Vaccine ID: 811 T. cruzi PAR1 protein vaccine VIOLIN Vaccine ID: 806 A T. cruzi subunit vaccine that uses T. cruzi PAR1 protein as protective antigen. YH T. cruzi PAR2 protein vaccine YH A T. cruzi subunit vaccine that uses T. cruzi PAR2 protein as protective antigen. VIOLIN Vaccine ID: 810 T. cruzi vaccine using attenuated Salmonella expressing T. cruzi Cruzipain A T. cruzi vaccine that uses attenuated Salmonella to express T. cruzi Cruzipain protein. VIOLIN Vaccine ID: 804 YH T. cruzi vaccine using Sendai virus vector expressing amastigote surface protein-2 YH A T. cruzi vaccine that uses Sendai virus vector to express T. cruzi amastigote surface protein-2. VIOLIN Vaccine ID: 802 vaccine made with different preparation methods YH a vaccine that is made with different preperation methods (e.g., DNA vaccine and protein subunit vaccine). vaccine containing subunit component and inactivated whole organism YH a vaccine that contains both subunit component and inactivated whole organism. vaccine containing DNA vaccine for priming and subunit vaccine for boosting YH a vaccine that contains a DNA vaccine for priming and a subunit vaccine for boosting vaccine containing DNA vaccine for priming and Ad vector vaccine for boosting a vaccine that contains a DNA vaccine for priming and a subunit vaccine for boosting YH funsion protein vaccine An example of fusion protein vaccine is Mtb72f fusion protein vaccine. Reference: PubMed: 15187142. Funsion protein vaccine is a subunit vaccine that fuses more than one open reading frames of protective antigens. YH Brucella melitensis gene YH, RR A Brucella gene that is from B. melitensis. Brucella suis gene A Brucella gene that is from B. suis. YH Bacillus anthracis gene A bacterial gene that is from Bacillus anthracis. YH, RR Listeria monocytogenes gene YH, RR A bacterial gene that is from Listeria monocytogenes. Mycobacterium avium gene YH, RR A bacterial gene that is from Mycobacterium avium. Staphylococcus aureus gene A bacterial gene that is from Staphylococcus aureus. YH, RR Aeromonas hydrophila gene YH, RR A bacterial gene that is from Aeromonas hydrophila. Bordetella bronchiseptica gene YH, RR A bacterial gene that is from Bordetella bronchiseptica. Aeromonas salmonicida gene YH, RR A bacterial gene that is from Aeromonas salmonicida. Bordetella pertussis gene A bacterial gene that is from Bordetella pertussis. YH, RR Borrelia burgdorferi gene A bacterial gene that is from Borrelia burgdorferi. YH, RR Burkholderia pseudomallei gene YH, RR A bacterial gene that is from Burkholderia pseudomallei. Edwardsiella ictaluri gene A bacterial gene that is from Burkholderia pseudomallei. YH, RR Edwardsiella tarda gene YH, RR A bacterial gene that is from Edwardsiella tarda. Francisella tularensis gene A bacterial gene that is from Francisella tularensis. YH, RR Mannheimia haemolytica gene YH, RR A bacterial gene that is from Mannheimia haemolytica. Mycoplasma gallisepticum gene A bacterial gene that is from Mycoplasma gallisepticum. YH, RR Neisseria meningitidis gene YH, RR A bacterial gene that is from Neisseria meningitidis. Pasteurella multocida gene A bacterial gene that is from Pasteurella multocida. YH, RR Salmonella Typhi gene A bacterial gene that is from Salmonella Typhi. YH, RR Salmonella Gallinarum gene A bacterial gene that is from Salmonella Gallinarum. YH, RR 'Salmonella Typhimurium gene YH, RR A bacterial gene that is from Salmonella Typhimurium. Salmonella Enteritidis gene YH, RR A bacterial gene that is from Salmonella Enteritidis. Vibrio cholerae gene A bacterial gene that is from Vibrio cholerae. YH, RR Bovine herpesvirus 1 gene YH, RR A viral gene that is from Bovine herpesvirus 1. Yersinia enterocolitica gene A bacterial gene that is from Yersinia enterocolitica. YH, RR Yersinia pestis gene YH, RR A bacterial gene that is from Yersinia pestis. Yersinia pseudotuberculosis gene A bacterial gene that is from Yersinia pseudotuberculosis. YH, RR Yersinia ruckeri gene A bacterial gene that is from Yersinia ruckeri. YH, RR Bovine Respiratory Syncytial Virus gene A viral gene that is from Bovine Respiratory Syncytial Virus. YH, RR Classical swine fever virus gene YH, RR A viral gene that is from Classical swine fever virus. Equid herpesvirus gene A viral gene that is from Equid herpesvirus 1. YH, RR Feline herpesvirus 1 gene YH, RR A viral gene that is from Feline herpesvirus 1. Feline immunodeficiency virus gene YH, RR A viral gene that is from Feline immunodeficiency virus. Feline infectious peritonitis virus gene A viral gene that is from Feline infectious peritonitis virus. YH, RR Gallid herpesvirus 1 gene A viral gene that is from Gallid herpesvirus 1. YH, RR Hepatitis B virus gene A viral gene that is from Hepatitis B virus. YH, RR Human herpesvirus 1 gene A viral gene that is from Human herpesvirus 1. YH, RR Human metapneumovirus gene A viral gene that is from Human metapneumovirus. YH, RR Human Respiratory Syncytial Virus gene A viral gene that is from Human Respiratory Syncytial Virus. YH, RR Infectious Hematopoietic Necrosis Virus gene A viral gene that is from Infectious Hematopoietic Necrosis Virus. YH, RR Porcine respiratory and reproductive syndrome virus gene YH, RR A viral gene that is from Porcine respiratory and reproductive syndrome virus. Pseudorabies virus gene Suid herpesvirus 1 gene A viral gene that is from Pseudorabies virus. YH, RR Rabies virus gene A viral gene that is from Rabies virus. YH, RR SARS-CoV gene YH, RR A viral gene that is from SARS-CoV. Simian Immunodeficiency Virus gene A viral gene that is from Simian Immunodeficiency Virus. YH, RR Tick-borne Encephalitis Virus gene A viral gene that is from Tick-borne Encephalitis Virus. YH, RR VEE Virus gene YH, RR A viral gene that is from VEE Virus. West Nile virus gene YH, RR A viral gene that is from West Nile virus. Western equine encephalomyelitis virus gene YH, RR A viral gene that is from Western equine encephalomyelitis virus. Leishmania donovani gene A protozoan gene that is from Leishmania donovani. YH, RR Plasmodium berghei gene YH, RR A Plasmodium gene that is from Plasmodium berghei. Plasmodium yoelii gene A Plasmodium gene that is from Plasmodium yoelii. YH, RR Toxoplasma gondii gene YH, RR A protozoan gene that is from Toxoplasma gondii. 'Human herpesvirus 2 gene' A viral gene that is from Human herpesvirus 2. YH, RR vaccination with Afluria Erysipelothrix rhusiopathiae vaccine generated using OntoRat YL bacterial vaccine that is used to protect against Erysipelothrix rhusiopathiae infection Trichomonas foetus vaccine protozoan vaccine that is used to protect against Tritrichomonas suis infection YL generated using OntoRat Eimeria spp. vaccine protozoan vaccine that is used to protect against Eimeria spp. (Eimeria) infection YL generated using OntoRat Orf Virus vaccine YL generated using OntoRat viral vaccine that is used to protect against Orf Virus infection Aves vaccine Vaccine that used for immunizing Aves. YL. fish vaccine YL. vaccine that used for immunizing fishes Fowlpox virus vaccine viral vaccine that is used to protect against Fowlpox virus infection generated using OntoRat YL carnivora vaccine YL vaccine that used for immunizing carnivora. cat vaccine vaccine that used for immunizing cat (felis catus) cattle vaccine dog vaccine chicken vaccine Ducks vaccine catfish vaccine gray wolf vaccine horse vaccine parrot vaccine pig vaccine sei whale vaccine sheep vaccine salmoninae vaccine YL vaccine that used for immunizing salmoninae (tourts, salmons & chars ) turkey vaccine vaccine target specification Pigeonpox virus vaccine generated using OntoRat YL viral vaccine that is used to protect against Pigeonpox virus infection Bovine herpesvirus 1 vaccine generated using OntoRat YL viral vaccine that is used to protect against Bovine herpesvirus 1 infection Avipoxvirus vaccine Canary Pox Modified Live Virus Vaccine (USDA: 1623.10) USA licensed vaccine Equid herpesvirus 1 vaccine generated using OntoRat viral vaccine that is used to protect against Equid herpesvirus 1 infection YL Feline herpesvirus 1 vaccine generated using OntoRat YL viral vaccine that is used to protect against Feline herpesvirus 1 (Felid herpesvirus 1) infection Gallid herpesvirus 1 vaccine viral vaccine that is used to protect against Gallid herpesvirus 1 infection generated using OntoRat YL Canine adenovirus type 1 vaccine viral vaccine that is used to protect against Canine adenovirus type 1 (Canine adenovirus 1) infection YL generated using OntoRat Canine Adenovirus Type 2 vaccine viral vaccine that is used to protect against Canine Adenovirus Type 2 (Canine adenovirus 2) infection YL generated using OntoRat Bovine papillomavirus vaccine YL generated using OntoRat viral vaccine that is used to protect against Bovine papillomavirus infection Avian Polyomavirus vaccine YL generated using OntoRat viral vaccine that is used to protect against Avian Polyomavirus infection Mink enteritis virus vaccine viral vaccine that is used to protect against Mink enteritis virus infection YL generated using OntoRat Porcine parvovirus vaccine YL generated using OntoRat viral vaccine that is used to protect against Porcine parvovirus infection Porcine rotavirus vaccine generated using OntoRat YL viral vaccine that is used to protect against Porcine rotavirus infection Equine rotavirus vaccine YL viral vaccine that is used to protect against Equine rotavirus infection generated using OntoRat Infectious Bursal Disease Virus vaccine generated using OntoRat viral vaccine that is used to protect against Infectious Bursal Disease Virus (IBDV) infection YL Eastern Equine Encephalitis Virus vaccine YL generated using OntoRat viral vaccine that is used to protect against Eastern Equine Encephalitis Virus infection VEE Virus vaccine viral vaccine that is used to protect against VEE Virus (Venezuelan equine encephalitis virus) infection generated using OntoRat YL Equine arteritis virus vaccine YL viral vaccine that is used to protect against Equine arteritis virus infection generated using OntoRat Bovine viral diarrhea virus 1 vaccine YL viral vaccine that is used to protect against Bovine viral diarrhea virus 1 infection generated using OntoRat Infectious Bronchitis Virus vaccine viral vaccine that is used to protect against Infectious Bronchitis Virus (IBV) infection YL generated using OntoRat Bovine coronavirus vaccine viral vaccine that is used to protect against Bovine coronavirus infection generated using OntoRat YL Feline infectious peritonitis virus vaccine viral vaccine that is used to protect against Feline infectious peritonitis virus infection generated using OntoRat YL Transmissible gastroenteritis virus vaccine viral vaccine that is used to protect against Transmissible gastroenteritis virus infection generated using OntoRat YL Bovine Parainfluenza 3 Virus vaccine YL generated using OntoRat viral vaccine that is used to protect against Bovine Parainfluenza 3 Virus (BPIV-3) (Bovine parainfluenza virus 3) infection Bovine Respiratory Syncytial Virus vaccine viral vaccine that is used to protect against Bovine Respiratory Syncytial Virus infection generated using OntoRat YL Feline immunodeficiency virus vaccine viral vaccine that is used to protect against Feline immunodeficiency virus infection generated using OntoRat YL Feline calicivirus vaccine viral vaccine that is used to protect against Feline calicivirus infection YL generated using OntoRat Chicken Anemia Virus vaccine YL generated using OntoRat viral vaccine that is used to protect against Chicken Anemia Virus infection Porcine respiratory and reproductive syndrome virus vaccine YL generated using OntoRat viral vaccine that is used to protect against Porcine respiratory and reproductive syndrome virus (Porcine reproductive and respiratory syndrome virus) infection Riemerella anatipestifer vaccine generated using OntoRat YL bacterial vaccine that is used to protect against Riemerella anatipestifer infection Avian Reovirus vaccine viral vaccine that is used to protect against Avian Reovirus (Avian orthoreovirus) infection YL generated using OntoRat Avian pneumovirus vaccine generated using OntoRat viral vaccine that is used to protect against Avian pneumovirus (Avian metapneumovirus) infection YL Bluetongue virus vaccine viral vaccine that is used to protect against Bluetongue virus infection YL generated using OntoRat Turkey hemorrhagic enteritis virus vaccine generated using OntoRat YL viral vaccine that is used to protect against Turkey hemorrhagic enteritis virus (Turkey adenoirus 3) infection Canarypox virus vaccine viral vaccine that is used to protect against Canarypox virus infection YL generated using OntoRat Psittacid herpesvirus 1 vaccine generated using OntoRat YL viral vaccine that is used to protect against Psittacid herpesvirus 1 infection Vibrio anguillarum vaccine YL generated using OntoRat bacterial vaccine that is used to protect against Vibrio anguillarum (Listonella anguillarum) infection Infectious salmon anemia virus vaccine viral vaccine that is used to protect against Infectious salmon anemia virus infection generated using OntoRat YL Edwardsiella ictaluri vaccine YL generated using OntoRat bacterial vaccine that is used to protect against Edwardsiella ictaluri infection Avian Encephalomyelitis Virus vaccine YL generated using OntoRat viral vaccine that is used to protect against Avian Encephalomyelitis Virus infection Mannheimia haemolytica vaccine bacterial vaccine that is used to protect against Mannheimia haemolytica infection YL generated using OntoRat Porcine circovirus 2 vaccine YL generated using OntoRat viral vaccine that is used to protect against Porcine circovirus 2 infection Duck enteritis virus vaccine generated using OntoRat YL viral vaccine that is used to protect against Duck enteritis virus (Anatid herpesvirus 1) infection Canine parainfluenza virus vaccine viral vaccine that is used to protect against Canine parainfluenza virus infection YL generated using OntoRat Avian Paramyxovirus vaccine viral vaccine that is used to protect against Avian Paramyxovirus infection generated using OntoRat YL Duck hepatitis virus 1 vaccine generated using OntoRat YL viral vaccine that is used to protect against Duck hepatitis virus 1 (Duck hepatitis A virus) infection country YH USA YH USA is a country that exists in north America. Rubella virus vaccine MeSH: D012411 A viral vaccine that protects against infection with Rubella virus. YH vaccine saftey regulation YH A vaccine regulation for vaccine safety. review of vaccine license application A vaccine regulatory process that is for vaccine regulatory agent to review vaccine license application from vaccine producer. YH Actacel todo: Proteins + Conjugate Trade Name: Actacel YH, ZX Avaxim todo: Killed virus Trade Name: Avaxim YH, ZX Avaxim - Pediatric todo: Killed virus YH, ZX Trade Name: Avaxim - Pediatric BCG Vaccine (Freeze-Dried) todo: Live bacteria Trade Name: BCG Vaccine (Freeze-Dried) YH, ZX DT Polio Adsorbed todo: Proteins + killed virus Trade Name: DT Polio Adsorbed YH, ZX Dukoral todo: Proteins + killed bacteria YH, ZX Trade Name: Dukoral Engerix-B Product Name: Hepatitis B Vaccine (Recombinant) Trade Name: Engerix-B CVX: 08 CVX: 44 YH, ZX Eolarix todo: Live virus YH, ZX todo: assign parent immunogen: M, R Trade Name: Eolarix Epaxal todo: Killed virus Trade Name: Epaxal YH, ZX FSME - IMMUN todo: Inactivated whole virus YH, ZX Trade Name: FSME - IMMUN todo: assign parent immunogen: TBE Hiberix todo: Conjugate CVX: 48 YH, ZX Trade Name: Hiberix Imovax Polio todo: Killed virus Trade Name: Imovax Polio YH, ZX Imovax Rabies todo: Killed virus Trade Name: Imovax Rabies YH, ZX Inactived Poliomyelitis Vaccine - IPV todo: Killed virus Trade Name: Inactived Poliomyelitis Vaccine - IPV YH, ZX Infanrix-hexa todo: Proteins + killed viruses + conjugate Trade Name: Infanrix-hexa YH, ZX Infanrix/Hib todo: Proteins + conjugate YH, ZX Trade Name: Infanrix/Hib Infanrix-IPV todo: Proteins + killed virus YH, ZX Trade Name: Infanrix-IPV Infanrix -IPV/Hib todo: Proteins + killed virus + conjugate YH, ZX Trade Name: Infanrix -IPV/Hib CVX: 120 Liquid Pedvax HIB todo: Conjugate YH, ZX Trade Name: Liquid Pedvax HIB Meningitec todo: Conjugate Trade Name: Meningitec YH, ZX Meningococcal Polysaccharide Vaccine, Groups A & C, Menomune A/C todo: Polysaccharide Trade Name: Meningococcal Polysaccharide Vaccine, Groups A & C, Menomune A/C YH, ZX Menjugate todo: Conjugate Trade Name: Menjugate YH, ZX Menomune A/C/Y/W-135 todo: Polysaccharide YH, ZX Trade Name: Menomune A/C/Y/W-135 Mutacol todo: Live bacteria YH, ZX Trade Name: Mutacol Neisvac-C todo: Conjugate Trade Name: Neisvac-C YH, ZX Pediacel todo: Proteins, killed virus + conjugate Trade Name: Pediacel YH, ZX Pneumo 23 todo: Polysaccharide YH, ZX Trade Name: Pneumo 23 Pneumovax 23 todo: Polysaccharide YH, ZX Trade Name: Pneumovax 23 Prevnar todo: Conjugate YH, ZX Trade Name: Prevnar Priorix todo: Live virus Trade Name: Priorix YH, ZX Priorix-Tetra todo: Live virus YH, ZX Trade Name: Priorix-Tetra todo: assign parent immunogen: M, M, R, Var Quadracel todo: Proteins + killed virus Trade Name: Quadracel YH, ZX Recombivax HB todo: Recombinant protein YH, ZX Trade Name: Recombivax HB CVX: 08 CVX: 43 CVX: 44 Rotarix todo: Live virus Trade Name: Rotarix ROTARIX YH, ZX todo: assign parent immunogen: ROT Td Adsorbed todo: Proteins YH, ZX Trade Name: Td Adsorbed Tripacel todo: Proteins Trade Name: Tripacel YH, ZX Twinrix Junior todo: Recombinant protein + killed virus YH, ZX Trade Name: Twinrix Junior Typherix todo: Polysaccharide YH, ZX Trade Name: Typherix Vaqta todo: Killed virus YH, ZX VAQTA Trade Name: Vaqta Varilrix todo: Live virus Trade Name: Varilrix YH, ZX Varivax III todo: Live virus YH, ZX Trade Name: Varivax III ViVaxim todo: Polysaccharide + killed virus Trade Name: ViVaxim YH, ZX todo: assign parent immunogen: Typh-I + (HA) Vivotif todo: Live virus Trade Name: Vivotif YH, ZX bacterium protein YH, ZX G+ bacterium protein YH, ZX G- bacterium protein YH, ZX virus protein YH, ZX parasite protein YH, ZX fungus protein YH, ZX Bacillus anthracis protein YH, ZX Brucella protein YH, ZX Yersinia pestis protein YH, ZX Francisella tularensis protein YH, ZX Ebola virus protein YH, ZX Clostridium botulinum protein YH, ZX Lassa Fever Virus protein YH, ZX Variola virus protein YH, ZX Campylobacter jejuni protein YH, ZX Escherichia coli protein YH, ZX Human Immunodeficiency Virus protein YH, ZX Hantavirus protein YH, ZX Marburg Virus protein YH, ZX Mycobacterium tuberculosis protein YH, ZX Plasmodium spp. protein YH, ZX Haemophilus influenzae protein YH, ZX Coxiella burnetii protein YH, ZX VEE Virus protein YH, ZX Clostridium tetani protein YH, ZX Salmonella spp. protein YH, ZX Shigella protein YH, ZX Neisseria meningitidis protein YH, ZX Streptococcus pneumoniae protein YH, ZX Hepatitis A virus protein YH, ZX Hepatitis B virus protein YH, ZX Influenza virus protein YH, ZX Japanese encephalitis virus protein YH, ZX Measles virus protein YH, ZX Mumps virus protein YH, ZX Human papillomavirus protein YH, ZX Poliovirus protein YH, ZX Rabies virus protein YH, ZX Rotavirus protein YH, ZX Rubella virus protein YH, ZX Yellow fever virus protein YH, ZX Varicella-zoster virus protein YH, ZX Tick-borne Encephalitis Virus (TBEV) protein YH, ZX Chlamydophila pneumoniae protein YH, ZX Chlamydia muridarum protein YH, ZX Yersinia pseudotuberculosis protein YH, ZX Bovine Leukemia virus protein YH, ZX Corynebacterium diphtheriae protein YH, ZX Porcine circovirus 2 protein YH, ZX Pseudorabies virus protein YH, ZX Classical swine fever virus protein YH, ZX Bovine herpesvirus 1 protein YH, ZX West Nile virus protein YH, ZX Marek's disease virus protein YH, ZX Newcastle disease virus protein YH, ZX Feline leukemia virus protein YH, ZX Canine parvovirus protein YH, ZX Canine coronavirus protein YH, ZX Canine distemper virus protein YH, ZX Infectious Hematopoietic Necrosis Virus protein YH, ZX Lawsonia intracellularis protein YH, ZX Porphyromonas gulae protein YH, ZX Yersinia ruckeri protein YH, ZX Aeromonas salmonicida protein YH, ZX Vibrio anguillarum (Listonella anguillarum) protein YH, ZX Streptococcus equi protein YH, ZX Chlamydophila abortus protein YH, ZX Mycoplasma synoviae protein YH, ZX Mycoplasma gallisepticum protein YH, ZX Bordetella avium protein YH, ZX Actinobacillus pleuropneumoniae protein YH, ZX Eimeria spp. protein YH, ZX Eimeria tenella protein YH, ZX Theileria parva protein YH, ZX Theileria annulata protein YH, ZX Toxoplasma gondii protein YH, ZX Babesia bovis protein YH, ZX Neospora caninum protein YH, ZX Giardia duodenalis protein YH, ZX Sarcocystis neurona protein YH, ZX Babesia canis protein YH, ZX Leishmania donovani protein YH, ZX Eimeria maxima protein YH, ZX Herpes simplex virus type 1 and 2 protein YH, ZX Leishmania major protein YH, ZX Leishmania infantum protein YH, ZX Leishmania amazonensis protein YH, ZX Trypanosoma cruzi protein YH, ZX Chlamydophila psittaci protein YH, ZX Burkholderia pseudomallei protein YH, ZX Western equine encephalomyelitis virus protein YH, ZX Cryptosporidium parvum protein YH, ZX Hendra virus protein YH, ZX Dengue Virus protein YH, ZX Nipah virus protein YH, ZX Rickettsia spp protein YH, ZX Bordetella pertussis protein YH, ZX Vibrio cholerae protein YH, ZX Rift Valley Fever virus protein YH, ZX SARS-CoV protein YH, ZX Yersinia enterocolitica protein YH, ZX Entamoeba histolytica protein YH, ZX Coccidioides spp. protein YH, ZX Trypanosoma brucei protein YH, ZX Helicobacter pylori protein YH, ZX SodC from B. abortus strain 2308 YH, ZX Protegen ID: 3; NCBI Gene GI: 3827840; NCBI Protein GI: 83269434; NCBI Protein Accession: YP_418725.1; NCBITaxon: 234 IMMUNOGENICITY: Induces antigen-specific Th1 immune response, as indicated by the specific induction of serum IgG2a, but not IgG1, antibodies and by the secretion of IFN-alpha but not IL-4, by the Cu/Zn SOD-stimulated splenocytes. Has been used for vaccine development [PubMed: 10816475][PubMed: 11953393][PubMed: 12933826]. MUTATION: An isogenic sodC mutant constructed from B abortus 2308 by gene replacement exhibited much greater susceptibility to killing by exogenous O(2)(-) than the parental 2308 strain, supporting a role for SodC in protecting this bacterium from O(2)(-) stress. The B abortus sodC mutant was much more sensitive to killing by cultured resident peritoneal macrophages from C57BL6J mice than 2308, and its attenuation in cultured murine macrophages was enhanced when these phagocytes were treated with gamma interferon. The attenuation of the B abortus sodC mutant in both resting and IFN-gamma-activated macrophages was alleviated in the presence of the NADPH oxidase inhibitor apocynin. Consistently, the B abortus sodC mutant also displayed significant attenuation in infected C57BL6J mice compared to the parental strain. These findings suggest that SodC protects B abortus 2308 from the respiratory burst of host macrophages [PubMed: 15845493]. Lef from B. anthracis str. A2012 YH, ZX Protegen ID: 5; NCBI Gene GI: 1158731; NCBI Protein GI: 40646957; NCBI Protein Accession: AAR88323.1; NCBITaxon: 32630 EBOV GP Protegen ID: 10; NCBI Gene GI: 955190 YH, ZX EBOV NP Protegen ID: 11; NCBI Gene GI: 955194; NCBI Protein GI: 22789223; NCBI Protein Accession: NP_690580; NCBITaxon: 186539 YH, ZX VP24 from Reston ebolavirus YH, ZX Protegen ID: 12; NCBI Gene GI: 955193; NCBI Protein GI: 22789228; NCBI Protein Accession: NP_690586; NCBITaxon: 186539 VP40 from Reston ebolavirus Protegen ID: 13; NCBI Gene GI: 955192; NCBI Protein GI: 22789225; NCBI Protein Accession: NP_690582; NCBITaxon: 186539 YH, ZX VP30 from Reston ebolavirus YH, ZX Protegen ID: 14; NCBI Gene GI: 955196; NCBI Protein GI: 22789227; NCBI Protein Accession: NP_690585; NCBITaxon: 186539 VP35 from Reston ebolavirus Protegen ID: 15; NCBI Gene GI: 955189; NCBI Protein GI: 22789224; NCBI Protein Accession: NP_690581; NCBITaxon: 186539 YH, ZX VP35 from Zaire ebolavirus VP35 expressed from alphavirus replicons induced a protective immune response in C57BL/6 mice when challenged with Ebola virus Zaire [PubMed: 11485406]. YH, ZX Protegen ID: 16; NCBI Gene GI: 911827; NCBI Protein GI: 10313992; NCBI Protein Accession: NP_066244; NCBITaxon: 186538 Tbp2 Protegen ID: 277; NCBI Gene GI: 3430457; NCBI Protein GI: 68249580; NCBI Protein Accession: YP_248692; NCBITaxon: 281310 Recombinant Tbp1 and Tbp2 proteins were expressed from Escherichia coli and antisera were raised to the purified proteins. In a passive model of bacteraemia, infant rats were protected from challenge with Hib after transfer of anti-rTbp2 antiserum, but not after anti-rTbp1 antiserum [PubMed: 8830248]. YH, ZX VP24 from Zaire ebolavirus Protegen ID: 17; NCBI Gene GI: 911828; NCBI Protein GI: 10313998; NCBI Protein Accession: NP_066250; NCBITaxon: 186538 YH, ZX VP24 expressed from alphavirus replicons induced a protective immune response in BALB/c mice when challenged with Ebola virus Zaire [PubMed: 11485406]. VP30 from Zaire ebolavirus VP30 expressed from alphavirus replicons induced a protective immune response in BALB/c mice when challenged with Ebola virus Zaire [PubMed: 11485406]. YH, ZX Protegen ID: 18; NCBI Gene GI: 911826; NCBI Protein GI: 10313997; NCBI Protein Accession: NP_066249; NCBITaxon: 186538 VP40 from Zaire ebolavirus YH, ZX Vaccination of BALB/c or C57BL/6 mice with eVLPs, composed of the EBOV glycoprotein and matrix viral protein (VP)40 with a lipid membrane, in conjunction with QS-21 adjuvant resulted in mixed IgG subclass responses, a Th1-like memory cytokine response, and protection from lethal EBOV challenge [PubMed: 16002721]. VP40 expressed from alphavirus replicons induced a protective immune response in BALB/c mice when challenged with Ebola virus Zaire [PubMed: 11485406]. Protegen ID: 19; NCBI Gene GI: 911825; NCBI Protein GI: 10313993; NCBI Protein Accession: NP_066245; NCBITaxon: 186538 LASVsSgp2 glycoprotein HLA-A*0201 mice immunized with either GPC(42-50) from LASVsSgp2 glycoprotein or GPC(60-68) were protected against challenge with a recombinant vaccinia virus that expressed LASV GPC [PubMed: 16912286]. Protegen ID: 20; NCBI Gene GI: 956585; NCBI Protein GI: 23343511; NCBI Protein Accession: NP_694870; NCBITaxon: 11620 YH, ZX Caf1 from Y. pestis biovar Microtus str. 91001 YH, ZX Protegen ID: 23; NCBI Gene GI: 2767670; NCBI Protein GI: 45478667; NCBI Protein Accession: NP_995523; NCBITaxon: 229193 L1R from Monkeypox virus Zaire-96-I-16 It has previously been shown that a DNA subunit vaccine (4pox) based on four orthopoxvirus immunogens (L1R, B5R, A27L and A33R) can produce protective immunity against lethal orthopoxvirus challenges in mice and nonhuman primates. the immunogenicity of an L1R construct to which a tissue plasminogen activator signal sequence was placed in frame with the full-length L1R gene was tested. When the tPA-L1R construct was substituted for the unmodified L1R gene in the 4pox vaccine, given as a prime and single boost, animals were better protected from lethal challenge with vaccinia virus (VACV) [PubMed: 18485547]. Protegen ID: 28; NCBI Gene GI: 928938; NCBI Protein GI: 17974998; NCBI Protein Accession: NP_536512; NCBITaxon: 619591 YH, ZX PagA from B. anthracis str. 'Ames Ancestor' Protegen ID: 32; NCBI Gene GI: 2820165; NCBI Protein GI: 47566476; NCBI Protein Accession: NC_007322.2 YH, ZX Lef from B. anthracis str. Ames Ancestor' Protegen ID: 38; NCBI Gene GI: 2820148; NCBI Protein GI: 47566484; NCBI Protein Accession: NC_007322.2 YH, ZX LcrV from y. pestis CO92 MAb BA5 protected animals against plague, neutralized the Y. pestis type III secretion pathway and promoted opsonophagocytic clearance of bacteria in blood. LcrV residues 196-225 were necessary and sufficient for MAb BA5 binding. These results identify LcrV residues 196-225 as a linear epitope that is recognized by the murine immune system to confer plague protection [PubMed: 20005318]. Protegen ID: 44; NCBI Gene GI: 1172676; NCBI Protein GI: 16082719; NCBI Protein Accession: NP_395165; NCBITaxon: 214092 YH, ZX LcrV from Y. pestis KIM 10 An LcrV variant lacking amino acid residues 271 to 300 (rV10) elicited immune responses that protected mice against a lethal challenge with Y. pestis [PubMed: 16041032]. Protegen ID: 45; NCBI Gene GI: 1149310; NCBI Protein GI: 31795491; NCBI Protein Accession: NP_857946; NCBITaxon: 187410 YH, ZX V antigen Protegen ID: 46; NCBI Gene GI: 4118094 YH, ZX Pla Study evaluated the humoral immune response of mice that survived lethal Y. pestis aerosol challenge after antibiotic treatment. Results indicated that one of the predominant antibody response of mice surviving pneumonic plague after treatment with antibiotics was to pla [PubMed: 10085037]. Protegen ID: 48; NCBI Gene GI: 1172643; NCBI Protein GI: 16082686; NCBI Protein Accession: NP_395233; NCBITaxon: 214092 YH, ZX YopD from Y. pestis CO92 YH, ZX The type III secretion apparatus encoded on the low-calcium response (LCR) virulence plasmid, pCD1 in strain KIM5, of Y. pestis is a conserved virulence mechanism that is absolutely required for virulence of Y. pestis. YscF is a surface localized protein required both to secrete Yops and to translocate toxins into eukaryotic cells. YscF polymerization is possibly required for a YscF needle to puncture eukaryotic cell membranes. It is also likely that YscF and its homologs function to provide a base that a translocon complex is built upon, or that YscF builds a conduit from the bacterium to the eukaryotic membrane - this suggestion seems more likely given that other proteins such as YopB, YopD, and LcrV are also required for translocation into eukaryotic cells. YscF is thought to be a surface-expressed protein in Y. pestis and is required for virulence. YscF has been found to function as a protective antigen against experimental plague infection [PubMed: 15978133]. Protegen ID: 49; NCBI Gene GI: 1172673; NCBI Protein GI: 16082716; NCBI Protein Accession: NP_395162; NCBITaxon: 214092 GatA YH, ZX Genetic immunization was used to functionally test the genes of C. abortus as vaccines in a mouse challenge system. Glu-tRNA Gln Amidotransferase (CP #3, gatA) was found to be protective. Three of the clones (CP #1) elicited protection that was statistically higher than the unvaccinated control, which has high variance [PubMed: 15811648]. Note: Part of CP #3 also belongs to gatB Protegen ID: 422; NCBI Protein GI: 62184918; NCBITaxon: 218497 GatB Protegen ID: 424; NCBI Protein GI: 62147986; NCBITaxon: 218497 YH, ZX Genetic immunization was used to functionally test the genes of C. abortus as vaccines in a mouse challenge system. Glu-tRNA Gln Amidotransferase (CP #3, gatB) was found to be protective. Three of the clones (CP #1) elicited protection that was statistically higher than the unvaccinated control, which has high variance [PubMed: 15811648]. Note: Part of CP #3 also belongs to gatA Omp1 YH, ZX Protegen ID: 425; NCBI Protein GI: 40601; NCBITaxon: 83555 The MOMP (omp1) DNA immunization induced a non-specific and partial protection in OF1 outbred mice fetuses against challenge with C. abortus [PubMed: 12488563]. DnaK In pregnant mice, the dnaK vaccine induced a non-specific partial protection from abortion after challenge with Chlamydophila abortus [PubMed: 12056482]. Protegen ID: 426; NCBI Protein GI: 26006347; NCBITaxon: 83555 YH, ZX LcrE YH, ZX Protegen ID: 428; NCBI Gene GI: 895078; NCBI Protein GI: 15618244; NCBI Protein Accession: NP_224529; NCBITaxon: 115713 The immunogenicity and protective effect of recombinant LcrE protein combined either with Freund's or Alum adjuvant were investigated in mice. The immunization with both protocols resulted in a significant reduction of the number of viable C. pneumoniae in the lungs after challenge. Results confirm that LcrE induces protective immunity in mice [PubMed: 19451031]. CopN Results of this study showed that intranasal immunization of BALB/c mice with heat-aggregated CopN protein and an Escherichia coli heat-labile toxin (LT) induced a strong immune response. The immunization induced statistically significant protection against intranasal C. pneumoniae challenge, the level of which correlated with the magnitude of CopN-specific lymphocyte proliferation [PubMed: 16949182]. Protegen ID: 429; NCBI Protein GI: 33241669; NCBITaxon: 182082 YH, ZX TC0512 outer membrane protein, putative Following vaginal challenge with live Chlamydia, the groups of female BALB/c mice immunized intra-abdominally with TC0512 showed significant levels of protection when compared to negative control animals. At 9 days following challenge TC0512 showed a 73% reduction in the number of recoverable Chlamydia compared with vector only immunized controls [PubMed: 17239501]. Protegen ID: 430; NCBI Gene GI: 1245872; NCBI Protein GI: 15835130; NCBI Protein Accession: NP_296889; NCBITaxon: 243161 YH, ZX TC0757 hypothetical protein Protegen ID: 431; NCBI Gene GI: 1246122; NCBI Protein GI: 15835371; NCBI Protein Accession: NP_297130; NCBITaxon: 243161 YH, ZX Following vaginal challenge with live Chlamydia, the groups of female BALB/c mice immunized intra-abdominally with TC0757 showed significant levels of protection when compared to negative control animals [PubMed: 17239501]. TC0439 adherence factor YH, ZX Following vaginal challenge with live Chlamydia, the groups of female BALB/c mice immunized intra-abdominally with TC0439 showed significant levels of protection when compared to negative control animals [PubMed: 17239501]. Protegen ID: 432; NCBI Gene GI: 1245792; NCBI Protein GI: 15835057; NCBI Protein Accession: NP_296816; NCBITaxon: 243161 TC0767 hypothetical protein Following vaginal challenge with live Chlamydia, the groups of female BALB/c mice immunized intra-abdominally with TC0767/768 showed significant levels of protection when compared to negative control animals [PubMed: 17239501]. YH, ZX Protegen ID: 433; NCBI Gene GI: 1246132; NCBI Protein GI: 15835381; NCBI Protein Accession: NP_297140; NCBITaxon: 243161 TC0768 hypothetical protein Protegen ID: 434; NCBI Gene GI: 1246133; NCBI Protein GI: 15835382; NCBI Protein Accession: NP_297141; NCBITaxon: 243161 YH, ZX Following vaginal challenge with live Chlamydia, the groups of female BALB/c mice immunized intra-abdominally with TC0767/768 showed significant levels of protection when compared to negative control animals [PubMed: 17239501]. MOMP Female BALB/c mice were immunized with chlamydial major outer membrane protein (MOMP) mixed with cholera toxin and CpG oligodeoxynucleotide adjuvants by either the IN or TCI routes. Both intranasal and transcutaneous immunization protected mice against respiratory challenge with Chlamydia [PubMed: 16153755]. YH, ZX Protegen ID: 435; NCBI Protein GI: 1518659; NCBITaxon: 83560 PmpG-1 Mice vaccinated with DCs transfected with individual Chlamydia protein PmpG-1(25-500), RplF, or PmpE/F-2(25-575) exhibited significant resistance to challenge infection. Overall, vaccination with DCs transfected with PmpG-1(25-500) exhibited the greatest degree of protective immunity among the four Chlamydia Ags tested [PubMed: 19155509]. Protegen ID: 436; NCBI Gene GI: 1246433; NCBI Protein GI: 15834883; NCBI Protein Accession: NP_296642; NCBITaxon: 243161 YH, ZX RplF Mice vaccinated with DCs transfected with individual Chlamydia protein PmpG-1(25-500), RplF, or PmpE/F-2(25-575) exhibited significant resistance to challenge infection. In addition, RplF was able to engender protective immunity against challenge with C. muridarum [PubMed: 19155509]. YH, ZX Protegen ID: 437; NCBI Gene GI: 1246168; NCBI Protein GI: 15835415; NCBI Protein Accession: NP_297174; NCBITaxon: 243161 PmpE/F-2 YH, ZX Protegen ID: 438; NCBI Gene GI: 1246432; NCBI Protein GI: 15834882; NCBI Protein Accession: NP_296641; NCBITaxon: 243161 Mice vaccinated with DCs transfected with individual Chlamydia protein PmpG-1(25-500), RplF, or PmpE/F-2(25-575) exhibited significant resistance to challenge infection. In addition, pmpE/F-2 was able to engender protective immunity against challenge with C. muridarum [PubMed: 19155509]. PknD Protegen ID: 439; NCBI Gene GI: 895704; NCBI Protein GI: 161353778; NCBI Protein Accession: NP_224303; NCBITaxon: 115713 YH, ZX IM-ID vaccination with CPn0095 (pknD) generated a response that resulted in moderately, but significantly reduced total C. pneumoniae lung loads as compared to control mice vaccinated with a plasmid expressing a non-Chlamydia ORF (p0.019). This resulted in the ability of CPN0095 to mediate a moderate, but statistically significant level of protection in an inbred A/J mouse respiratory challenge model [PubMed: 16434129]. FabD Protegen ID: 440; NCBI Gene GI: 894994; NCBI Protein GI: 15618217; NCBI Protein Accession: NP_224502; NCBITaxon: 115713 YH, ZX M-ID vaccination with fabD generated a response that resulted in moderately, but significantly reduced total C. pneumoniae lung loads as compared to control mice vaccinated with a plasmid expressing a non-Chlamydia ORF (p 0.019). This resulted in the ability of fabD to mediate a moderate, but statistically significant level of protection in an inbred A/J mouse respiratory challenge model [PubMed: 16434129]. Ssb Mice vaccinated with candidate gene ssb showed significant reduction of spleen chlamydial loads as compared to nave, non-protected control mice (p 0.048). This resulted in the ability of ssb to mediate a modest, but significant level of protection in an inbred A/J mouse respiratory challenge model [PubMed: 16434129]. Protegen ID: 441; NCBI Gene GI: 894901; NCBI Protein GI: 15618301; NCBI Protein Accession: NP_224586; NCBITaxon: 115713 YH, ZX E2 YH, ZX Pigs were subjected to challenge infection with a dose of 1x10(5)TCID(50) (50% tissue culture infective dose) virulent CSFV strain. At 1 week post challenge infection, all of the yE2-immunized pigs were alive and without symptoms or signs of CSF. The yeast-expressed E2 protein retains correct immunogenicity and is able to induce a protective immune response against CSFV infection [PubMed: 19625145]. In a seperate study, swine vaccinated with VVR expressing E0 and/or E2 resisted a lethal challenge infection with CSFV. Glycoprotein E0 represents a second determinant for the induction of protective immunity against classical swine fever [PubMed: 7666549]. Protegen ID: 442; NCBI Gene GI: 920146; NCBI Protein GI: 12657942; NCBI Protein Accession: NP_075354; NCBITaxon: 11096 E0 Protegen ID: 443; NCBI Protein GI: 115343287; NCBITaxon: 11096 Swine vaccinated with VVR expressing E0 and/or E2 resisted a lethal challenge infection with CSFV. Glycoprotein E0 represents a second determinant for the induction of protective immunity against classical swine fever [PubMed: 7666549]. YH, ZX Gp55 Protegen ID: 444; NCBI Protein GI: 1763691; NCBITaxon: 11096 YH, ZX Intramuscular vaccination of pigs with immunoaffinity-purified E1 (gp55) in a double water-oil emulsion elicited high titers of neutralizing antibodies between 2 and 4 weeks after vaccination at the lowest dose tested (20 micrograms). The vaccinated pigs were completely protected against intranasal challenge with 100 50% lethal doses of HCV (Classical swine fever virus) strain Brescia [PubMed: 8350404]. BoNT/A1 from C. botulinum Protegen ID: 445; NCBI Protein GI: 241183337; NCBITaxon: 1491 A single dose of ciBoNT/A1 HP provided equivalent or greater protective immunity, not only against the homologous toxin, but also against two distinct toxin subtypes with significant amino acid divergence in mice when challenged with BoNT/A subtypes /A1, /A2, and /A3 from Clostridium botulinum [PubMed: 19450643]. YH, ZX FHc Protegen ID: 446; NCBI Protein GI: 166236883; NCBITaxon: 32630 Purified FHc was used to vaccinate mice and evaluate their survival against challenge with active botulinum neurotoxin serotype F (BoNT/F). Mice that received one injection of 5 microg or two injections of >or=0.04 microg of FHc were completely protected [PubMed: 18845829]. YH, ZX BotA YH, ZX A completely synthetic gene encoding fragment C, a approximately 50-kDa fragment, of botulinum neurotoxin serotype A was constructed from oligonucleotides. Mice given three subcutaneous vaccinations were protected against an intraperitoneal administration of 10^6 50% lethal doses (ID50) of serotype A toxin [PubMed: 7790092]. Protegen ID: 447; NCBI Protein GI: 733429; NCBITaxon: 32630 BoNT/A1 from C. botulinum A str. Hall Protegen ID: 448; NCBI Gene GI: 5398487; NCBI Protein GI: 153936924; NCBI Protein Accession: YP_001386738; NCBITaxon: 441771 YH, ZX Mice and rabbits were immunized with recombinant HCR/A1 (rHCR/A1) from the classical type A-Hall strain (ATCC 3502) (BoNT/A1) and rHCR/E from BoNT serotype E Beluga (BoNT/E(B)). The protection elicited by rHCR/A1 to BoNT/A1 and BoNT/A2 and by rHCR/E(B) to BoNT/E(A) indicate that immunization with receptor binding domains elicit protection within sub-serotypes of BoNT [PubMed: 16177380]. BoNT/B YH, ZX Protegen ID: 449; NCBI Gene GI: 6030102; NCBI Protein GI: 169834607; NCBI Protein Accession: YP_001693307; NCBITaxon: 498213 The DNA replicon vaccine (pSCARSBHc) encoding the Hc domain of BoNT/B (BHc) induced better responses and protection against BoNT/B mouse challenge than conventional DNA vaccine. Recombinant SFV particle VRP-BHc protected mice from high-dose BoNT/B challenge [PubMed: 19712769]. BoNT/C(Hc50) YH, ZX Researchers constructed a replication-incompetent adenovirus encoding a synthesized codon-optimized gene for expression of the heavy chain C-fragment (H(C)50) of botulinum neurotoxin type C (BoNT/C). After a single dose of 2 x 10^7pfu adenoviral vectors in a mouse model, the animals were completely protected against intraperitoneal challenge with 100 x MLD(50) of active BoNT/C [PubMed: 17897756]. Protegen ID: 450; NCBI Protein GI: 217781; NCBI Protein Accession: BAA14235.1; NCBITaxon: 12336 HAVgp2 Protegen ID: 680; NCBI Gene GI: 1493919; NCBI Protein GI: 9626734; NCBI Protein Accession: NP_041008; NCBITaxon: 12092 YH, ZX A recombinant vaccinia virus containing most of the P1 region of hepatitis A virus (HAV) was constructed bearing epitopes from structural polypeptides VP4, -3 and -2, and the N terminus of VP. Inoculation of tamarin monkeys with the recombinant virus resulted in the development of a specific anti-HAV immune response which was protective against challenge with a virulent strain of HAV [PubMed: 1654376]. Bfr from B. abortus S19 YH, ZX Following two intragastric immunizations in BALB/c mice, the Yersinia vectors harboring a DNA vaccine encoding BFR (P39) induced antigen-specific serum immunoglobulin and Th1-type responses among splenocytes. The best protection was conferred by a serotype O:9 strain carrying pCIP39, confirming the importance of the P39 T-cell antigen in this mechanism [PubMed: 11895955]. Protegen ID: 681; NCBI Gene GI: 6326162; NCBI Protein GI: 189022832; NCBI Protein Accession: YP_001932573; NCBITaxon: 430066 RplL Study was designed to evaluate the immunogenicity and the protective efficacy of a divalent fusion DNA vaccine encoding both the Brucella abortus L7/L12 protein (ribosomal protein, rplL) and Omp16 protein (outer membrane lipoprotein). This divalent DNA vaccine induced a significant level of protection against challenge with the virulent B. abortus in BALB/c mice [PubMed: 16622210]. Protegen ID: 682; NCBI Gene GI: 3788918; NCBI Protein GI: 82700077; NCBI Protein Accession: YP_414651; NCBITaxon: 359391 YH, ZX TTC Protegen ID: 451; NCBI Protein GI: 157829735; NCBITaxon: 1513 The fragment C of tetanus toxin was amplified from Clostridium tetani DNA by PCR. Immunization of mice with rTTC resulted in the production of antibodies that were able to protect mice against a challenge with tetanus toxin furthermore, rTTC in vivo appeared to be able to undergo retrograde axonal transport [PubMed: 12075415]. YH, ZX GP from Zaire ebolavirus Protegen ID: 452; NCBI Gene GI: 911829; NCBI Protein GI: 10313995; NCBI Protein Accession: NP_066246; NCBITaxon: 186538 YH, ZX Cynomolgus macaques were immunized with DNA/rAd5 vaccines expressing ZEBOV (GP) and SEBOV glycoprotein (GP) prior to lethal challenge with BEBOV. Vaccinated subjects developed robust, antigen-specific humoral and cellular immune responses against the GP from ZEBOV as well as cellular immunity against BEBOV GP, and immunized macaques were uniformly protected against lethal challenge with BEBOV [PubMed: 20502688]. GP from Sudan ebolavirus Protegen ID: 453; NCBI Gene GI: 3160774; NCBI Protein GI: 55770812; NCBI Protein Accession: YP_138523; NCBITaxon: 186540 YH, ZX Cynomolgus macaques were immunized with DNA/rAd5 vaccines expressing ZEBOV (GP) and SEBOV glycoprotein (GP) prior to lethal challenge with BEBOV. Vaccinated subjects developed robust, antigen-specific humoral and cellular immune responses against the GP from ZEBOV as well as cellular immunity against BEBOV GP, and immunized macaques were uniformly protected against lethal challenge with BEBOV [PubMed: 20502688]. NP YH, ZX Protegen ID: 454; NCBI Gene GI: 911830; NCBI Protein GI: 10314000; NCBI Protein Accession: NP_066243; NCBITaxon: 186538 Guinea pigs infected with a single intranasal inoculation of HPIV3/EboGP-NP showed no apparent signs of disease yet developed a strong humoral response specific to the EV proteins. When these animals were challenged with an intraperitoneal injection of 10(3) PFU of EV, there were no outward signs of disease, no viremia or detectable EV antigen in the blood, and no evidence of infection in the spleen, liver, and lungs. In contrast, all of the control animals died or developed severe EV disease following challenge [PubMed: 16474134]. YscF from Y. pestis CO92 YH, ZX Protegen ID: 54; NCBI Gene GI: 1172700; NCBI Protein GI: 16082743; NCBI Protein Accession: NP_395189; NCBITaxon: 214092 Ten mice were inoculated subcutaneously, administered booster injections after one month, and challenged with 130 LD(50) of wild type Y. pestis CO92. The vaccinated animals produced high levels of specific antibodies against YscF as determined by Western blot. The data were statistically significant (P = 0.053 by two-tailed Fisher's test), suggesting that the YscF protein can provide a protective immune response against lethal plague challenge during subcutaneous plague infection [PubMed: 15939303]. P4 The P4 protein is an integral outer membrane protein that has a role in acquiring hemin and nucleosides [PubMed: 1715322 ]. YH, ZX Protegen ID: 100; NCBITaxon: 727 Pal YH, ZX Protegen ID: 101; NCBI Gene GI: 3429820; NCBI Protein GI: 68248984; NCBI Protein Accession: YP_248096; NCBITaxon: 281310 Recombinant P6 (pal) was capable of eliciting a protective antibody response against live H. influenzae type b challenge in a modified infant rat model of bacteremia [PubMed: 9261944]. Hap from H. influenzae YH, ZX Protegen ID: 102; NCBI Protein GI: 21686508; NCBITaxon: 727 When mice immunized intranasally with recombinant protein corresponding to the C-terminal region of Hap(S) from H. influenzae strains N187, P860295, and TN106 plus mutant cholera toxin CT-E29H were challenged with strain TN106, they were protected against nasopharyngeal colonization [PubMed: 15557618]. Hap from H. influenzae Protegen ID: 103; NCBITaxon: 727 YH, ZX Omp26 Protegen ID: 276; NCBI Nucleotide GI: 4574245; NCBI Protein GI: 4574246; NCBI Protein Accession: AAD23967.1; NCBITaxon: 727 OMP26 was used to immunize rats via intestinal Peyer's patches, followed by an intratracheal boost. Immunization was found to significantly enhance bacterial clearance following pulmonary challenge with both the homologous NTHI strain and a different NTHI strain [PubMed: 9573117]. YH, ZX EsxA YH, ZX Protegen ID: 104; NCBI Gene GI: 886209; NCBI Protein GI: 57117165; NCBI Protein Accession: NC_000962.2; NCBITaxon: 1773 The heterologous prime-boost strategy of live Salmonella vaccine expressing Mycobacterium tuberculosis fusion antigen Age5B-ESAT6 (esxA) from the chromosome followed by a systemic boost of antigen and adjuvant reduced the levels of M. tuberculosis bacteria in the lungs and spleen to the same extent as BCG. Additionally, this vaccination regimen was observed to be statistically equivalent in terms of protection to immunisation with BCG [PubMed: 19755145]. TRAP from P. falciparum YH, ZX Protegen ID: 138; NCBI Gene GI: 814170; NCBI Protein GI: 124513464; NCBI Protein Accession: XP_001350088; NCBITaxon: 36329 LolC/E Protegen ID: 768; NCBI Gene GI: 3093214; NCBI Protein GI: 53719887; NCBI Protein Accession: YP_108873; NCBITaxon: 272560 LolC was evaluated as an antigen for a vaccine candidate against B. pseudomallei infection. Nonmembrane regions of the B. pseudomallei protein was expressed and purified from Escherichia coli and then evaluated as a vaccine candidate in an established mouse model of B. pseudomallei infection. When delivered with the monophosphoryl lipid A-trehalose dicorynomycolate adjuvant, the protein stimulated antigen-specific humoral and cellular immune responses. Immunization with the LolC protein domain afforded significant protection against a subsequent challenge with B. pseudomallei. LolC provided a greater level of protection when it was administered with immune-stimulating complexes complexed with CpG oligodeoxynucleotide 10103. Immunization with LolC also protected against a subsequent challenge with a heterologous strain of B. pseudomallei, demonstrating the potential utility of this protein as a vaccine antigen for melioidosis [PubMed: 17517877]. YH, ZX PotF PotF was evaluated as an antigen for a vaccine candidate against B. pseudomallei infection. Nonmembrane regions of the B. pseudomallei protein was expressed and purified from Escherichia coli and then evaluated as a vaccine candidate in an established mouse model of B. pseudomallei infection. When delivered with the monophosphoryl lipid A-trehalose dicorynomycolate adjuvant, the protein stimulated antigen-specific humoral and cellular immune responses. Immunization with the PotF protein domain afforded significant protection against a subsequent challenge with B. pseudomallei [PubMed: 17517877]. YH, ZX Protegen ID: 769; NCBI Gene GI: 3095748; NCBI Protein GI: 53721504; NCBI Protein Accession: YP_110489; NCBITaxon: 272560 AMA1 from P. falciparum 3D7 Protegen ID: 139; NCBI Gene GI: 810891; NCBI Protein GI: 124804478; NCBI Protein Accession: XP_001348015; NCBITaxon: 36329 YH, ZX OmpA Protegen ID: 766; NCBI Protein GI: 94467392; NCBITaxon: 83554 YH, ZX The ompA codon was adapted to the codon usage in birds, resulting in pcDNA1/MOMP(opt). Researchers examined the capacity of nebulised or intramuscularly (IM) administered brPEI-pcDNA1/MOMP(opt) to induce a significant protective immune response in SPF turkeys experimentally infected with 10^8 TCID(50) of a virulent Cp. psittaci strain. Vaccinated groups were significantly protected against Cp. psittaci challenge [PubMed: 20199760]. MOMP from C. psittaci Protegen ID: 767; NCBI Nucleotide GI: 144544; NCBI Protein GI: 144545; NCBI Protein Accession: AAA17396.1; NCBITaxon: 83554 Plasmid DNA (pcDNA1::MOMP A) expressing the major outer membrane protein (MOMP) of Chlamydophila psittaci genotype A strain 89/1051 has been tested for its ability to induce protective immunity against Cp. psittaci challenge in budgerigars. DNA immunisation significantly reduced clinical signs, macroscopic lesions, pharyngeal and cloacal excretion as well as chlamydial replication, even in the presence of pre-existing serum antibodies, as compared to the placebo-vaccinated controls [PubMed: 19640395]. YH, ZX ABRA YH, ZX Protective antigen [PubMed: 11489167] Protegen ID: 137; NCBITaxon: 5835 ORF Protegen ID: 113; NCBI Nucleotide GI: 599653; NCBI Protein GI: 599654; NCBI Protein Accession: CAA86936.1; NCBITaxon: 235 YH, ZX This gene was originally isolated from a lambda gt11 expression library probed with sera from Brucella-infected sheep. Sequence analysis of the cloned gene revealed the presence of an open reading frame of 158 amino acids encoding a protein of 17.3 kDa [PubMed: 7664168 ]. It was later identified as a cytoplasmic protein lumazine synthase [PubMed: 10482294 ]. This gene can be used for diagnosis [PubMed: 7664168 ] [PubMed: 10482294 ] and vaccine development [PubMed: 11953389 ]. B. abortus strain 19 L7/L12 YH, ZX Protegen ID: 114; NCBI Protein GI: 304271 VP35 Protegen ID: 167; NCBI Gene GI: 920948; NCBI Protein GI: 13489277; NCBI Protein Accession: NP_042026.1; NCBITaxon: 11269 YH, ZX Guinea pigs were vaccinated with recombinant VEE replicons (packaged into VEE-like particles), inoculated with MBGV, and evaluated for viremia and survival after challenge with typical MGBV disease. Results indicated that VP35 afforded incomplete protection [PubMed: 9813200 ]. P1 Protegen ID: 171; NCBI Protein GI: 30025845; NCBITaxon: 777 The purified recombinant proteins, P1, HspB, and P1-HspB, and whole-cell antigen (WCA) of C. burnetii were used to immunize BALB/c mice. Protective immunity against Q fever was induced with a recombinant P1 antigen fused with HspB after Coxiella burnetii challenge [PubMed: 16481504 ]. YH, ZX NP from Zaire ebolavirus YH, ZX Protegen ID: 172; NCBI Gene GI: 911830; NCBI Protein GI: 10314000; NCBI Protein Accession: NP_066243; NCBITaxon: 186538 GP from Zaire ebolavirus YH, ZX Protegen ID: 173; NCBI Protein GI: 21702651; NCBITaxon: 186538 NP Marburgvirus - Ravn Protegen ID: 174; NCBI Protein GI: 91177744; NCBITaxon: 378809 YH, ZX HspB Protegen ID: 175; NCBI Protein GI: 197253489; NCBITaxon: 777 The purified recombinant proteins, P1, HspB, and P1-HspB, and whole-cell antigen (WCA) of C. burnetii were used to immunize BALB/c mice. Protective immunity against Q fever was induced with a recombinant P1 antigen fused with HspB after Coxiella burnetii challenge [PubMed: 16481504 ]. YH, ZX H3L Protegen ID: 62; NCBI Gene GI: 3707557; NCBI Protein GI: 66275898; NCBI Protein Accession: YP_232983; NCBITaxon: 10245 YH, ZX Mice were immunized with recombinant H3L protein to examine H3L-specific antibody responses in greater detail. H3L-immunized mice developed high-titer vaccinia virus-neutralizing antibodies (mean PRNT50 = 1:3,760). Importantly, H3L-immunized mice were subsequently protected against lethal intranasal challenges with 1 or 5 50% lethal doses (LD50) of pathogenic vaccinia virus strain WR, demonstrating the in vivo value of an anti-H3L response. To formally demonstrate that neutralizing anti-H3L antibodies are protective in vivo, we performed anti-H3L serum passive-transfer experiments. Mice receiving H3L-neutralizing antiserum were protected from a lethal challenge with 3 LD50 of vaccinia virus strain WR (5/10 versus 0/10; P < 0.02) [PubMed: 16140750]. Ag85A YH, ZX Protegen ID: 154; NCBITaxon: 1773 Env Gp160 Protegen ID: 153; NCBITaxon: 11676 YH, ZX StxB2 YH, ZX Protegen ID: 225; NCBI Gene GI: 1262010; NCBI Protein GI: 9632507; NCBI Protein Accession: NP_049501; NCBITaxon: 10730 Omp31 Protegen ID: 231; NCBI Gene GI: 3788834; NCBI Protein GI: 82700421; NCBI Protein Accession: YP_414995; NCBITaxon: 359391 YH, ZX Tir YH, ZX Protegen ID: 199; NCBI Gene GI: 960860; NCBI Protein GI: 15804222; NCBI Protein Accession: NP_290261.1; NCBITaxon: 562 CS1 Protegen ID: 79; NCBI Gene GI: 4188469; NCBI Protein GI: 110643341; NCBI Protein Accession: YP_671071; NCBITaxon: 362663 YH, ZX ETEC also expresses a range of colonisation factor antigens (CFAs), which allow adherence to the mucosal surface and therefore colonisation of the intestine. Some CFAs are sub-divided into coli surface (CS) antigens [PubMed: 17566016]. FlaA from C. jejuni NCTC 11168 YH, ZX Protegen ID: 87; NCBI Gene GI: 905631; NCBI Protein GI: 15792662; NCBI Protein Accession: NP_282485.1; NCBITaxon: 197 EltB Protegen ID: 92; NCBI Protein GI: 157021162; NCBITaxon: 562 LT is a hetero-oligomeric AB5 type enterotoxin composed of a 27 kDa A subunit with toxic ADP ribosyl transferase activity and a stable noncovalent-linked pentamer of 11.6 kDa B subunits. ETEC infection and colonization of the small intestine, and the production of LT, causes acute diarrhea that can be fatal without intervention [PubMed: 17188785]. YH, ZX Eae Protegen ID: 93; NCBI Gene GI: 960862; NCBI Protein GI: 15804220; NCBI Protein Accession: NP_290259; NCBITaxon: 155864 YH, ZX EHEC strains produce intimin, an outer membrane adhesin encoded by the eae gene located in a chromosomal pathogenicity island termed the locus of enterocyte effacement [PubMed: 17258324]. FimH from E. coli UTI89 Protegen ID: 263; NCBI Gene GI: 3992235; NCBI Protein GI: 91213965; NCBI Protein Accession: YP_543951; NCBITaxon: 364106 FimH is a protective antigen [PubMed: 9110982] YH, ZX GNA2132 Protegen ID: 264; NCBI Gene GI: 903357; NCBI Protein GI: 15677945; NCBI Protein Accession: NP_275117; NCBITaxon: 122586 YH, ZX Protective antigen [PubMed: 10710308]. GNA2001 YH, ZX Protective antigen [PubMed: 10710308] Protegen ID: 265; NCBI Gene GI: 904124; NCBI Protein GI: 15677829; NCBI Protein Accession: NP_274993; NCBITaxon: 122586 B. melitensis M5 P39 The 39-kDa protein is immunogenic. Protegen ID: 110; NCBI Protein GI: 122892474; NCBI Protein Accession: ABM67295 YH, ZX Gag protein from SIV-mnd 2 YH, ZX A novel primate lentivirus was identified in Mandrillus sphinx. One of the newly isolated SIV strains was intravenously inoculated into two rhesus macaques and resulted in chronic infection. These SIVs do not cluster with SIVmndGB1, the former representative strain of SIVmnd, but form a new, independent lineage. These results indicate that these SIVmnds are a novel type of SIVmnd and have infected Cameroonian mandrills for a long time. To date, M. sphinx is the only primate species other than humans that is naturally infected with two different types of SIV [PubMed: 11522184]. Protegen ID: 98; NCBI Gene GI: 956108; NCBITaxon: 159122 SecA2 Vaccination of mice and guinea pigs with a secA2 mutant significantly increased resistance to M. tuberculosis challenge compared with standard M. bovis bacille Calmette-Gurin vaccination [PubMed: 17671656]. Protegen ID: 117; NCBI Gene GI: 885594; NCBI Protein GI: 15608958; NCBI Protein Accession: NP_216337; NCBITaxon: 83332 YH, ZX EsxB YH, ZX The 10-kDa culture filtrate protein (CFP-10, esxB) and 6-kDa early secretory antigen of T cells (ESAT-6) are secreted in abundance by Mycobacterium tuberculosis. Study demonstrated that protective immunity is induced by CFP-10 DNA vaccination in C3H mice as measured by a CFU reduction in the lung and spleen 4 and 8 weeks after challenge with M. tuberculosis [PubMed: 18332205]. Protegen ID: 121; NCBI Gene GI: 886194; NCBI Protein GI: 15611010; NCBI Protein Accession: NP_218391; NCBITaxon: 83332 FbpA Protegen ID: 122; NCBI Gene GI: 886132; NCBI Protein GI: 15610940; NCBI Protein Accession: NC_000962.2; NCBITaxon: 1773 YH, ZX Researchers have developed DNA vaccines expressing M. tuberculosis antigen 85A (Ag85A, fbpA) and cytokine granulocyte macrophage colony stimulating factor (GM-CSF). The immune strategy of BCG-prime and DNA vaccine boost induced mice to generate efficient immune protection against M. tuberculosis challenge [PubMed: 19450898]. PepA YH, ZX Protegen ID: 123; NCBI Gene GI: 886924; NCBI Protein GI: 15607267; NCBI Protein Accession: NC_000962.2; NCBITaxon: 1773 PPE18 Protegen ID: 124; NCBI Gene GI: 886073; NCBI Protein GI: 57116841; NCBI Protein Accession: NC_000962.2; NCBITaxon: 1773 YH, ZX CjaA from C. jejuni RM 1221 YH, ZX Protegen ID: 133; NCBI Gene GI: 3231573; NCBI Protein GI: 57237809; NCBI Protein Accession: YP_179057.1; NCBITaxon: 197 CjaA from C. jejuni Protegen ID: 134; NCBI Protein GI: 1813949; NCBITaxon: 197 YH, ZX A total of 840 Light Sussex chickens were used to evaluate a Salmonella enterica serovar Typhimurium DeltaaroA vaccine expressing the C. jejuni amino acid binding protein CjaA. Chickens were given the vaccine at 1-day-old and two weeks later by oral gavage, then challenged after a further two weeks with C. jejuni. Across six biological replicates, statistically significant reductions in caecal C. jejuni of c. 1.4log(10) colony-forming units/g were observed at three and four weeks post-challenge relative to age-matched unvaccinated birds. Protection was associated with the induction of CjaA-specific serum IgY and biliary IgA [PubMed: 19853682]. Pvs25 YH, ZX Protegen ID: 141; NCBITaxon: 5855 MSP1 from P. falciparum Protegen ID: 143; NCBI Protein GI: 94420988; NCBITaxon: 5833 Aotus monkeys were challenged with the virulent Vietnam Oak Knoll (FVO) strain of P. falciparum. Vaccination of A. nancymai with yMSP1(19) induced protective immune responses. Both of the A. nancymai vaccinated with yMSP1(19) self-resolved an otherwise lethal infection [PubMed: 8529111]. YH, ZX RESA YH, ZX Protegen ID: 144 S nucleocapsid protein from Dobrava-Belgrade virus Study compared the immunogenicity and protective efficacy of recombinant DOBV nucleocapsid protein (rDOBV N, S) given with Alum or Freund's as adjuvant, or PBS, in C57/BL6 mice. Mice receiving rDOBV N with Freund's adjuvant were protected from challenge (75% protected) [PubMed: 15364453]. YH, ZX Protegen ID: 146; NCBI Gene GI: 2656266; NCBI Protein GI: 38505524; NCBI Protein Accession: NP_942553; NCBITaxon: 12506 GP from Lake Victoria marburgvirus YH, ZX Protegen ID: 150; NCBI Protein GI: 77543430; NCBITaxon: 33727 Study developed replication-competent vaccines against EBOV and MARV based on attenuated recombinant vesicular stomatitis virus vectors expressing either the EBOV glycoprotein or MARV glycoprotein from Lake Victoria marburgvirus - Musoke. A single intramuscular injection of the EBOV or MARV vaccine elicited completely protective immune responses in nonhuman primates against lethal EBOV or MARV challenges [PubMed: 15937495]. Bp26 This is a protective antigen [PubMed: 17239499]. YH, ZX Protegen ID: 232; NCBI Gene GI: 1196247; NCBI Protein GI: 17986819; NCBI Protein Accession: NP_539453; NCBITaxon: 224914 RpsL Protegen ID: 236; NCBI Gene GI: 1196463; NCBI Protein GI: 161511151; NCBI Protein Accession: NP_539669; NCBITaxon: 224914 YH, ZX Iss YH, ZX Protegen ID: 240; NCBI Gene GI: 5616654; NCBI Protein GI: 157418230; NCBI Protein Accession: YP_001481302; NCBITaxon: 405955 FyuA Protegen ID: 247; NCBI Gene GI: 4492541; NCBI Protein GI: 117624167; NCBI Protein Accession: YP_853080; NCBITaxon: 405955 YH, ZX Omp25 YH, ZX Protegen ID: 253; NCBI Gene GI: 1196960; NCBI Protein GI: 17987532; NCBI Protein Accession: NP_540166; NCBITaxon: 224914 Brucella Omp25 is a protective antigen [PubMed: 17049676]. IalB Protegen ID: 254; NCBI Gene GI: 1197295; NCBI Protein GI: 17987867; NCBI Protein Accession: NP_540501; NCBITaxon: 224914 YH, ZX Brucella IalB is a protective antigen [PubMed: 17049676]. Bfr from B. melitensis biovar Abortus 2308 Brucella bacterioferritin is a protective antigen [PubMed: 11447155 ] Protegen ID: 255; NCBI Gene GI: 3828133; NCBI Protein GI: 83269559; NCBI Protein Accession: YP_418850; NCBITaxon: 359391 YH, ZX Tig Protegen ID: 256; NCBI Gene GI: 1196780; NCBI Protein GI: 17987352; NCBI Protein Accession: NP_539986; NCBITaxon: 224914 YH, ZX protective antigen [PubMed: 17239499] DnaK YH, ZX Brucella DnaK is a protective antigen [PubMed: 17686554]. Protegen ID: 257; NCBI Gene GI: 3341115; NCBI Protein GI: 62290965; NCBI Protein Accession: YP_222758; NCBITaxon: 262698 SurA YH, ZX Brucella SurA is a protective antigen [PubMed: 17686554]. Protegen ID: 258; NCBI Gene GI: 3787419; NCBI Protein GI: 82699574; NCBI Protein Accession: YP_414148; NCBITaxon: 359391 Omp19 Brucella Omp19 is a protective antigen [PubMed: 18981242]. YH, ZX Protegen ID: 259; NCBI Gene GI: 3788831; NCBI Protein GI: 82700695; NCBI Protein Accession: YP_415269; NCBITaxon: 359391 Omp16 Brucella Omp16 is a protective antigen [PubMed: 18981242]. Protegen ID: 260; NCBI Gene GI: 3788229; NCBI Protein GI: 82700483; NCBI Protein Accession: YP_415057; NCBITaxon: 359391 YH, ZX GNA1946 Protective antigen [PubMed: 10710308] YH, ZX Protegen ID: 266; NCBI Gene GI: 904205; NCBI Protein GI: 15677776; NCBI Protein Accession: NP_274940; NCBITaxon: 122586 GNA1220 Protective antigen [PubMed: 10710308] Protegen ID: 267; NCBI Gene GI: 903642; NCBI Protein GI: 15677093; NCBI Protein Accession: NP_274245; NCBITaxon: 122586 YH, ZX GNA1162 Protegen ID: 268; NCBI Gene GI: 903582; NCBI Protein GI: 15677037; NCBI Protein Accession: NP_274189; NCBITaxon: 122586 Protective antigen[PubMed: 10710308] YH, ZX GNA992 (hsf) Protegen ID: 269; NCBI Gene GI: 903112; NCBI Protein GI: 15676883; NCBI Protein Accession: NP_274028; NCBITaxon: 122586 Protective antigen [PubMed: 10710308] YH, ZX GNA33 Protegen ID: 270; NCBI Gene GI: 902136; NCBI Protein GI: 15675973; NCBI Protein Accession: NP_273099; NCBITaxon: 122586 YH, ZX Protective antigen [PubMed: 10710308] NspA from N. meningitidis MC58 YH, ZX Protective antigen [PubMed: 9104804] Protegen ID: 271; NCBI Gene GI: 902774; NCBI Protein GI: 15676561; NCBI Protein Accession: NP_273705; NCBITaxon: 122586 NadA Protegen ID: 272; NCBI Gene GI: 904134; NCBI Protein GI: 15677822; NCBI Protein Accession: NP_274986; NCBITaxon: 122586 YH, ZX Protective antigen [PubMed: 16825336][PubMed: 12045242] with GeneID: 902509. However, according to sequence analysis, this nadA is not the same NadA that was found to be protective antigen [PubMed: 16825336][PubMed: 12045242]. GNA1870 Protective antigen [PubMed: 16825336] Protegen ID: 273; NCBI Gene GI: 904318; NCBI Protein GI: 15677705; NCBI Protein Accession: NP_274866; NCBITaxon: 122586 YH, ZX GNA2091 Protective antigen as shown in some assays [PubMed: 16825336] YH, ZX Protegen ID: 274; NCBI Gene GI: 903958; NCBI Protein GI: 15677911; NCBI Protein Accession: NP_275079; NCBITaxon: 122586 GNA1030 Protegen ID: 275; NCBI Gene GI: 903167; NCBI Protein GI: 15676917; NCBI Protein Accession: NP_274064; NCBITaxon: 122586 Protective antigen as shown in some assays [PubMed: 16825336] YH, ZX Hma A vaccine made by Hma from E. coli strain CFT073 and 536 induced protection to the infection of virulent strain CFT073 and 536, respectively, in the bladder in the CBA/J mice. [PubMed: 19806177]. Protegen ID: 278; NCBI Gene GI: 1037732; NCBI Protein GI: 26248334; NCBI Protein Accession: NP_754374; NCBITaxon: 199310 YH, ZX IreA YH, ZX Protegen ID: 279; NCBI Gene GI: 1037614; NCBI Protein GI: 26250982; NCBI Protein Accession: NP_757022; NCBITaxon: 199310 Immunization with IreA protects against urinary tract colinization by E.coli CFT073 and reduces colinization by E.coli 536 in the bladder of CBA/J mice [PubMed: 19806177]. IutA Protegen ID: 280; NCBI Gene GI: 1039578; NCBI Protein GI: 26249458; NCBI Protein Accession: NP_755498; NCBITaxon: 199310 Immunization with IutA protects against urinary tract colinization by E.coli CFT073 in the bladders of CBA/J mice [PubMed: 19806177]. YH, ZX FimH from E. coli str. K-12 substr. MG1655 Protegen ID: 281; NCBI Gene GI: 948847; NCBI Protein GI: 16132141; NCBI Protein Accession: NP_418740; NCBITaxon: 511145 YH, ZX Antibodies directed at the putative binding region of FimH (anti- s-FimH1-25) significantly reduced E. coli bladder infections in the experimental mouse model of urinary tract infections [PubMed: 9276729]. IroN Active immunization of BALB/c mice with IroN antigen in Freund's adjuvant protects mice from lethal challenge with ExPEC strain S26 [PubMed: 17145948 ]. Protegen ID: 282; NCBI Gene GI: 7379404; NCBI Protein GI: 222104801; NCBI Protein Accession: YP_002539290; NCBITaxon: 562 YH, ZX C0393 YH, ZX Protegen ID: 283; NCBI Gene GI: 1034958; NCBI Protein GI: 26246291; NCBI Protein Accession: NP_752330; NCBITaxon: 199310 Active immunization of BALB/c mice with C0393 antigen in Freund's adjuvant protects mice from lethal challenge with ExPEC strain S26 [PubMed: 17145948]. C4424 Protegen ID: 284; NCBI Gene GI: 1038067; NCBI Protein GI: 26250246; NCBI Protein Accession: NP_756286; NCBITaxon: 199310 YH, ZX Active immunization of BALB/c mice with C4424 antigen in Freund's adjuvant protects mice from lethal challenge with ExPEC strain S26 [PubMed: 17145948]. C3389 YH, ZX Active immunization of BALB/c mice with recombinant E. coli protein C3389 antigen in Freund's adjuvant protects mice from lethal challenge with ExPEC strain S26 [PubMed: 17145948]. Protegen ID: 285; NCBI Gene GI: 1039252; NCBI Protein GI: 26249224; NCBI Protein Accession: NP_755264; NCBITaxon: 199310 Spa32 Protegen ID: 288; NCBI Gene GI: 876502; NCBI Protein GI: 13449098; NCBI Protein Accession: NP_085314; NCBITaxon: 424718 S. flexneri M90T is a colonisation-defective mutant with a transposon in fnr, which encodes a regulator of anaerobic metabolism. To establish whether FNR-mediated repression of spa32 and spa33 contributes to increased Shigella entry into cells in an anaerobic cabinet, recombinant M90T strains were constructed which contain spa32 and spa33 under the control of either their native promoters (M90Tp32/33) or promoters with disrupted FNR boxes (M90Tp#32/#33).The presence in M90T of spa32 and spa33 alleles that are not repressed by FNR led to IpaB secretion during anaerobic growth, and loss of the increased entry of Shigella into cells in an anaerobic cabinet [PubMed: 20436458]. YH, ZX ECSE_P3-0034 Protegen ID: 289; NCBI Gene GI: 7003192; NCBI Protein GI: 209921909; NCBI Protein Accession: YP_002295988; NCBITaxon: 409438 Oral immunization of FaeG-expressing L. lactis exhibits a protective response against ETEC infection in mice [PubMed: 19277476]. YH, ZX IpaB YH, ZX Protegen ID: 307; NCBI Protein GI: 22036246; NCBITaxon: 42897 The invasiveness and virulence of Shigella spp. are largely due to the expression of plasmid-encoded virulence factors, among which are the invasion plasmid antigens (IpaB, IpaC, and IpaD). Recent observations have indicated that the Ipa proteins (IpaB, IpaC, and possibly IpaD) form a multiprotein complex capable of inducing the phagocytic event which internalizes the bacterium. Researchers isolated a complex of invasins and LPS from water-extractable antigens of virulent shigellae. Western blot analysis of the complex indicates that all of the major virulence antigens of Shigella, including IpaB, IpaC, and IpaD, and LPS are components of this macromolecular complex. Guinea pigs (keratoconjunctivitis model) or mice (lethal lung model) immunized intranasally with purivied invasin complex (invaplex) on days 0, 14, and 28 and challenged 3 weeks later with virulent shigellae were protected from disease (P<0.01 for both animal models) [PubMed: 11083774]. IpaC YH, ZX The invasiveness and virulence of Shigella spp. are largely due to the expression of plasmid-encoded virulence factors, among which are the invasion plasmid antigens (IpaB, IpaC, and IpaD). Recent observations have indicated that the Ipa proteins (IpaB, IpaC, and possibly IpaD) form a multiprotein complex capable of inducing the phagocytic event which internalizes the bacterium. Researchers isolated a complex of invasins and LPS from water-extractable antigens of virulent shigellae. Western blot analysis of the complex indicates that all of the major virulence antigens of Shigella, including IpaB, IpaC, and IpaD, and LPS are components of this macromolecular complex. Guinea pigs (keratoconjunctivitis model) or mice (lethal lung model) immunized intranasally with purivied invasin complex (invaplex) on days 0, 14, and 28 and challenged 3 weeks later with virulent shigellae were protected from disease (P<0.01 for both animal models) [PubMed: 11083774]. Protegen ID: 308; NCBI Protein GI: 47056; NCBITaxon: 42897 IpaD The invasiveness and virulence of Shigella spp. are largely due to the expression of plasmid-encoded virulence factors, among which are the invasion plasmid antigens (IpaB, IpaC, and IpaD). Recent observations have indicated that the Ipa proteins (IpaB, IpaC, and possibly IpaD) form a multiprotein complex capable of inducing the phagocytic event which internalizes the bacterium. Researchers isolated a complex of invasins and LPS from water-extractable antigens of virulent shigellae. Western blot analysis of the complex indicates that all of the major virulence antigens of Shigella, including IpaB, IpaC, and IpaD, and LPS are components of this macromolecular complex. Guinea pigs (keratoconjunctivitis model) or mice (lethal lung model) immunized intranasally with purivied invasin complex (invaplex) on days 0, 14, and 28 and challenged 3 weeks later with virulent shigellae were protected from disease (P<0.01 for both animal models) [PubMed: 11083774]. YH, ZX Protegen ID: 309; NCBI Protein GI: 22036352; NCBITaxon: 42897 IroN YH, ZX Protegen ID: 318; NCBI Protein GI: 259475459; NCBITaxon: 90371 Thirty-day-old chickens were immunized intramuscularly with purified IroN from Salmonella Typhimurium mixed with Freund's incomplete adjuvant; the chickens were then challenged intravenously with Salmonella Enteritidis. The mortality rate of immunized chickens was 10%. On the other hand, that of control chickens was 80% [PubMed: 20095157]. GroEL Protegen ID: 320; NCBI Gene GI: 1068458; NCBI Protein GI: 29144631; NCBI Protein Accession: NP_807973; NCBITaxon: 209261 Researchers evaluated the immunogenicity and protective efficacy of GroEL of Salmonella enterica serovar Typhi against lethal infection by S. typhi Ty2 in mice with or without adjuvants. Immunization of mice with GroEL-alone, GroEL + alum, and GroEL + CFA provided 70, 50 and 80% protection, respectively, against lethal challenge by S. typhi in mice. The present study shows that GroEL forms an ideal candidate molecule to develop a recombinant protein based vaccine against human typhoid [PubMed: 19851830]. YH, ZX SopB The entire SopB and SifB genes were cloned into DNA vaccine vectors and were administered along with live attenuated Salmonella. It was found that SopB vaccination reduced the bacterial burden of organs by about 5-fold on day 4 and day 8 after challenge with virulent Salmonella and proved to be a more efficient vaccination strategy than live attenuated bacteria alone [PubMed: 19428891]. YH, ZX Protegen ID: 321; NCBI Protein GI: 54036439; NCBITaxon: 90371 SAG1 YH, ZX Oral immunization of mice with ZJ111/pcDNA3-SAG1 elicited specific humoral responses and stimulated proliferation of splenocytes (P<0.05). Mice immunized with ZJ111/pcDNA3-SAG1 displayed significant protection against an intraperitoneally challenge with 500 tachyzoite forms of T. gondii RH strain. Vaccination at 10(7) and 10(8)CFU per mice provided a 20% and 10% survival rate comparing 100% mortality of the non-immunized mice, exhibiting longer living time and better survival rate [PubMed: 18590785]. Protegen ID: 326; NCBI Gene GI: 7900172; NCBI Protein GI: 237839159; NCBI Protein Accession: XP_002368877; NCBITaxon: 508771 YscF from Y. pestis KIM 10 Modified YscF antigens were able to partially protect immunized mice at various levels against lethal challenge with Y. pestis KIM 1001 strain [PubMed: 18291562]. YH, ZX Protegen ID: 338; NCBI Gene GI: 1149286; NCBI Protein GI: 31795470; NCBI Protein Accession: NP_857922; NCBITaxon: 187410 YopD from Y. pestis KIM 10 Protegen ID: 339; NCBI Gene GI: 1149313; NCBI Protein GI: 31795494; NCBI Protein Accession: NP_857949; NCBITaxon: 187410 Modified yopD antigens were able to partially protect immunized mice at various levels against lethal challenge with Y. pestis KIM 1001 strain [PubMed: 18291562]. YH, ZX YopO Modified yopO antigens were able to partially protect immunized mice at various levels against lethal challenge with Y. pestis KIM 1001 strain [PubMed: 18291562]. Protegen ID: 340; NCBI Gene GI: 5798322; NCBI Protein GI: 162417777; NCBI Protein Accession: YP_001604502; NCBITaxon: 349746 YH, ZX YPMT1.84 (F1 capsule antigen) YH, ZX Protegen ID: 341; NCBI Gene GI: 1172839; NCBI Protein GI: 16082876; NCBI Protein Accession: NP_395430; NCBITaxon: 214092 Intranasal immunization with flagellin and the F1 antigen was protective against intranasal challenge with virulent Y. pestis CO92, with 93 to 100% survival of immunized mice. Lastly, vaccination of cynomolgus monkeys with flagellin and a fusion of the F1 and V antigens of Y. pestis induced a robust antigen-specific IgG antibody response [PubMed: 16428759]. YapF YH, ZX Protegen ID: 342; NCBI Gene GI: 1173449; NCBI Protein GI: 218927800; NCBI Protein Accession: YP_002345675; NCBITaxon: 214092 Using a mouse model, YPO0606 (yapF) partially protected mice from infection with Y. pestis at a high challenge dosage (200x LD(50)) [PubMed: 19651863]. Irp7 Using a mouse plague model, YPO1914 (irp7) may provide partial protection against challenge with a low dose (20 times the 50% lethal dose [20x LD(50)]) of Y. pestis [PubMed: 19651863]. Protegen ID: 343; NCBI Gene GI: 1174753; NCBI Protein GI: 218929030; NCBI Protein Accession: YP_002346905; NCBITaxon: 214092 YH, ZX YPO0612 YH, ZX Using a mouse plague model, YPO0612 may provide partial protection against challenge with a low dose (20 times the 50% lethal dose [20x LD(50)]) of Y. pestis [PubMed: 19651863]. Protegen ID: 344; NCBI Gene GI: 1173455; NCBI Protein GI: 218927806; NCBI Protein Accession: YP_002345681; NCBITaxon: 214092 HtpG YH, ZX Protegen ID: 345; NCBI Gene GI: 1175934; NCBI Protein GI: 218930152; NCBI Protein Accession: YP_002348027; NCBITaxon: 214092 Using a mouse plague model, YPO3119 (htpG) may provide partial protection against challenge with a low dose (20 times the 50% lethal dose [20x LD(50)]) of Y. pestis [PubMed: 19651863]. YdeN Using a mouse plague model, YPO3047 (ydeN) may provide partial protection against challenge with a low dose (20 times the 50% lethal dose [20x LD(50)]) of Y. pestis [PubMed: 19651863]. YH, ZX Protegen ID: 346; NCBI Gene GI: 1175868; NCBI Protein GI: 218930092; NCBI Protein Accession: YP_002347967; NCBITaxon: 214092 LolA YH, ZX Using a mouse plague model, YPO1377 (lolA) may provide partial protection against challenge with a low dose (20 times the 50% lethal dose [20x LD(50)]) of Y. pestis [PubMed: 19651863]. Protegen ID: 347; NCBI Gene GI: 1174218; NCBI Protein GI: 218928525; NCBI Protein Accession: YP_002346400; NCBITaxon: 214092 YerA Protegen ID: 348; NCBI Gene GI: 1172650; NCBI Protein GI: 16082696; NCBI Protein Accession: NP_395142; NCBITaxon: 214092 Using a mouse plague model, YPCD1.05c (yerA) may provide partial protection against challenge with a low dose (20 times the 50% lethal dose [20x LD(50)]) of Y. pestis [PubMed: 19651863]. YH, ZX YPO0420 Using a mouse plague model, YPO0420 may provide partial protection against challenge with a low dose (20 times the 50% lethal dose [20x LD(50)]) of Y. pestis [PubMed: 19651863]. Protegen ID: 349; NCBI Gene GI: 1173265; NCBI Protein GI: 218927621; NCBI Protein Accession: YP_002345496; NCBITaxon: 214092 YH, ZX HpmB Using a mouse plague model, YPO3720 (hpmB) may provide partial protection against challenge with a low dose (20 times the 50% lethal dose [20x LD(50)]) of Y. pestis [PubMed: 19651863]. YH, ZX Protegen ID: 350; NCBI Gene GI: 1176539; NCBI Protein GI: 218930726; NCBI Protein Accession: YP_002348601; NCBITaxon: 214092 Psn Protegen ID: 351; NCBI Gene GI: 1147351; NCBI Protein GI: 22126288; NCBI Protein Accession: NP_669711; NCBITaxon: 187410 YH, ZX Study tested the efficacy of 2 proteins, Psn and a portion of LcrV in protecting mice against virulent Yersinia pestis challenge. Results show that the truncated LcrV protein delivered by RASV is sufficient to afford a full protective immune response in a mouse model of bubonic plague and the Psn protein afforded partial protection in a non-optimized system [PubMed: 17966435]. YopH from Y. pestis CO92 YH, ZX Study evaluated the humoral immune response of mice that survived lethal Y. pestis aerosol challenge after antibiotic treatment. Results indicated that one of the predominant antibody response of mice surviving pneumonic plague after treatment with antibiotics was to yopH [PubMed: 10085037]. Protegen ID: 352; NCBI Gene GI: 1172712; NCBI Protein GI: 16082755; NCBI Protein Accession: NP_395201; NCBITaxon: 214092 pYV0055 YH, ZX Protegen ID: 354; NCBI Gene GI: 2952948; NCBI Protein GI: 51593897; NCBI Protein Accession: YP_068464; NCBITaxon: 273123 Complexes of YopB (pYV0055), YopD, and YopE (BDE) secreted by Yersinia pseudotuberculosis were purified by affinity chromatography and used as immunogens to determine if antibodies to the translocon could provide protection against Y. pestis in mice. The YopB protein or a complex of YopB and YopD (BD) was purified and determined by vaccination to be immunogenic in mice. Mice actively vaccinated with BD or passively vaccinated with anti-BD serum were protected against lethal challenge with F1(-) Y. pestis [PubMed: 18765742]. Caf1 from Y. pestis Protegen ID: 355; NCBI Protein GI: 48621; NCBITaxon: 632 YH, ZX Vaccination of mice with deF1 DNA conferred protection against subcutaneous infection with the virulent Y. pestis Kimberley53 strain, even at challenge amounts as high as 4,000 50% lethal doses [PubMed: 12496187 ]. P145 YH, ZX Following passive immunization, antisera partially protected infant rats from bacteremia resulting from intraperitoneal challenge with bacteria. As assessed by immunoblotting, pooled adult human sera contained antibodies reactive with P145. Following passive immunization, these antisera partially protected infant rats from bacteremia resulting from intraperitoneal challenge with bacteria. Antibody to P145 may contribute to protection against Brazilian purpuric fever [PubMed: 1937817]. Protegen ID: 356 ApxIA Protegen ID: 358; NCBI Protein GI: 312899; NCBITaxon: 715 The ApxI antigen is an important factor in the protection against Actinobacillus pleuropneumoniae serotype 5 infection; therefore, the protective immunity in mice following oral immunization with Saccharomyces cerevisiae expressing either ApxIA (group C) or ApxIIA (group D) alone or both (group E) was compared with that in two control groups (group A and B). The immunogenicity of the rApxIA antigen derived from the yeast was confirmed by a high survival rate and an ApxIA-specific IgG antibody response (p < 0.01) [PubMed: 17993753]. YH, ZX ApxIIA YH, ZX The levels of local and systemic antibodies specific to the Apx antigens were investigated in mice orally immunized with Apx antigen-expressing yeast. Specific IgA responses to ApxIA or ApxIIA in the intestines and lungs from mice immunized with yeast expressing Apx antigens were significantly higher than those in the control groups after the second and third immunizations, respectively (p < 0.05). All mice were monitored for up to 72 h after challenge with the MLD of an A. pleuropneumoniae field isolate. Overall, the final survival rates of the vaccinated groups were higher than those of the control groups at each time point [PubMed: 17993753]. Protegen ID: 360; NCBI Protein GI: 52630374; NCBITaxon: 715 CP YH, ZX Following a booster vaccination, a significant (P < 0.05) IgG antibody response to the CP (cps5C), LPS, and HP was detected in the vaccinated pigs. The pigs vaccinated with the CP-HP and LPS-HP conjugates exhibited significantly less mortality (P < 0.05) and significantly greater weight gain (P < 0.001) than unvaccinated pigs. Vaccinated pigs exhibited significantly fewer and less extensive gross pulmonary lesions (P < 0.001) when compared with unvaccinated pigs [PubMed: 1455686]. Protegen ID: 361 APP7_1016 YH, ZX Following a booster vaccination, a significant (P < 0.05) IgG antibody response to the CP, LPS, and HP (APP7_1016) was detected in the vaccinated pigs. The pigs vaccinated with the CP-HP and LPS-HP conjugates exhibited significantly less mortality (P < 0.05) and significantly greater weight gain (P < 0.001) than unvaccinated pigs. Vaccinated pigs exhibited significantly fewer and less extensive gross pulmonary lesions (P < 0.001) when compared with unvaccinated pigs [PubMed: 1455686]. Protegen ID: 362; NCBI Gene GI: 6398034; NCBI Protein GI: 190150285; NCBI Protein Accession: YP_001968810; NCBITaxon: 537457 Lipopolysaccharide Following a booster vaccination, a significant (P < 0.05) IgG antibody response to the CP, LPS (wzxE), and HP was detected in the vaccinated pigs. The pigs vaccinated with the CP-HP and LPS-HP conjugates exhibited significantly less mortality (P < 0.05) and significantly greater weight gain (P < 0.001) than unvaccinated pigs. Vaccinated pigs exhibited significantly fewer and less extensive gross pulmonary lesions (P < 0.001) when compared with unvaccinated pigs [PubMed: 1455686]. YH, ZX Protegen ID: 363; NCBITaxon: 434271 AroA Protegen ID: 366; NCBI Protein GI: 512545; NCBITaxon: 645 The aroA gene of A. salmonicida was cloned in Escherichia coli, and the nucleotide sequence was determined. Vaccination of brown trout with 10(7) CFU of A. salmonicida 644Rb aroA by intraperitoneal injection resulted in a 253-fold increase in the 50% lethal dose (LD50) compared with unvaccinated controls challenged with a virulent clinical isolate 9 weeks later [PubMed: 8478107]. YH, ZX AsaP1 Protegen ID: 367; NCBI Gene GI: 4998702; NCBITaxon: 382245 Passive immunisation of Atlantic salmon with rainbow trout or rabbit anti-AsaP1 antisera conferred significant protection against challenge with a virulent A. salmonicida [Ref1011:Gudmundsdottir et al., 1997] YH, ZX RAP-1 RAP-1 (21B4) is a candidate for inclusion in a B. bovis vaccine based on its ability to induce partial protection in vaccinates, defined as a significant reduction in parasitemia upon challenge [PubMed: 1441189]. YH, ZX Protegen ID: 368; NCBI Gene GI: 5479143; NCBI Protein GI: 156087004; NCBI Protein Accession: XP_001610909; NCBITaxon: 484906 12D3 Protegen ID: 371; NCBI Gene GI: 5478971; NCBI Protein GI: 156086656; NCBI Protein Accession: XP_001610737; NCBITaxon: 484906 Crude extracts of Babesia bovis parasites were systematically fractionated and tested in numerous sequential vaccination/challenge experiments in adult cattle. Two of these, GST-12D3 and GST-11C5, when used in combination were almost as protective as has been previously shown for the commercially available live attenuated vaccine [PubMed: 1441189]. YH, ZX 21B4 YH, ZX Protegen ID: 373; NCBI Protein GI: 1246924; NCBITaxon: 5865 Crude extracts of Babesia bovis parasites were systematically fractionated and tested in numerous sequential vaccination/challenge experiments in adult cattle. A short fragment of the third antigen (21B4) has been shown to be protective [PubMed: 1441189]. PagA from B. anthracis YH, ZX Protegen ID: 374; NCBI Protein GI: 9280533; NCBITaxon: 1392 Study described the construction and evaluation of an adenovirus vaccine expressing domain 4 of Bacillus anthracis protective antigen, Ad.D4. Ad.D4 elicited antibodies to protective antigen 14 days after a single intramuscular injection, which were further increased upon boosting. Furthermore, two doses of Ad.D4 4 weeks apart were sufficient to protect 67% of mice from toxin challenge [PubMed: 16428747]. FhaB YH, ZX Protegen ID: 375; NCBI Protein GI: 3980256; NCBITaxon: 520 A combination of the 69-kDa outer membrane protein and filamentous hemagglutinin (fhaB), both isolated from lymphocytosis promoting factor (LPF; pertussis toxin) minus mutants of Bordetella pertussis, is protective in the mouse intracerebral challenge potency (Kendrick) test [PubMed: 2056199]. CyaA YH, ZX A study demonstrated that passive immunization with specific anti-B. pertussis adenylate cyclase antibodies or active immunization with purified B. pertussis secreted adenylate cyclase (cyaA) protect mice against a lethal respiratory challenge with B. pertussis or B. parapertussis. Results suggest that adenylate cyclase might be the primary cytotoxin responsible for mouse pulmonary lesions during respiratory tract infection with B. pertussis or with the related species B. parapertussis and is a protective antigen of B. pertussis [PubMed: 2622329]. Protegen ID: 376; NCBI Protein GI: 580668; NCBITaxon: 520 PtxD Protegen ID: 377; NCBI Protein GI: 225311181; NCBITaxon: 520 YH, ZX BALB/c mice were immunized with PTx vaccine on day 6 of life and then challenged with B. pertussis using the aerosol challenge model. These primed mice were significantly better protected against leukocytosis, weight loss, and proliferation of B. pertussis in the lungs following aerosol challenge than the nonprimed group. This protection correlated with levels of anti-PT antibody in serum present on the day of aerosol challenge [PubMed: 12117973]. Prn Protegen ID: 378; NCBI Gene GI: 2664290; NCBI Protein GI: 33592195; NCBI Protein Accession: NP_879839; NCBITaxon: 257313 YH, ZX Researchers constructed isogenic mutants of B. pertussis Tohama expressing the alleles ptxA1 or ptxA2 and prn1 or prn2 and compared the efficacies of an acellular pertussis vaccine against the mutants in a mouse model. While the vaccine was effective against all of the B. pertussis strains regardless of the allele expression pattern, the strain expressing ptxA1 and prn2 displayed a survival advantage over the other strains [PubMed: 20357056]. PtxA BALB/c mice were immunized with PTx vaccine on day 6 of life and then challenged with B. pertussis using the aerosol challenge model. These primed mice were significantly better protected against leukocytosis, weight loss, and proliferation of B. pertussis in the lungs following aerosol challenge than the nonprimed group. This protection correlated with levels of anti-PT antibody in serum present on the day of aerosol challenge [PubMed: 12117973]. YH, ZX Protegen ID: 379; NCBI Gene GI: 2665068; NCBI Protein GI: 33594638; NCBI Protein Accession: NP_882282; NCBITaxon: 257313 Cpn60 Protegen ID: 382; NCBI Protein GI: 968920; NCBITaxon: 520 YH, ZX A soluble fraction obtained from Bordetella pertussis was evaluated as adjuvant for the pertussis component of the Diphtheria-Pertussis-Tetanus (DPT) vaccine. High levels of antibodies were induced, and a 78% protection rate of mice challenged with live B. pertussis was observed. Two proteins were identified as the 73 kDa N-terminal alpha-domain of BrkA autotransporter protein and the Cpn60/60 kDa chaperonin. Both stimulated antibodies against pertussis and induced a 42% protection rate against the challenge [PubMed: 17011680]. BrkA YH, ZX A soluble fraction obtained from Bordetella pertussis was evaluated as adjuvant for the pertussis component of the Diphtheria-Pertussis-Tetanus (DPT) vaccine. High levels of antibodies were induced, and a 78% protection rate of mice challenged with live B. pertussis was observed. Two proteins were identified as the 73 kDa N-terminal alpha-domain of BrkA autotransporter protein and the Cpn60/60 kDa chaperonin. Both stimulated antibodies against pertussis and induced a 42% protection rate against the challenge [PubMed: 17011680]. Protegen ID: 383; NCBI Protein GI: 562026; NCBITaxon: 520 PtxB YH, ZX BALB/c mice were immunized with PTx vaccine on day 6 of life and then challenged with B. pertussis using the aerosol challenge model. These primed mice were significantly better protected against leukocytosis, weight loss, and proliferation of B. pertussis in the lungs following aerosol challenge than the nonprimed group. This protection correlated with levels of anti-PT antibody in serum present on the day of aerosol challenge [PubMed: 12117973]. Protegen ID: 384; NCBI Protein GI: 225311180; NCBITaxon: 520 PtxC YH, ZX Protegen ID: 385; NCBI Protein GI: 225311183; NCBITaxon: 520 BALB/c mice were immunized with PTx vaccine on day 6 of life and then challenged with B. pertussis using the aerosol challenge model. These primed mice were significantly better protected against leukocytosis, weight loss, and proliferation of B. pertussis in the lungs following aerosol challenge than the nonprimed group. This protection correlated with levels of anti-PT antibody in serum present on the day of aerosol challenge [PubMed: 12117973]. PtxE Protegen ID: 386; NCBI Protein GI: 225311182; NCBITaxon: 520 YH, ZX BALB/c mice were immunized with PTx vaccine on day 6 of life and then challenged with B. pertussis using the aerosol challenge model. These primed mice were significantly better protected against leukocytosis, weight loss, and proliferation of B. pertussis in the lungs following aerosol challenge than the nonprimed group. This protection correlated with levels of anti-PT antibody in serum present on the day of aerosol challenge [PubMed: 12117973]. UL49 Protegen ID: 389; NCBI Gene GI: 1487397; NCBI Protein GI: 9629826; NCBI Protein Accession: NP_045310; NCBITaxon: 10320 Protection against a BHV-1 challenge was obtained in calves immunized with the plasmid encoding tgD-VP22 (UL49), as shown by significant reductions in viral excretion [PubMed: 15650221]. YH, ZX US6 Calves were injected intranasally with either AdCMVgC or AdCMVgD (US6) or a combination of these two recombinants or a commercially available live vaccine for comparison. The highest BHV-1 neutralizing antibody titres were obtained with AdCMVgD (US6) followed by the live vaccine and to a lower extent with the combination of the two recombinants. Calves were protected against intranasal BHV-1 challenge performed 3 weeks after the second immunization [PubMed: 11818166]. YH, ZX Protegen ID: 390; NCBI Gene GI: 1487406; NCBI Protein GI: 9629886; NCBI Protein Accession: NP_045370; NCBITaxon: 10320 US7 YH, ZX Immunization of calves with truncated gpI (US7) protein induced gpI-specific nasal IgA, IgG1, serum neutralizing antibodies and gpI-specific peripheral lymphocyte proliferation. All immunized calves were protected from clinical disease after BHV-1 challenge. Further, nine of ten immunized calves had no intranasal viral shedding [PubMed: 8147097]. Protegen ID: 392; NCBI Gene GI: 4783432; NCBI Protein GI: 9629887; NCBI Protein Accession: NP_045371; NCBITaxon: 10320 UL44 Protegen ID: 393; NCBI Gene GI: 4783424; NCBI Protein GI: 9629830; NCBI Protein Accession: NP_045314; NCBITaxon: 10320 A DNA vaccine expressing glycoprotein C (gC, UL44) of bovine herpesvirus-1 (BHV-1) was evaluated for inducing immunity in bovines. Results indicate that DNA immunization with gC could induce neutralizing antibody and lymphoproliferative responses with BHV-1 responsive memory B cells in bovines. However, the immunity developed sufficient for only partial protection against BHV-1 challenge [PubMed: 11182496]. YH, ZX CadF Chitosan-DNA vaccines were prepared by embedding pcDNA3.1(+)-cadF and pcDNA3.1(+)-peblA with chitosan respectively. The mice immunized with chitosan-DNA vaccines have generated high levels of IgA and IgG from the sera and IgA from the intestinal secretions and the P/N value went up to 20.58, 30.13 and 6.87 respectively. The chitosan-DNA vaccines induced strongest level of protection in BALB/c mice against challenge with C. jejuni HS:19 strain and the protective efficacies was 93.70 [PubMed: 18206008]. Protegen ID: 396; NCBI Protein GI: 4704601; NCBITaxon: 197 YH, ZX Peb1A Protegen ID: 397; NCBI Protein GI: 112360246; NCBITaxon: 192222 Chitosan-DNA vaccines were prepared by embedding pcDNA3.1(+)-cadF and pcDNA3.1(+)-peblA with chitosan respectively. The mice immunized with chitosan-DNA vaccines have generated high levels of IgA and IgG from the sera and IgA from the intestinal secretions and the P/N value went up to 20.58, 30.13 and 6.87 respectively. The chitosan-DNA vaccines induced strongest level of protection in BALB/c mice against challenge with C. jejuni HS:19 strain and the protective efficacies was 93.70 [PubMed: 18206008]. YH, ZX FlaA from C. jejuni 81-176 YH, ZX Mice were immunized intranasally with two doses of 3 to 50 microgram of MBP-FlaA. The protective efficacies of a 50 microgram of MBP-FlaA plus LT(R192G) dose against disease symptoms and intestinal colonization were 81.1 and 84%, respectively. When mice which had been immunized with 50 microgram of MBP-FlaA plus LT(R192G) intranasally were challenged orally with 8 x 10(10), 8 x 10(9), or 8 x 10(8) cells of strain 81-176, the protective efficacies against intestinal colonization at 7 days postinfection were 71.4, 71.4, and 100%, respectively [PubMed: 10531231]. Protegen ID: 398; NCBI Gene GI: 4682159; NCBI Protein GI: 121612545; NCBI Protein Accession: YP_001000997; NCBITaxon: 354242 FspA1 YH, ZX Immunogenicity and protective efficacy of three Campylobacter jejuni flagellum-secreted proteins, FlaC, FspA1, and FspA2, were compared by use of a mouse model. Immunization with FspA1 resulted in 57.8% protection without adjuvant or 63.8% protection with adjuvant against homologous challenge with 81-176 [PubMed: 18426878]. Protegen ID: 399; NCBI Protein GI: 116292649; NCBITaxon: 197 FlaC Immunogenicity and protective efficacy of three Campylobacter jejuni flagellum-secreted proteins, FlaC, FspA1, and FspA2, were compared by use of a mouse model. All three proteins were immunogenic, FlaC provided an 18% protection against disease from C. jejuni 81-176 [PubMed: 18426878]. YH, ZX Protegen ID: 400; NCBI Gene GI: 4682885; NCBI Protein GI: 121612344; NCBI Protein Accession: YP_001000416; NCBITaxon: 354242 FspA2 YH, ZX Immunogenicity and protective efficacy of three Campylobacter jejuni flagellum-secreted proteins, FlaC, FspA1, and FspA2, were compared by use of a mouse model. Immunization with FspA2 provided 38.4% (without adjuvant) or 47.2% (with adjuvant) protection against disease from homologous challenge with CG8486 [PubMed: 18426878]. Protegen ID: 409; NCBI Protein GI: 116292677; NCBITaxon: 197 Tax A DNA vaccination trial was performed on sheep to determine whether vaccination with bovine leukemia virus (BLV) transactivator Tax DNA is effective against BLV infection. Results showed higher levels of virus titers in control sheep than those in Tax-vaccinated sheep. Higher levels of IFN-gamma mRNA expression have been demonstrated in vaccinated sheep after the challenge. These results suggested that Th1 type immune response induced by Tax DNA vaccine inhibited BLV propagation in vaccinated sheep at the early phase of infection [PubMed: 14665749]. Protegen ID: 410; NCBI Gene GI: 2760848; NCBI Protein GI: 9626228; NCBI Protein Accession: NP_056895; NCBITaxon: 11901 YH, ZX Env/Rex/Tax The bovine leukemia virus (BLV) envelope gene encoding extracellular glycoprotein gp51 (encoded by env gene) and transmembrane glycoprotein gp30 was cloned into a vehicle expression vector under the human cytomegalovirus (CMV) intermediate early promoter. The intramuscular injection of this plasmid vector generated a cellular immune response. Seven out of ten cows vaccinated with the DNA construct resisted a drastic challenge [PubMed: 10824867]. Protegen ID: 411; NCBI Gene GI: 2760849; NCBI Protein GI: 9626230; NCBI Protein Accession: NP_056898; NCBITaxon: 11901 YH, ZX CDVgp6 haemagglutinin protein H YH, ZX Protegen ID: 412; NCBI Gene GI: 1489792; NCBI Protein GI: 9630651; NCBI Protein Accession: NP_047206; NCBITaxon: 11232 Young mink kits (n=8) were vaccinated with DNA plasmids encoding the viral haemagglutinin protein (H) of a vaccine strain of Canine distemper virus (CDV). The mink were protected against viraemia, lymphopenia, clinical disease and changes in the percentage of IFN-gamma producing peripheral blood leucocytes after challenge inoculation with a recent wild type strain of CDV. Essentially, these results demonstrate that early life DNA vaccination with the H gene of a CDV vaccine strain induced robust protective immunity against a recent wild type CDV [PubMed: 19596418]. CDVgp5 YH, ZX Protegen ID: 413; NCBI Gene GI: 1489793; NCBI Protein GI: 9630650; NCBI Protein Accession: NP_047205; NCBITaxon: 11232 Study reports the engineering and the characterization of two replication-competent canine adenovirus type 2 (CAV2)-based vaccines expressing, respectively, the CDV hemagglutinin (HA) and fusion (F) antigens (CDVgp5). We first demonstrated that the intranasal vaccination with a mixture of both recombinant CAV2s provides an excellent level of protection in seronegative puppies, confirming the value of replication-competent adenovirus-based vectors for mucosal vaccination [PubMed: 12297394]. VP2 Protegen ID: 414; NCBI Gene GI: 1489588; NCBITaxon: 10788 YH, ZX A vaccine based upon a recombinant plant virus (CPMV-PARVO1), displaying a peptide derived from the VP2 capsid protein of canine parvovirus (CPV), has previously been described. To date, studies with the vaccine have utilized viable plant chimaeric particles (CVPs). Results show that the inactivated CVP is able to protect dogs from a lethal challenge with CPV following parenteral immunization with the vaccine. Dogs immunized with the inactivated CPMV-PARVO1 in adjuvant displayed no clinical signs of disease and shedding of CPV in faeces was limited following CPV challenge. [PubMed: 11395200]. VP1 This study shows that a plasmid DNA (pGT36VP1) encoding the full length VP1 region of canine parvovirus (CPV) induces immunity that protects dogs against challenge with virulent virus [PubMed: 9569471]. Protegen ID: 415; NCBI Gene GI: 1489587; NCBITaxon: 10788 YH, ZX DnaX YH, ZX Protegen ID: 416; NCBI Protein GI: 62148024; NCBITaxon: 218497 Genetic immunization was used to functionally test the genes of C. abortus as vaccines in a mouse challenge system. DNA pol III Gamma and Tau (CP #1, dnaX) was found to be protective. CP #1 (dnaX) was more protective than the live-vaccine, positive control. [PubMed: 15811648]. GatC Protegen ID: 417; NCBI Protein GI: 62184917; NCBITaxon: 218497 Genetic immunization was used to functionally test the genes of C. abortus as vaccines in a mouse challenge system. Glu-tRNA Gln Amidotransferase (CP #2, gatC) was found to be protective. Three of the clones (CP #1) elicited protection that was statistically higher than the unvaccinated control, which has high variance [PubMed: 15811648]. YH, ZX Pomp90A Genetic immunization was used to functionally test the genes of C. abortus as vaccines in a mouse challenge system. Protective clone CP #4 (OMP90A, pomp90A) was diluted 1/2000 in a non-protective sublibrary pool of clones. This CP #4-spiked sublibrary conferred protection. Five clones were significantly more protective than the genes encoding fewer than 50 amino acids (CP #1 and 7, p-value of less than 0.05 when comparing lung weights). [PubMed: 15811648]. YH, ZX Protegen ID: 418; NCBI Protein GI: 187438939; NCBITaxon: 83555 CAB049 putative penicillin-binding protein Genetic immunization was used to functionally test the genes of C. abortus as vaccines in a mouse challenge system. CP #5 (Transglycolase/transpeptidase, CAB049 putative penicillin-binding protein) was significantly more protective than the genes encoding fewer than 50 amino acids (p-value of less than 0.05 when comparing lung weights). The chlamydial loads generally tracked with protection and the most protective genes were significantly lower than in unvaccinated controls (p < 0.05 in the Mannhitney U-test for genes CP #1, 2, 4, 9, 10) [PubMed: 15811648]. Protegen ID: 419; NCBI Protein GI: 62184696; NCBITaxon: 218497 YH, ZX OmlA Protegen ID: 420; NCBI Protein GI: 62184824; NCBITaxon: 218497 YH, ZX Genetic immunization was used to functionally test the genes of C. abortus as vaccines in a mouse challenge system. CP #7 (omlA) was significantly more protective than the genes encoding fewer than 50 amino acids (p-value of less than 0.05 when comparing lung weights). The chlamydial loads generally tracked with protection and the most protective genes were significantly lower than in unvaccinated controls (p < 0.05 in the Mannhitney U-test for genes CP #1, 2, 4, 9, 10) [PubMed: 15811648]. CAB613 putative peptidase YH, ZX Protegen ID: 421; NCBI Protein GI: 62185225; NCBITaxon: 218497 Genetic immunization was used to functionally test the genes of C. abortus as vaccines in a mouse challenge system. Of the 14 individually tested clones, CP #1 through CP #9 had positive relative protection scores. CP #8 (CAB613, Oligopeptidase) was found to confer protection [PubMed: 15811648]. Gam82 YH, ZX Protegen ID: 457; NCBI Protein GI: 38565038; NCBITaxon: 5804 Animals vaccinated with Gam82 and challenged with E. maxima showed lower oocyst shedding and reduced intestinal pathology compared with non-vaccinated and parasite-challenged animals. Gam82 vaccination also stimulated the production of antigen-specific serum antibodies and induced greater levels of IL-2 and IL-15 mRNAs compared with non-vaccinated controls. These results demonstrate that the Gam82 recombinant protein protects against E. maxima and augments humoral and cell-mediated immunity [PubMed: 20178868]. MIC2 Birds vaccinated with Eimeria tenella microneme recombinant gene (EtMIC2) and encoded protein developed protective immunity against infection by E. tenella as assessed by significantly increased body weight gain and decreased fecal oocyst shedding compared with non-vaccinated controls. Vaccination with the EtMIC2 gene also led to protective immunity against infection by E. acervulina, but not E. maxima [PubMed: 15882535]. YH, ZX Protegen ID: 459; NCBI Protein GI: 225579627; NCBITaxon: 5802 Rho YH, ZX Two recombinant Mycobacterium bovis BCG (rBCG) strains carrying the Eimeria tenella rhomboid gene (Rho) delivered by extrachromosomal vector pMV261 and integrative vector pMV361 were evaluated for their ability to protect chickens against E. tenella challenge. Chickens were immunized intranasal with BCG, rBCG pMV261-Rho, or rBCG pMV361-Rho twice at a 2-week interval. All the recombinant BCG immunized chickens developed specific immune responses, and there was a significant increases of the percentages of CD4(+) and CD8(+) cells compared to the control (P<0.05). Challenge experiments demonstrated that the two rBCG strains could provide significant protection against E. tenella challenge [PubMed: 19117681]. Protegen ID: 460; NCBI Protein GI: 84043169; NCBITaxon: 5802 TA4 The immunization procedure of DNA vaccine pcDNA-TA4-IL-2 of Eimeria tenella, including route, dose, time of immunization and age of primary immunization of chicken, was optimized. results illustrated that 25 microg was the optimal dose and intramuscular injection was the most effective route to induce protective immunity in Chinese Yellow chickens [PubMed: 19019543]. YH, ZX Protegen ID: 461; NCBI Protein GI: 84783094; NCBITaxon: 5802 3-1E Protegen ID: 463; NCBI Protein GI: 126362934; NCBITaxon: 5802 YH, ZX The Eimeria tenella antigen gene (3-1E) and chicken interferon gamma gene (ChIFN-gamma) were subcloned into the mammalian expression vector proVAX forming the plasmids proE and prol. After challenge the proIE-vaccinated chickens showed protective immunity as demonstrated by significantly reduced oocyst shedding [PubMed: 17274297]. GX3262 Protegen ID: 464; NCBI Protein GI: 102304; NCBITaxon: 5802 A cDNA clone derived from sporulated oocysts of Eimeria tenella and encoding the expression product GX3262 was identified using a monoclonal antibody raised against Eimeria acervulina sporozoites. After challenge with an experimental E. tenella infection, the greatest degree of protection in immunized broiler chickens was seen after only a single immunization of 2-day-old birds with a live recombinant E. coli preparation [PubMed: 2659532]. YH, ZX Env Study describes experiments which demonstrate that the vaccine, (EURIFEL FeLV; Merial) that expresses the FeLV env and gag protective genes, is effective against any oronasal FeLV challenge. The protection was shown to be solid against an oronasal challenge one year after the initial vaccination, and was effective against a very severe 'in-contact' challenge [PubMed: 12934796]. YH, ZX Protegen ID: 465; NCBI Gene GI: 1491868; NCBI Protein GI: 9630709; NCBI Protein Accession: NP_047256; NCBITaxon: 11768 Gag Protegen ID: 466; NCBI Protein GI: 323916; NCBITaxon: 11768 YH, ZX The vaccine, (EURIFEL FeLV; Merial) that expresses the FeLV env and gag protective genes, is effective against any oronasal FeLV challenge. The protection was shown to be solid against an oronasal challenge one year after the initial vaccination, and was effective against a very severe 'in-contact' challenge [PubMed: 12934796]. FopB YH, ZX Intranasal immunization of HLA-DR4 tg mice with the single antigen FopB from F. tularensis subsp. novicida conferred significant protection against lethal pulmonary challenge with an F. tularensis subsp. holarctica live vaccine strain. Protegen ID: 468; NCBI Gene GI: 4547777; NCBI Protein GI: 118496734; NCBI Protein Accession: YP_897784; NCBITaxon: 401614 IglB YH, ZX Protegen ID: 469; NCBI Gene GI: 4548125; NCBI Protein GI: 118497903; NCBI Protein Accession: YP_898953; NCBITaxon: 401614 Intranasal vaccination with KKF235 (F. tularensis subsp. novicida mutant (DeltaiglB) ) protected mice from subsequent homotypic challenge with U112 as well as heterotypic challenge with F. tularensis subsp. holarctica (LVS). Most significantly, oral immunization with KKF235 protected mice from a highly lethal subsp. tularensis (SCHU S4) pulmonary challenge [PubMed: 20016043]. IglC1 Mice immunized with rLm/iglC were protected against lethal challenge with F. tularensis LVS administered by the intranasal route, a route chosen to mimic airborne infection, and, most importantly, against aerosol challenge with the highly virulent Type A F. tularensis SchuS4 strain [PubMed: 19126421]. YH, ZX Protegen ID: 470; NCBI Gene GI: 3191591; NCBI Protein GI: 56708413; NCBI Protein Accession: YP_170309; NCBITaxon: 177416 IglC2 Mice immunized with rLm/iglC were protected against lethal challenge with F. tularensis LVS administered by the intranasal route, a route chosen to mimic airborne infection, and, most importantly, against aerosol challenge with the highly virulent Type A F. tularensis SchuS4 strain [PubMed: 19126421]. Protegen ID: 471; NCBI Gene GI: 3191814; NCBI Protein GI: 56708721; NCBI Protein Accession: YP_170617; NCBITaxon: 177416 YH, ZX WbtI Immunization with WbtI(G191V) protected mice against a relatively low-dose intraperitoneal challenge with LVS (F. tularensis subspecies holarctica live vaccine strain), but was less protective against a high-dose challenge [PubMed: 17768257]. YH, ZX Protegen ID: 472; NCBI Gene GI: 5522688; NCBI Protein GI: 156502002; NCBI Protein Accession: YP_001428067; NCBITaxon: 458234 GroEL Researchers have shown that mice that had been immunized with purified heat shock protein 60 (Hsp60, groEL) isolated from Francisella tularensis were protected against a subsequent challenge with some strains of the bacterium [PubMed: 15213156]. YH, ZX Protegen ID: 473; NCBI Protein GI: 282159959; NCBITaxon: 510831 TUL4 A 17-kDa lipoprotein, TUL4, of the facultative intracellular bacterium Francisella tularensis is one of several membrane proteins that induce an in vitro response in T cells from F. tularensis-primed humans. When mice were immunized with S. typhimurium chi 4072(pTUL4-15), some animals showed an antibody response and a T-cell response to TUL4. The present study demonstrated that the 17-kDa lipoprotein TUL4 of F. tularensis is involved in a protective immunity to tularemia [PubMed: 1612751]. Protegen ID: 474; NCBI Protein GI: 148688; NCBITaxon: 263 YH, ZX SodB from F. tularensis SCHU S4 YH, ZX C57BL/6 mice were vaccinated intranasally (i.n.) with the sodB(Ft) mutant and challenged i.n. with lethal doses of F. tularensis SchuS4. SodB(Ft) vaccinated mice following SchuS4 challenge exhibited significantly reduced bacterial burden in lungs, liver and spleen, regulated production of pro-inflammatory cytokines and less severe histopathological lesions compared to the LVS vaccinated mice. The sodB(Ft) vaccination induced a potent humoral immune response and protection against SchuS4 required both CD4 and CD8 T cells in the vaccinated mice [PubMed: 18692537]. Protegen ID: 475; NCBI Gene GI: 3190713; NCBI Protein GI: 56707247; NCBI Protein Accession: YP_169143; NCBITaxon: 177416 FopA YH, ZX Anti-FopA MAbs protected 90% of nave C3H/HeN mice from lethal challenge with F. tularensis LVS when administered prophylactically as well as therapeutically [PubMed: 19176692]. Protegen ID: 476; NCBI Gene GI: 4306351; NCBI Protein GI: 115315051; NCBI Protein Accession: YP_763774; NCBITaxon: 393011 LpnA YH, ZX Anti-lpnA MAbs conferred significant, although not complete, protection of nave C3H/HeN mice from lethal challenge with F. tularensis LVS when administered therapeutically [PubMed: 19176692]. Protegen ID: 477; NCBI Gene GI: 3191792; NCBI Protein GI: 56708002; NCBI Protein Accession: YP_169898; NCBITaxon: 177416 CWP2 YH, ZX The gene encoding the full length cyst wall protein-2 (CWP2) from Giardia lamblia was subcloned into the pCDNA3 mammalian expression vector and stably introduced into S. typhimurium STM1. Challenge infection with live Giardia muris cysts revealed that mice receiving the CWP2-encoding DNA vaccine were able to reduce cyst shedding by approximately 60% compared to control mice [PubMed: 17996337]. Protegen ID: 479; NCBI Gene GI: 5703171; NCBI Protein GI: 159120052; NCBI Protein Accession: XP_001710242; NCBITaxon: 50803 Hpd Protegen ID: 480; NCBI Protein GI: 148971; NCBITaxon: 727 Rats vaccinated with PD (hpd) cleared NT H. influenzae better after middle ear and pulmonary bacterial challenge, and chinchillas vaccinated with PD showed significant protection against NT H. influenzae-dependent acute otitis media. In a clinical trial involving children, PD was used as an antigenically active carrier protein in an 11-valent pneumococcal conjugate investigational vaccine; significant protection was achieved against acute otitis media not only caused by pneumococci but also caused by NT H. influenzae [PubMed: 18230042]. YH, ZX OmpP5 Protegen ID: 482; NCBI Gene GI: 3430592; NCBI Protein GI: 68249712; NCBI Protein Accession: YP_248824; NCBITaxon: 281310 In a chinchilla model of otitis media, initial screening of P5-fimbrin, delivered singly or in combination with either Freund's adjuvant or alum, indicated that augmented bacterial clearance from the nasopharynx, the middle ears, or both anatomical sites could be induced by parenteral immunization with P5-fimbrin combined with lipoprotein D, lipoprotein D alone, or the synthetic chimeric peptide LB1 (derived from P5-fimbrin), respectively [PubMed: 10338477]. YH, ZX D15 Purified rD15 was found to be highly immunogenic in mice, guinea pigs, and rabbits, and passive transfer of anti-rD15 antibodies protected infant rats from challenge with H. influenzae type b or type a in infant rat models of bacteremia [PubMed: 9284140]. YH, ZX Protegen ID: 483; NCBI Gene GI: 3430379; NCBI Protein GI: 68249503; NCBI Protein Accession: YP_248615; NCBITaxon: 281310 OmpP2 Rabbit antibody prepared against P2 from one strain was cross-reactive with P2 isolated from the other two heterologous strains by Western blot. This antibody passively protected infant rats against type b Haemophilus infection caused by the homologous organism, but not against challenge by a strain with the heterologous 36,500 mol wt P2 protein [PubMed: 6603479]. Protegen ID: 485; NCBI Gene GI: 3429565; NCBI Protein GI: 68248747; NCBI Protein Accession: YP_247859; NCBITaxon: 281310 YH, ZX Gc Seoul virus (SEOV) is one of the four known hantaviruses causing hemorrhagic fever with renal syndrome (HFRS). A replication-competent recombinant canine adenovirus type 2 expressing the Gc protein of SEOV (rCAV-2-Gc) in BALB/c mice induced complete protection against a intensive infectious challenge with ~1,000 50% infective doses (ID50) for SEOV strain CC-2 [PubMed: 20181748]. YH, ZX Protegen ID: 486; NCBI Protein GI: 284157806; NCBITaxon: 11608 G1 Protegen ID: 487; NCBI Protein GI: 1113859; NCBITaxon: 37705 YH, ZX Study used a deer mouse infection model to test the protective efficacy of genetic vaccine candidates for Sin Nombre (SN) virus that were known to provoke immunological responses in BALB/c mice. Protective epitopes were localized in each of four overlapping cDNA fragments that encoded portions of the SN virus G1 glycoprotein antigen; the nucleocapsid gene also was protective [PubMed: 12075094]. SNVsSgp1 Protegen ID: 489; NCBI Gene GI: 2943142; NCBI Protein GI: 38371726; NCBI Protein Accession: NP_941975; NCBITaxon: 37705 Study used a deer mouse infection model to test the protective efficacy of genetic vaccine candidates for Sin Nombre (SN) virus that were known to provoke immunological responses in BALB/c mice. Protective epitopes were localized in each of four overlapping cDNA fragments that encoded portions of the SN virus G1 glycoprotein antigen; the nucleocapsid gene (SNVsSgp1) also was protective [PubMed: 12075094]. YH, ZX PUUVsSgp1 Protegen ID: 490; NCBI Gene GI: 2943083; NCBI Protein GI: 38371721; NCBI Protein Accession: NP_941984; NCBITaxon: 11604 YH, ZX To investigate the ability of recombinant N (rN, nucleocapsid proteins) from different hantaviruses to elicit cross-protection, we immunized bank voles with rN from Puumala (PUUV), Topografov (TOPV), Andes (ANDV), and Dobrava (DOBV) viruses and subsequently challenged them with PUUV. All animals immunized with PUUV (PUUVsSgp1) and TOPV rN were completely protected [PubMed: 12050380]. N protein [Topografov virus] Protegen ID: 491; NCBI Protein GI: 4757106; NCBITaxon: 83192 YH, ZX To investigate the ability of recombinant N (rN, nucleocapsid proteins) from different hantaviruses to elicit cross-protection, we immunized bank voles with rN from Puumala (PUUV), Topografov (TOPV), Andes (ANDV), and Dobrava (DOBV) viruses and subsequently challenged them with PUUV. All animals immunized with PUUV and TOPV rN were completely protected [PubMed: 12050380]. M Segment Researchers vaccinated hamsters with a vaccinia virus-vectored vaccine expressing the M and the S segments of Hantaan (HTN) virus and challenged them with HTN, Seoul (SEO), or Puumala (PUU) virus. Study found that vaccinated hamsters, challenged with HTN or SEO virus, were neither viremic nor had evidence of virus in their lungs or kidneys [PubMed: 7666542]. Protegen ID: 492; NCBI Protein GI: 1389703; NCBITaxon: 11599 YH, ZX HTNVsSgp1 Protegen ID: 493; NCBI Gene GI: 2943078; NCBI Protein GI: 38371711; NCBI Protein Accession: NP_941977; NCBITaxon: 11599 YH, ZX Passive transfer of spleen cells from mice immunized with rNP (HTNVsSgp1) conferred partial protection or prolongation of time to death from fatal Hantaan virus infection in suckling mice which were challenged with Hantaan virus at 40 LD50 (survival rate: 43%) or 4 LD50 (survival rate: 43%) [PubMed: 8517793]. ANDVsSgp1 Nonreplicating adenovirus (Ad) vectors that express Andes hantavirus (ANDV) nucleocapsid protein (AdN, ANDVsSgp1) or glycoproteins (AdG(N) and AdG(C)) were constructed . When administered once, all three Ad vectors, individually or in combination, elicited a robust immune response that protected Syrian hamsters from a lethal ANDV infection that mimics the pulmonary disease seen in humans. No vaccinated animal died, and there were no obvious clinical signs of disease [PubMed: 19403663]. YH, ZX Protegen ID: 494; NCBI Gene GI: 991232; NCBI Protein GI: 19744950; NCBI Protein Accession: NP_604471; NCBITaxon: 46607 Hepatitis B surface antigen Protegen ID: 495; NCBI Protein GI: 128168861; NCBITaxon: 10407 YH, ZX Study compared a current HBV vaccine that contains recombinant hepatitis B surface antigen HBsAg) adsorbed to alum in chimpanzees, with two novel vaccine strategies that have proven superior to the current vaccine in mice. All animals receiving either control or CpG-containing subunit vaccines at 0 and 4 weeks attained titers of HBsAg-specific antibody (anti-HBs) considered protective (> or =10 mIU/ml) and were indeed protected from challenge at 8 weeks with 10(3.5) 50% chimp infectious doses (CID(50)) of intravenous HBV [PubMed: 16428890]. PreS2 middle surface protein Protegen ID: 496; NCBI Protein GI: 113207330; NCBITaxon: 10407 YH, ZX The immunological protection of pVAX-PS, a DNA vaccine, was assessed in the tree shrews model. pVAX-PS was constructed by inserting the gene encoding the middle (pre-S2 plus S) envelope protein of HBV into a plasmid vector pVAX1. Results indicated that pVAX-PS immunization could induce remarkable humoral immune response and prevent the experimental tree shrews from infection of HBV [PubMed: 12932306]. HBVgp2 pre-S1/pre-S2/S Protegen ID: 497; NCBI Gene GI: 944569; NCBI Protein GI: 77680739; NCBI Protein Accession: YP_355333; NCBITaxon: 10407 Immunisation with a plasmid encoding the DHBV large (L) envelope protein (HBVgp2 pre-S1/pre-S2/S) induced a strong, specific, highly neutralising and long-lasting anti-preS humoral response in uninfected ducks. Importantly, maternal antibodies elicited by such DNA immunisation were vertically transmitted and protected progeny against viral challenge [PubMed: 12531335]. YH, ZX US6 The herpes simplex virus type 2 (HSV-2) glycoprotein D (gD2) gene was inserted into an intergenic site in the unique short region of the Oka VZV genome. Expression of gD2 in cells infected with the recombinant Oka strain VZV (ROka-gD2) was confirmed by antibody staining of fixed cells and by immunoblot analysis. Forty days after the third inoculation, guinea pigs were challenged intravaginally with HSV-2. Inoculation of guinea pigs with ROka-gD2 significantly reduced the severity of primary HSV-2 infection (P < 0.001) [PubMed: 7494331]. YH, ZX Protegen ID: 499; NCBI Gene GI: 1487358; NCBI Protein GI: 9629336; NCBI Protein Accession: NP_044536; NCBITaxon: 10310 UL27 from Herpes simplex virus type 2 Protegen ID: 500; NCBI Protein GI: 1869850; NCBITaxon: 10310 YH, ZX The present study evaluated the modulatory functions of salbutamol co-administered with DNA vaccine expressing gB (UL27) of herpes simplex virus (HSV) via intranasal (i.n.) route. The enhanced immune responses caused by co-administration of salbutamol provided effective and rapid responses to HSV mucosal challenge, thereby conferring prolonged survival and reduced inflammation against viral infection [PubMed: 19641376]. US5 Protegen ID: 501; NCBI Gene GI: 2703406; NCBI Protein GI: 9629447; NCBI Protein Accession: NP_044668; NCBITaxon: 10298 BALB/c mice receiving a glycoprotein D1 (gD1, US5) DNA vaccine alone were 80% protected against a subsequent HSV-1 challenge. Results also indicate that the administration of NLX as an adjuvant improved protective immunity against HSV-1 [PubMed: 19174474]. YH, ZX UL27 from Herpes simplex virus type 1 Study demonstrated that recombinant Listeria monocytogenes (Lm) expressing the H-2K(b) glycoprotein B (gB, UL27)(498-505) peptide from HSV-1 triggers a robust CD8 T cell response to this Ag resulting in protective immunity to HSV infection in mice [PubMed: 17404252]. YH, ZX Protegen ID: 502; NCBI Gene GI: 2703455; NCBI Protein GI: 9629408; NCBI Protein Accession: NP_044629; NCBITaxon: 10298 ICP27 from Herpes simplex virus type 2 Protegen ID: 503; NCBI Protein GI: 124181; NCBITaxon: 10315 YH, ZX Particle-mediated DNA vaccination of mice with a DNA plasmid-encoding ICP27 resulted in the induction of ICP27-specific IFN-gamma and TNF-alpha production in Balb/c mice. When the DNA vaccine was supplemented with as little as 50ng of a vector encoding the A and B subunits of the Escherichia coli heat labile enterotoxin (LT), animals were profoundly protected from morbidity and mortality [PubMed: 16621198]. ICP27 from Herpes simplex virus type 1 Protegen ID: 504; NCBI Protein GI: 75812153; NCBITaxon: 10298 Epitopes from the ICP27 (H1, H2), glycoprotein B (gB) and glycoprotein D (gD) proteins of HSV-1 were attached to either the J TCBL/ICBL or the G TCBL/ICBL. The JH1, JH2, JgB and JgD vaccines elicited DTH responses without antibody but conferred protection upon lethal challenge with HSV [PubMed: 15569635]. YH, ZX US4 In two experiments, mice immunised with phage displaying a single epitope of gG2 (US4) were protected against challenge with a lethal dose of whole HSV-2 [PubMed: 10725197]. Protegen ID: 505; NCBI Gene GI: 1487356; NCBI Protein GI: 9629334; NCBI Protein Accession: NP_044534; NCBITaxon: 10310 YH, ZX UL44 Protegen ID: 506; NCBI Gene GI: 2703410; NCBI Protein GI: 9629425; NCBI Protein Accession: NP_044646; NCBITaxon: 10298 YH, ZX Protection against a lethal intraperitoneal challenge of HSV-1 (5 x 10(4) pfu) with gC (UL44) or gE plasmid vaccination could be demonstrated if the inoculating dose of DNA was 250 microg. All mice immunized with vaccinia recombinants expressing either gC or gE survived HSV-1 challenge [PubMed: 9728527]. US8 YH, ZX Protection against a lethal intraperitoneal challenge of HSV-1 (5 x 10(4) pfu) with gC or gE (US8) plasmid vaccination could be demonstrated if the inoculating dose of DNA was 250 microg. All mice immunized with vaccinia recombinants expressing either gC or gE survived HSV-1 challenge [PubMed: 9728527]. Protegen ID: 507; NCBI Gene GI: 2703448; NCBI Protein GI: 9629449; NCBI Protein Accession: NP_044670; NCBITaxon: 10298 E7 Researchers combined the HPV16 E7 peptide(38-61) with a murine IgG heavy chain constant region to construct a chimeric protein compound. The chimeric vaccine candidate was able to effectively protect mice against the challenge of HPV16-positive tumor cells, and to eradicate HPV16-expressing tumors in mice [PubMed: 15661238]. Protegen ID: 509; NCBI Gene GI: 1489079; NCBI Protein GI: 9627105; NCBI Protein Accession: NP_041326; NCBITaxon: 333760 YH, ZX L2 Protegen ID: 510; NCBI Gene GI: 1489081; NCBI Protein GI: 9627107; NCBI Protein Accession: NP_041331; NCBITaxon: 333760 Antibody responses of mice (n = 120) and rabbits (n = 23) to vaccination with HPV-16 amino-terminal L2 polypeptides or multitype L2 fusion proteins were compared. 11-200 x 3 formulated in GPI-0100 adjuvant or alum with 1018 ISS protected mice against HPV-16 challenge (reduction in HPV-16 infection vs phosphate-buffered saline control, P < .001) 4 months after vaccination as well as HPV-16 L1 VLPs [PubMed: 19470949]. YH, ZX E6 YH, ZX Protegen ID: 511; NCBI Gene GI: 1489078; NCBI Protein GI: 9627104; NCBI Protein Accession: NP_041325; NCBITaxon: 333760 C57BL/6 mice vaccinated with pNGVL4a-E6/opt are able to generate potent protective and therapeutic antitumor effects against challenge with E6-expressing tumor cell line, TC-1 of HPV [PubMed: 16649071]. L1 rAAV5, -8 and -9 vectors expressing an HPV16 L1/E7 fusion gene were generated and applied intranasally for combined prophylactic and therapeutic vaccination of mice. Vaccination with the rAAV vectors led to a significant protection of animals against a challenge with different HPV tumour cell lines [PubMed: 20032542]. YH, ZX Protegen ID: 512; NCBI Gene GI: 1489082; NCBI Protein GI: 9627108; NCBI Protein Accession: NP_041332; NCBITaxon: 333760 G glycoprotein Protegen ID: 513; NCBI Gene GI: 1489848; NCBI Protein GI: 9628086; NCBI Protein Accession: NP_042679; NCBITaxon: 11290 YH, ZX The DNA vaccine pIHNw-G encodes the glycoprotein of the fish rhabdovirus infectious hematopoietic necrosis virus (IHNV). Vaccine performance in rainbow trout was measured 3, 6, 13, 24, and 25 months after vaccination. At three months all fish vaccinated with 0.1 microg pIHNw-G had detectable neutralizing antibody (NAb) and they were completely protected from lethal IHNV challenge with a relative percent survival (RPS) of 100% compared to control fish [PubMed: 16154239]. NP from Influenza B virus YH, ZX Protegen ID: 514; NCBI Gene GI: 956539; NCBI Protein GI: 8486155; NCBI Protein Accession: NP_056661; NCBITaxon: 11520 BALB/c mice were immunized intranasally with an adjuvant (cholera toxin B subunit containing 0.2% of the whole toxin)-combined with A or B virus recombinant NP. The NP-immune mice, when challenged intranasally with a sublethal dose of the virus 3 wk after immunization, had accelerated virus clearance from the nasal site in both an influenza type-specific and a nonspecific manner, as shown by the protection from high morbidity from the second day after challenge [PubMed: 8621928]. NP from Influenza A virus H3N2 YH, ZX Protegen ID: 515; NCBI Protein GI: 3722159; NCBITaxon: 41857 BALB/c mice were immunized intranasally with an adjuvant (cholera toxin B subunit containing 0.2% of the whole toxin)-combined with A or B virus recombinant NP. The NP-immune mice, when challenged intranasally with a sublethal dose of the virus 3 wk after immunization, had accelerated virus clearance from the nasal site in both an influenza type-specific and a nonspecific manner, as shown by the protection from high morbidity from the second day after challenge [PubMed: 8621928]. HA from Equine influenza virus H3N8 YH, ZX Protegen ID: 516; NCBI Protein GI: 404517; NCBITaxon: 31660 Skin and mucosal vaccination provided complete protection from clinical signs of infection with ponies subjected to a challenge infection of Equine influenza virus, while skin vaccination provided partial protection; DNA vaccination provided partial protection from viral shedding [PubMed: 10403592]. HA from Influenza A virus (A/WSN/1933(H1N1)) A nonpathogenic vector of the cytoplasmic domain of the VSV G protein and expressing influenza virus HA (derived from Influenza A virus (A/WSN/1933(H1N1))) provides complete protection from lethal influenza virus challenge after intranasal administration. A second vector with VSV G deleted and expressing HA (DeltaG-HA) is also protective and nonpathogenic and has the advantage of not inducing neutralizing antibodies to the vector itself [PubMed: 10196265]. YH, ZX Protegen ID: 518; NCBI Protein GI: 324200; NCBITaxon: 382835 HA from Influenza A virus (A/Puerto Rico/8/1934(H1N1)) YH, ZX Protegen ID: 519; NCBI Protein GI: 126599271; NCBITaxon: 211044 A recombinant baculovirus expressing the hemagglutinin gene of the influenza virus, A/PR/8/34 (H1N1), under the control of the chicken beta-actin promoter, was constructed. Protection from a lethal challenge of the influenza virus was achieved by intranasal immunization of the recombinant baculovirus [PubMed: 12874198]. HA from Influenza A virus (A/Aichi/2/1968(H3N2)), (X31) YH, ZX Protegen ID: 520; NCBI Protein GI: 324132; NCBITaxon: 387139 Two cyclic peptide analogues corresponding to residues 139-146 (site A) of influenza A virus haemagglutinin (strain X31) were synthesized. When OF1 mice were immunized with cyclic peptides, approximately 80% of the animals were protected against an intranasal challenge with influenza virus [PubMed: 2396470]. HA from Influenza A virus (A/chicken/Italy/13474/99(H7N1)) Protegen ID: 521; NCBI Protein GI: 32261025; NCBITaxon: 199442 Mice and ferrets were immunised with two doses of the split virus vaccine (12-24 microg haemagglutinin derived from Influenza A virus (A/chicken/Italy/13474/99(H7N1))) with or without aluminium hydroxide adjuvant and challenged 3 weeks after second dose with the highly pathogenic A/chicken/Italy/13474/99 (H7N1) virus. The vaccine induced significant protection from disease after challenge with the wild-type virus. In the murine lethal challenge model, vaccination effectively prevented death and, furthermore, formulation with adjuvant reduced excessive weight loss and viral shedding [PubMed: 19453487]. YH, ZX HA from Influenza B virus (Strain B/England/222/82) Immunization and challenge experiments in mice indicated that even though vaccination with the recombinant HA vaccinia viruses derived from Influenza B virus (Strain B/England/222/82) induced different levels of cross-reactive neutralizing antibodies, mice vaccinated with either recombinant vaccinia virus were protected from infection with either subpopulation of influenza virus [PubMed: 3318092]. YH, ZX Protegen ID: 522; NCBI Protein GI: 122955; NCBITaxon: 11527 HA from Influenza A virus (A/duck/Badung-Bali/05/2005(H5N1)) YH, ZX Mice vaccinated with a recombinant VLP vaccine from both influenza A H5N1 clade 1 and clade 2 isolates (Influenza A virus (A/duck/Badung-Bali/05/2005(H5N1))) with pandemic potential were protected against challenge with lethal reassortant viruses expressing the H5N1 HA and NA, regardless if the H5N1 clade was homologous or heterologous to the vaccine [PubMed: 18231588]. Protegen ID: 523; NCBI Protein GI: 190344179; NCBITaxon: 389226 M2 from Influenza A virus (A/Puerto Rico/8/34(H1N1)) YH, ZX A targeted fusion protein based on the CTA1-DD adjuvant and containing tandem repeats of the matrix protein 2 (M2e) ectodomain epitope derived from Influenza A virus (A/Puerto Rico/8/34(H1N1)), CTA1-3M2e-DD, confers strong protective immunity against a potentially lethal challenge infection with influenza virus in mice. The formulation was highly effective for mucosal immunizations and promoted high M2e-specific serum IgG and mucosal IgA antibody titers and an hitherto unknown anti-M2e CD4 T cell immunity [PubMed: 18243429]. Protegen ID: 524; NCBI Gene GI: 956528; NCBI Protein GI: 56583270; NCBI Protein Accession: NP_040979; NCBITaxon: 211044 HA from Influenza A virus (A/Hong Kong/1/68(H3N2)) Vaccination with HA-VRP derived from Influenza A virus (A/Hong Kong/1/68(H3N2)) did not strongly stimulate either neutralizing or IgG1 antibodies but did induce IgG2a antibodies. Expression of IgG2a antibodies in this context correlated with clearance of virus and increased protection against lethal influenza challenge [PubMed: 16960108]. YH, ZX Protegen ID: 525; NCBI Protein GI: 16960108; NCBITaxon: 10090 HA from Influenza A virus (A/environment/Hong Kong/156/1997(H5N1)) YH, ZX Researchers report that a DNA vaccine encoding hemagglutinin from the index human influenza isolate A/HK/156/97 provides immunity against H5N1 infection of mice [PubMed: 9971791]. Protegen ID: 527; NCBI Protein GI: 269826115; NCBITaxon: 680785 NP from Influenza A virus (A/Puerto Rico/8/34(H1N1)) YH, ZX Protegen ID: 528; NCBI Gene GI: 956531; NCBI Protein GI: 8486130; NCBI Protein Accession: NP_040982; NCBITaxon: 211044 A simian adenovirus 24 (AdC7) vector expressing the influenza A/Puerto Rico/8/34 NP was tested for its efficacy in protecting BALB/c mice against two H5N1 strains. When tested in a mouse challenge model, there was a significantly improved survival rate following challenge with the Vietnam/1203/04 strain of H5N1 that has caused human outbreaks [PubMed: 17728024]. NA from Influenza A virus (A/Aichi/2/1968(H3N2)) Protegen ID: 530; NCBI Protein GI: 46401580; NCBITaxon: 387139 YH, ZX The protective effect of neuraminidase (NA) was studied in a mouse protection test using isolated neuraminidase of A2/Aichi/68(H3N2) virus and the complete recombinant virus A/eq(Heq-1)-HK(N2) as antigens. Immunized mice were protected against A2/Aichi(H3N2) challenge virus; however, the protection rate was low in comparison to animals immunized with comparable amounts of the complete A2/68(H3N2) virus9 [PubMed: 1126575]. HA from Influenza A virus (A/Solomon Islands/3/2006(H1N1)) In mouse models of influenza infection, the vaccines derived from Influenza A virus (A/Solomon Islands/3/2006(H1N1)) hemagglutinin elicit robust antibody responses that mitigate disease and protect mice from lethal challenge [PubMed: 18493310]. YH, ZX Protegen ID: 531; NCBI Protein GI: 156123416; NCBITaxon: 464623 HA from Influenza A virus (A/Goose/Guangdong/1/96(H5N1)) YH, ZX Protegen ID: 532; NCBI Gene GI: 3654620; NCBI Protein GI: 73852955; NCBI Protein Accession: YP_308669; NCBITaxon: 93838 Results indicated that two doses of 10 microg of pCAGGoptiHA derived from Influenza A virus (A/Goose/Guangdong/1/96(H5N1)) could induce complete protection in chickens against H5 lethal virus challenge [PubMed: 17451817]. HA from Influenza A virus (A/Yamagata/120/1986(H1N1)) YH, ZX The inoculation of HA vaccine prepared from influenza viruses A/Yamagata/120/86 (H1N1) or A/Fukuoka/C29/85 (H3N2) together with CTB provided partial protection against PR-8 infection in Balb/c mice [PubMed: 2781859]. Protegen ID: 533; NCBI Protein GI: 221344; NCBITaxon: 379740 HA from Influenza A virus (A/Fukuoka/C29/85(H3N2)) Protegen ID: 534; NCBI Protein GI: 221306; NCBITaxon: 62549 YH, ZX The inoculation of HA vaccine prepared from influenza viruses A/Yamagata/120/86 (H1N1) or A/Fukuoka/C29/85 (H3N2) together with CTB provided partial protection against PR-8 infection in Balb/c mice [PubMed: 2781859]. HA from Influenza B virus (B/Ibaraki/2/85) YH, ZX Protection against a lethal influenza B virus infection was examined in BALB/c mice immunized with plasmid DNAs encoding hemagglutinin (HA), neuraminidase (NA and NB) and nucleoprotein (NP) from the B/Ibaraki/2/85 virus. Both HA and NA DNAs conferred complete protection against the lethal challenge in all the tested mouse strains [PubMed: 11163667]. Protegen ID: 535; NCBI Protein GI: 122959; NCBITaxon: 107411 NA from Influenza B virus (B/Ibaraki/2/85) YH, ZX Protegen ID: 536; NCBI Protein GI: 53829726; NCBITaxon: 107411 Protection against a lethal influenza B virus infection was examined in BALB/c mice immunized with plasmid DNAs encoding hemagglutinin (HA), neuraminidase (NA and NB) and nucleoprotein (NP) from the B/Ibaraki/2/85 virus. Both HA and NA DNAs conferred complete protection against the lethal challenge in all the tested mouse strains [PubMed: 11163667]. HA from Influenza A virus (A/Indonesia/CDC669/2006(H5N1)) YH, ZX Viral challenge studies showed that live BacHA derived from Influenza A virus (A/Indonesia/CDC669/2006(H5N1)) was able to provide 100% protection against 5 50% mouse lethal doses (MLD(50)) of homologous (clade 2.1) and heterologous (clade 1) H5N1 [PubMed: 20071572]. Protegen ID: 537; NCBI Protein GI: 113497156; NCBITaxon: 400828 HA from Influenza A virus (A/Indonesia/CDC594/2006(H5N1)) Viral challenge studies showed that live BacHA derived from Influenza A virus (A/Indonesia/CDC594/2006(H5N1)) was able to provide 100% protection against 5 50% mouse lethal doses (MLD(50)) of homologous (clade 2.1) and heterologous (clade 1) H5N1 [PubMed: 20071572]. YH, ZX Protegen ID: 538; NCBI Protein GI: 113495780; NCBITaxon: 400810 HA from Influenza A virus (A/Hawaii/01/1991(H3N2)) Protegen ID: 539; NCBI Protein GI: 110313990; NCBITaxon: 387158 YH, ZX A DNA vaccine encoding HA (from Influenza A virus (A/Hawaii/01/1991(H3N2))), NP and M1 (from a 1989 strain) protected ferrets better against challenge with the antigenic drift variant A/Georgia/03/93 than did the inactivated vaccine from the 1992-93 influenza season. Researchers report that the same DNA vaccine protected ferrets against a second, further divergent, drift variant (A/Johannesburg/33/94) [PubMed: 9234535]. HA from Influenza A virus (A/chicken/Henan/12/2004(H5N1)) Plasmids carrying the HA, NA, NP, M1, and M2 genes, respectively, of the avian influenza virus (AIV) A/Chicken/Henan/12/2004(H5N1) strain were administered to mice, and the mice were challenged with the homologous virus later. The mice immunized with HA plasmid once and the NA plasmid twice survived 100% [PubMed: 19067149]. YH, ZX Protegen ID: 540; NCBI Protein GI: 61698018; NCBITaxon: 319102 NP from Influenza A virus (A/chicken/Henan/12/2004(H5N1)) Protegen ID: 541; NCBI Protein GI: 61698066; NCBITaxon: 319102 YH, ZX Plasmids carrying the HA, NA, NP, M1, and M2 genes, respectively, of the avian influenza virus (AIV) A/Chicken/Henan/12/2004(H5N1) strain were administered to mice, and the mice were challenged with the homologous virus later. The mice immunized with NP plasmid showed 60-80% survival rate with at least three immunizations. The mixture of M1 and NP plasmids protected 95% of the mice against the homologous virus, and 80% of the mice against a challenge with heterologous H1N1 (PR8) virus [PubMed: 19067149]. NA from Influenza A virus (A/chicken/Henan/12/2004(H5N1)) YH, ZX Protegen ID: 542; NCBI Protein GI: 61698053; NCBITaxon: 319102 Plasmids carrying the HA, NA, NP, M1, and M2 genes, respectively, of the avian influenza virus (AIV) A/Chicken/Henan/12/2004(H5N1) strain were administered to mice, and the mice were challenged with the homologous virus later. The mice immunized with HA plasmid once and the NA plasmid twice survived 100% [PubMed: 19067149]. M1 from Influenza A virus (A/chicken/Henan/12/2004(H5N1)) Protegen ID: 543; NCBI Protein GI: 61698034; NCBITaxon: 319102 Plasmids carrying the HA, NA, NP, M1, and M2 genes, respectively, of the avian influenza virus (AIV) A/Chicken/Henan/12/2004(H5N1) strain were administered to mice, and the mice were challenged with the homologous virus later. The mice immunized with M1 plasmid survived 25% with five immunizations. The mixture of M1 and NP plasmids protected 95% of the mice against the homologous virus, and 80% of the mice against a challenge with heterologous H1N1 (PR8) virus [PubMed: 19067149]. YH, ZX NP from Influenza A virus (A/chicken/Hubei/489/2004(H5N1)) YH, ZX Protegen ID: 544; NCBI Protein GI: 55233233; NCBITaxon: 298603 Vaccination with ptPAs/NP derived from Influenza A virus (A/chicken/Hubei/489/2004(H5N1)) efficiently cleared the homologous H5N1 influenza virus in the infected lungs and induced partial cross-protection against heterologous, highly pathogenic H5N1 strains in mice [PubMed: 18789973]. HA from Influenza A virus (A/Viet Nam/1203/2004(H5N1)) YH, ZX Protegen ID: 545; NCBI Protein GI: 159144921; NCBITaxon: 284218 Researchers evaluated the immunogenicity and efficacy of a panel of flagellin-based hemagglutinin (HA) globular head fusion vaccines in inbred mice. The HA globular head of these vaccines was derived from the A/Vietnam/1203/04 (VN04; H5N1) HA molecule. Results show that replacement of domain D3 of flagellin with the VN04 HA globular head creates a highly effective vaccine that elicits protective HAI titers which protect mice against disease and death in a lethal challenge model with H5 VN virus [PubMed: 19654064]. HA from Influenza A virus (A/chicken/Guangdong/02/2007(H9N2)) YH, ZX Using reverse genetics, we constructed a recombinant NDV expressing an H9 AIV hemagglutinin (HA) from an H9N2 field isolate, A/Chicken/ Shandong/2/2007. When tested, 90% of chickens were protected from clinical disease, mortality, and virus shedding against challenge with homologous H9N2 AIV [PubMed: 20521648]. Protegen ID: 546; NCBI Protein GI: 206812650; NCBITaxon: 563925 HA from Influenza A virus (A/Thailand/1(KAN-1)/2004(H5N1)) Immunization with DNA/rAd5 vaccines encoding HA derived from Influenza A virus (A/Thailand/1(KAN-1)/2004(H5N1)) conferred protection in ferrets against a stringent virus challenge [PubMed: 20352112]. Protegen ID: 547; NCBI Nucleotide GI: 46578137; NCBI Protein GI: 46578138; NCBI Protein Accession: AAS65615.2; NCBITaxon: 266827 YH, ZX HA from Influenza A virus (A/turkey/Ireland/1378/1983(H5N8)) Protegen ID: 549; NCBI Protein GI: 115279333; NCBITaxon: 380285 YH, ZX All specific-pathogen-free chickens immunized with (vFP89) expressing the native hemagglutinin (HA) gene from H5N8 A/turkey/ Ireland/1378/83 were clinically protected from HPAI challenge [PubMed: 20521642]. HA from Influenza A virus (A/chicken/Indonesia/7/2003(H5N1)) Protegen ID: 550; NCBI Protein GI: 129282887; NCBITaxon: 430432 All specific-pathogen-free chickens immunized with (vFP2211) expressing a modified synthetic HA gene from H5N1 A/chicken/Indonesia/7/2003 were clinically protected from HPAI challenge [PubMed: 20521642]. YH, ZX HA from Influenza A virus (A/Hatay/2004/(H5N1)) A neutralizing monoclonal antibody (mAb) 9F4 against the hemagglutinin (HA) of the influenza A/chicken/hatay/2004 H5N1 virus was generated. MAb 9F4 was found to be protective, both prophylactically and therapeutically, against lethal viral challenge of mice [PubMed: 20519402]. YH, ZX Protegen ID: 551; NCBI Protein GI: 56311402; NCBITaxon: 303316 HA from Influenza A virus (A/whooper swan/Mongolia/3/05(H5N1)) Chickens immunized with attenuated Salmonella strains expressing the hemagglutinin (HA1) gene from a highly pathogenic avian influenza (HPAI) H5N1 (A/whooper swan/Mongolia/3/2005) demonstrated a statistically significant increase in survival compared to control groups [PubMed: 20406663]. YH, ZX Protegen ID: 553; NCBI Protein GI: 81687119; NCBITaxon: 344596 Envelope protein Researchers constructed a recombinant pseudotype baculovirus encoding the JEV envelope (E) protein and demonstrated that it could elicit high protective immunity in mice. Intramuscular injections of BV-G-E at various doses into mice produced higher levels of JEV-specific neutralizing antibodies, IFN-gamma and better protective efficacy against a lethal challenge with JEV than that of pc-E. Furthermore, BV-G-E could elicit a higher level of cellular immunity response and provide equal protective efficacy against JEV challenge compared to inactivated vaccine [PubMed: 19006097]. YH, ZX Protegen ID: 554; NCBI Protein GI: 16445023; NCBITaxon: 11072 PrM Researchers established a simple and effective method for DNA immunization against Japanese encephalitis virus (JEV) infection with plasmids encoding the viral PrM and E proteins and colloidal gold. After being inoculated twice, BALB/c mice were found to resist challenge with 100,000 times the 50% lethal dose (LD(50)) of JEV (Beijing-1 strain) even when immunized with a relatively small dose of 0.5 micro g of plasmid DNA [PubMed: 12634382]. Protegen ID: 555; NCBI Protein GI: 90019439; NCBITaxon: 11072 YH, ZX NS1 Balb/c mice and swine vaccinated with TK(-)/gG(-)/NS1(+) expressing NS1 protein of JEV could confer protective immunity against lethal challenge of the virulent PRV Ea strain and develop a good humoral and cellular immune response against JEV [PubMed: 15121294]. YH, ZX Protegen ID: 556; NCBI Protein GI: 18418672; NCBITaxon: 11072 NS3 Protegen ID: 557; NCBI Protein GI: 27696332; NCBITaxon: 11072 YH, ZX Researchers constructed plasmid DNAs encoding JE virus proteins. Cytotoxic T lymphocytes (CTLs) were induced by NS3 in a mouse model. Three immunizations with pUJENS3 provided a 50% partial protection from a lethal dose of JE virus [PubMed: 12922097]. NS5 Protegen ID: 558; NCBI Protein GI: 158702649; NCBITaxon: 11072 Researchers constructed plasmid DNAs encoding JE virus proteins. Cytotoxic T lymphocytes (CTLs) were induced by NS5 in a mouse model. Three immunizations with pUJENS5 provided a 57% partial protection from a lethal dose of JE virus [PubMed: 12922097]. YH, ZX PreM A cDNA clone representing the genome of structural proteins of Japanese encephalitis virus (JEV) was inserted into the thymidine kinase gene of vaccinia virus strains LC16mO and WR. Inoculation of rabbits with the infectious recombinant vaccinia virus resulted in rapid production of antiserum specific for the PreM and E glycoproteins of JEV. Mice vaccinated with the recombinant produced JEV-neutralizing antibodies and were resistant to challenge with JEV [PubMed: 2159544]. YH, ZX Protegen ID: 559; NCBI Protein GI: 14600066; NCBITaxon: 11072 LASVsSgp1 nucleoprotein Protegen ID: 560; NCBI Gene GI: 956584; NCBI Protein GI: 23343510; NCBI Protein Accession: NP_694869; NCBITaxon: 11620 YH, ZX Vaccine efficacy trials in guinea pigs indicated that the nucleoprotein is capable of eliciting a protective immune response against a lethal dose of Lassa virus. Ninety-four percent of the animals vaccinated with V-LSN survived a Lassa virus challenge in which only 14% of unvaccinated animals and 39% of animals vaccinated with the New York Board of Health (NYBH) strain of vaccinia virus survived [PubMed: 2741340]. GRP-78 BALB/c mice were immunized with a vaccine expressing the 78kDa (GRP-78) antigen of Leishmania donovani. Challenge infection was given intracardially after 2 weeks of second booster. A significant decrease in parasite burden was seen in vaccinees over the infected controls on all post challenge days and was found that maximum protection was provided by 78kDa+rIL-12 vaccine. It was highly immunogenic as depicted by the reduction in parasite load (71-94.8%) [PubMed: 20093205]. YH, ZX Protegen ID: 561; NCBI Protein GI: 16797868; NCBITaxon: 5661 A2 Study results show that a single intraperitoneal administration of the A2-recombinant L. tarentolae strain expressing the Leishmania donovani A2 antigen protects BALB/c mice against L. infantum challenge and that protective immunity is associated with high levels of IFN-gamma production prior and after challenge [PubMed: 19818721]. YH, ZX Protegen ID: 563; NCBI Protein GI: 30385439; NCBITaxon: 5671 F1-ATPase Study compared the vaccine efficacy of various L. donovani antigens encapsulated in cationic liposomes in BALB/c mice against challenge infection with L. donovani. Results demonstrated that liposomal LD31 (ATP synthase alpha chain) reduced parasite burden by 74%-77% [PubMed: 19503834]. Protegen ID: 564; NCBI Protein GI: 722242; NCBITaxon: 5661 YH, ZX Beta-tubulin Protegen ID: 565; NCBI Protein GI: 262233287; NCBITaxon: 5661 Study compared the vaccine efficacy of various L. donovani antigens encapsulated in cationic liposomes in BALB/c mice against challenge infection with L. donovani. Results demonstrated that liposomal LD51 (beta-tubulin) reduced parasite burden by 72%-75% [PubMed: 19503834]. YH, ZX Hsp70 Study compared the vaccine efficacy of various L. donovani antigens encapsulated in cationic liposomes in BALB/c mice against challenge infection with L. donovani. Results demonstrated that liposomal LD72 (Hsp70) reduced parasite burden by 65%-67% [PubMed: 19503834]. Protegen ID: 566; NCBI Protein GI: 281426606; NCBITaxon: 5661 YH, ZX KMP-11 KMP-11 DNA vaccination alone in an experimental BALB/c mice model showed significant potential in terms of resolution of splenic and hepatic parasite burden against virulent LD challenge. KMP-11 DNA immunization significantly protects against L. donovani infection [PubMed: 19162111]. YH, ZX Protegen ID: 567; NCBI Protein GI: 7579896; NCBITaxon: 5661 MspC YH, ZX Protegen ID: 568; NCBI Protein GI: 21954466; NCBITaxon: 5661 Study showed that cationic distearoyl phosphatidylcholine (DSPC) liposomes, when used as vaccine adjuvant with the immunodominant 63-kDa glycoprotein (gp63, mspC) of Leishmania donovani promastigotes, induced significant protection against progressive visceral leishmaniasis in susceptible BALB/c mice. gp63 used without adjuvant elicited partial protection but in association with liposomes exhibited marked resistance in both the livers and spleens of the mice challenged 10 days after the last vaccination [PubMed: 18195029]. ORFF YH, ZX An expression plasmid encoding both p35 and p40 subunits of IL-12 when co-administered with a recombinant open-reading frame (rORFF) gene from the LD1 locus of Leishmania donovani induces significant protection with around 82% protection in both liver and spleen of BALB/c mice when challenged with L. donovani [PubMed: 16413950]. Protegen ID: 569; NCBI Protein GI: 703122; NCBITaxon: 5661 BT1 YH, ZX Protegen ID: 570; NCBI Protein GI: 703123; NCBITaxon: 5661 Immunization of mice with recombinant BT1 proteins (a biopterin transporter) from multigenic LD1 locus on chromosome 35 of L. donovani conferred partial protection against challenge with Leishmania donovani in a BALB/c mice [PubMed: 15357215]. NH Protegen ID: 571; NCBI Protein GI: 19697561; NCBITaxon: 5661 Experimental infection of immunized BALB/c mice demonstrated that the VR1012-NH36 DNA vaccine derived from the nucleoside hydrolase gene (NH) of L. donovani induced an 88% reduction in L. chagasi parasite load and a 65% reduction in L. mexicana lesion size [PubMed: 15664920]. YH, ZX HASPB1 Protegen ID: 572; NCBI Protein GI: 51847753; NCBITaxon: 5661 Study demonstrated for the first time that a recombinant stage-specific hydrophilic surface protein of Leishmania donovani, recombinant hydrophilic acylated surface protein B1 (HASPB1), is able to confer protection against experimental challenge with L. donovani in BALB/c mice [PubMed: 11120835]. YH, ZX NP from Lake Victoria marburgvirus Nonhuman primates (cynomolgus macaques) were inoculated with VEE replicons expressing MBGV GP and/or NP and challenged with MGBV. MBGV NP afforded incomplete (partial) protection, sufficient to prevent death but not disease in two of three macaques [PubMed: 9813200 ]. YH, ZX Protegen ID: 573; NCBI Protein GI: 332181; NCBITaxon: 11269 MDV040 Recombinant fowl poxviruses (rFPVs) were constructed to express genes from serotype 1 Marek's disease virus (MDV, Gallid herpesvirus 2). rFPV/gB1 expressing MDV040 conferred 42% protection in maternal antibody-positive chickens when challenged with highly virulent MDV isolates [PubMed: 14562881]. YH, ZX Protegen ID: 574; NCBI Gene GI: 4811501; NCBI Protein GI: 125745079; NCBI Protein Accession: YP_001033956; NCBITaxon: 10390 MDV095 YH, ZX Recombinant fowl poxviruses (rFPVs) were constructed to express genes from serotype 1 Marek's disease virus (MDV, Gallid herpesvirus 2). rFPV/gI expressing MDV095 conferred 43% protection in maternal antibody-positive chickens when challenged with highly virulent MDV isolates [PubMed: 14562881]. Protegen ID: 575; NCBI Gene GI: 4811454; NCBI Protein GI: 125745128; NCBI Protein Accession: YP_001034012; NCBITaxon: 10390 H hemagglutinin protein Chimeric Venezuelan equine encephalitis/Sindbis virus (VEE/SIN) replicon particles were used to express the hemagglutinin (H) and fusion (F) proteins of measles virus (MV). When challenged with wild-type MV 12 to 17 months after vaccination, all vaccinated juvenile and infant monkeys vaccinated with VEE/SIN-H, VEE/SIN-H+F, and LAV were protected from rash and viremia [PubMed: 20130066]. Protegen ID: 577; NCBI Gene GI: 1489801; NCBI Protein GI: 9626951; NCBI Protein Accession: NP_056923; NCBITaxon: 11234 YH, ZX F fusion protein YH, ZX Protegen ID: 578; NCBI Gene GI: 1489800; NCBI Protein GI: 9626950; NCBI Protein Accession: NP_056922; NCBITaxon: 11234 Mice vaccinated with a vaccinia virus recombinant encoding the fusion protein of Measles virus developed measles neutralizing antibodies. The mice also resisted a normally lethal intracerebral inoculation of a cell-associated measles virus subacute sclerosing panencephalitis strain [PubMed: 3422488]. N nucleocapsid protein Lewis rats were immunized with recombinant vaccinia virus (VV) expressing various proteins of measles virus (MV). VVN (Nucleocapsid Protein) -immunized rats survived a MV challenge infection [PubMed: 1833505]. YH, ZX Protegen ID: 579; NCBI Gene GI: 1489804; NCBI Protein GI: 9626946; NCBI Protein Accession: NP_056918; NCBITaxon: 11234 P phosphoprotein Protegen ID: 580; NCBI Gene GI: 1489805; NCBI Protein GI: 9626947; NCBI Protein Accession: NP_056919; NCBITaxon: 11234 YH, ZX Lewis rats were immunized with recombinant vaccinia virus (VV) expressing various proteins of measles virus (MV). VVP (Phosphoprotein) -immunized rats were partially protected from MV challenge [PubMed: 1833505]. M matrix protein YH, ZX Lewis rats were immunized with recombinant vaccinia virus (VV) expressing various proteins of measles virus (MV). VVM (Matrix Protein) -immunized rats were partially protected from MV challenge [PubMed: 1833505]. Protegen ID: 581; NCBI Gene GI: 1489803; NCBI Protein GI: 9626949; NCBI Protein Accession: NP_056921; NCBITaxon: 11234 HN YH, ZX Protegen ID: 582; NCBI Gene GI: 1489765; NCBI Protein GI: 9695422; NCBI Protein Accession: NP_054713; NCBITaxon: 11161 A novel mumps vaccine with good immunity and safety was developed by selecting an antigen (HN) component of the mumps virus. The clinical and pathological observations after challenge of vaccinated rhesus monkeys indicated further that the immune response induced by this vaccine provided complete protection from wild-type virus infection [PubMed: 18597904]. FbpB from M. tuberculosis YH, ZX Protegen ID: 583; NCBI Gene GI: 885785; NCBI Protein GI: 15609023; NCBI Protein Accession: NP_216402; NCBITaxon: 83332 Immunization with DNA encoding Ag85B (fbpB), a candidate vaccine antigen of Mycobacterium tuberculosis, elicited in mice a low but protective CD4(+) T cell-mediated IFN-gamma response [PubMed: 20544034]. Mtb72F Our lead construct, Mtb72F, codes for a 72-kDa polyprotein genetically linked in tandem in the linear order Mtb32(C)-Mtb39-Mtb32(N). All forms of Mtb72F immunization tested resulted in the protection of C57BL/6 mice against aerosol challenge with a virulent strain of M. tuberculosis [PubMed: 15187142]. YH, ZX Protegen ID: 584; NCBI Protein GI: 283801990; NCBITaxon: 32630 MIC3 YH, ZX Protegen ID: 587; NCBI Gene GI: 7901253; NCBI Protein GI: 237841071; NCBI Protein Accession: XP_002369833; NCBITaxon: 508771 Protective experiments of DNA vaccine pcDNA3-MIC3 (pMIC3i) in Kumming mice showed that the vaccine could significantly prolong the survival time of the mice challenged by virulent RH strains of T. gondii [PubMed: 19800170]. Apa We show that the 50- to 55-kDa Apa protein, specified by the Rv1860 gene of M. tuberculosis, can elicit both lymphoproliferative response and gamma interferon (IFN-gamma) production. A poxvirus recombinant expressing the Apa protein conferred a significant level of protective immunity in guinea pigs against a challenge dose of virulent M. tuberculosis [PubMed: 12654810]. YH, ZX Protegen ID: 588; NCBI Gene GI: 885896; NCBI Protein GI: 57116926; NCBI Protein Accession: YP_177849; NCBITaxon: 83332 Mpt63 MPT63 (Rv1926c), a major secreted protein of Mycobacterium tuberculosis, is immunoreactive in antibody assays in humans and animals and provides protection as a combined DNA vaccine in mice [PubMed: 19281533]. Protegen ID: 589; NCBI Gene GI: 885334; NCBI Protein GI: 15609063; NCBI Protein Accession: NP_216442; NCBITaxon: 83332 YH, ZX E protein Protegen ID: 590; NCBI Protein GI: 111145461; NCBITaxon: 11082 The immunogenicity and protective efficacy of a recombinant subunit West Nile virus (WNV) vaccine was evaluated in rhesus macaques (Macaca mulatta). The vaccine consisted of a recombinant envelope (E) protein truncated at the C-terminal end, resulting in a polypeptide containing 80% of the N-terminal amino acids of the native WNV protein (WN-80E), mixed with an adjuvant (GPI-0100). Groups of monkeys were immunized with the WN-80E/GPI-0100 vaccine or an adjuvant-only control formulation. Animals were then challenged by inoculation of wild-type WNV, and the level of viremia in each animal was monitored daily for 10 days. The results showed that whereas all animals in the control group had detectable viremia for at least 3 days after challenge, all of the vaccinated animals were negative on all days after challenge. Thus, the WN-80E vaccine was 100% efficacious in protecting monkeys against infection with WNV [PubMed: 19641099]. YH, ZX TM-1 YH, ZX Protegen ID: 591; NCBI Protein GI: 7249262; NCBITaxon: 2096 An antiserum raised in chicken against the TM-1 polypeptide, which was produced by recombinant Escherichia coli cells and purified by column chromatography, inhibited growth of M.g. cells in vitro. Moreover, chickens immunized with this 29 kDa polypeptide (TM-1) were partially protected from a challenge with virulent M.g [PubMed: 8212828]. PrM Starting with a previously designed eukaryotic expression vector, a recombinant plasmid (pCBWN) that expressed the WN virus prM and E proteins was constructed. A single intramuscular injection of pCBWN DNA induced protective immunity, preventing WN virus infection in mice and horses when subjected to challenge with the NY99-6480 strain of WNV [PubMed: 11287553]. Protegen ID: 592; NCBI Gene GI: 5714902; NCBI Protein GI: 158516888; NCBI Protein Accession: YP_001527877; NCBITaxon: 11082 YH, ZX P1 Seventeen monoclonal antibodies to one of three main cell surface antigens of Neisseria meningitidis group B were tested for protective efficacy in the infant rat using as challenge seven strains of different class 2/3 protein serotypes. Survival of the animals was regularly obtained with antibodies to the P1 protein and to LPS [PubMed: 2510417]. YH, ZX Protegen ID: 594; NCBI Gene GI: 902192; NCBI Protein GI: 15676020; NCBI Protein Accession: NP_273150; NCBITaxon: 122586 LpdA YH, ZX Sera of the challenge group immunized with CCPS-P64kR showed a three-fold higher bactericidal response than the sera of the group immunized with the plain CCPS and they were able to protect against challenge with Neisseria meningococci in the infant rat protection model [PubMed: 15039094]. Protegen ID: 596; NCBI Protein GI: 1017430; NCBITaxon: 487 TBP2 Mice immunized with purified Tbp2 survived a lethal challenge to a similar degree as animals immunized with the Tbp1-Tbp2 complex, demonstrating that Tbp2 played an important role in the protective activity observed with the complex, eliciting antibodies that are not only bactericidal but also inhibitory for meningococcal growth [PubMed: 7868259]. Protegen ID: 597; NCBI Protein GI: 1017433; NCBITaxon: 487 YH, ZX P67 Immunization with recombinant forms of a sporozoite surface antigen (r-p67), derived from either bacterial or insect cells, induces high levels of sporozoite neutralizing antibodies in cattle.In vivo immunization studies have shown that approximately 30% of immunized cattle are nonreactors to a needle LD70 sporozoite challenge, 40% experience a mild disease reaction from which they recover, and the remaining 30% suffer severe disease and are clinically indistinguishable from controls. Transient parasitosis and mild clinical reactions are also observed in challenge of cattle immunized by infection and treatment and such responses constitute immunity to ECF. Hence, p67 is able to routinely induce immunity at a level of about 70% [PubMed: 11193661]. Protegen ID: 598; NCBI Protein GI: 4106806; NCBITaxon: 5875 YH, ZX NspA from N. meningitidis Protegen ID: 599; NCBI Protein GI: 5825543; NCBITaxon: 487 YH, ZX NspA-containing outer membrane vesicles conferred protection against otherwise lethal intraperitoneal challenge of mice with N. meningitidis serogroup B, and sera raised against them mediated opsonophagocytosis of meningococcal strains expressing this antigen [PubMed: 15501782]. LctP Protegen ID: 600; NCBI Protein GI: 254667969; NCBITaxon: 662598 YH, ZX A total of 11 meningococcal proteins that are necessary for establishing systemic infection were expressed as recombinant antigens and assessed for their ability to protect mice against live bacterial challenge against N. meningitidis; the lactate permease (LctP) elicited protective immunity [PubMed: 15964482]. ExbB YH, ZX Protegen ID: 601; NCBI Gene GI: 903370; NCBI Protein GI: 15677575; NCBI Protein Accession: NP_274732; NCBITaxon: 122586 A total of 11 meningococcal proteins that are necessary for establishing systemic infection were expressed as recombinant antigens and assessed for their ability to protect mice against live bacterial challenge against N. meningitidis; ExbB, which is required for iron acquisition, elicited protective immunity [PubMed: 15964482]. Spag-1 YH, ZX The trial vaccination of cattle against T. annulata using recombinant sporozoite antigens (SPAG-1 and p67) and/or merozoite antigens (TAMS 1-1 and 1-2). The aim of these trials was to try and enhance the levels of protection induced compared with previous trials. Different approaches were tried. SPAG-1 was expressed as a fusion protein with a His6 tag and then either incorporated into ISCOMs, with or without TAMS 1-1 and 1-2, or administered with RWL, a proprietary saponin-based adjuvant. Cross-protection studies were also performed by immunizing cattle with the T. parva sporozoite antigen, p67, and then challenging with a T. annulata sporozoite stabilate.All the data collected from these two trials indicate that SPAG-1 administered with RWL is better at inducing an effective immune response than SPAG-1 incorporated into ISCOMs, with or without the presence of merozoite antigens [PubMed: 9668470]. Protegen ID: 602; NCBI Protein GI: 161885; NCBITaxon: 5874 TA17050 merozoite-piroplasm surface antigen Tams1 YH, ZX To test the potential of subunit vaccines against T. annulata infection, we immunized four groups of three calves with either recombinant (re-) (Tams1-1 and Tams1-2) proteins or naked DNA encoding these antigens. All calves vaccinated with ISCOMs proved to be protected from T. annulata infection and had generated antibodies against both re-(Tams1-1 and Tams1-2) at the time of challenge [PubMed: 9364686]. Protegen ID: 603; NCBI Gene GI: 3864438; NCBI Protein GI: 84997996; NCBI Protein Accession: XP_953719; NCBITaxon: 353154 NcMAG1 Protegen ID: 604; NCBI Protein GI: 147886433; NCBITaxon: 29176 YH, ZX Intraperitoneal application of NcMAG1 suspended in saponin adjuvants lead to protection against disease in 50% of animals vaccinated in a C57Bl/6 mouse cerebral infection model [PubMed: 19835644]. PsaA Protegen ID: 605; NCBI Protein GI: 209867628; NCBITaxon: 1313 Vaccination with an RASV synthesizing full-length PsaA induced high titers of anti-PsaA antibodies in both systemic (IgG in serum) and mucosal (IgA in vaginal washes, nasal washes, and lung homogenates) sites. BALB/c (haplotype H2(d)) or C57BL/6 (haplotype H2(b)) mice vaccinated either orally or intranasally exhibited a significant reduction in colonization of nasopharyngeal tissues after intranasal challenge with S. pneumoniae strains compared to controls, although protection was not observed with all challenge strains. None of the vaccine constructs provided protection against intraperitoneal challenge with S. pneumoniae strain WU2 (serotype 3) [PubMed: 20479086]. YH, ZX NcPDI A 90% protection rate was achieved following intra-nasal vaccination with recNcPDI emulsified in cholera toxin employing the C57Bl/6 mouse cerebral infection model when challenged with Neospora caninum tachyzoites [PubMed: 19835644]. Protegen ID: 606; NCBI Protein GI: 82568727; NCBITaxon: 29176 YH, ZX Ply Protegen ID: 607; NCBI Gene GI: 4441611; NCBI Protein GI: 116515376; NCBI Protein Accession: YP_817150; NCBITaxon: 373153 The protective effects a pneumolysin mutant (DeltaA146 Ply) against pneumococcal infections in mice was evaluated. Vaccinated mice were challenged with pneumococcal strain D39 at 1,500 times the LD50 (1.5 x 105 CFU) and the vaccinated mice survived significantly longer than control mice after challenge [PubMed: 20038538]. YH, ZX ClpP YH, ZX Protegen ID: 608; NCBI Gene GI: 4441476; NCBI Protein GI: 116516216; NCBI Protein Accession: YP_816144; NCBITaxon: 373153 The protective effects of ATP-dependent caseinolytic protease (ClpP) was evaluated. Vaccinated mice were intraperitoneally and/or intranasally challenged with different pneumococcal strains. In intraperitoneal challenge models with pneumococcal strain D39 (serotype 2), clpP elicited some protection in mice [PubMed: 20038538]. LplA YH, ZX Protegen ID: 609; NCBI Gene GI: 934072; NCBI Protein GI: 15903091; NCBI Protein Accession: NP_358641; NCBITaxon: 171101 The production of a recombinant vaccine was achieved following PCR amplification of putative lipoate protein ligase (Lpl), with subsequent cloning and expression of the genes in E. coli. The putative lipoate protein ligase (Lpl) , resulted in a reduced CFU titre and a trend towards reduced mortality in an animal sepsis model [PubMed: 18034862]. NcSRS2 YH, ZX Protegen ID: 610; NCBI Protein GI: 5579384; NCBITaxon: 29176 NcSAG1 and NcSRS2, the two major immunodominant tachyzoite surface antigens of the apicomplexan parasite Neospora caninum, were investigated for their potential as vaccine candidates in mice. Results suggest that a combined DNA/recombinant antigen-vaccine, based on NcSAG1 and NcSRS2, respectively, exhibited a highly significant protective effect against experimentally induced cerebral neosporosis in mice [PubMed: 12741509]. NcSAG1 NcSAG1 and NcSRS2, the two major immunodominant tachyzoite surface antigens of the apicomplexan parasite Neospora caninum, were investigated for their potential as vaccine candidates in mice. Results suggest that a combined DNA/recombinant antigen-vaccine, based on NcSAG1 and NcSRS2, respectively, exhibited a highly significant protective effect against experimentally induced cerebral neosporosis in mice [PubMed: 12741509]. Protegen ID: 611; NCBI Protein GI: 4583447; NCBITaxon: 29176 YH, ZX PsrP Mice immunized with recombinant (r)PsrP(BR) had significantly less bacteria in their blood and improved survival versus controls following intranasal challenge [PubMed: 19627498]. Protegen ID: 613; NCBI Gene GI: 7329552; NCBI Protein GI: 221232510; NCBI Protein Accession: YP_002511663; NCBITaxon: 561276 YH, ZX MIC10 YH, ZX Protegen ID: 614; NCBI Protein GI: 11141617; NCBITaxon: 29176 This study used an immunisation/challenge model of transplacental transmission, based on the Qs mouse with an Nc-Liverpool challenge to investigate the vaccine potential of a number of formulations based on four recombinant proteins of N. caninum. A mixture of MIC10 and p24B produced partial protection against transplacental transmission of N. caninum in this mouse model [PubMed: 18789996]. Note: MIC10 must be used in conjunction with p24B in order to confer protection against N. caninum. SrtA Intraperitoneal immunization with recombinant SrtA was found to have conferred to mice protection against S. pneumoniae intraperitoneal challenge and the passive transfer of immune serum before intraperitoneal challenge was also protective. Moreover, by using the intranasal challenge model, significant reduction of bacteremia when mice were intraperitoneally immunized with SrtA was observed, while a moderate decrease of lung infection was achieved by intranasal immunization, even though no influence on nasopharynx colonization was seen [PubMed: 19433540]. Protegen ID: 615; NCBI Gene GI: 4442999; NCBI Protein GI: 116515518; NCBI Protein Accession: YP_816547; NCBITaxon: 373153 YH, ZX NcMIC1 Protegen ID: 616; NCBI Protein GI: 17226315; NCBITaxon: 29176 YH, ZX Study assessed the potential protectivity of NcMIC1-based vaccination against experimental N. caninum infection in mice. Quantitative real-time PCR revealed that the infection intensity was significantly reduced in the group vaccinated with recNcMIC1 antigen. Serological analysis showed that only recNcMIC1-immunized animals generated detectable antibody levels recognizing native NcMIC1. Thus, of all protocols applied, only recNcMIC1 vaccination appears to be suited to reduce cerebral infection in mice challenged with N. caninum tachyzoites [PubMed: 16108562]. GltX Glutamyl tRNA synthetase (GtS) has been found to be among the Streptococcus pneumoniae cell wall-derived proteins that have age-dependent immunogenicity in children. Here, GtS was cloned, expressed, and purified and then was used to immunize 7-week-old BALB/c OlaHsd mice. Thirty-nine percent of rGtS-immunized mice survived a lethal bacterial challenge, whereas no control mice survived [PubMed: 17703427]. YH, ZX Protegen ID: 617; NCBI Gene GI: 931970; NCBI Protein GI: 15901888; NCBI Protein Accession: NP_346492; NCBITaxon: 170187 NcDG1 Separate groups of gerbils were immunized with purified recombinant proteins singly or in combinations and animals were then challenged with N. caninum. The protective efficacy of each vaccination was determined by assessing animal survival rate. The highest protection efficacy was observed for combined vaccination with NcSRS2 and NcDG1 (67.5% survival) compared to control (17.4% survival). Vaccination with NcDG1 alone elicited 62.5% survival in the challenge model [PubMed: 15793355]. YH, ZX Protegen ID: 618; NCBI Protein GI: 2149142; NCBITaxon: 29176 CbpA YH, ZX Mice were actively immunized with a fragment of choline binding protein A (CbpA; also known as PspC, Hic, and SpsA). CbpA was able to protect mice from intraperitoneal challenge with medium to very high doses of a highly virulent capsular type 2 pneumococcal strain, D39 [PubMed: 11553536]. Protegen ID: 619; NCBI Gene GI: 4441159; NCBI Protein GI: 116515359; NCBI Protein Accession: YP_817402; NCBITaxon: 373153 PspA YH, ZX Groups of BALB/c mice immunized with choline binding protein PspA were challenged with either D39 or WCH16. PspA elicited protection by using moderate challenge doses of S. pneumoniae [PubMed: 17088353]. Protegen ID: 620; NCBI Gene GI: 4441373; NCBI Protein GI: 116515876; NCBI Protein Accession: YP_815641; NCBITaxon: 373153 NcDG2 YH, ZX Protegen ID: 621; NCBI Protein GI: 3237325; NCBITaxon: 29176 Separate groups of gerbils were immunized with purified recombinant proteins singly or in combinations and animals were then challenged with N. caninum. The protective efficacy of each vaccination was determined by assessing animal survival rate. All experimental groups showed protective effects. Vaccination with NcDG2 alone elicited 50% survival rate compared to a control survival rate of 17.4% [PubMed: 15793355]. Gnd YH, ZX Protegen ID: 622; NCBI Gene GI: 4441177; NCBI Protein GI: 116515453; NCBI Protein Accession: YP_815856; NCBITaxon: 373153 BALB/c mice were immunized with recombinant 6-Phosphogluconate dehydrogenase (r6PGD) and boosted after 3 weeks. Immunized mice were challenged intranasally with a lethal dose of S. pneumoniae. Immunization of mice with r6PGD protected 60% (P < 0.001) of mice for 5 days and 40% (P < 0.05) of the mice for 21 days following intranasal lethal challenge [PubMed: 16634799]. PiaA Mice immunized with recombinant PiaA were protected against systemic challenge to a degree similar to those immunized with an existing protein vaccine candidate, PdB (a genetically modified pneumolysin toxoid). Immunization with a combination of both PiuA and PiaA resulted in additive protection and was highly protective against systemic infection with S. pneumoniae [PubMed: 11598041]. Protegen ID: 623; NCBI Gene GI: 4442863; NCBI Protein GI: 116515816; NCBI Protein Accession: YP_815744; NCBITaxon: 373153 YH, ZX F fusion protein A recombinant fowlpox virus expressing the fusion protein of Newcastle disease virus strain F48E8 protected chickens against virulent NDV challenge. The protective rate was 96.7% [PubMed: 11191764]. YH, ZX Protegen ID: 624; NCBI Gene GI: 912271; NCBI Protein GI: 11545723; NCBI Protein Accession: NP_071469; NCBITaxon: 11176 HN hemagglutinin-neuraminidase Protegen ID: 625; NCBI Gene GI: 912270; NCBI Protein GI: 11545724; NCBI Protein Accession: NP_071470; NCBITaxon: 11176 Recombinant baculoviruses containing the fusion (F) and hemagglutinin-neuraminidase (HN) glycoprotein gene of the viscerotropic velogenic (vv) Newcastle disease virus (NDV) isolate, Kr-005/00, and a lentogenic La Sota strain of the NDV were constructed. A single dose of rNDHN(V) had a protective effect against mortality (p <0.01) in chickens [PubMed: 18716451]. YH, ZX SERA-5 Protegen ID: 626; NCBI Protein GI: 238629807; NCBITaxon: 5833 Researchers constructed a new recombinant molecule of SERA5, namely SE36. Vaccination of Squirrel monkeys with SE36 protein and aluminium hydroxyl gel (SE36/AHG) conferred protection against high parasitemia and boosted serum anti-SE36 IgG after P. falciparum parasite challenge [PubMed: 20493274]. YH, ZX binding protein Eag Protegen ID: 627; NCBI Gene GI: 7696154; NCBI Protein GI: 225870123; NCBI Protein Accession: YP_002746070; NCBITaxon: 553482 YH, ZX Vaccination of mice with EAG (2-macroglobulin, albumin, and immunoglobulin G [IgG] binding protein) as a single antigen with EtxB (as an adjuvant) induced protection in mice against bacterial challenge, but was less protective than at affording protection than immunization with FNZ, SFS, EAG, and EtxB [PubMed: 15155624]. MSP1 from P. yoelii str. 17XNL YH, ZX Protegen ID: 628; NCBI Gene GI: 3791597; NCBI Protein GI: 82596427; NCBI Protein Accession: XP_726257; NCBITaxon: 352914 Researchers found that the cysteine-rich, carboxyl-terminal region of the MSP-1 protein from the rodent malarial parasite Plasmodium yoelii yoelii can be expressed in a native configuration as a fusion protein in Escherichia coli. This recombinant polypeptide elicits antibodies in mice which recognize the native parasite MSP-1. Most significantly, both inbred and outbred mice immunized with the fusion protein in Ribi adjuvant are partially and in some cases completely protected against challenge infection with an otherwise lethal parasite strain [PubMed: 8363656]. collagen binding, ancillary pilus subunit Cne Protegen ID: 629; NCBI Gene GI: 7695900; NCBI Protein GI: 225870316; NCBI Protein Accession: YP_002746263; NCBITaxon: 553482 YH, ZX Mice were immunised i.n. with collagen-binding protein (CNE) and were subsequently subjected to infection with S. equi subsp. equi. A control group of mice was given only adjuvant. The CNE vaccinated group had a delayed onset of infection compared to the control group. Immunization with CNE led to significant protection from infection [PubMed: 16580099]. Fnz Protegen ID: 630; NCBI Gene GI: 7695217; NCBI Protein GI: 225869227; NCBI Protein Accession: YP_002745175; NCBITaxon: 40041 YH, ZX Parts of the three recombinant proteins (FNZ (cell surface-bound fibronectin binding protein), SFS (secreted fibronectin binding protein), and EAG (alpha2-macroglobulin, albumin, and immunoglobulin G [IgG] binding protein)) were used to immunize mice, either subcutaneously or intranasally, prior to nasal challenge with S. equi subsp. equi. The adjuvant used was EtxB, a recombinant form of the B subunit of Escherichia coli heat-labile enterotoxin. It was shown that nasal colonization of S. equi subsp. equi and weight loss due to infection were significantly reduced after vaccination compared with a mock-vaccinated control group. This effect was more pronounced after intranasal vaccination than after subcutaneous vaccination; nearly complete eradication of nasal colonization was obtained after intranasal vaccination (P < 0.001) [PubMed: 15155624]. Sfs YH, ZX Parts of the three recombinant proteins (FNZ (cell surface-bound fibronectin binding protein), SFS (secreted fibronectin binding protein), and EAG (alpha2-macroglobulin, albumin, and immunoglobulin G [IgG] binding protein)) were used to immunize mice, either subcutaneously or intranasally, prior to nasal challenge with S. equi subsp. equi. The adjuvant used was EtxB, a recombinant form of the B subunit of Escherichia coli heat-labile enterotoxin. It was shown that nasal colonization of S. equi subsp. equi and weight loss due to infection were significantly reduced after vaccination compared with a mock-vaccinated control group. This effect was more pronounced after intranasal vaccination than after subcutaneous vaccination; nearly complete eradication of nasal colonization was obtained after intranasal vaccination (P < 0.001) [PubMed: 15155624]. Protegen ID: 631; NCBI Gene GI: 7696331; NCBI Protein GI: 225869898; NCBI Protein Accession: YP_002745845; NCBITaxon: 553482 Fbp Protegen ID: 632; NCBI Gene GI: 7697172; NCBI Protein GI: 225871286; NCBI Protein Accession: YP_002747233; NCBITaxon: 553482 YH, ZX The fibrinogen-binding protein (FgBP) reacted with serum taken from horses recovering from strangles and protected mice against lethal challenge from S. equi subsp. equi [PubMed: 9579073]. CS from P. berghei str. ANKA Protegen ID: 633; NCBI Gene GI: 3428738; NCBI Protein GI: 68076353; NCBI Protein Accession: XP_680096; NCBITaxon: 5823 Researchers produced a prototypic malaria vaccine based on a highly versatile self-assembling polypeptide nanoparticle (SAPN) platform that can repetitively display antigenic epitopes. Researchers used this platform to display a tandem repeat of the B cell immunodominant repeat epitope (DPPPPNPN)(2)D of the malaria parasite Plasmodium berghei circumsporozoite (CS) protein. Administered in saline, without the need for a heterologous adjuvant, the SAPN construct P4c-Mal conferred a long-lived, protective immune response to mice with a broad range of genetically distinct immune backgrounds including the H-2(b), H-2(d), and H-2(k) alleles. Mice were protected against an initial challenge of parasites up to 6 mo after the last immunization or for up to 15 mo against a second challenge after an initial challenge of parasites had successfully been cleared. [PubMed: 19915055]. YH, ZX CS from P. falciparum Protegen ID: 634; NCBI Protein GI: 552191; NCBITaxon: 5833 We employed a P. berghei parasite line that expresses a heterologous CSP (CS) from P. falciparum in order to assess the role of the CSP in the protection conferred by vaccination with radiation-attenuated P. berghei parasites. Our data demonstrated that sterile immunity could be obtained despite the absence of immune responses specific to the CSP expressed by the parasite used for challenge [PubMed: 18159254]. YH, ZX CS from P. yoelii str. 17XNL YH, ZX Protegen ID: 635; NCBI Gene GI: 3830374; NCBI Protein GI: 83317409; NCBI Protein Accession: XP_731149; NCBITaxon: 352914 Study showed that immunization with irradiated sporozoites (IrrSpz) of a P. berghei line whose endogenous CS was replaced by that of P. yoelii conferred sterile protection against challenge with wild type P. berghei sporozoites [PubMed: 19890387]. MSP3 YH, ZX Immunization with a recombinant yeast-expressed Plasmodium falciparum merozoite surface protein 3 (MSP3) protected Aotus nancymai monkeys against a virulent challenge infection [PubMed: 19073223]. Protegen ID: 636; NCBI Protein GI: 113207288; NCBITaxon: 5833 MSP8 YH, ZX Protegen ID: 637; NCBI Protein GI: 58197887; NCBITaxon: 5861 Immunization with Plasmodium yoelii merozoite surface protein (PyMSP)-8 protects mice from lethal malaria but does not prevent infection [PubMed: 18097046]. VP6 YH, ZX Protegen ID: 638; NCBI Protein GI: 268080815; NCBITaxon: 28327 Intranasal or oral delivery of the chimeric rotavirus VP6 protein MBP::VP6 to mice elicited >90% reductions in fecal rotavirus shedding after murine rotavirus challenge [PubMed: 17629371]. PF10_0155 enolase Protegen ID: 639; NCBI Gene GI: 810313; NCBI Protein GI: 124802328; NCBI Protein Accession: XP_001347440; NCBITaxon: 36329 Mice immunized with r-Pfen (recombinant P. falciparum enolase protein) showed protection against a challenge with the 17XL lethal strain of the mouse malarial parasite Plasmodium yoelii [PubMed: 17785475]. YH, ZX AMA-1 from P. berghei Mice immunized with recombinant PbAMA-1 were partially protected from the challenge of P. berghei [PubMed: 17639690]. Protegen ID: 640; NCBI Protein GI: 1438889; NCBITaxon: 5821 YH, ZX MSP1 from P. berghei Protegen ID: 641; NCBI Protein GI: 1762646; NCBITaxon: 5821 Mice vaccinated with recombinant rMSP1 (rPbMSP1), which was generated from Plasmodium berghei, in alum mounted significant protective immunity against challenge infection (P < 0.01). On day 121 after the booster, three out of ten mice immunized with rPbMSP1 in PBS survived parasite infection (P < 0.05) and eight out of ten mice vaccinated with r MSP1 in alum did (P < 0.01). Hence, immunization with MSP1 in alum obviously has conferred protective effects, which prevented death from P. berghei lethal infection in mice (P < 0.01) [PubMed: 17568385]. YH, ZX VP7 YH, ZX Protegen ID: 642; NCBI Protein GI: 195661008; NCBITaxon: 10927 Rotavirus structural proteins VP4, VP6 and VP7 from Bovine Rotavirus Strain C486 were cloned and expressed in a baculovirus expression system. Neonates of animals immunized with virus-like particles composed of VP7 assembled on VP6 spherical particles were protected against challenge with the homotypic virus and significantly protected from a heterotypic challenge. Unassembled VP7 protein provided partial protection against challenge [PubMed: 8382422]. VP4 Protegen ID: 643; NCBI Protein GI: 172054621; NCBITaxon: 10927 YH, ZX Rotavirus structural proteins VP4, VP6 and VP7 from Bovine Rotavirus Strain C486 were cloned and expressed in a baculovirus expression system. Challenge of neonates born to animals immunized with VP4 protein on assembled particles or in cell lysates showed protection against challenge with both homologous (bovine C486) and heterologous (SA-11) strains of rotavirus [PubMed: 8382422]. HEP17 Immunization of mice with subunit vaccines based on the Plasmodium yoelii 17kDa hepatocyte erythrocyte protein (PyHEP17), orthologue of Plasmodium falciparum exported protein 1 (PfExp1), induces antigen-specific immune responses and protects against sporozoite challenge [PubMed: 17303242]. YH, ZX Protegen ID: 644; NCBI Protein GI: 1399353; NCBITaxon: 5861 EMP1 YH, ZX Protegen ID: 645; NCBI Protein GI: 2961468; NCBITaxon: 5833 Immunized animals were challenged in vivo with various parasite strains or clones of malaria. Immunization with the PfEMP1-DBL1 alpha domain abolished the PfEMP1-dependent sequestration of the homologous strain in immunized rats and substantially inhibited parasite adhesion in immunized monkeys. Protection against sequestration of heterologous parasite strains was also confirmed by direct or indirect challenge in the rat model [PubMed: 17074852]. MSP1 from P. vivax Protegen ID: 646; NCBI Protein GI: 26985160; NCBITaxon: 5855 YH, ZX Immunization of BALB/c mice and Aotus monkeys with PvMSP-1 induced IgG antibodies (titer > 10(6)) that cross-reacted with P. vivax parasites. Immunized monkeys displayed partial protection against a challenge with P. vivax blood stages [PubMed: 16291762]. Glycoprotein YH, ZX A DNA vaccine based on lysosome-targeted glycoprotein of the rabies virus was evaluated in BALB/c mice. It imparted partial protection (60%) against challenge with 20 LD(50) of the challenge virus standard (CVS) strain of rabies virus [PubMed: 19741168]. Protegen ID: 647; NCBI Protein GI: 56384945; NCBITaxon: 11292 RABVgp1 nucleoprotein N YH, ZX Mice vaccinated intraperitoneally (i.p.) with 10^7 p.f.u. of a vaccinia virus recombinant expressing either the glycoprotein (rVac-G) or nucleoprotein (rVac-N) of rabies virus 3 weeks before challenge were protected against peripheral lethal infection [PubMed: 8207400]. Protegen ID: 648; NCBI Gene GI: 1489853; NCBI Protein GI: 9627198; NCBI Protein Accession: NP_056793; NCBITaxon: 11292 Kbeta YH, ZX Two large fragments of PfKbeta representing the N- and C-terminal halves were expressed in E. coli. The recombinant proteins were highly immunogenic in mice, and also found to be the target for immune response in natural infections of Plasmodium spp. Immunization with recombinant PfKbeta fragments was partially protective against a heterologous challenge infection in mice [PubMed: 15987343]. Protegen ID: 649; NCBI Gene GI: 813054; NCBI Protein GI: 124506397; NCBI Protein Accession: XP_001351796; NCBITaxon: 36329 OmpA Protegen ID: 650; NCBI Protein GI: 112710; NCBITaxon: 783 YH, ZX Immunization with one of the constructs of M. vaccae expressing OmpA in combination with booster immunization with the homologous recombinant protein protected a significant portion of mice from lethal challenge [PubMed: 11738766]. OmpB R. rickettsii OmpB contain B and T lymphocyte epitopes. Immunizations with each of two fragments from OmpB (rompB1550-2738 and rompB2459-4123) conferred protection against challenge with a lethal dose of R. conorii. Protection appeared to be better achieved among the groups that received both DNA and recombinant protein immunizations, although recombinant protein immunizations alone provided some protection [PubMed: 11693887]. Protegen ID: 651; NCBI Protein GI: 6685726; NCBITaxon: 783 YH, ZX MSP4/5 YH, ZX Oral immunization of mice with Escherichia coli-expressed Plasmodium yoelii merozoite surface protein 4/5 or the C-terminal 19-kDa fragment of merozoite surface protein 1 induced systemic antibody responses and protected mice against lethal malaria infection [PubMed: 15385527]. Protegen ID: 652; NCBI Protein GI: 49798469; NCBITaxon: 73239 AMA-1 from P. chabaudi Protegen ID: 653; NCBI Protein GI: 1469500; NCBITaxon: 5825 YH, ZX Mice immunized with a refolded, recombinant, Plasmodium chabaudi AMA1 fragment (AMA1B) can withstand subsequent challenge with P. chabaudi adami [PubMed: 10861076]. GB Recombinant adenovirus expressing gB (rAd-gB) was found to induce effective protective immunity against a virulent viral infection, regardless of whether it was administered via the muscular or systemic route [PubMed: 19116444]. Protegen ID: 654; NCBI Protein GI: 4138504; NCBITaxon: 10345 YH, ZX UL44 A trial vaccine containing pseudorabies virus (PRV) glycoprotein gC as the main component showed excellent protection against virulent virus infection in pigs [PubMed: 9300361]. Protegen ID: 655; NCBI Gene GI: 2952505; NCBI Protein GI: 51557513; NCBI Protein Accession: YP_068347; NCBITaxon: 10345 YH, ZX US6 The pseudorabies virus (PrV) DNA vaccine carrying the glycoprotein D (gD) gene delivered by E. coli was able to induce protective immune responses in mice against a lethal PrV challenge [PubMed: 11312026]. Immunization of mice with affinity-purified gD of Aujeszky's disease virus (ADV, Suid herpesvirus 1) induced a strong humoral immune response and protected mice against lethal ADV challenge [PubMed: 17601050]. Protegen ID: 656; NCBI Gene GI: 2952521; NCBI Protein GI: 51557553; NCBI Protein Accession: YP_068387; NCBITaxon: 10345 YH, ZX Hsp90 YH, ZX Protegen ID: 657; NCBI Protein GI: 1093612; NCBITaxon: 5833 A monkey vaccination trial using a Plasmodium falciparum protein fraction containing antigens of 90-110 kDa is reported. Three monkeys out of five resisted a heavy challenge dose of highly virulent parasites. Hsp90 was found in the immunoprecipitates obtained with SERP antisera. Interestingly, the response to hsp90 correlated with protection, high antibody titres being found only in the protected monkeys [PubMed: 8303938]. IE180 To examine the response by IE180 more closely, a vaccine trial in mice with a vector DNA construct that contains the gene encoding for IE180, designated pcDNAIE180 was conducted. Seven months after immunization with pcDNAIE180, an overall 25% of BALB/c, C3H/HeJ, and C57BL/6 mice receiving a lethal PrV challenge were protected [PubMed: 9586695]. Protegen ID: 658; NCBI Gene GI: 2952540; NCBI Protein GI: 51557548; NCBI Protein Accession: YP_068382; NCBITaxon: 10345 YH, ZX ORF2 An open reading frame 2 plasmid (pORF2) and the capsid protein (Cap) of PCV2 were used as DNA and subunit vaccines, respectively. In FCM analysis, although pORF2 and Cap alone showed comparable efficacy in eliciting lymphoproliferative responses and Cap-specific CD4(+) T cells, pORF2 was superior to the Cap protein in triggering CD8(+) T cells. Following virus challenge, real-time PCR and histopathological analysis confirmed that only low viral DNA loads and mild microscopic lesions appeared in pORF2-immunized mice [PubMed: 18632956]. YH, ZX Protegen ID: 659; NCBI Protein GI: 78217439; NCBITaxon: 85708 VP4 To examine the mechanism of immunity in vivo, researchers used poliovirus receptor-transgenic mice on a BALB/c (H-2d) background. Mice immunized with the vaccine strain were protected against a subsequent challenge with wild-type virus. Protection was observed when mice received primed B cells in the presence of a VP4-specific Th1 clone. Findings demonstrate that CD4+ T cells, specific for the internal poliovirus capsid protein, VP4, can provide effective help for a protective antibody response directed against surface capsid proteins [PubMed: 7699320]. YH, ZX Protegen ID: 660; NCBI Protein GI: 68532656; NCBITaxon: 12080 TBEVgp1 polyprotein YH, ZX Series of plasmid constructs encoding different forms of the envelope glycoprotein E of the flavivirus tick-borne encephalitis virus were constructed. These included a secreted recombinant subviral particle, a secreted carboxyl-terminally truncated soluble homodimer, a nonsecreted full-length form, and an inefficiently secreted truncated form. Mice were immunized using both i.m. injection and Gene Gun-mediated application of plasmids. The functional immune response was evaluated by determining specific neutralizing and hemagglutination-inhibiting Ab activities and by challenging the mice with a lethal dose of the virus.The plasmid construct encoding a secreted subviral particle, which carries multiple copies of the protective Ag on its surface, was superior to the other constructs in terms of extent and functionality of the Ab response as well as protection against virus challenge [PubMed: 10586074]. Protegen ID: 661; NCBI Gene GI: 1489719; NCBI Protein GI: 9628432; NCBI Protein Accession: NP_043135; NCBITaxon: 11084 ORF68 Protegen ID: 662; NCBI Gene GI: 1487709; NCBI Protein GI: 9625942; NCBI Protein Accession: NP_040190; NCBITaxon: 10335 Monoclonal antibodies to gE neutralize VZV in vitro in a complement- dependent manner [PubMed: 9125048]. Guinea pigs immunized with recombinant varicella-zoster virus (VZV) glycoproteins E (gE) and I (gI) developed antigen-specific antibodies in the sera, vitreous, and conjunctival washes. Sera from immunized animals neutralized both cell-free and cell-associated VZV, and peripheral blood lymphocytes proliferated in vitro in response to recombinant gE and gI and to antigens from VZV-infected cells. Immunized guinea pigs were inoculated intravitreally with VZV, which induces chronic uveitis. VZV DNA was more rapidly cleared and infectious VZV was isolated less frequently from the retinas of animals immunized with gE and gI compared with that in controls receiving adjuvant alone [PubMed: 9697709]. YH, ZX ORF67 Monoclonal antibodies to gI neutralize VZV in vitro in a complement- dependent manner [PubMed: 3021804]. Guinea pigs immunized with recombinant varicella-zoster virus (VZV) glycoproteins E (gE) and I (gI) developed antigen-specific antibodies in the sera, vitreous, and conjunctival washes. Sera from immunized animals neutralized both cell-free and cell-associated VZV, and peripheral blood lymphocytes proliferated in vitro in response to recombinant gE and gI and to antigens from VZV-infected cells. Immunized guinea pigs were inoculated intravitreally with VZV, which induces chronic uveitis. VZV DNA was more rapidly cleared and infectious VZV was isolated less frequently from the retinas of animals immunized with gE and gI compared with that in controls receiving adjuvant alone [PubMed: 9697709]. Protegen ID: 663; NCBI Gene GI: 1487689; NCBI Protein GI: 9625941; NCBI Protein Accession: NP_040189; NCBITaxon: 10335 YH, ZX Gp50 Protegen ID: 664; NCBI Protein GI: 2440155; NCBITaxon: 10345 YH, ZX A NYVAC vaccinia vector containing genes for pseudorables virus glycoproteins gII and gp50 was administered to pigs to determine if it would have a greater protective effect than a vector containing the gene for gp50 alone. Both NYVAC vectors protected pigs similarly from virulent pseudorabies virus challenge [PubMed: 8904669]. GII Protegen ID: 665; NCBI Protein GI: 1335775; NCBITaxon: 10345 A NYVAC vaccinia vector containing genes for pseudorables virus glycoproteins gII and gp50 was administered to pigs to determine if it would have a greater protective effect than a vector containing the gene for gp50 alone. Both NYVAC vectors protected pigs similarly from virulent pseudorabies virus challenge [PubMed: 8904669]. YH, ZX GIII Mice immunized with either gII, gIII, gVI antigen or a mixture of them were challenged intraperitoneally with 8.5 x 10(3) plaque forming units of PRV. All the mice immunized with 1.5 and 4.5 micrograms of the mixture and 4.5 micrograms of the gIII antigen survived [PubMed: 1322712]. YH, ZX Protegen ID: 667; NCBI Protein GI: 334050; NCBITaxon: 10345 GI Vaccination of mice with fusion proteins containing the N terminus of gI from Suid herpesvirus 1 are able to confer protection to mice against a lethal challenge of PRV [PubMed: 1693164]. Protegen ID: 668; NCBI Protein GI: 255957222; NCBITaxon: 10345 YH, ZX E (envelope glycoprotein) Protegen ID: 669; NCBI Protein GI: 262283879; NCBITaxon: 11089 YH, ZX A recombinant, vP869, expressing prM and E induced high titers of neutralizing and hemagglutination inhibiting antibodies in mice and was protective against intracranial challenge with the French neurotropic strain of YFV [PubMed: 1736531]. SAG1 YH, ZX Horses were vaccinated with adjuvanted recombinant SnSAG1 (rSnSAG1)and 5 control (sham vaccinated) horses were vaccinated with adjuvant only. The effect of vaccination with rSnSAG1 on in vivo infection by S. neurona was evaluated by challenging all the horses with S. neurona merozoites. The study showed that vaccination with rSnSAG-1 produced antibodies in horses that neutralized merozoites when tested by in vitro culture and significantly reduced clinical signs demonstrated by in vivo challenge [PubMed: 19794889]. Protegen ID: 672; NCBI Protein GI: 295682690; NCBITaxon: 42890 VP2 YH, ZX Protegen ID: 673; NCBI Protein GI: 431460; NCBITaxon: 10970 Both inbred BALB/c and outbred CD-1 mice were immunized with rotavirus VP2/6-rVLPs (2/6-VLPs) combined with CT-E29H, orally or intranasally (i.n.), and the comparative efficacy of different formulations was then determined. Two immunizations with 2-6VLPs and CT-E29H were sufficient to protect BALB/c mice, regardless of the route of administration [PubMed: 11270595]. VP4 YH, ZX Protegen ID: 675; NCBI Protein GI: 475695; NCBITaxon: 28327 Plasmid DNA vaccines encoding for murine rotaviral proteins VP4, VP6, and VP7 were tested in adult BALB/c mice for their ability to induce immune responses and provide protection against rotavirus challenge. Vaccines encoding VP4 were effective in protecting mice against infection after rotavirus (100 ID50) challenge [PubMed: 9015117]. VP7 Plasmid DNA vaccines encoding for murine rotaviral proteins VP4, VP6, and VP7 were tested in adult BALB/c mice for their ability to induce immune responses and provide protection against rotavirus challenge. Vaccines encoding VP7 were effective in protecting mice against infection after rotavirus (100 ID50) challenge [PubMed: 9015117]. Protegen ID: 676; NCBI Protein GI: 475697; NCBITaxon: 28327 YH, ZX VP6 VP6 derived from Group A rotavirus conferred in vivo partial protection against rotavirus challenge in a neonatal mouse model [PubMed: 18632867]. Protegen ID: 677; NCBI Gene GI: 7011372; NCBI Protein GI: 210136699; NCBI Protein Accession: YP_002302229; NCBITaxon: 28875 YH, ZX VP6 YH, ZX Rotavirus structural proteins VP4, VP6 and VP7 from Bovine Rotavirus Strain C486 were cloned and expressed in a baculovirus expression system. Challenge of neonates born to animals immunized with VP6 protein showed partial protection [PubMed: 8382422]. Protegen ID: 678; NCBI Protein GI: 195661002; NCBITaxon: 10927 NS1 (non-structural protein 1) Protection from lethal viral infection has been achieved with passively administered monoclonal antibody specific for flavivirus glycoprotein NS1 [PubMed: 1736531]. Immunization of monkeys with yellow fever virus-specified nonstructural protein NS1 resulted in protection against fatal hepatitis as well as marked reduction in the magnitude of viremia after subcutaneous challenge with yellow fever virus [PubMed: 3783816]. YH, ZX Protegen ID: 684; NCBITaxon: 11089 LACK Researchers evaluated the potency of different DNA vaccine candidates in BALB/c mice using high dose footpad parasite challenge. A truncated portion of the LACK antigen (LACKp24) was able to induce the highest protective effect compared to other constructs. The DNA vaccine encoding LACK was able to induce partial protection in mice [PubMed: 18951941]. Protegen ID: 734; NCBI Nucleotide GI: 1276476; NCBI Protein GI: 1276477; NCBI Protein Accession: AAA97577.1; NCBITaxon: 5664 YH, ZX Nef YH, ZX Study compared the handling of overlapping 24-mer peptides from HIV Nef either mixed or covalently linked in tandem in one protein. With adjuvant, overlapping peptides were capable of protecting Balb/c mice against lethal viral challenge with 3 108 plaque forming units of vv-nef, whereas the intact protein was less protective [PubMed: 19193636]. Protegen ID: 707; NCBI Gene GI: 156110; NCBI Protein GI: 28872818; NCBI Protein Accession: NP_057857; NCBITaxon: 11676 Tat YH, ZX HIV-1 DNA plasmids expressing Env, Gag and Tat, either alone or combined with the corresponding protein immunogens formulated in the MF59 adjuvant, resulted in protection against an experimental HIV-1 infection in C57Bl/6 mice [PubMed: 17707956]. Protegen ID: 711; NCBI Gene GI: 155871; NCBI Protein GI: 9629358; NCBI Protein Accession: NP_057853; NCBITaxon: 11676 Gag from HIV 1 YH, ZX Protegen ID: 713; NCBI Gene GI: 155030; NCBI Protein GI: 9629360; NCBI Protein Accession: NP_057850; NCBITaxon: 11676 HIV-1 DNA plasmids expressing Env, Gag and Tat, either alone or combined with the corresponding protein immunogens formulated in the MF59 adjuvant, resulted in protection against an experimental HIV-1 infection in C57Bl/6 mice [PubMed: 17707956]. NP from Influenza A virus (A/nt/60/1968(H3N2)) YH, ZX Mice immunized with Recombinant-derived nucleoprotein (rNP) from S. typhimurium expressing the cloned NP gene from A/NT/60/68 (Jones & Brownlee, 1985) were protected against a lethal challenge with Influenza A/Puerto Rico/8/34 (A/PR8) virus but showed considerable morbidity before recovery [PubMed: 2172156]. Protegen ID: 718; NCBI Protein GI: 324704; NCBITaxon: 384505 E2 envelope protein YH, ZX Protegen ID: 725; NCBI Protein GI: 25140296; NCBITaxon: 11036 Since the E2 amino-terminal sequence for all VEE subtype viruses is conserved, we tested the protective capacity in mice of passively transferred mAb 1A2B-10 and found it to protect from both epizootic and enzootic VEE virus challenge. Since horses are an important natural host for VEE virus, pep1-19 was used to immunize horses and was found to be immunogenic and to elicit virus-reactive antibody [PubMed: 7543231]. HslU Study demonstrated that a recombinant construction of heat-shock protein (hslU) with lypopolysaccharide (rcHSP-LPS) administered 24 hours before inoculation induced resistance to S. typhimurium infection. Protection formed after 3 injections of rcHSP-LPS with 10 mcg in each or single injection with 100 mcg/mouse. Forty to eighty percent of immunized mice survived after challenge while 90% of control animals died. Destruction of the HSP by boiling of the construction led to loss of protective effect [PubMed: 19621817]. Protegen ID: 726; NCBI Protein GI: 9650897; NCBITaxon: 90371 YH, ZX E1 glycoprotein The monoclonal antibody against E1 glycoprotein protect outbred albino mice from lethal infection caused by the virulent strain Trd of the VEE virus [PubMed: 7529989]. Protegen ID: 727; NCBI Protein GI: 798795; NCBITaxon: 11036 YH, ZX DnaJ YH, ZX Immunisation of mice with DnaJ derived from Salmonella enterica subsp. enterica serovar Typhi str. CT18 was found to provide 70% protection against lethal challenge by S. Typhimurium indicating the possible use of DnaJ as vaccine candidate against typhoid [PubMed: 16887241]. Protegen ID: 728; NCBI Gene GI: 1246524; NCBI Protein GI: 16759006; NCBI Protein Accession: NP_454623; NCBITaxon: 220341 TviB YH, ZX The viaB (tviB) gene coding for the Vi antigen of Salmonella typhi Ty2 was subcloned into expression vector pYA248. The recombinant plasmid was termed SMM202 and transformed into Salmonella typhimurium 4072, an attenuated crp mutant. Immunization of mice with Vi4072 afforded complete protection against fatal infection with virulent S. typhi Ty2 [PubMed: 1612747]. Protegen ID: 729; NCBI Gene GI: 1067316; NCBI Protein GI: 29144603; NCBI Protein Accession: NP_807945; NCBITaxon: 209261 CtxB The immune sera elicited by CTB DNA vaccine were functional and protective against V. cholerae O1 infection in mice [PubMed: 19443090]. YH, ZX Protegen ID: 731; NCBI Protein GI: 110264635; NCBITaxon: 127906 TcpA YH, ZX Antibodies against TCP were able to protect baby mice against challenge with V. cholerae O1 of the classical but not of the El Tor biotype [PubMed: 7911787]. Protegen ID: 732; NCBI Protein GI: 21616882; NCBITaxon: 127906 TcpF Antibodies generated against TcpF are protective against experimental V. cholerae infection in the infant mouse cholera model [PubMed: 16040956]. YH, ZX Protegen ID: 733; NCBI Gene GI: 2614504; NCBI Protein GI: 15640854; NCBI Protein Accession: NP_230485; NCBITaxon: 243277 TSA Researchers evaluated the potency of different DNA vaccine candidates in BALB/c mice using high dose footpad parasite challenge with L. major. Mice inoculated pCMV3ISS-TSA developed significantly smaller lesions in their footpads after challenge with the parasite. The vaccine was able to induce a partially protective effect [PubMed: 18951941]. Protegen ID: 735; NCBI Nucleotide GI: 3411093; NCBI Protein GI: 3411094; NCBI Protein Accession: AAC31146.1; NCBITaxon: 5664 YH, ZX LmSTI1 Researchers evaluated the potency of different DNA vaccine candidates in BALB/c mice using high dose footpad parasite challenge with L. major. Mice inoculated pCMV3ISS-LmSTI1 developed significantly smaller lesions in their footpads after challenge with the parasite. The vaccine was able to induce a partially protective effect [PubMed: 18951941]. YH, ZX Protegen ID: 736; NCBI Nucleotide GI: 1698879; NCBI Protein GI: 1698880; NCBI Protein Accession: AAB37318.1; NCBITaxon: 5664 Cpa YH, ZX Protegen ID: 737; NCBI Nucleotide GI: 71084305; NCBI Protein GI: 71084306; NCBI Protein Accession: AAZ23598.1; NCBITaxon: 5664 Researchers evaluated the potency of different DNA vaccine candidates in BALB/c mice using high dose footpad parasite challenge with L. major. Mice inoculated pCMV3ISS-CPa developed significantly smaller lesions in their footpads after challenge with the parasite. The vaccine was able to induce a partially protective effect [PubMed: 18951941]. SP YH, ZX Protegen ID: 738; NCBI Protein GI: 23168331; NCBITaxon: 5664 The potential protection of Lmjsp (Leishmania major signal peptidase) was evaluated in three different vaccination strategies (DNA/DNA, Protein/Protein and DNA/Protein), against L. major infection. We demonstrated that vaccination with SPase through all three mentioned strategies induced a parasite specific Th1 response and conferred partial protection against parasite challenge. However, our results indicated that DNA/DNA strategy developed more effective protective responses than the other two approaches and induced 81% reduction in L. major parasite load [PubMed: 16481076]. H2B Researchers tested the ability of the entire H2B protein of L. major, its divergent or conserved regions to provide protection against virulent L. major challenge. The divergent amino-terminal region of H2B is able to confer potent protection against a virulent challenge in BALB/c mice [PubMed: 16417957]. YH, ZX Protegen ID: 739; NCBI Protein GI: 13384083; NCBITaxon: 5664 Gp63 Protegen ID: 741; NCBI Protein GI: 259011719; NCBITaxon: 5664 Cell-mediated immunity to Leishmania major (L. major) was induced by injecting BALB/c mice intradermally with plasmid DNA expressing the conserved L. major cell surface glycoprotein gp63 (gp63-pcDNA-3). Challenge studies revealed that gp63-pcDNA-3 vaccination protected 30% of susceptible mice (21 of 70) from Leishmania infection [PubMed: 9741428]. YH, ZX PSA-2 Protegen ID: 742; NCBI Protein GI: 1129058; NCBITaxon: 5664 Intraperitoneal vaccination of C3H/He mice with PSA-2 with Corynebacterium parvum as an adjuvant resulted in complete protection from lesion development after challenge infection with virulent L. major. Significant protection was also obtained in the genetically susceptible BALB/cH-2k and BALB/c mice [PubMed: 7591056]. YH, ZX SW3.1 In a murine model of experimental cutaneous leishmaniasis, researchers investigated the protection elicited by injection of histone H1 (SW3.1) isolated from parasites by perchloric extraction, of a H1 recombinant protein produced in E. coli, and of H1 long and short synthetic peptides, against infection by L. major. Partial protection was achieved in most of the animals as shown by reduction in lesion size, upon immunization with histone H1 or its peptides, provided that the region 1-60 was present in the molecule [PubMed: 10580198]. YH, ZX Protegen ID: 743; NCBI Protein GI: 4008565; NCBITaxon: 5664 Cpb Protegen ID: 744; NCBI Protein GI: 54287314; NCBITaxon: 5664 YH, ZX Together with poloxamer 407 as adjuvant the recombinant type I (rCPB) cysteine proteinase of Leishmania major was screened as a potential vaccines against L. major in a mouse model. Using the footpad thickness increase to monitor the clinical outcome/cutaneous lesion at site of L. major delivery, it was possible to document that rCPB allowed BALB/c mice to mount a partial protective response [PubMed: 12057598]. SMT YH, ZX Protegen ID: 745; NCBI Protein GI: 146104463; NCBITaxon: 435258 Upon challenge with L. infantum, C57BL/6 mice immunized with SMT formulated in MPL-SE adjuvant showed significantly lower parasite burdens in both spleens and livers compared with non-immunized mice or mice injected with adjuvant alone [PubMed: 17804125]. LIPO-A Study examined the immunogenic properties of the Leishmania infantum acidic ribosomal protein P0 (LiP0) in the BALB/c mouse model. When mice were immunized with pcDNA3-LiP0, noticeable protection against L. major infection was achieved [PubMed: 14573678]. YH, ZX Protegen ID: 746; NCBI Protein GI: 730579; NCBITaxon: 5671 P36/LACK BALB/c mice immunized with a DNA vector expressing p36/LACK of Leishmania infantum followed by a booster with VVp36/LACK induced significant protection against Leishmania major infection [PubMed: 11489418]. Protegen ID: 747; NCBI Protein GI: 134085114; NCBITaxon: 5671 YH, ZX H1 YH, ZX Protegen ID: 748; NCBI Nucleotide GI: 78146499; NCBI Protein GI: 78146500; NCBI Protein Accession: ABB22792.1; NCBITaxon: 5671 Following infection with L. infantum promastigotes, five out of eight beagle dogs immunized with H1 Montanide remained free of clinical signs, compared to two out of eight dogs in the control group. The results demonstrate that H1 antigens with Montanide were able to induce partial protection against canine leishmaniasis, even under extreme experimental challenge conditions [PubMed: 17576026]. HASPB1 YH, ZX Following infection with L. infantum promastigotes, four out of eight beagle dogs immunized with HASPB1 Montanide remained free of clinical signs, compared to two out of eight dogs in the control group. The results demonstrate that HASPB1 antigens with Montanide were able to induce partial protection against canine leishmaniasis, even under extreme experimental challenge conditions [PubMed: 17576026]. Protegen ID: 749; NCBI Nucleotide GI: 3724133; NCBI Protein GI: 3724134; NCBI Protein Accession: CAA09789.1; NCBITaxon: 5661 Tox YH, ZX In 1923, it was discovered that treatment with formalin eliminated the toxicity of diphtheria toxin (DT) without destroying its immunogenicity. Formalinreated DT, now called diphtheria toxoid, rapidly became the preferred vaccine against diphtheria, and diphtheria toxoid (usually in combined vaccines, such as diphtheriaetanus toxoidsertussis vaccine [DTP] or diphtheriaetanus toxoidscellular pertussis vaccine [DTaP] for children and tetanusiphtheria toxoids vaccine for adults [Td]) is still used throughout the world for active immunization against diphtheria [PubMed: 10657208]. Protegen ID: 750; NCBI Protein GI: 38199106; NCBITaxon: 1717 P4 Protegen ID: 751; NCBI Nucleotide GI: 29165286; NCBI Protein GI: 29165287; NCBI Protein Accession: AAO65599.1; NCBITaxon: 5659 Susceptible BALB/c mice were immunized with the DNA encoding P4 alone, P4/IL-12, or P4/HSP70 prior to challenge with L. amazonensis promastigotes. Mice immunized with P4 alone had a delayed onset of lesion development and significantly smaller lesions than the infection control group at 11 weeks postinfection (P < 0.05). P4/IL-12 immunized animals showed no sign of lesion development in three independent experiments (P < 0.01). Our results indicate that different vaccine combinations, including DNA encoding P4, HSP70, or IL-12, can provide significant protection against both Old World and New World cutaneous leishmaniasis [PubMed: 14573646]. YH, ZX T. cruzi amastigote surface protein-2 Protegen ID: 752; NCBI Protein GI: 284180153; NCBITaxon: 5693 To examine the efficacy of a new mode of recombinant viral vaccine, a vaccine was constructed of two non-transmissible Sendai viruses (rSeV/dF) encoding the full-length parasite antigen amastigote surface protein-2 (ASP2) or ASP2 fused with a mono-ubiquitin on its N-terminus (UASP2). C57BL/6 mice immunized intranasally with rSeV/dF expressing either ASP2 or UASP2 showed significantly suppressed parasitemia and could be protected from lethal T. cruzi challenge [PubMed: 19712768]. YH, ZX WD Protegen ID: 753; NCBI Nucleotide GI: 38455440; NCBI Protein GI: 38455441; NCBI Protein Accession: AAR20840.1; NCBITaxon: 5659 DNA vaccination in BALB/c mice with the LAWD (for Leishmania antigenic WD protein) and IL-12 genes significantly delayed lesion development from challenge with Leishmania amazonensis, which correlated with a dramatic reduction in parasite burdens [PubMed: 15039343]. YH, ZX M2 YH, ZX Protegen ID: 754; NCBI Nucleotide GI: 2828562; NCBI Protein GI: 2828563; NCBI Protein Accession: AAC08302.1; NCBITaxon: 5659 Immunization of CBA mice with the M-2 glycoprotein of L. amazonensis and C. parvum adjuvant resulted in complete protection against a challenge infection of 10^4 and 10^6 late log-phase promastigotes of L. amazonensis. In the BALB/c strain, complete protection was observed in some of the immunized animals (28 to 50%); in the rest of the mice the onset of infection was significantly delayed. Protective immunity for C57BL/6 mice was observed only at the low infecting dose (10(4) L. amazonensis organisms) [PubMed: 3182080]. Gp46 YH, ZX cDNAs encoding L. m. amazonensis gp46 antigen were subcloned into the VR1012 plasmid, and susceptible BALB/c mice were immunised with two i.m. injections of 100 microg of plasmid DNA. Mice were challenged by the injection of 4 x 10^6 L. m. mexicana parasites in the foot pad to evaluate protection. Measurement of lesion size indicated that mice immunised with VR012-GP46 were partially protected against infection [PubMed: 11713811]. Protegen ID: 755; NCBI Nucleotide GI: 159320; NCBI Protein GI: 159321; NCBI Protein Accession: AAA29234.1; NCBITaxon: 5659 T. cruzi Cruzipain YH, ZX Protegen ID: 756; NCBI Protein GI: 1136308; NCBITaxon: 5693 To study the protective effects in vivo of cruzipain-specific Th1 responses against systemic T. cruzi challenges, mice were immunized with recombinant cruzipain plus interleukin 12 (IL-12) and a neutralizing anti-IL-4 MAb. These immunized mice developed potent cruzipain-specific memory Th1 cell responses and were significantly protected against normally lethal systemic T. cruzi challenges. To study whether cruzipain could induce mucosal immune responses relevant for vaccine development, recombinant attenuated Salmonella enterica serovar Typhimurium vaccines expressing cruzipain were prepared. BALB/c mice immunized with salmonella expressing cruzipain were significantly protected against T. cruzi mucosal infection [PubMed: 12183554]. T. cruzi TS Protegen ID: 757; NCBI Protein GI: 258547365; NCBITaxon: 5693 To develop a vaccine strategy taking advantage of activated CD8(+)T cells,a DNA vaccine, designated pGFP-TSA1, encoding a fusion protein linking GFP to a single CTL epitope of TSA1(TS), a leading candidate for vaccine against T. cruzi was constructed. C57BL/6 mice vaccinated with this plasmid showed suppressed parasitemia and prolonged survival. Vaccination with pGFP-TSA1 enhanced epitope-specific cytotoxicity and IFN-gamma secretion by CD8(+)T cells [PubMed: 18321749]. YH, ZX CP cysteine proteinase A 500 bp fragment encoding an isoform of cysteine proteinase (CP) from Leishmania (Leishmania) amazonensis was subcloned and expressed in the pHis vector, resulting in a recombinant protein of 24 kDa, rLacys24. Immunization of BALB/c mice with rLacys24 plus CFA adjuvant resulted in a low but significant decrease of foot lesions after challenge with L. (L.) amazonensis compared to those exhibited by control mice [PubMed: 19735658]. YH, ZX Protegen ID: 758; NCBI Nucleotide GI: 30142041; NCBI Protein GI: 30142042; NCBI Protein Accession: AAN34826.1; NCBITaxon: 5659 T. cruzi TSA-1 Protegen ID: 759; NCBI Protein GI: 162315; NCBITaxon: 5693 YH, ZX Following the intramuscular immunization of H-2(b) and H-2(d) mice with a plasmid DNA encoding an N-terminally truncated TSA-1 lacking or containing the C-terminal nonapeptide tandem repeats, the antibody level, CTL response, and protection against challenge with T. cruzi were assessed. In H-2(b) mice, antiparasite antibodies were induced only by immunization with the DNA construct encoding TSA-1 containing the C-terminal repeats. However, both DNA constructs were efficient in eliciting long-lasting CTL responses against the protective H-2Kb-restricted TSA-1515-522 epitope. In H-2(d) mice, inoculation with either of the two TSA-1-expressing vectors effectively generated antiparasite antibodies and primed CTLs that lysed T. cruzi-infected cells in an antigen-specific, MHC class I-restricted, and CD8(+)-T-cell-dependent manner. When TSA-1 DNA-vaccinated animals were challenged with T. cruzi, 14 of 22 (64%) H-2(b) and 16 of 18 (89%) H-2(d) mice survived the infection [PubMed: 9784506]. T. cruzi CRP-10 Protegen ID: 760; NCBI Protein GI: 1389837; NCBITaxon: 5693 YH, ZX A complement regulatory protein (CRP) of Trypanosoma cruzi was evaluated as a vaccine candidate in a murine model of experimental T. cruzi infection. Recombinant CRP derived from an Escherichia coli expression system and a plasmid encoding the full-length crp structural gene under the control of a eukaryotic promoter were used to immunize BALB/c mice. Immunization with both protein and DNA vaccines resulted in a Th1-type T-cell response, comparable antibody titers, and similar immunoglobulin G isotype profiles. Only mice immunized with the crp DNA plasmid produced antibodies capable of lysing the parasites in the presence of complement and were protected against a lethal challenge with T. cruzi trypomastigotes [PubMed: 10948115]. T. cruzi G4 Protegen ID: 761; NCBI Protein GI: 52424038; NCBITaxon: 5693 The vaccine efficacy of a putative candidate antigen against T. cruzi infection and disease in a mouse model. C57BL/6 mice vaccinated with a T. cruzi G4-encoding plasmid and cytokine (interleukin-12 and granulocyte-macrophage colony-stimulating factor) expression plasmids elicited a strong Th1-type antibody response dominated by immunoglobulin G2b (IgG2b)/IgG1 isotypes. The dominant IgG2b/IgG1 antibody response was maintained after a challenge infection and was associated with 90% control of the acute-phase tissue parasite burden and an almost undetectable level of tissue parasites during the chronic phase, as determined by a sensitive T. cruzi 18S rRNA gene-specific real-time PCR approach [PubMed: 18550728]. YH, ZX T. cruzi G2 Protegen ID: 762; NCBI Protein GI: 205278890; NCBITaxon: 5693 YH, ZX The vaccine efficacy of a putative candidate antigen against T. cruzi infection and disease in a mouse model. C57BL/6 mice vaccinated with a T. cruzi G2-encoding plasmid and cytokine (interleukin-12 and granulocyte-macrophage colony-stimulating factor) expression plasmids elicited a strong Th1-type antibody response dominated by immunoglobulin G2b (IgG2b)/IgG1 isotypes. The dominant IgG2b/IgG1 antibody response was maintained after a challenge infection and was associated with 50% control of the acute-phase tissue parasite burden and an almost undetectable level of tissue parasites during the chronic phase, as determined by a sensitive T. cruzi 18S rRNA gene-specific real-time PCR approach [PubMed: 18550728]. T. cruzi PAR2 YH, ZX Protegen ID: 763; NCBI Gene GI: 3532027; NCBI Protein GI: 71398801; NCBI Protein Accession: XP_802646; NCBITaxon: 353153 C57BL/6 mice were immunized s.c. with recombinant PFR-2 (PAR2) protein co-adsorbed to alum with rIL-12. rPFR-2 immunized animals were able to successfully resolve parasitemia by day 30 p.i., with the peak parasitemia occurring between days 17 and 21 p.i. [PubMed: 12798650]. Tc00.1047053434931.10 T. cruzi PAR1 C57BL/6 mice were immunized s.c. with recombinant PFR-1 (PAR1) protein co-adsorbed to alum with rIL-12. rPFR-1 immunized animals were able to successfully resolve parasitemia by day 30 p.i., with the peak parasitemia occurring between days 17 and 21 p.i. [PubMed: 12798650]. Protegen ID: 764; NCBI Protein GI: 2209137; NCBITaxon: 5693 YH, ZX HA from Influenza A virus (A/equine/Kentucky/1/1981(H3N8)) YH, ZX Skin and mucosal vaccination of ponies with HA from influenza virus A/equine/Ky/1/81 provided complete protection from clinical signs of infection after challenge, while skin vaccination provided partial protection; DNA vaccination provided partial protection from viral shedding [PubMed: 10403592]. Protegen ID: 765; NCBI Nucleotide GI: 166079523; NCBI Protein GI: 166079524; NCBI Protein Accession: ABY81481.1; NCBITaxon: 475467 FliC Protegen ID: 770; NCBI Protein GI: 1929918; NCBITaxon: 28450 Flagellin encoding plasmid DNA was injected into Balb/c mice intramuscularly and this elicited both a humoral and a cellular immune response. Subsequent intravenous challenge of the vaccinated Balb/c mice with 10^5CFU of B. pseudomallei resulted in the number of bacterial cells detected in liver and/or spleen being significantly reduced in the flagellin plasmid DNA vaccinated mice. At 7 days subsequent to infection of B. pseudomallei, 5/6 (83%) of flagellin plasmid DNA vaccinated mice had survived [PubMed: 16169637]. YH, ZX MOMP from C. psittaci 6BC YH, ZX Transgenic rice immunization expressing the Chlamydophila psittaci (Cp. psittaci) antigen (MOMP) fused to the B subunit of Escherichia coli heat-labile enterotoxin (LTB) induced partial protection (53.3%) against a lethal challenge with the highly virulent Cp. psittaci 6BC strain in a BALB/c mouse model [PubMed: 19146896]. Protegen ID: 771; NCBI Nucleotide GI: 40568; NCBI Protein GI: 40569; NCBI Protein Accession: CAA40300.1; NCBITaxon: 331636 E2 YH, ZX Protegen ID: 773; NCBI Protein GI: 29611992; NCBITaxon: 11039 This report describes the successful cloning of the E2 gene of WEEV and expression in Escherichia coli as inclusion bodies. The immunogenicity of the refolded rE2 protein was demonstrated by strong humoral and cell mediated immune (CMI) responses in rE2-immunized BALB/c mice. The current study also demonstrated that rE2-immunized mice could be partially protected from lethal challenge of WEEV [PubMed: 17499379]. E1 DNA vaccines encoding different portions of the structural proteins of western equine encephalitis virus were tested for the efficacy of their protection in a 100% lethal mouse model of the virus. The 6K-E1 structural protein encoded by the DNA vaccine conferred complete protection against challenge with the homologous strain and limited protection against challenge with a heterologous strain [PubMed: 19923571]. Note: The E1 glycoprotein is part of the 6K-E1 structural protein Protegen ID: 774; NCBI Nucleotide GI: 17148716; NCBI Protein GI: 17148717; NCBI Protein Accession: AAL35792.1; NCBITaxon: 11039 YH, ZX 6K Protegen ID: 775; NCBI Protein GI: 29611993; NCBITaxon: 11039 DNA vaccines encoding different portions of the structural proteins of western equine encephalitis virus were tested for the efficacy of their protection in a 100% lethal mouse model of the virus. The 6K-E1 structural protein encoded by the DNA vaccine conferred complete protection against challenge with the homologous strain and limited protection against challenge with a heterologous strain [PubMed: 19923571]. Note: The 6K protein is part of the 6K-E1 structural protein YH, ZX CP23 Protegen ID: 776; NCBI Protein GI: 88659549; NCBITaxon: 5807 In this study, Cp23 antigen was investigated as a vaccine candidate using the DNA vaccine model in adult interleukin-12 (IL-12) knockout (KO) mice, which are susceptible to C. parvum infection. Cp23-DNA vaccination induced a 50-60% reduction in oocysts shedding, indicating a partial protection against C. parvum infection in IL-12 KO mice [PubMed: 17487508]. YH, ZX CP15/60 Protegen ID: 777; NCBI Nucleotide GI: 170676501; NCBI Protein GI: 170676502; NCBI Protein Accession: ACB30404.1; NCBITaxon: 5807 YH, ZX Preparturient cows were immunized three times over a six-week period with recombinant plasmid DNA encoding the Cryptosporidium parvum CP15/60 antigen by injecting the DNA in the mammary gland. Colostrum from these cows contained Ab specific for C. parvum sporozoites and oocysts as indicated by immunofluorescence Ab (IFA) staining. Mice receiving immune colostrum showed partial protection (about 50% reduction) against intestinal C. parvum development compared to mice receiving control colostrum. This protection was evident at a challenge dose of 10^3 C. parvum oocysts per mouse [PubMed: 10392628]. G glycoprotein A subunit vaccine formulation containing only recombinant, soluble, attachment glycoprotein G from HeV (sG(HeV)) and CpG adjuvant was evaluated as a potential NiV vaccine in the cat model. Upon oronasal challenge with NiV (50,000TCID50), all vaccinated cats were protected from disease although virus was detected on day 21 post-challenge in one animal [PubMed: 18556094]. YH, ZX Protegen ID: 779; NCBI Gene GI: 1446471; NCBI Protein GI: 29468607; NCBI Protein Accession: NP_047112; NCBITaxon: 63330 E protein Protegen ID: 780; NCBI Protein GI: 202078796; NCBITaxon: 11060 YH, ZX A recombinant baculovirus encoding a dengue (DEN)-2 virus envelope glycoprotein truncated of 102 amino acids (aa) at its C-terminus (D2EA102) was constructed. Both intracellular and extracellular D2EA102 induced neutralizing antibodies in mice and were thus immunogenic. Sixty eight percent (P < 0.001) of mice vaccinated with 5 gg of extracellular D2EA102 protein were protected against lethal challenge [PubMed: 7826210]. NS1 The protective efficacy and immune responses of mice intramuscularly injected with plasmid encoding DEN-2 non-structural protein 1 (NS1) was evaluated. Intravenously challenged by lethal DEN-2, mice vaccinated with NS1-DNA exhibited a delay onset of paralysis, a marked decrease of morbidity, and a significant enhancement of survival [PubMed: 12922127]. YH, ZX Protegen ID: 781; NCBI Protein GI: 288848; NCBITaxon: 11060 G glycoprotein Protegen ID: 782; NCBI Gene GI: 920955; NCBI Protein GI: 13559814; NCBI Protein Accession: NP_112027; NCBITaxon: 121791 Hamsters were immunized subcutaneously with either 107 PFU of VV-NiV.G or VV-NiV.F expressing the G and F glycoproteins, respectively, or with the two combined. When the VV-NiV.G-vaccinated animals were challenged with Nipah virus 3 months after the last immunization (1,000 PFU/animal intraperitoneally), there was complete protection against mortality [PubMed: 14694115]. YH, ZX F fusion protein YH, ZX Hamsters were immunized subcutaneously with either 10^7 PFU of VV-NiV.G or VV-NiV.F expressing the G and F glycoproteins, respectively, or with the two combined. When the VV-NiV.F-vaccinated animals were challenged with Nipah virus 3 months after the last immunization (1,000 PFU/animal intraperitoneally), there was complete protection against mortality [PubMed: 14694115]. Protegen ID: 783; NCBI Nucleotide GI: 8164021; NCBI Protein GI: 8164022; NCBI Protein Accession: AAF73956.1; NCBITaxon: 121791 PrM A recombinant vaccinia virus that expressed the pre-M protein of Dengue 4 virus was constructed. Mice immunized with the recombinant virus were protected against subsequent dengue 4 encephalitis challenge [PubMed: 1926792]. YH, ZX Protegen ID: 784; NCBI Protein GI: 18308086; NCBITaxon: 11070 M protein Protegen ID: 785; NCBI Protein GI: 73671170; NCBITaxon: 11070 YH, ZX A recombinant vaccinia virus that expressed the M protein of Dengue 4 virus was constructed. Mice immunized with the recombinant virus were protected against subsequent dengue 4 encephalitis challenge [PubMed: 1926792]. SpaP Guinea pigs immunized with different doses of the SPA appear to be protected against challenge with live organisms as compared with nonimmunized controls [PubMed: 2122457]. Protegen ID: 786; NCBI Protein GI: 152498; NCBITaxon: 782 YH, ZX RVFVsMgp1 M protein Protegen ID: 787; NCBI Gene GI: 956559; NCBI Protein GI: 27881464; NCBI Protein Accession: NP_777376; NCBITaxon: 11588 The glycoprotein (GP) and nucleocapsid (NC) genes of Rift Valley fever virus (RVFV) were expressed in different expression systems and were evaluated for their ability to protect mice from virulent challenge using a prime-boost regime. Mice vaccinated with a lumpy skin disease virus-vectored recombinant vaccine (rLSDV-RVFV) expressing the two RVFV glycoproteins (G1 and G2, expressed by the RVFV M Segment) developed neutralising antibodies and were fully protected when challenged, as were those vaccinated with a crude extract of truncated G2 glycoprotein (tG2) [PubMed: 16870311]. YH, ZX RVFVsSgp2 N protein YH, ZX Protegen ID: 788; NCBI Gene GI: 956562; NCBI Protein GI: 9632367; NCBI Protein Accession: NP_049344; NCBITaxon: 11588 Immunisation of mice with cDNA encoding the nucleocapsid protein induced strong humoral and lymphocyte proliferative immune responses. Even though complete protection was not achieved by genetic immunisation, four out of eight mice vaccinated with cDNA encoding the nucleocapsid protein displayed no clinical signs of infection after challenge. In contrast, all fourteen control animals displayed clinical manifestations of Rift Valley Fever after challenge [PubMed: 19149901]. S protein The receptor-binding domain (RBD) of SARS-CoV spike (S) protein is an important target in developing safe and effective SARS vaccines. A previous study has demonstrated that vaccination with adeno-associated virus encoding RBD (RBD-rAAV) induces high titer of neutralizing antibodies. The immune responses and protective effect of the immunization with RBD-rAAV prime/RBD-specific T cell peptide boost were assessed. Compared with the RBD-rAAV prime/boost vaccination, RBD-rAAV prime/RBD-peptide (RBD-Pep) boost induced similar levels of Th1 and neutralizing antibody responses that protected the vaccinated mice from subsequent SARS-CoV challenge, but stronger Th2 and CTL responses. No significant immune responses and protective effects were detected in mice vaccinated with RBD-Pep or blank AAV alone [PubMed: 18289745]. Protegen ID: 789; NCBI Gene GI: 1489668; NCBI Protein GI: 29836496; NCBI Protein Accession: NP_828851; NCBITaxon: 694009 YH, ZX LcrV YH, ZX Protegen ID: 790; NCBI Gene GI: 1449458; NCBI Protein GI: 32470278; NCBI Protein Accession: NP_863514; NCBITaxon: 630 Mice actively immunized using a recombinant V antigen (rVagHis, encoded by lcrV gene) of Y. enterocolitica were completely protected against challenge with both, Y. enterocolitica 0:8 and Y. pseudotuberculosis serotype III [PubMed: 10089162]. GEh29 Protegen ID: 791; NCBI Nucleotide GI: 399673; NCBI Protein GI: 399674; NCBI Protein Accession: CAA50324.1; NCBITaxon: 5759 80% of C3H/HeJ mice immunized with Eh29 administered in combination with a subclinical dose of whole cholera toxin, but not as an Eh29-CTxB fusion, showed no evidence of infection in tissue sections harvested following intracecal challenge with virulent E. histolytica trophozoites. These results suggest that Eh29 is capable of inducing protective anti-amoebic immune responses in mice following oral immunization and could be used in the development of oral vaccines against amoebiasis [PubMed: 20303954]. YH, ZX Gal/GalNAc lectin Protegen ID: 792; NCBI Gene GI: 3404842; NCBI Protein GI: 67469085; NCBI Protein Accession: XP_650534; NCBITaxon: 294381 Study tested if vaccination with the E. histolytica Gal/GalNAc lectin could prevent cecal infection in a C3H mouse model of amebic colitis. Vaccination prevented intestinal infection with efficacies of 84 and 100% in the two native lectin trials and 91 and 34% in the two LecA trials. Results show for the first time that immunization with the Gal/GalNAc lectin can prevent intestinal amebiasis in mice [PubMed: 14741152]. YH, ZX SREHP Report describes a recombinant fusion protein containing the serine-rich Entamoeba histolytica protein (SREHP), a protective antigen derived from virulent amebae, and a bacterially derived maltose-binding protein (MBP) from an attenuated strain of Salmonella typhimurium. Gerbils vaccinated with S typhimurium SREHP-MBP were protected against amebic liver abscess after challenge with E. histolytica, the most common extraintestinal complication of amebiasis [PubMed: 8613356]. YH, ZX Protegen ID: 793; NCBI Gene GI: 3402462; NCBI Protein GI: 67463194; NCBI Protein Accession: XP_648254; NCBITaxon: 294381 PEP1 Protegen ID: 794; NCBI Protein GI: 73915320; NCBITaxon: 199306 YH, ZX Groups of C57BL/6 mice (20 per group) vaccinated with rPep1 (1 mug per dose) plus adjuvant and challenged with an intranasal inoculum began to die at about 14 to 16 days but then showed significantly greater survival than the control mice [PubMed: 16369008]. CEL-170/4 Protegen ID: 795; NCBI Protein GI: 401088; NCBITaxon: 5759 Researcherse tested the ability of the galactose-specific adherence lectin of E. histolytica to elicit a protective immune response in conjunction with Freund's incomplete and complete adjuvants. Four independent trials demonstrated complete protection from amebic liver abscess formation in 67% of lectin-immunized gerbils. The gerbil antilectin antibodies were shown by Western immunoblotting to be directed to the heavy subunit (CEL-170/4) but not the light subunit of the lectin [PubMed: 1987067]. YH, ZX PLB Protegen ID: 796; NCBI Protein GI: 74486661; NCBITaxon: 199306 C57BL/6 mice immunized with rPlb showed a significant reduction of the fungal burden in their lungs at 90 days postchallenge compared to the control mice at 15 days [PubMed: 16369008]. YH, ZX AMN1 Protegen ID: 797; NCBI Protein GI: 76786276; NCBITaxon: 199306 YH, ZX C57BL/6 mice immunized with rAMN1 showed a significant reduction of the fungal burden in their lungs at 90 days postchallenge compared to the control mice at 15 days [PubMed: 16369008]. ELI-Ag1 YH, ZX ELI-Antigen 1 (ELI-Ag1) was tested for its protective capacity in BALB/c mice against intraperitoneal challenge with 2500 arthroconidia of this dimorphic fungus and was found to be highly protective [PubMed: 14505918]. Protegen ID: 798; NCBI Protein GI: 37779128; NCBITaxon: 5501 GEL1 The GEL1 mRNA of C. posadasii was detected at the highest level during the endosporulation stage of the parasitic cycle, and the mature protein was immunolocalized to the surface of endospores. BALB/c or C57BL/6 mice were immunized subcutaneously with the bacterium-expressed recombinant protein (rGel1p) to evaluate its protective efficacy against a lethal challenge of C. posadasii by either the intraperitoneal or intranasal route. In both cases, rGel1p-immune mice infected with the pathogen showed a significant reduction in fungal burden and increased survival compared to nonimmune mice [PubMed: 12761077]. YH, ZX Protegen ID: 799; NCBI Protein GI: 14582416; NCBITaxon: 199306 URE Recombinant urease (rURE) of C. immitis was expressed in Escherichia coli and tested asa vaccine candidate in BALB/c mice. BALB/c mice immunized subcutaneously with rURE and subsequently challenged by the intraperitoneal (i.p.) route with a lethal inoculum of C. immitis arthroconidia demonstrated a significant reduction in the level of C. immitis infection compared to control animals [PubMed: 11292702]. YH, ZX Protegen ID: 800; NCBI Protein GI: 73808050; NCBITaxon: 5501 Pmp1 Recombinant Pmp1 was reactive with serum from individuals with both acute and protracted disease, and evoked protection in two murine models of infection with C. posadasii [PubMed: 16495561]. YH, ZX Protegen ID: 801; NCBI Protein GI: 78364922; NCBITaxon: 199306 Pra Protegen ID: 802; NCBI Protein GI: 42742528; NCBITaxon: 5501 C57BL6 mice were immunized with syngeneic, bone marrow-derived DCs (JAWS II cells) transfected with a cDNA encoding the protective Coccidioides-Ag2/proline-rich Ag (pra). The immunized mice were lethally challenged with C. posadasii through either an i.p. or intranasal route. Upon necropsy after 10 days of infection, fungal burden in lung and spleen of immunized mice was significantly reduced as compared with the control animals. The lung tissue homogenates of immunized animals showed higher levels of IFN-gamma. Histologically, lung tissues of immunized mice were in better condition than the control mice [PubMed: 16148136]. YH, ZX MAPP15 The microtubule-associate protein (MAP p15) was tested as a vaccine in mice, and tests showed that p15 (native or recombinant) generated up to 100% protection from an otherwise lethal challenge of a heterologous strain of Trypanosoma brucei [PubMed: 15161078]. Protegen ID: 803; NCBI Protein GI: 777767; NCBITaxon: 5691 YH, ZX UreB Vaccination with poliovirus vector containing the gene for the B subunit of H. pylori urease provides significant prophylactic and strong therapeutic protection against H. pylori in mice [PubMed: 15603891]. YH, ZX Protegen ID: 804; NCBI Protein GI: 40737733; NCBITaxon: 210 Hsp60 YH, ZX Protegen ID: 805; NCBI Protein GI: 397869; NCBITaxon: 210 Researchers prepared an oral liposome-encapsulated recombinant Helicobacter pylori (Hp) heat shock protein 60 (Hsp60) vaccine and investigate its effect against Hp infection in mice. rHsp60 plus CT (choleratoxin), liposome-encapsulated rHsp60 and liposome-encapsulated rHsp60 plus CT had protective rates against Hp infection of 73.3%, 66.7% and 86.7%, respectively [PubMed: 15897126]. NAP Protegen ID: 806; NCBI Protein GI: 8777456; NCBITaxon: 210 YH, ZX A study shows that vaccination of mice with HP-NAP (H. pylori NAP) induces protection against H. pylori challenge, and that the majority of infected patients produce antibodies specific for HP-NAP, suggesting an important role of this factor in immunity [PubMed: 10790422]. TSA BALB-c mice immunized intramuscularly with a single dose (100 microg) of a plasmid DNA encoding the 5'-terminal region of the trans-sialidase (nTSA) gene of T. brucei brucei are able to produce IgG antibodies that bind to the bloodstream form of T. brucei-protein extract and recognize the recombinant nTSA protein, expressed in Escherichia coli. Furthermore, this DNA vaccination process was able to protect 60% of mice submitted to a challenge assay with the infective form of T. brucei brucei parasites [PubMed: 19582478]. Protegen ID: 807; NCBI Protein GI: 62175539; NCBITaxon: 5691 YH, ZX Catalase Protegen ID: 808; NCBI Protein GI: 3128145; NCBITaxon: 210 YH, ZX Recombinant H. pylori catalase plus CT was used for immunization, and groups of mice were challenged with the Sydney strain of H. pylori. Immunization with recombinant catalase protected a significant proportion (9 of 10) of the mice from H. pylori challenge, indicating that this enzyme should be considered as a candidate for a future vaccine [PubMed: 9353048]. Rop2 A study to examine the immunostimulatory properties of Leishmania infantum Hsp83 (83) to elicit humoral and cellular response against the Toxoplasma gondii Rop2 protein in an adjuvant-free vaccination system was conducted. Mice immunized with fusion Rop2-83 elicited a stronger humoral and cellular response in comparison to mice immunized with Rop2 alone, or a mix of LiHsp83 and Rop2. The fusion protein induced a Th1 type response, with predominance of specific IgG2a/IgG2c isotype and IFN-gamma secretions, whereas Rop2 alone or mixed with LiHsp83 produced a Th1/Th2 mixed response. Vaccination with fusion protein conferred a remarkable resistance against oral infection with ME49 cysts in C57BL/6 and C3H mice, in comparison to mice immunized with Rop2 alone or the protein mixture. Following lethal challenge, a significant survival rate was observed in Rop2-83 immunized Balb/c and C57BL/6 mice in comparison to control groups [PubMed: 16545504]. YH, ZX Protegen ID: 809; NCBI Protein GI: 115299638; NCBITaxon: 5811 VacA Treatment of the Helicobacter pylori vacuolating cytotoxin with very low concentrations of formaldehyde resulted in abrogation of toxic activity in both a HeLa cell vacuolation assay and an in vivo assay of gastric epithelial damage. Detoxification had only a minimal effect on the integrity of the oligomeric or monomeric structure. The toxoid retained the ability to bind to target cells and to induce high-titer neutralizing antibodies after immunization of rabbits. Furthermore, oral immunization of mice with the toxoid resulted in protection against infective challenge with mouse-adapted strains of H. pylori [PubMed: 9353041]. YH, ZX Protegen ID: 810; NCBI Protein GI: 50313203; NCBITaxon: 210 TcrP Protegen ID: 811; NCBI Protein GI: 13508695; NCBITaxon: 5501 YH, ZX The immunogenicity of a 48-kDa T-cell-reactive protein (TCRP) was investigated. Immunization of BALB/c and C3H/HeN mice with the rTCRP affords a modest but significant level of protection against an intraperitoneal challenge with C. immitis. It is suggested that the rTCRP may be able to contribute to a multicomponent vaccine designed to stimulate CMI response against the parasitic cycle of C. immitis. GLURP YH, ZX Some of the S. sciureus monkeys immunized with MSP-3(212-380)-AS02 or GLURP(27-500)-alum were able to fully or partially control parasitaemia upon an experimental P. falciparum [Falciparum Uganda Palo Alto (FUP-SP) strain] blood-stage infection, and this protection was related to the prechallenge antibody titres induced. The data are indicative that MSP-3 and GLURP can induce protective immunity against an experimental P. falciparum infection using adjuvants that are acceptable for human use and this should trigger further studies with those new antigens [PubMed: 15049780]. Protegen ID: 812; NCBI Gene GI: 810501; NCBI Protein GI: 124802897; NCBI Protein Accession: XP_001347628; NCBITaxon: 36329 OmpU YH, ZX Asian seabass vaccinated with the OMP38 (OmpU) DNA vaccine was challenged with pathogenic V. anguillarum by intramuscular injection. A relative percent survival (RPS) rate of 55.6% was recorded [PubMed: 17337208]. Protegen ID: 813; NCBI Protein GI: 26513901; NCBITaxon: 55601 Japanese encephalitis virus DNA vaccine encoding PrM VIOLIN Vaccine ID: 1067 YH, ZX DeltaFTT0918 VIOLIN Vaccine ID: 439 YH, ZX rLm/iglC VIOLIN Vaccine ID: 440 YH, ZX 5CVMB YH, ZX VIOLIN Vaccine ID: 438 L. amazonensis DNA vaccine encoding WD protein YH, ZX VIOLIN Vaccine ID: 1041 L. infantum H1 protein vaccine VIOLIN Vaccine ID: 1042 YH, ZX L. infantum HASPB1 protein vaccine YH, ZX VIOLIN Vaccine ID: 1043 Japanese encephalitis virus DNA vaccine pUJENS5 VIOLIN Vaccine ID: 1036 YH, ZX Japanese encephalitis virus DNA vaccine encoding E protein VIOLIN Vaccine ID: 1037 YH, ZX L. amazonensis DNA vaccine encoding GP46 VIOLIN Vaccine ID: 1038 YH, ZX L. amazonensis M2 protein vaccine YH, ZX VIOLIN Vaccine ID: 1039 A. pleuropneumoniae ApxIA protein vaccine VIOLIN Vaccine ID: 782 YH, ZX B. pertussis Cpn60 protein vaccine VIOLIN Vaccine ID: 797 YH, ZX B. pertussis CyaA protein vaccine VIOLIN Vaccine ID: 799 YH, ZX V. cholerae CTB DNA Vaccine YH, ZX VIOLIN Vaccine ID: 800 B. pertussis PTx protein vaccine VIOLIN Vaccine ID: 801 YH, ZX C. parvum DNA vaccine encoding CP23 VIOLIN Vaccine ID: 1050 YH, ZX Cancer Her-2/neu Protein Subunit Vaccine YH, ZX VIOLIN Vaccine ID: 1051 Cancer DNA Vaccine encoding hNIS protein YH, ZX VIOLIN Vaccine ID: 1052 Cancer DNA Vaccine encoding Survivin VIOLIN Vaccine ID: 1053 YH, ZX Cancer Subunit NY-ESO-1 Protein Vaccine YH, ZX VIOLIN Vaccine ID: 1047 Cancer DNA Vaccine encoding Endoglin Boosted with Recombinant Endoglin Protein VIOLIN Vaccine ID: 1048 YH, ZX Cancer DNA Vaccine encoding H-2Kb YH, ZX VIOLIN Vaccine ID: 1049 Cancer DNA Vaccine encoding TEM8 VIOLIN Vaccine ID: 1046 YH, ZX Cancer EPCAM protein vaccine VIOLIN Vaccine ID: 1064 YH, ZX Cancer VEGFA protein vaccine VIOLIN Vaccine ID: 1066 YH, ZX Cancer Retroviral Vector Vaccine encoding Cd40lg YH, ZX VIOLIN Vaccine ID: 1058 Cancer DNA Vaccine encoding Cd86 YH, ZX VIOLIN Vaccine ID: 1059 Phleum pratense Allergy Phl p 12 Subunit Vaccine VIOLIN Vaccine ID: 1054 YH, ZX B. bovis GST-12D3 VIOLIN Vaccine ID: 791 YH, ZX B. pertussis BrkA protein vaccine YH, ZX VIOLIN Vaccine ID: 796 Bovine leukemia virus DNA vaccine encoding Env YH, ZX VIOLIN Vaccine ID: 825 Bovine leukemia virus DNA vaccine encoding Tax YH, ZX VIOLIN Vaccine ID: 828 B. abortus DNA vaccine encoding RplL and Omp16 VIOLIN Vaccine ID: 831 YH, ZX Bovine herpesvirus 1 DNA vaccine AdCMVgD VIOLIN Vaccine ID: 821 YH, ZX Bovine herpesvirus 1 DNA vaccine AdCMVgC VIOLIN Vaccine ID: 823 YH, ZX Bovine herpesvirus 1 GPI protein vaccine YH, ZX VIOLIN Vaccine ID: 824 A. pleuropneumoniae ApxIa and ApxIIa protein vaccine VIOLIN Vaccine ID: 784 YH, ZX A. pleuropneumoniae HS93C-Ampr VIOLIN Vaccine ID: 786 YH, ZX A. salmonicida live-attenuated vaccine encoding AroA YH, ZX VIOLIN Vaccine ID: 788 NP-VRP YH, ZX VIOLIN Vaccine ID: 443 Rickettsia rickettsii vaccine using M. vaccae expressing R. rickettsii OmpA Protein YH, ZX VIOLIN Vaccine ID: 1044 Rickettsia DNA Vaccine encoding OmpB Protein boosted with Recombinant OmpB VIOLIN Vaccine ID: 1045 YH, ZX B. pertussis DNA vaccine encoding Prn VIOLIN Vaccine ID: 808 YH, ZX Marek's Disease Virus Vaccine rFPV/gI VIOLIN Vaccine ID: 993 YH, ZX Marek's Disease Virus Vaccine rFPV/gB1 YH, ZX VIOLIN Vaccine ID: 994 Marburg Virus Nucleoprotein Vaccine YH, ZX VIOLIN Vaccine ID: 997 Human papillomavirus E7 protein vaccine YH, ZX VIOLIN Vaccine ID: 986 P. falciparum Hsp90 Protein Subunit Vaccine YH, ZX VIOLIN Vaccine ID: 987 Human papillomavirus L2 protein vaccine YH, ZX VIOLIN Vaccine ID: 988 IHNV DNA vaccine pIHNw-G YH, ZX VIOLIN Vaccine ID: 989 Rift Valley Fever Virus DNA Vaccine encoding N Protein VIOLIN Vaccine ID: 990 YH, ZX Puumala virus PUUVsSgp1 (NP) protein vaccine VIOLIN Vaccine ID: 949 YH, ZX Sin Nombre virus DNA vaccine encoding G1 VIOLIN Vaccine ID: 950 YH, ZX Seoul virus vaccine rCAV-2-Gc VIOLIN Vaccine ID: 951 YH, ZX Topografov virus N protein vaccine VIOLIN Vaccine ID: 952 YH, ZX Hepatitis B virus DNA vaccine pVAX-PS VIOLIN Vaccine ID: 968 YH, ZX Herpes simplex virus type 2 DNA vaccine encoding ICP27 VIOLIN Vaccine ID: 969 YH, ZX Herpes simplex virus type 2 DNA vaccine encoding GB VIOLIN Vaccine ID: 970 YH, ZX NIpah Virus G and F Proteins Subunit Vaccine YH, ZX VIOLIN Vaccine ID: 971 Herpes simplex virus type 1 DNA vaccine encoding GC VIOLIN Vaccine ID: 972 YH, ZX Hendra virus G protein vaccine YH, ZX VIOLIN Vaccine ID: 963 M. tuberculosis DNA Vaccine encoding Ag85B Protein VIOLIN Vaccine ID: 964 YH, ZX Hepatitis B virus DNA vaccine encoding HBVgp2 pre-S1/pre-S2/S YH, ZX VIOLIN Vaccine ID: 965 M. tuberculosis Mtb72F Protein Subunit Vaccine VIOLIN Vaccine ID: 967 YH, ZX B. pertussis DNA vaccine encoding TcfA VIOLIN Vaccine ID: 813 YH, ZX E. histolytica CEL-170/4 protein vaccine YH, ZX VIOLIN Vaccine ID: 918 P. falciparum Subunit SE36 Protein Vaccine YH, ZX VIOLIN Vaccine ID: 919 E. histolytica SREHP protein vaccine YH, ZX VIOLIN Vaccine ID: 920 E. coli C3389 protein vaccine YH, ZX VIOLIN Vaccine ID: 921 P. falciparum Pfen Protein Subunit Vaccine VIOLIN Vaccine ID: 922 YH, ZX Mumps HN Protein Subunit Vaccine YH, ZX VIOLIN Vaccine ID: 973 Herpes simplex virus type 2 vaccine using phage displaying GG protein VIOLIN Vaccine ID: 974 YH, ZX Herpes simplex virus type 1 DNA vaccine encoding GD YH, ZX VIOLIN Vaccine ID: 975 Measles Virus vaccine VEE/SIN-H+F VIOLIN Vaccine ID: 976 YH, ZX Herpes simplex virus type 1 DNA vaccine encoding GE YH, ZX VIOLIN Vaccine ID: 977 C. pneumoniae DNA vaccine encoding PknD YH, ZX VIOLIN Vaccine ID: 887 C. pneumoniae DNA vaccine encoding Ssb VIOLIN Vaccine ID: 888 YH, ZX C. psittaci DNA vaccine pcDNA1/MOMP YH, ZX VIOLIN Vaccine ID: 889 Classical swine fever virus vaccine VAC-E0 VIOLIN Vaccine ID: 890 YH, ZX C. abortus DNA vaccine encoding GatC VIOLIN Vaccine ID: 878 YH, ZX C. abortus DNA vaccine encoding OmlA YH, ZX VIOLIN Vaccine ID: 879 C. abortus DNA vaccine encoding MOMP VIOLIN Vaccine ID: 880 YH, ZX C. abortus DNA vaccine Pomp90A YH, ZX VIOLIN Vaccine ID: 881 C. pneumoniae CopN protein vaccine VIOLIN Vaccine ID: 882 YH, ZX Prostate Cancer DNA Vaccine Encoding Prostatic Acid Phosphatase (PAP) VIOLIN Vaccine ID: 883 YH, ZX C. pneumoniae DNA vaccine encoding FabD YH, ZX VIOLIN Vaccine ID: 884 C. pneumoniae LcrE protein vaccine VIOLIN Vaccine ID: 885 YH, ZX B. pseudomallei Subunit LolC Protein Vaccine YH, ZX VIOLIN Vaccine ID: 860 C. muridarum RplF protein vaccine VIOLIN Vaccine ID: 861 YH, ZX B. pseudomallei Subunit PotF Protein Vaccine VIOLIN Vaccine ID: 862 YH, ZX P. yoelii MSP1 and MSP4/5 Proteins Subunit Vaccine YH, ZX VIOLIN Vaccine ID: 984 P. falciparum MSP3 Protein Subunit Vaccine YH, ZX VIOLIN Vaccine ID: 985 Lassa Virus Nucleoprotein Subunit Vaccine YH, ZX VIOLIN Vaccine ID: 1035 E. coli C4424 protein vaccine VIOLIN Vaccine ID: 923 YH, ZX E. coli Hma protein vaccine YH, ZX VIOLIN Vaccine ID: 924 E. coli IreA protein vaccine YH, ZX VIOLIN Vaccine ID: 925 E. coli IutA protein vaccine YH, ZX VIOLIN Vaccine ID: 926 F. tularensis GroEL protein vaccine YH, ZX VIOLIN Vaccine ID: 928 F. tularensis DNA vaccine rLm/iglC YH, ZX VIOLIN Vaccine ID: 929 E. tenella vaccine rBCG pMV361-Rho VIOLIN Vaccine ID: 912 YH, ZX E. tenella DNA vaccine pcDNA-TA4-IL-2 VIOLIN Vaccine ID: 913 YH, ZX E. histolytica Eh29 protein vaccine VIOLIN Vaccine ID: 915 YH, ZX E. histolytica Gal/GalNAc lectin protein vaccine VIOLIN Vaccine ID: 916 YH, ZX Dengue Vaccine using Vaccinia Virus expressing prM Protein YH, ZX VIOLIN Vaccine ID: 853 C. muridarum MOMP protein vaccine VIOLIN Vaccine ID: 854 YH, ZX Dengue DNA Vaccine encoding NS1 Protein YH, ZX VIOLIN Vaccine ID: 855 Dengue Vaccine using Vaccinia Virus expressing M Protein YH, ZX VIOLIN Vaccine ID: 856 C. muridarum PmpE/F-2 protein vaccine YH, ZX VIOLIN Vaccine ID: 857 Dengue Subunit E Protein Vaccine YH, ZX VIOLIN Vaccine ID: 858 C. muridarum PmpG-1 protein vaccine VIOLIN Vaccine ID: 859 YH, ZX Canine distemper virus DNA vaccine encoding HA YH, ZX VIOLIN Vaccine ID: 847 C. posadasii Subunit PMP1 Protein Vaccine VIOLIN Vaccine ID: 848 YH, ZX C. posadasii DNA Vaccine encoding PRA Protein YH, ZX VIOLIN Vaccine ID: 849 Canine parvovirus DNA vaccine pGT36VP1 VIOLIN Vaccine ID: 850 YH, ZX C. immitis Subunit URE Protein Vaccine VIOLIN Vaccine ID: 851 YH, ZX Canine parvovirus CPMV-PARVO1 protein vaccine VIOLIN Vaccine ID: 852 YH, ZX Ebola virus DNA vaccine encoding ZEBOV GP and SEBOV GP VIOLIN Vaccine ID: 901 YH, ZX S. flexneri Invaplex 24 Subunit Vaccine YH, ZX VIOLIN Vaccine ID: 902 E. maxima Gam82 protein vaccine YH, ZX VIOLIN Vaccine ID: 903 S. flexneri Invaplex 50 Subunit Vaccine VIOLIN Vaccine ID: 904 YH, ZX E. tenella DNA vaccine proIE VIOLIN Vaccine ID: 905 YH, ZX E. tenella GX3262 protein vaccine YH, ZX VIOLIN Vaccine ID: 907 E. tenella DNA vaccine EtMIC2 VIOLIN Vaccine ID: 909 YH, ZX E. tenella DNA vaccine rBCG pMV261-Rho VIOLIN Vaccine ID: 910 YH, ZX Vaxxitek HVT+IBD VIOLIN Vaccine ID: 397 YH, ZX Newcastle disease virus vaccine by Dow AgroSciences YH, ZX VIOLIN Vaccine ID: 398 Theileria parva vaccine by Centre for Ticks and Tickborne Disease, Malawi YH, ZX VIOLIN Vaccine ID: 427 Theileria annulata vaccine by Local veterinary institutes VIOLIN Vaccine ID: 428 YH, ZX H. pylori DNA vaccine encoding UreB YH, ZX VIOLIN Vaccine ID: 960 M. tuberculosis DNA Vaccine APADNA priming and APAMVA boosting YH, ZX VIOLIN Vaccine ID: 961 H. pylori VacA protein vaccine VIOLIN Vaccine ID: 962 YH, ZX Human papillomavirus DNA vaccine pNGVL4a-E6/opt VIOLIN Vaccine ID: 981 YH, ZX PCV2 DNA Vaccine encoding ORF2 Protein VIOLIN Vaccine ID: 982 YH, ZX Td Polio Adsorbed YH, ZX VIOLIN Vaccine ID: 630 Td Polio Adsorbed VIOLIN Vaccine ID: 629 YH, ZX Td Polio Adsorbed VIOLIN Vaccine ID: 628 YH, ZX C. jejuni FspA1 protein vaccine VIOLIN Vaccine ID: 841 YH, ZX SARS Subunit Spike Protein Vaccine YH, ZX VIOLIN Vaccine ID: 842 C. jejuni FspA2 protein vaccine VIOLIN Vaccine ID: 843 YH, ZX C. jejuni DNA vaccine pcDNA3.1(+)-peblA YH, ZX VIOLIN Vaccine ID: 844 Canine distemper virus DNA vaccine encoding F and HA VIOLIN Vaccine ID: 845 YH, ZX C. posadasii Subunit GEL1 Protein Vaccine YH, ZX VIOLIN Vaccine ID: 846 T. brucei DNA Vaccine encoding TSA protein VIOLIN Vaccine ID: 836 YH, ZX T. brucei Subunit p15 Protein Vaccine VIOLIN Vaccine ID: 837 YH, ZX C. jejuni MBP-FlaA protein vaccine VIOLIN Vaccine ID: 838 YH, ZX T. parva Subunit p67 Protein Vaccine YH, ZX VIOLIN Vaccine ID: 839 C. jejuni FlaC protein vaccine VIOLIN Vaccine ID: 840 YH, ZX B. pertussis FhaB and 69 kDa OMP protein vaccine YH, ZX VIOLIN Vaccine ID: 805 H. influenzae Hap protein vaccine VIOLIN Vaccine ID: 936 YH, ZX Japanese encephalitis virus DNA vaccine encoding NS1 (pUSK-NS1) VIOLIN Vaccine ID: 1033 YH, ZX Japanese encephalitis virus DNA vaccine pUJENS3 YH, ZX VIOLIN Vaccine ID: 1034 C. parvum DNA vaccine encoding CP15/60 VIOLIN Vaccine ID: 900 YH, ZX Y. enterocolititica Subunit V Antigen Protein Vaccine YH, ZX VIOLIN Vaccine ID: 896 C. botulinum FHc protein vaccine VIOLIN Vaccine ID: 897 YH, ZX WEEV DNA Vaccine encoding 6K-E1 Protein YH, ZX VIOLIN Vaccine ID: 898 WEEV Subunit E2 Protein Vaccine VIOLIN Vaccine ID: 899 YH, ZX Cancer Subunit GV1001 Protein Vaccine VIOLIN Vaccine ID: 891 YH, ZX Classical swine fever virus vaccine VAC-E2 VIOLIN Vaccine ID: 892 YH, ZX Classical swine fever virus E1 protein vaccine VIOLIN Vaccine ID: 893 YH, ZX Cancer Subunit DC (Tat-CEA) vaccine VIOLIN Vaccine ID: 894 YH, ZX C. botulinum DNA vaccine pSCARSBHc YH, ZX VIOLIN Vaccine ID: 895 Dobrava-Belgrade virus S nucleocapsid protein vaccine VIOLIN Vaccine ID: 954 YH, ZX H. pylori catalase protein vaccine VIOLIN Vaccine ID: 955 YH, ZX H. pylori NAP protein vaccine YH, ZX VIOLIN Vaccine ID: 958 M. gallisepticum TM-1 Protein Subunit Vaccine VIOLIN Vaccine ID: 959 YH, ZX Japanese encephalitis virus vaccine BV-G-E VIOLIN Vaccine ID: 1027 YH, ZX T. annulata Subunit SPAG-1 Protein Vaccine VIOLIN Vaccine ID: 873 YH, ZX C. abortus DNA vaccine encoding DnaK VIOLIN Vaccine ID: 874 YH, ZX C. abortus DNA vaccine encoding DnaX YH, ZX VIOLIN Vaccine ID: 875 C. abortus DNA vaccine encoding GatA/GatB YH, ZX VIOLIN Vaccine ID: 876 T. gondii Subunit Rop2-Hsp83 Fusion Protein Vaccine YH, ZX VIOLIN Vaccine ID: 866 C. muridarum DNA vaccine encoding TC0757 YH, ZX VIOLIN Vaccine ID: 867 T. gondii DNA vaccine pcDNA3-MIC3 VIOLIN Vaccine ID: 868 YH, ZX C. muridarum DNA vaccine encoding TC0767/768 YH, ZX VIOLIN Vaccine ID: 869 T. gondii DNA Vaccine encoding SAG1 Protein VIOLIN Vaccine ID: 870 YH, ZX C. abortus DNA vaccine encoding CAB049 YH, ZX VIOLIN Vaccine ID: 871 C. abortus DNA vaccine encoding CAB613 YH, ZX VIOLIN Vaccine ID: 872 Infleunza virus DNA vaccine encoding NP from Influenza A virus (A/chicken/Henan/12/2004(H5N1)) YH, ZX VIOLIN Vaccine ID: 1023 Influenza virus DNA vaccine encoding NP from Influenza A virus (A/chicken/Hubei/489/2004(H5N1)) VIOLIN Vaccine ID: 1024 YH, ZX L. donovani DNA Vaccine KMP-11 Protein VIOLIN Vaccine ID: 1025 YH, ZX Influenza virus NP protein vaccine (Influenza A virus (A/nt/60/1968(H3N2))) VIOLIN Vaccine ID: 1026 YH, ZX L. donovani gp63 Protein Subunit Vaccine YH, ZX VIOLIN Vaccine ID: 1022 C. muridarum DNA vaccine encoding TC0439 VIOLIN Vaccine ID: 864 YH, ZX C. muridarum DNA vaccine encoding TC0512 VIOLIN Vaccine ID: 865 YH, ZX Measles Virus Vaccine VVN YH, ZX VIOLIN Vaccine ID: 978 Measles Virus Vaccine VVP YH, ZX VIOLIN Vaccine ID: 979 Measles Virus Vaccine VVM YH, ZX VIOLIN Vaccine ID: 980 B. pseudomallei DNA vaccine encoding Flagellin Protein VIOLIN Vaccine ID: 863 YH, ZX L. donovani ORFF Protein Subunit Vaccine VIOLIN Vaccine ID: 1017 YH, ZX Influenza virus DNA vaccine encoding NA from Influenza B virus (B/Ibaraki/2/85) VIOLIN Vaccine ID: 1018 YH, ZX Influenza virus DNA vaccine encoding NA from Influenza A virus (A/chicken/Henan/12/2004(H5N1)) YH, ZX VIOLIN Vaccine ID: 1019 L. donovani DNA Vaccine encoding NH36 Protein VIOLIN Vaccine ID: 1020 YH, ZX Sin Nombre virus DNA vaccine encoding SNVsSgp1 (NP) YH, ZX VIOLIN Vaccine ID: 945 S. equi Subunit EAG, FNZ and SFS Protein Vaccine YH, ZX VIOLIN Vaccine ID: 832 C. jejuni DNA vaccine pcDNA3.1(+)-cadF VIOLIN Vaccine ID: 833 YH, ZX S. equi Subunit CNE Protein Vaccine YH, ZX VIOLIN Vaccine ID: 834 F. tularensis DNA vaccine pTUL4-15 VIOLIN Vaccine ID: 930 YH, ZX Plasmodium berghei CS Protein Subunit Vaccine VIOLIN Vaccine ID: 931 YH, ZX G. duodenalis DNA vaccine encoding CWP2 VIOLIN Vaccine ID: 932 YH, ZX H. influenzae D15 protein vaccine VIOLIN Vaccine ID: 933 YH, ZX Newcastle Disease Virus HN Glycoprotein Subunit Vaccine YH, ZX VIOLIN Vaccine ID: 934 Rabies DNA Vaccine encoding Rabies virus Glycoprotein YH, ZX VIOLIN Vaccine ID: 816 Bovine herpesvirus 1 DNA vaccine tgD-VP22 YH, ZX VIOLIN Vaccine ID: 817 Rabies vaccine rVac-N YH, ZX VIOLIN Vaccine ID: 818 Vivotif L YH, ZX VIOLIN Vaccine ID: 645 Bovine herpesvirus 1 DNA vaccine pRSV-gC YH, ZX VIOLIN Vaccine ID: 815 Ixiaro VIOLIN Vaccine ID: 741 YH, ZX CVX: 134 Cervarix VIOLIN Vaccine ID: 740 YH, ZX CVX: 118 Andes virus vaccine using adenovirus viral vector expressing ANDV NP VIOLIN Vaccine ID: 943 YH, ZX H. influenzae Omp26 protein vaccine VIOLIN Vaccine ID: 938 YH, ZX N. caninum NcMIC1 Protein Subunit Vaccine VIOLIN Vaccine ID: 939 YH, ZX N. caninum NcMAG1 Protein Subunit Vaccine YH, ZX VIOLIN Vaccine ID: 941 N. caninum NcDG2 Protein Subunit Vaccine VIOLIN Vaccine ID: 942 YH, ZX preparation of Anthrax Vaccine Adsorbed (AVA) A Bacillus anthracis vaccine preparation that results in the generation of a Anthrax Vaccine Adsorbed (AVA) VIOLIN Vaccine ID: 15 YH, ZX preparation of Quadracel A Bordetella pertussis vaccine preparation that results in the generation of a Quadracel VIOLIN Vaccine ID: 770 YH, ZX preparation of Td Adsorbed A Corynebacterium diphtheriae vaccine preparation that results in the generation of a Td Adsorbed YH, ZX VIOLIN Vaccine ID: 771 preparation of Boostrix A Bordetella pertussis vaccine preparation that results in the generation of a Boostrix VIOLIN Vaccine ID: 772 YH, ZX preparation of Recombinant B. abortus RB51WboA A Brucella vaccine preparation that results in the generation of a Recombinant B. abortus RB51WboA VIOLIN Vaccine ID: 13 YH, ZX preparation of Recombinant B. abortus RB51SOD VIOLIN Vaccine ID: 11 A Brucella vaccine preparation that results in the generation of a Recombinant B. abortus RB51SOD YH, ZX preparation of B. abortus vaccine strain RB51 YH, ZX VIOLIN Vaccine ID: 10 A Brucella vaccine preparation that results in the generation of a B. abortus vaccine strain RB51 preparation of Anthrax Spore Vaccine YH, ZX A Bacillus anthracis vaccine preparation that results in the generation of a Anthrax Spore Vaccine VIOLIN Vaccine ID: 17 preparation of delta ureC hly+ rBCG YH, ZX VIOLIN Vaccine ID: 437 A Mycobacterium tuberculosis vaccine preparation that results in the generation of a delta ureC hly+ rBCG preparation of Recombinant PA domain 4 VIOLIN Vaccine ID: 20 A Bacillus anthracis vaccine preparation that results in the generation of a Recombinant PA domain 4 YH, ZX preparation of Plague vaccine USP YH, ZX A Yersinia pestis vaccine preparation that results in the generation of a Plague vaccine USP VIOLIN Vaccine ID: 31 preparation of Yersinia EV76 VIOLIN Vaccine ID: 32 A Yersinia pestis vaccine preparation that results in the generation of a Yersinia EV76 YH, ZX preparation of DNA vaccine encoding PA (PA63) A Bacillus anthracis vaccine preparation that results in the generation of a DNA vaccine encoding PA (PA63) VIOLIN Vaccine ID: 23 YH, ZX preparation of DAAV using PA and PGA A Bacillus anthracis vaccine preparation that results in the generation of a DAAV using PA and PGA VIOLIN Vaccine ID: 24 YH, ZX preparation of pCLF4 A Bacillus anthracis vaccine preparation that results in the generation of a pCLF4 YH, ZX VIOLIN Vaccine ID: 28 preparation of Japanese encephalitis virus DNA vaccine encoding PrM YH, ZX A Japanese encephalitis virus vaccine preparation that results in the generation of a Japanese encephalitis virus DNA vaccine encoding PrM VIOLIN Vaccine ID: 1067 preparation of pCMV/ER-PA83 VIOLIN Vaccine ID: 29 YH, ZX A Bacillus anthracis vaccine preparation that results in the generation of a pCMV/ER-PA83 preparation of pSecTag-PA83 YH, ZX A Bacillus anthracis vaccine preparation that results in the generation of a pSecTag-PA83 VIOLIN Vaccine ID: 451 preparation of DNA vaccine encoding PA83 and LF VIOLIN Vaccine ID: 30 YH, ZX A Bacillus anthracis vaccine preparation that results in the generation of a DNA vaccine encoding PA83 and LF preparation of Modified Y. pestis with TLR4-stimulating LPS A Yersinia pestis vaccine preparation that results in the generation of a Modified Y. pestis with TLR4-stimulating LPS YH, ZX VIOLIN Vaccine ID: 35 preparation of Recombinant O. anthropi 49237SOD VIOLIN Vaccine ID: 113 A Brucella vaccine preparation that results in the generation of a Recombinant O. anthropi 49237SOD YH, ZX preparation of B. abortus strain 19 VIOLIN Vaccine ID: 109 YH, ZX A Brucella vaccine preparation that results in the generation of a B. abortus strain 19 preparation of B. melitensis vaccine strain Rev. 1 YH, ZX A Brucella vaccine preparation that results in the generation of a B. melitensis vaccine strain Rev. 1 VIOLIN Vaccine ID: 110 preparation of Y. pestis F1 protein vaccine A Yersinia pestis vaccine preparation that results in the generation of a Y. pestis F1 protein vaccine YH, ZX VIOLIN Vaccine ID: 36 preparation of Recombinant Y. pestis YopD protein vaccine VIOLIN Vaccine ID: 37 A Yersinia pestis vaccine preparation that results in the generation of a Recombinant Y. pestis YopD protein vaccine YH, ZX preparation of Recombinant Y. pestis V antigen vaccine YH, ZX A Yersinia pestis vaccine preparation that results in the generation of a Recombinant Y. pestis V antigen vaccine VIOLIN Vaccine ID: 44 preparation of VSV vector expressing Y. pestis lcrV VIOLIN Vaccine ID: 47 YH, ZX A Yersinia pestis vaccine preparation that results in the generation of a VSV vector expressing Y. pestis lcrV preparation of AdsecV A Yersinia pestis vaccine preparation that results in the generation of a AdsecV YH, ZX VIOLIN Vaccine ID: 48 preparation of Recombinant Yersinia rV10 vaccine YH, ZX A Yersinia pestis vaccine preparation that results in the generation of a Recombinant Yersinia rV10 vaccine VIOLIN Vaccine ID: 54 preparation of rF1 + rV YH, ZX VIOLIN Vaccine ID: 50 A Yersinia pestis vaccine preparation that results in the generation of a rF1 + rV preparation of LVS A Francisella tularensis vaccine preparation that results in the generation of a LVS VIOLIN Vaccine ID: 52 YH, ZX preparation of Adacel A Bordetella pertussis vaccine preparation that results in the generation of a Adacel VIOLIN Vaccine ID: 774 YH, ZX preparation of sodB(Ft) A Francisella tularensis vaccine preparation that results in the generation of a sodB(Ft) VIOLIN Vaccine ID: 55 YH, ZX preparation of Microencapsulated Caf1 and LcrV vaccine YH, ZX VIOLIN Vaccine ID: 56 A Yersinia pestis vaccine preparation that results in the generation of a Microencapsulated Caf1 and LcrV vaccine preparation of FSC043 A Francisella tularensis vaccine preparation that results in the generation of a FSC043 YH, ZX VIOLIN Vaccine ID: 57 preparation of DeltaFTT0918 VIOLIN Vaccine ID: 439 YH, ZX A Francisella tularensis vaccine preparation that results in the generation of a DeltaFTT0918 preparation of rLm/iglC YH, ZX A Francisella tularensis vaccine preparation that results in the generation of a rLm/iglC VIOLIN Vaccine ID: 440 preparation of F. tularensis vaccine LVS LPS A Francisella tularensis vaccine preparation that results in the generation of a F. tularensis vaccine LVS LPS YH, ZX VIOLIN Vaccine ID: 58 preparation of KKF24 YH, ZX A Francisella tularensis vaccine preparation that results in the generation of a KKF24 VIOLIN Vaccine ID: 60 preparation of Yersinia PAV A Yersinia pestis vaccine preparation that results in the generation of a Yersinia PAV VIOLIN Vaccine ID: 62 YH, ZX preparation of PGA/ME YH, ZX A Bacillus anthracis vaccine preparation that results in the generation of a PGA/ME VIOLIN Vaccine ID: 450 preparation of VRP expressing VP24 YH, ZX A Ebola virus vaccine preparation that results in the generation of a VRP expressing VP24 VIOLIN Vaccine ID: 65 preparation of VRP expressing VP30 YH, ZX A Ebola virus vaccine preparation that results in the generation of a VRP expressing VP30 VIOLIN Vaccine ID: 66 preparation of VRP expressing VP35 A Ebola virus vaccine preparation that results in the generation of a VRP expressing VP35 YH, ZX VIOLIN Vaccine ID: 67 preparation of VRP expressing VP40 A Ebola virus vaccine preparation that results in the generation of a VRP expressing VP40 VIOLIN Vaccine ID: 68 YH, ZX preparation of DNA vaccine expressing sGP YH, ZX VIOLIN Vaccine ID: 73 A Ebola virus vaccine preparation that results in the generation of a DNA vaccine expressing sGP preparation of Tripacel VIOLIN Vaccine ID: 778 A Bordetella pertussis vaccine preparation that results in the generation of a Tripacel YH, ZX preparation of CGV2631 A Brucella vaccine preparation that results in the generation of a CGV2631 VIOLIN Vaccine ID: 779 YH, ZX preparation of rPA Nanoemulsion-Based Anthrax Vaccine VIOLIN Vaccine ID: 309 YH, ZX A Bacillus anthracis vaccine preparation that results in the generation of a rPA Nanoemulsion-Based Anthrax Vaccine preparation of DAPTACEL YH, ZX A Bordetella pertussis vaccine preparation that results in the generation of a DAPTACEL VIOLIN Vaccine ID: 775 preparation of Infanrix YH, ZX VIOLIN Vaccine ID: 776 A Bordetella pertussis vaccine preparation that results in the generation of a Infanrix preparation of Tripedia YH, ZX VIOLIN Vaccine ID: 777 A Bordetella pertussis vaccine preparation that results in the generation of a Tripedia preparation of Y. pestis YscF subunit vaccine A Yersinia pestis vaccine preparation that results in the generation of a Y. pestis YscF subunit vaccine YH, ZX VIOLIN Vaccine ID: 81 preparation of Dryvax VIOLIN Vaccine ID: 94 A Variola virus vaccine preparation that results in the generation of a Dryvax YH, ZX preparation of ACAM2000 VIOLIN Vaccine ID: 96 A Variola virus vaccine preparation that results in the generation of a ACAM2000 YH, ZX preparation of B. abortus subunit vaccine using L7/L12 VIOLIN Vaccine ID: 111 YH, ZX A Brucella vaccine preparation that results in the generation of a B. abortus subunit vaccine using L7/L12 preparation of Live attenuated ETEC vaccine ACAM2007 YH, ZX A Escherichia coli vaccine preparation that results in the generation of a Live attenuated ETEC vaccine ACAM2007 VIOLIN Vaccine ID: 115 preparation of Live attenuated ETEC vaccine ACAM2010 YH, ZX VIOLIN Vaccine ID: 116 A Escherichia coli vaccine preparation that results in the generation of a Live attenuated ETEC vaccine ACAM2010 preparation of Live attenuated ETEC vaccine ACAM2017 A Escherichia coli vaccine preparation that results in the generation of a Live attenuated ETEC vaccine ACAM2017 VIOLIN Vaccine ID: 117 YH, ZX preparation of E. coli vaccine using intimin polypeptide A Escherichia coli vaccine preparation that results in the generation of a E. coli vaccine using intimin polypeptide VIOLIN Vaccine ID: 122 YH, ZX preparation of B. abortus strain 45/20 A Brucella vaccine preparation that results in the generation of a B. abortus strain 45/20 VIOLIN Vaccine ID: 123 YH, ZX preparation of soybean-expressed E. coli LTB vaccine YH, ZX A Escherichia coli vaccine preparation that results in the generation of a soybean-expressed E. coli LTB vaccine VIOLIN Vaccine ID: 125 preparation of 5CVMB A Neisseria meningitidis vaccine preparation that results in the generation of a 5CVMB YH, ZX VIOLIN Vaccine ID: 438 preparation of E. coli vaccine based on recombinant protein FyuA A Escherichia coli vaccine preparation that results in the generation of a E. coli vaccine based on recombinant protein FyuA YH, ZX VIOLIN Vaccine ID: 126 preparation of E.coli vaccine based on recombinant protein IroN A Escherichia coli vaccine preparation that results in the generation of a E.coli vaccine based on recombinant protein IroN VIOLIN Vaccine ID: 127 YH, ZX preparation of E. coli vaccine based on recombinant protein CO393 YH, ZX VIOLIN Vaccine ID: 128 A Escherichia coli vaccine preparation that results in the generation of a E. coli vaccine based on recombinant protein CO393 preparation of B. melitensis strain VTRM1 VIOLIN Vaccine ID: 135 A Brucella vaccine preparation that results in the generation of a B. melitensis strain VTRM1 YH, ZX preparation of B. suis strain VTRS1 YH, ZX A Brucella vaccine preparation that results in the generation of a B. suis strain VTRS1 VIOLIN Vaccine ID: 136 preparation of B. melitensis lipopolysaccharide (LPS) vaccine A Brucella vaccine preparation that results in the generation of a B. melitensis lipopolysaccharide (LPS) vaccine YH, ZX VIOLIN Vaccine ID: 137 preparation of B. abortus DNA vaccine pcDNA-SOD YH, ZX A Brucella vaccine preparation that results in the generation of a B. abortus DNA vaccine pcDNA-SOD VIOLIN Vaccine ID: 138 preparation of Brucella DNA vaccine encoding chimera BLSOmp31 VIOLIN Vaccine ID: 139 A Brucella vaccine preparation that results in the generation of a Brucella DNA vaccine encoding chimera BLSOmp31 YH, ZX preparation of Bacille Calmette-Gurin (BCG) VIOLIN Vaccine ID: 143 A Mycobacterium tuberculosis vaccine preparation that results in the generation of a Bacille Calmette-Gurin (BCG) YH, ZX preparation of DNA and adenoviral vector Ad5 expressing SIV gag protein YH, ZX A Human Immunodeficiency Virus vaccine preparation that results in the generation of a DNA and adenoviral vector Ad5 expressing SIV gag protein VIOLIN Vaccine ID: 145 preparation of DNA and Ad5/35 vector expressing HIV gp160 protein YH, ZX A Human Immunodeficiency Virus vaccine preparation that results in the generation of a DNA and Ad5/35 vector expressing HIV gp160 protein VIOLIN Vaccine ID: 146 preparation of DNA vaccine expressing multiple HIV epitopes VIOLIN Vaccine ID: 149 YH, ZX A Human Immunodeficiency Virus vaccine preparation that results in the generation of a DNA vaccine expressing multiple HIV epitopes preparation of Brucella recombinant SurA protein vaccine A Brucella vaccine preparation that results in the generation of a Brucella recombinant SurA protein vaccine VIOLIN Vaccine ID: 445 YH, ZX preparation of DNA/MVA prime-boost HIV vaccine VIOLIN Vaccine ID: 152 A Human Immunodeficiency Virus vaccine preparation that results in the generation of a DNA/MVA prime-boost HIV vaccine YH, ZX preparation of MVA expressing HIV Gag, Pol and Env proteins A Human Immunodeficiency Virus vaccine preparation that results in the generation of a MVA expressing HIV Gag, Pol and Env proteins VIOLIN Vaccine ID: 153 YH, ZX preparation of B. melitensis P39 deletion vaccine VIOLIN Vaccine ID: 448 YH, ZX A Brucella vaccine preparation that results in the generation of a B. melitensis P39 deletion vaccine preparation of B. abortus P39 deletion vaccine VIOLIN Vaccine ID: 449 A Brucella vaccine preparation that results in the generation of a B. abortus P39 deletion vaccine YH, ZX preparation of DNA and poxvirus priming-boosting SIV vaccine YH, ZX VIOLIN Vaccine ID: 154 A Human Immunodeficiency Virus vaccine preparation that results in the generation of a DNA and poxvirus priming-boosting SIV vaccine preparation of Gag-VRPs VIOLIN Vaccine ID: 156 YH, ZX A Human Immunodeficiency Virus vaccine preparation that results in the generation of a Gag-VRPs preparation of B. melitensis DNA vaccine encoding Omp31 boosted with Omp31 YH, ZX VIOLIN Vaccine ID: 446 A Brucella vaccine preparation that results in the generation of a B. melitensis DNA vaccine encoding Omp31 boosted with Omp31 preparation of B. suis strain 2 VIOLIN Vaccine ID: 447 YH, ZX A Brucella vaccine preparation that results in the generation of a B. suis strain 2 preparation of ActHIB VIOLIN Vaccine ID: 157 YH, ZX A Haemophilus influenzae vaccine preparation that results in the generation of a ActHIB preparation of L. amazonensis DNA vaccine encoding WD protein YH, ZX VIOLIN Vaccine ID: 1041 A Leishmania amazonensis vaccine preparation that results in the generation of a L. amazonensis DNA vaccine encoding WD protein preparation of L. infantum H1 protein vaccine VIOLIN Vaccine ID: 1042 YH, ZX A Leishmania infantum vaccine preparation that results in the generation of a L. infantum H1 protein vaccine preparation of L. infantum HASPB1 protein vaccine VIOLIN Vaccine ID: 1043 A Leishmania infantum vaccine preparation that results in the generation of a L. infantum HASPB1 protein vaccine YH, ZX preparation of RTS,S/AS02A YH, ZX VIOLIN Vaccine ID: 200 A Plasmodium spp. vaccine preparation that results in the generation of a RTS,S/AS02A preparation of B. abortus pcDNA-BLS YH, ZX VIOLIN Vaccine ID: 199 A Brucella vaccine preparation that results in the generation of a B. abortus pcDNA-BLS preparation of HIBTITER A Haemophilus influenzae vaccine preparation that results in the generation of a HIBTITER YH, ZX VIOLIN Vaccine ID: 160 preparation of PedvaxHIB VIOLIN Vaccine ID: 161 A Haemophilus influenzae vaccine preparation that results in the generation of a PedvaxHIB YH, ZX preparation of Japanese encephalitis virus DNA vaccine pUJENS5 VIOLIN Vaccine ID: 1036 A Japanese encephalitis virus vaccine preparation that results in the generation of a Japanese encephalitis virus DNA vaccine pUJENS5 YH, ZX preparation of Japanese encephalitis virus DNA vaccine encoding E protein YH, ZX A Japanese encephalitis virus vaccine preparation that results in the generation of a Japanese encephalitis virus DNA vaccine encoding E protein VIOLIN Vaccine ID: 1037 preparation of L. amazonensis DNA vaccine encoding GP46 VIOLIN Vaccine ID: 1038 A Leishmania amazonensis vaccine preparation that results in the generation of a L. amazonensis DNA vaccine encoding GP46 YH, ZX preparation of L. amazonensis M2 protein vaccine YH, ZX A Leishmania amazonensis vaccine preparation that results in the generation of a L. amazonensis M2 protein vaccine VIOLIN Vaccine ID: 1039 preparation of ProHIBiT A Haemophilus influenzae vaccine preparation that results in the generation of a ProHIBiT YH, ZX VIOLIN Vaccine ID: 162 preparation of Killed nontypeable H. influenzae whole-cell vaccine A Haemophilus influenzae vaccine preparation that results in the generation of a Killed nontypeable H. influenzae whole-cell vaccine YH, ZX VIOLIN Vaccine ID: 163 preparation of H. influenzae Type b Capsular Polysaccharide Vaccine VIOLIN Vaccine ID: 165 A Haemophilus influenzae vaccine preparation that results in the generation of a H. influenzae Type b Capsular Polysaccharide Vaccine YH, ZX preparation of DNA vaccine Rv1806-1807 VIOLIN Vaccine ID: 166 YH, ZX A Mycobacterium tuberculosis vaccine preparation that results in the generation of a DNA vaccine Rv1806-1807 preparation of Nontypeable H. influenzae LOS-TT conjugate vaccine YH, ZX VIOLIN Vaccine ID: 164 A Haemophilus influenzae vaccine preparation that results in the generation of a Nontypeable H. influenzae LOS-TT conjugate vaccine preparation of Non-typeable H. influenzae rLP4/rLP6 and Moraxella catarrhalis UspA2 protein vaccine VIOLIN Vaccine ID: 169 A Haemophilus influenzae vaccine preparation that results in the generation of a Non-typeable H. influenzae rLP4/rLP6 and Moraxella catarrhalis UspA2 protein vaccine YH, ZX preparation of Shigella ribosome-based Vaccine (SRB) A Shigella vaccine preparation that results in the generation of a Shigella ribosome-based Vaccine (SRB) VIOLIN Vaccine ID: 273 YH, ZX preparation of E. coli O157:H7 subunit vaccine expressing Esps and Tir YH, ZX A Escherichia coli vaccine preparation that results in the generation of a E. coli O157:H7 subunit vaccine expressing Esps and Tir VIOLIN Vaccine ID: 274 preparation of NPAP Brucella vaccine YH, ZX A Brucella vaccine preparation that results in the generation of a NPAP Brucella vaccine VIOLIN Vaccine ID: 275 preparation of A. pleuropneumoniae ApxIA protein vaccine VIOLIN Vaccine ID: 782 A Actinobacillus pleuropneumoniae vaccine preparation that results in the generation of a A. pleuropneumoniae ApxIA protein vaccine YH, ZX preparation of B. pertussis Cpn60 protein vaccine VIOLIN Vaccine ID: 797 YH, ZX A Bordetella pertussis vaccine preparation that results in the generation of a B. pertussis Cpn60 protein vaccine preparation of B. pertussis CyaA protein vaccine VIOLIN Vaccine ID: 799 A Bordetella pertussis vaccine preparation that results in the generation of a B. pertussis CyaA protein vaccine YH, ZX preparation of V. cholerae CTB DNA Vaccine VIOLIN Vaccine ID: 800 YH, ZX A Vibrio cholerae vaccine preparation that results in the generation of a V. cholerae CTB DNA Vaccine preparation of B. pertussis PTx protein vaccine YH, ZX A Bordetella pertussis vaccine preparation that results in the generation of a B. pertussis PTx protein vaccine VIOLIN Vaccine ID: 801 preparation of Nontypeable H. influenzae Hap Protein Vaccine VIOLIN Vaccine ID: 170 A Haemophilus influenzae vaccine preparation that results in the generation of a Nontypeable H. influenzae Hap Protein Vaccine YH, ZX preparation of Ag85B and ESAT-6 fusion protein VIOLIN Vaccine ID: 171 A Mycobacterium tuberculosis vaccine preparation that results in the generation of a Ag85B and ESAT-6 fusion protein YH, ZX preparation of BCG mutant secreting listeriolysin YH, ZX A Mycobacterium tuberculosis vaccine preparation that results in the generation of a BCG mutant secreting listeriolysin VIOLIN Vaccine ID: 173 preparation of C. parvum DNA vaccine encoding CP23 VIOLIN Vaccine ID: 1050 YH, ZX A Cryptosporidium parvum vaccine preparation that results in the generation of a C. parvum DNA vaccine encoding CP23 preparation of Cancer Her-2/neu Protein Subunit Vaccine YH, ZX A Cancer vaccine preparation that results in the generation of a Cancer Her-2/neu Protein Subunit Vaccine VIOLIN Vaccine ID: 1051 preparation of Cancer DNA Vaccine encoding hNIS protein VIOLIN Vaccine ID: 1052 A Cancer vaccine preparation that results in the generation of a Cancer DNA Vaccine encoding hNIS protein YH, ZX preparation of Cancer DNA Vaccine encoding Survivin YH, ZX VIOLIN Vaccine ID: 1053 A Cancer vaccine preparation that results in the generation of a Cancer DNA Vaccine encoding Survivin preparation of Cancer Subunit NY-ESO-1 Protein Vaccine YH, ZX VIOLIN Vaccine ID: 1047 A Cancer vaccine preparation that results in the generation of a Cancer Subunit NY-ESO-1 Protein Vaccine preparation of Cancer DNA Vaccine encoding Endoglin Boosted with Recombinant Endoglin Protein YH, ZX VIOLIN Vaccine ID: 1048 A Cancer vaccine preparation that results in the generation of a Cancer DNA Vaccine encoding Endoglin Boosted with Recombinant Endoglin Protein preparation of Cancer DNA Vaccine encoding H-2Kb YH, ZX VIOLIN Vaccine ID: 1049 A Cancer vaccine preparation that results in the generation of a Cancer DNA Vaccine encoding H-2Kb preparation of recombinant S. typhimurium secreting M. tuberculosis ESAT-6 A Mycobacterium tuberculosis vaccine preparation that results in the generation of a recombinant S. typhimurium secreting M. tuberculosis ESAT-6 VIOLIN Vaccine ID: 176 YH, ZX preparation of attenuated M. bovis strain WAg539 VIOLIN Vaccine ID: 177 YH, ZX A Mycobacterium tuberculosis vaccine preparation that results in the generation of a attenuated M. bovis strain WAg539 preparation of M. tuberculosis phoP mutant SO2 A Mycobacterium tuberculosis vaccine preparation that results in the generation of a M. tuberculosis phoP mutant SO2 VIOLIN Vaccine ID: 178 YH, ZX preparation of M. bovis WAg520 strain VIOLIN Vaccine ID: 179 A Mycobacterium tuberculosis vaccine preparation that results in the generation of a M. bovis WAg520 strain YH, ZX preparation of M. bovis WAg522 strain A Mycobacterium tuberculosis vaccine preparation that results in the generation of a M. bovis WAg522 strain VIOLIN Vaccine ID: 180 YH, ZX preparation of EcSf2a-2 A Shigella vaccine preparation that results in the generation of a EcSf2a-2 YH, ZX VIOLIN Vaccine ID: 267 preparation of FMP1/AS02A YH, ZX A Plasmodium spp. vaccine preparation that results in the generation of a FMP1/AS02A VIOLIN Vaccine ID: 232 preparation of Nontypeable H. influenzae protein P6 with cholera toxin A Haemophilus influenzae vaccine preparation that results in the generation of a Nontypeable H. influenzae protein P6 with cholera toxin YH, ZX VIOLIN Vaccine ID: 188 preparation of Heat-killed Virulent Shigella flexneri 2a VIOLIN Vaccine ID: 268 YH, ZX A Shigella vaccine preparation that results in the generation of a Heat-killed Virulent Shigella flexneri 2a preparation of S. flexneri strain Sfl 124 VIOLIN Vaccine ID: 269 A Shigella vaccine preparation that results in the generation of a S. flexneri strain Sfl 124 YH, ZX preparation of S. flexneri 2a LPS vaccine complexed with N. meningitidis proteosomes A Shigella vaccine preparation that results in the generation of a S. flexneri 2a LPS vaccine complexed with N. meningitidis proteosomes YH, ZX VIOLIN Vaccine ID: 270 preparation of CVD 1208S A Shigella vaccine preparation that results in the generation of a CVD 1208S VIOLIN Vaccine ID: 272 YH, ZX preparation of CVD 1204(pGA1-CS2) VIOLIN Vaccine ID: 265 A Shigella vaccine preparation that results in the generation of a CVD 1204(pGA1-CS2) YH, ZX preparation of CVD 1204(pGA1-CS3) A Shigella vaccine preparation that results in the generation of a CVD 1204(pGA1-CS3) VIOLIN Vaccine ID: 442 YH, ZX preparation of S. sonnei strain WRSS1 YH, ZX A Shigella vaccine preparation that results in the generation of a S. sonnei strain WRSS1 VIOLIN Vaccine ID: 264 preparation of Cancer DNA Vaccine encoding TEM8 YH, ZX VIOLIN Vaccine ID: 1046 A Cancer vaccine preparation that results in the generation of a Cancer DNA Vaccine encoding TEM8 preparation of recombinant nontypeable H. influenzae protein P6 with AdDP YH, ZX VIOLIN Vaccine ID: 189 A Haemophilus influenzae vaccine preparation that results in the generation of a recombinant nontypeable H. influenzae protein P6 with AdDP preparation of nontypeable H. influenzae P5 peptide MVF/H3 vaccine VIOLIN Vaccine ID: 193 A Haemophilus influenzae vaccine preparation that results in the generation of a nontypeable H. influenzae P5 peptide MVF/H3 vaccine YH, ZX preparation of Nontypeable H. influenzae cell membrane (CM-Hi) vaccine VIOLIN Vaccine ID: 194 A Haemophilus influenzae vaccine preparation that results in the generation of a Nontypeable H. influenzae cell membrane (CM-Hi) vaccine YH, ZX preparation of Nontypeable H. influenzae rTbpB vaccine VIOLIN Vaccine ID: 195 A Haemophilus influenzae vaccine preparation that results in the generation of a Nontypeable H. influenzae rTbpB vaccine YH, ZX preparation of rBCG-Ag85A[Tokyo] A Mycobacterium tuberculosis vaccine preparation that results in the generation of a rBCG-Ag85A[Tokyo] VIOLIN Vaccine ID: 236 YH, ZX preparation of B. melitensis P39 protein vaccine VIOLIN Vaccine ID: 198 A Brucella vaccine preparation that results in the generation of a B. melitensis P39 protein vaccine YH, ZX preparation of Cancer EPCAM protein vaccine VIOLIN Vaccine ID: 1064 A Cancer vaccine preparation that results in the generation of a Cancer EPCAM protein vaccine YH, ZX preparation of Cancer VEGFA protein vaccine VIOLIN Vaccine ID: 1066 YH, ZX A Cancer vaccine preparation that results in the generation of a Cancer VEGFA protein vaccine preparation of B. abortus DNA vaccine expressiong BCSP31, SOD and L7/L12 A Brucella vaccine preparation that results in the generation of a B. abortus DNA vaccine expressiong BCSP31, SOD and L7/L12 VIOLIN Vaccine ID: 211 YH, ZX preparation of Cancer Retroviral Vector Vaccine encoding Cd40lg YH, ZX VIOLIN Vaccine ID: 1058 A Cancer vaccine preparation that results in the generation of a Cancer Retroviral Vector Vaccine encoding Cd40lg preparation of Cancer DNA Vaccine encoding Cd86 VIOLIN Vaccine ID: 1059 YH, ZX A Cancer vaccine preparation that results in the generation of a Cancer DNA Vaccine encoding Cd86 preparation of S. dysenteriae 1 strain WRSd1 YH, ZX VIOLIN Vaccine ID: 263 A Shigella vaccine preparation that results in the generation of a S. dysenteriae 1 strain WRSd1 preparation of Adenoviral vector Ad5 expressing SIV gag protein YH, ZX A Human Immunodeficiency Virus vaccine preparation that results in the generation of a Adenoviral vector Ad5 expressing SIV gag protein VIOLIN Vaccine ID: 444 preparation of Recombinant ABRA protein vaccine VIOLIN Vaccine ID: 204 YH, ZX A Plasmodium spp. vaccine preparation that results in the generation of a Recombinant ABRA protein vaccine preparation of P. falciparum vaccine Combination B A Plasmodium spp. vaccine preparation that results in the generation of a P. falciparum vaccine Combination B YH, ZX VIOLIN Vaccine ID: 206 preparation of MSP3-LSP with aluminium hydroxide VIOLIN Vaccine ID: 207 YH, ZX A Plasmodium spp. vaccine preparation that results in the generation of a MSP3-LSP with aluminium hydroxide preparation of P. vivax PVS25 with Montanide ISA-720 YH, ZX VIOLIN Vaccine ID: 208 A Plasmodium spp. vaccine preparation that results in the generation of a P. vivax PVS25 with Montanide ISA-720 preparation of DNA and MVA encoding ME-TRAP VIOLIN Vaccine ID: 210 A Plasmodium spp. vaccine preparation that results in the generation of a DNA and MVA encoding ME-TRAP YH, ZX preparation of S. flexneri 2a strain CVD 1207 A Shigella vaccine preparation that results in the generation of a S. flexneri 2a strain CVD 1207 VIOLIN Vaccine ID: 260 YH, ZX preparation of Recombinant chimera vaccine BLSOmp31 VIOLIN Vaccine ID: 212 A Brucella vaccine preparation that results in the generation of a Recombinant chimera vaccine BLSOmp31 YH, ZX preparation of Phleum pratense Allergy Phl p 12 Subunit Vaccine A Allergy vaccine preparation that results in the generation of a Phleum pratense Allergy Phl p 12 Subunit Vaccine VIOLIN Vaccine ID: 1054 YH, ZX preparation of DNA vaccine encoding L7/L12-P39 YH, ZX A Brucella vaccine preparation that results in the generation of a DNA vaccine encoding L7/L12-P39 VIOLIN Vaccine ID: 214 preparation of B. bovis GST-12D3 YH, ZX VIOLIN Vaccine ID: 791 A Babesia bovis vaccine preparation that results in the generation of a B. bovis GST-12D3 preparation of B. pertussis BrkA protein vaccine YH, ZX VIOLIN Vaccine ID: 796 A Bordetella pertussis vaccine preparation that results in the generation of a B. pertussis BrkA protein vaccine preparation of Vivotif YH, ZX A Salmonella spp. vaccine preparation that results in the generation of a Vivotif VIOLIN Vaccine ID: 248 preparation of Bovine leukemia virus DNA vaccine encoding Env VIOLIN Vaccine ID: 825 A Bovine Leukemia virus vaccine preparation that results in the generation of a Bovine leukemia virus DNA vaccine encoding Env YH, ZX preparation of Bovine leukemia virus DNA vaccine encoding Tax YH, ZX VIOLIN Vaccine ID: 828 A Bovine Leukemia virus vaccine preparation that results in the generation of a Bovine leukemia virus DNA vaccine encoding Tax preparation of B. abortus DNA vaccine encoding RplL and Omp16 A Brucella vaccine preparation that results in the generation of a B. abortus DNA vaccine encoding RplL and Omp16 YH, ZX VIOLIN Vaccine ID: 831 preparation of SC602 A Shigella vaccine preparation that results in the generation of a SC602 YH, ZX VIOLIN Vaccine ID: 259 preparation of CVD 1208 VIOLIN Vaccine ID: 441 YH, ZX A Shigella vaccine preparation that results in the generation of a CVD 1208 preparation of P. falciparum MSP1 from transgenic mice with Freund's adjuvant YH, ZX A Plasmodium spp. vaccine preparation that results in the generation of a P. falciparum MSP1 from transgenic mice with Freund's adjuvant VIOLIN Vaccine ID: 234 preparation of M. tuberculosis secA2 mutant YH, ZX A Mycobacterium tuberculosis vaccine preparation that results in the generation of a M. tuberculosis secA2 mutant VIOLIN Vaccine ID: 222 preparation of Arabinomannan-tetanus toxoid conjugate A Mycobacterium tuberculosis vaccine preparation that results in the generation of a Arabinomannan-tetanus toxoid conjugate YH, ZX VIOLIN Vaccine ID: 223 preparation of Typhim Vi A Salmonella spp. vaccine preparation that results in the generation of a Typhim Vi YH, ZX VIOLIN Vaccine ID: 352 preparation of Bovine herpesvirus 1 DNA vaccine AdCMVgD VIOLIN Vaccine ID: 821 A Bovine herpesvirus 1 vaccine preparation that results in the generation of a Bovine herpesvirus 1 DNA vaccine AdCMVgD YH, ZX preparation of Bovine herpesvirus 1 DNA vaccine AdCMVgC A Bovine herpesvirus 1 vaccine preparation that results in the generation of a Bovine herpesvirus 1 DNA vaccine AdCMVgC YH, ZX VIOLIN Vaccine ID: 823 preparation of Bovine herpesvirus 1 GPI protein vaccine VIOLIN Vaccine ID: 824 YH, ZX A Bovine herpesvirus 1 vaccine preparation that results in the generation of a Bovine herpesvirus 1 GPI protein vaccine preparation of Recombinant SFL124-27 expressing S. dysenteriae type 1 O antigen VIOLIN Vaccine ID: 258 YH, ZX A Shigella vaccine preparation that results in the generation of a Recombinant SFL124-27 expressing S. dysenteriae type 1 O antigen preparation of A. pleuropneumoniae ApxIa and ApxIIa protein vaccine VIOLIN Vaccine ID: 784 YH, ZX A Actinobacillus pleuropneumoniae vaccine preparation that results in the generation of a A. pleuropneumoniae ApxIa and ApxIIa protein vaccine preparation of A. pleuropneumoniae HS93C-Ampr VIOLIN Vaccine ID: 786 YH, ZX A Actinobacillus pleuropneumoniae vaccine preparation that results in the generation of a A. pleuropneumoniae HS93C-Ampr preparation of A. salmonicida live-attenuated vaccine encoding AroA A Aeromonas salmonicida vaccine preparation that results in the generation of a A. salmonicida live-attenuated vaccine encoding AroA YH, ZX VIOLIN Vaccine ID: 788 preparation of NP-VRP A Ebola virus vaccine preparation that results in the generation of a NP-VRP VIOLIN Vaccine ID: 443 YH, ZX preparation of E. coli O157:H7 intimin vaccine VIOLIN Vaccine ID: 277 A Escherichia coli vaccine preparation that results in the generation of a E. coli O157:H7 intimin vaccine YH, ZX preparation of inactivated ETEC expressing expressing CFA/I and CFA/II A Escherichia coli vaccine preparation that results in the generation of a inactivated ETEC expressing expressing CFA/I and CFA/II VIOLIN Vaccine ID: 286 YH, ZX preparation of Live attenuated B. abortus with deletion of znuA VIOLIN Vaccine ID: 288 YH, ZX A Brucella vaccine preparation that results in the generation of a Live attenuated B. abortus with deletion of znuA preparation of Porin and S-LPS Extracted from Virulent Brucella abortus 2308 A Brucella vaccine preparation that results in the generation of a Porin and S-LPS Extracted from Virulent Brucella abortus 2308 YH, ZX VIOLIN Vaccine ID: 291 preparation of Recombinant Brucella DnaK protein vaccine YH, ZX A Brucella vaccine preparation that results in the generation of a Recombinant Brucella DnaK protein vaccine VIOLIN Vaccine ID: 292 preparation of B. melitensis 16M DNA vaccine expressing Omp31 VIOLIN Vaccine ID: 293 YH, ZX A Brucella vaccine preparation that results in the generation of a B. melitensis 16M DNA vaccine expressing Omp31 preparation of B. melitensis with deleted bp26 (CGV26) VIOLIN Vaccine ID: 295 A Brucella vaccine preparation that results in the generation of a B. melitensis with deleted bp26 (CGV26) YH, ZX preparation of Dukoral YH, ZX VIOLIN Vaccine ID: 759 A Vibrio cholerae vaccine preparation that results in the generation of a Dukoral preparation of Pediarix VIOLIN Vaccine ID: 760 YH, ZX A Bordetella pertussis vaccine preparation that results in the generation of a Pediarix preparation of Actacel A Bordetella pertussis vaccine preparation that results in the generation of a Actacel YH, ZX VIOLIN Vaccine ID: 761 preparation of Infantrix/Hib A Bordetella pertussis vaccine preparation that results in the generation of a Infantrix/Hib YH, ZX VIOLIN Vaccine ID: 762 preparation of Infanrix-hexa A Bordetella pertussis vaccine preparation that results in the generation of a Infanrix-hexa VIOLIN Vaccine ID: 763 YH, ZX preparation of Infanrix -IPV/Hib A Bordetella pertussis vaccine preparation that results in the generation of a Infanrix -IPV/Hib YH, ZX VIOLIN Vaccine ID: 764 preparation of Pentacel VIOLIN Vaccine ID: 765 A Bordetella pertussis vaccine preparation that results in the generation of a Pentacel YH, ZX preparation of Pediacel A Bordetella pertussis vaccine preparation that results in the generation of a Pediacel VIOLIN Vaccine ID: 766 YH, ZX preparation of Infanrix-IPV YH, ZX VIOLIN Vaccine ID: 767 A Bordetella pertussis vaccine preparation that results in the generation of a Infanrix-IPV preparation of E. Coli Escheriosome-mediated Cytosolic Delivery of recombinant Brucella rL7/L12 Protein VIOLIN Vaccine ID: 298 YH, ZX A Brucella vaccine preparation that results in the generation of a E. Coli Escheriosome-mediated Cytosolic Delivery of recombinant Brucella rL7/L12 Protein preparation of Recombinant Brucella melitensis bp26 and trigger factor Nasal Vaccine A Brucella vaccine preparation that results in the generation of a Recombinant Brucella melitensis bp26 and trigger factor Nasal Vaccine VIOLIN Vaccine ID: 300 YH, ZX preparation of Brucella abortus bacA mutant A Brucella vaccine preparation that results in the generation of a Brucella abortus bacA mutant YH, ZX VIOLIN Vaccine ID: 301 preparation of Divalent DNA B. abortus Vaccine A Brucella vaccine preparation that results in the generation of a Divalent DNA B. abortus Vaccine VIOLIN Vaccine ID: 302 YH, ZX preparation of Microencapsulated B. meletensis Mutant Vaccine YH, ZX VIOLIN Vaccine ID: 304 A Brucella vaccine preparation that results in the generation of a Microencapsulated B. meletensis Mutant Vaccine preparation of Rickettsia rickettsii vaccine using M. vaccae expressing R. rickettsii OmpA Protein VIOLIN Vaccine ID: 1044 YH, ZX A Rickettsia spp vaccine preparation that results in the generation of a Rickettsia rickettsii vaccine using M. vaccae expressing R. rickettsii OmpA Protein preparation of Rickettsia DNA Vaccine encoding OmpB Protein boosted with Recombinant OmpB YH, ZX A Rickettsia spp vaccine preparation that results in the generation of a Rickettsia DNA Vaccine encoding OmpB Protein boosted with Recombinant OmpB VIOLIN Vaccine ID: 1045 preparation of B. melitensis LPS-GBOMP Subunit Vaccine YH, ZX A Brucella vaccine preparation that results in the generation of a B. melitensis LPS-GBOMP Subunit Vaccine VIOLIN Vaccine ID: 307 preparation of B. melitensis WR201 (16MpurEK) YH, ZX A Brucella vaccine preparation that results in the generation of a B. melitensis WR201 (16MpurEK) VIOLIN Vaccine ID: 308 preparation of Recombinant HIV gp120 with NE Adjuvant A Human Immunodeficiency Virus vaccine preparation that results in the generation of a Recombinant HIV gp120 with NE Adjuvant VIOLIN Vaccine ID: 310 YH, ZX preparation of Tetanus Toxoid Adsorbed by Sanofi Pasteur Inc VIOLIN Vaccine ID: 313 YH, ZX A Clostridium tetani vaccine preparation that results in the generation of a Tetanus Toxoid Adsorbed by Sanofi Pasteur Inc preparation of Mycobax A Mycobacterium tuberculosis vaccine preparation that results in the generation of a Mycobax VIOLIN Vaccine ID: 315 YH, ZX preparation of Menomune-A/C/Y/W-135 A Neisseria meningitidis vaccine preparation that results in the generation of a Menomune-A/C/Y/W-135 YH, ZX VIOLIN Vaccine ID: 316 preparation of Pneumovax 23 A Streptococcus pneumoniae vaccine preparation that results in the generation of a Pneumovax 23 YH, ZX VIOLIN Vaccine ID: 317 preparation of Prevnar VIOLIN Vaccine ID: 318 A Streptococcus pneumoniae vaccine preparation that results in the generation of a Prevnar YH, ZX preparation of B. pertussis DNA vaccine encoding Prn YH, ZX VIOLIN Vaccine ID: 808 A Bordetella pertussis vaccine preparation that results in the generation of a B. pertussis DNA vaccine encoding Prn preparation of Plague Vaccine (by Greer Laboratories Inc.) A Yersinia pestis vaccine preparation that results in the generation of a Plague Vaccine (by Greer Laboratories Inc.) YH, ZX VIOLIN Vaccine ID: 319 preparation of Havrix VIOLIN Vaccine ID: 320 YH, ZX A Hepatitis A virus vaccine preparation that results in the generation of a Havrix preparation of VAQTA YH, ZX A Hepatitis A virus vaccine preparation that results in the generation of a VAQTA VIOLIN Vaccine ID: 321 preparation of Recombivax HB VIOLIN Vaccine ID: 322 A Hepatitis B virus vaccine preparation that results in the generation of a Recombivax HB YH, ZX preparation of Marek's Disease Virus Vaccine rFPV/gI A Marek's; disease virus vaccine preparation that results in the generation of a Marek's Disease Virus Vaccine rFPV/gI YH, ZX VIOLIN Vaccine ID: 993 preparation of Marek's Disease Virus Vaccine rFPV/gB1 YH, ZX VIOLIN Vaccine ID: 994 A Marek's; disease virus vaccine preparation that results in the generation of a Marek's Disease Virus Vaccine rFPV/gB1 preparation of Marburg Virus Nucleoprotein Vaccine A Marburg Virus vaccine preparation that results in the generation of a Marburg Virus Nucleoprotein Vaccine VIOLIN Vaccine ID: 997 YH, ZX preparation of Engerix-B A Hepatitis B virus vaccine preparation that results in the generation of a Engerix-B YH, ZX VIOLIN Vaccine ID: 323 preparation of Human papillomavirus E7 protein vaccine VIOLIN Vaccine ID: 986 A Human papillomavirus vaccine preparation that results in the generation of a Human papillomavirus E7 protein vaccine YH, ZX preparation of P. falciparum Hsp90 Protein Subunit Vaccine A Plasmodium spp. vaccine preparation that results in the generation of a P. falciparum Hsp90 Protein Subunit Vaccine YH, ZX VIOLIN Vaccine ID: 987 preparation of Human papillomavirus L2 protein vaccine VIOLIN Vaccine ID: 988 YH, ZX A Human papillomavirus vaccine preparation that results in the generation of a Human papillomavirus L2 protein vaccine preparation of IHNV DNA vaccine pIHNw-G A Infectious Hematopoietic Necrosis Virus vaccine preparation that results in the generation of a IHNV DNA vaccine pIHNw-G VIOLIN Vaccine ID: 989 YH, ZX preparation of Rift Valley Fever Virus DNA Vaccine encoding N Protein A Rift Valley Fever virus vaccine preparation that results in the generation of a Rift Valley Fever Virus DNA Vaccine encoding N Protein YH, ZX VIOLIN Vaccine ID: 990 preparation of Influenza Virus Vaccine H5N1 by Sanofi Pasteur Inc YH, ZX VIOLIN Vaccine ID: 324 A Influenza virus vaccine preparation that results in the generation of a Influenza Virus Vaccine H5N1 by Sanofi Pasteur Inc preparation of Puumala virus PUUVsSgp1 (NP) protein vaccine YH, ZX VIOLIN Vaccine ID: 949 A Hantavirus vaccine preparation that results in the generation of a Puumala virus PUUVsSgp1 (NP) protein vaccine preparation of Sin Nombre virus DNA vaccine encoding G1 VIOLIN Vaccine ID: 950 YH, ZX A Hantavirus vaccine preparation that results in the generation of a Sin Nombre virus DNA vaccine encoding G1 preparation of Seoul virus vaccine rCAV-2-Gc VIOLIN Vaccine ID: 951 YH, ZX A Hantavirus vaccine preparation that results in the generation of a Seoul virus vaccine rCAV-2-Gc preparation of Topografov virus N protein vaccine VIOLIN Vaccine ID: 952 A Hantavirus vaccine preparation that results in the generation of a Topografov virus N protein vaccine YH, ZX preparation of Afluria YH, ZX VIOLIN Vaccine ID: 325 A Influenza virus vaccine preparation that results in the generation of a Afluria preparation of Fluarix VIOLIN Vaccine ID: 326 A Influenza virus vaccine preparation that results in the generation of a Fluarix YH, ZX preparation of Hepatitis B virus DNA vaccine pVAX-PS VIOLIN Vaccine ID: 968 A Hepatitis B virus vaccine preparation that results in the generation of a Hepatitis B virus DNA vaccine pVAX-PS YH, ZX preparation of Herpes simplex virus type 2 DNA vaccine encoding ICP27 YH, ZX VIOLIN Vaccine ID: 969 A Herpes simplex virus type 1 and 2 vaccine preparation that results in the generation of a Herpes simplex virus type 2 DNA vaccine encoding ICP27 preparation of Herpes simplex virus type 2 DNA vaccine encoding GB YH, ZX VIOLIN Vaccine ID: 970 A Herpes simplex virus type 1 and 2 vaccine preparation that results in the generation of a Herpes simplex virus type 2 DNA vaccine encoding GB preparation of NIpah Virus G and F Proteins Subunit Vaccine YH, ZX VIOLIN Vaccine ID: 971 A Nipah virus vaccine preparation that results in the generation of a NIpah Virus G and F Proteins Subunit Vaccine preparation of Herpes simplex virus type 1 DNA vaccine encoding GC VIOLIN Vaccine ID: 972 YH, ZX A Herpes simplex virus type 1 and 2 vaccine preparation that results in the generation of a Herpes simplex virus type 1 DNA vaccine encoding GC preparation of FluLaval A Influenza virus vaccine preparation that results in the generation of a FluLaval YH, ZX VIOLIN Vaccine ID: 327 preparation of Hendra virus G protein vaccine VIOLIN Vaccine ID: 963 YH, ZX A Hendra virus vaccine preparation that results in the generation of a Hendra virus G protein vaccine preparation of M. tuberculosis DNA Vaccine encoding Ag85B Protein A Mycobacterium tuberculosis vaccine preparation that results in the generation of a M. tuberculosis DNA Vaccine encoding Ag85B Protein YH, ZX VIOLIN Vaccine ID: 964 preparation of Hepatitis B virus DNA vaccine encoding HBVgp2 pre-S1/pre-S2/S YH, ZX A Hepatitis B virus vaccine preparation that results in the generation of a Hepatitis B virus DNA vaccine encoding HBVgp2 pre-S1/pre-S2/S VIOLIN Vaccine ID: 965 preparation of M. tuberculosis Mtb72F Protein Subunit Vaccine VIOLIN Vaccine ID: 967 A Mycobacterium tuberculosis vaccine preparation that results in the generation of a M. tuberculosis Mtb72F Protein Subunit Vaccine YH, ZX preparation of FluMist A Influenza virus vaccine preparation that results in the generation of a FluMist YH, ZX VIOLIN Vaccine ID: 328 preparation of B. pertussis DNA vaccine encoding TcfA VIOLIN Vaccine ID: 813 A Bordetella pertussis vaccine preparation that results in the generation of a B. pertussis DNA vaccine encoding TcfA YH, ZX preparation of Fluvirin YH, ZX VIOLIN Vaccine ID: 329 A Influenza virus vaccine preparation that results in the generation of a Fluvirin preparation of Fluzone YH, ZX A Influenza virus vaccine preparation that results in the generation of a Fluzone VIOLIN Vaccine ID: 330 preparation of JE-Vax A Japanese encephalitis virus vaccine preparation that results in the generation of a JE-Vax VIOLIN Vaccine ID: 331 YH, ZX preparation of Attenuvax VIOLIN Vaccine ID: 335 YH, ZX A Measles virus vaccine preparation that results in the generation of a Attenuvax preparation of Mumpsvax VIOLIN Vaccine ID: 336 A Mumps virus vaccine preparation that results in the generation of a Mumpsvax YH, ZX preparation of E. histolytica CEL-170/4 protein vaccine VIOLIN Vaccine ID: 918 YH, ZX A Entamoeba histolytica vaccine preparation that results in the generation of a E. histolytica CEL-170/4 protein vaccine preparation of P. falciparum Subunit SE36 Protein Vaccine VIOLIN Vaccine ID: 919 A Plasmodium spp. vaccine preparation that results in the generation of a P. falciparum Subunit SE36 Protein Vaccine YH, ZX preparation of E. histolytica SREHP protein vaccine VIOLIN Vaccine ID: 920 YH, ZX A Entamoeba histolytica vaccine preparation that results in the generation of a E. histolytica SREHP protein vaccine preparation of E. coli C3389 protein vaccine A Escherichia coli vaccine preparation that results in the generation of a E. coli C3389 protein vaccine YH, ZX VIOLIN Vaccine ID: 921 preparation of P. falciparum Pfen Protein Subunit Vaccine A Plasmodium spp. vaccine preparation that results in the generation of a P. falciparum Pfen Protein Subunit Vaccine VIOLIN Vaccine ID: 922 YH, ZX preparation of Gardasil A Human papillomavirus vaccine preparation that results in the generation of a Gardasil YH, ZX VIOLIN Vaccine ID: 337 preparation of Mumps HN Protein Subunit Vaccine A Mumps virus vaccine preparation that results in the generation of a Mumps HN Protein Subunit Vaccine VIOLIN Vaccine ID: 973 YH, ZX preparation of Herpes simplex virus type 2 vaccine using phage displaying GG protein VIOLIN Vaccine ID: 974 A Herpes simplex virus type 1 and 2 vaccine preparation that results in the generation of a Herpes simplex virus type 2 vaccine using phage displaying GG protein YH, ZX preparation of Herpes simplex virus type 1 DNA vaccine encoding GD VIOLIN Vaccine ID: 975 A Herpes simplex virus type 1 and 2 vaccine preparation that results in the generation of a Herpes simplex virus type 1 DNA vaccine encoding GD YH, ZX preparation of Measles Virus vaccine VEE/SIN-H+F VIOLIN Vaccine ID: 976 YH, ZX A Measles virus vaccine preparation that results in the generation of a Measles Virus vaccine VEE/SIN-H+F preparation of Herpes simplex virus type 1 DNA vaccine encoding GE YH, ZX A Herpes simplex virus type 1 and 2 vaccine preparation that results in the generation of a Herpes simplex virus type 1 DNA vaccine encoding GE VIOLIN Vaccine ID: 977 preparation of IPOL YH, ZX A Poliovirus vaccine preparation that results in the generation of a IPOL VIOLIN Vaccine ID: 338 preparation of C. pneumoniae DNA vaccine encoding PknD YH, ZX VIOLIN Vaccine ID: 887 A Chlamydophila pneumoniae vaccine preparation that results in the generation of a C. pneumoniae DNA vaccine encoding PknD preparation of C. pneumoniae DNA vaccine encoding Ssb YH, ZX A Chlamydophila pneumoniae vaccine preparation that results in the generation of a C. pneumoniae DNA vaccine encoding Ssb VIOLIN Vaccine ID: 888 preparation of C. psittaci DNA vaccine pcDNA1/MOMP A Chlamydophila psittaci vaccine preparation that results in the generation of a C. psittaci DNA vaccine pcDNA1/MOMP YH, ZX VIOLIN Vaccine ID: 889 preparation of Classical swine fever virus vaccine VAC-E0 A Classical swine fever virus vaccine preparation that results in the generation of a Classical swine fever virus vaccine VAC-E0 YH, ZX VIOLIN Vaccine ID: 890 preparation of Poliovax YH, ZX A Poliovirus vaccine preparation that results in the generation of a Poliovax VIOLIN Vaccine ID: 339 preparation of C. abortus DNA vaccine encoding GatC A Chlamydophila abortus vaccine preparation that results in the generation of a C. abortus DNA vaccine encoding GatC YH, ZX VIOLIN Vaccine ID: 878 preparation of C. abortus DNA vaccine encoding OmlA VIOLIN Vaccine ID: 879 YH, ZX A Chlamydophila abortus vaccine preparation that results in the generation of a C. abortus DNA vaccine encoding OmlA preparation of C. abortus DNA vaccine encoding MOMP A Chlamydophila abortus vaccine preparation that results in the generation of a C. abortus DNA vaccine encoding MOMP YH, ZX VIOLIN Vaccine ID: 880 preparation of C. abortus DNA vaccine Pomp90A YH, ZX A Chlamydophila abortus vaccine preparation that results in the generation of a C. abortus DNA vaccine Pomp90A VIOLIN Vaccine ID: 881 preparation of C. pneumoniae CopN protein vaccine VIOLIN Vaccine ID: 882 YH, ZX A Chlamydophila pneumoniae vaccine preparation that results in the generation of a C. pneumoniae CopN protein vaccine preparation of Prostate Cancer DNA Vaccine Encoding Prostatic Acid Phosphatase (PAP) A Cancer vaccine preparation that results in the generation of a Prostate Cancer DNA Vaccine Encoding Prostatic Acid Phosphatase (PAP) VIOLIN Vaccine ID: 883 YH, ZX preparation of C. pneumoniae DNA vaccine encoding FabD A Chlamydophila pneumoniae vaccine preparation that results in the generation of a C. pneumoniae DNA vaccine encoding FabD YH, ZX VIOLIN Vaccine ID: 884 preparation of C. pneumoniae LcrE protein vaccine VIOLIN Vaccine ID: 885 A Chlamydophila pneumoniae vaccine preparation that results in the generation of a C. pneumoniae LcrE protein vaccine YH, ZX preparation of Rabies Vaccine Adsorbed (RVA) A Rabies virus vaccine preparation that results in the generation of a Rabies Vaccine Adsorbed (RVA) VIOLIN Vaccine ID: 340 YH, ZX preparation of Imovax Rabies A Rabies virus vaccine preparation that results in the generation of a Imovax Rabies VIOLIN Vaccine ID: 341 YH, ZX preparation of RabAvert YH, ZX A Rabies virus vaccine preparation that results in the generation of a RabAvert VIOLIN Vaccine ID: 342 preparation of ROTARIX YH, ZX A Rotavirus vaccine preparation that results in the generation of a ROTARIX VIOLIN Vaccine ID: 343 preparation of RotaTeq A Rotavirus vaccine preparation that results in the generation of a RotaTeq VIOLIN Vaccine ID: 344 YH, ZX preparation of Meruvax II VIOLIN Vaccine ID: 345 YH, ZX A Rubella virus vaccine preparation that results in the generation of a Meruvax II preparation of B. pseudomallei Subunit LolC Protein Vaccine VIOLIN Vaccine ID: 860 A Burkholderia pseudomallei vaccine preparation that results in the generation of a B. pseudomallei Subunit LolC Protein Vaccine YH, ZX preparation of C. muridarum RplF protein vaccine YH, ZX VIOLIN Vaccine ID: 861 A Chlamydia muridarum vaccine preparation that results in the generation of a C. muridarum RplF protein vaccine preparation of B. pseudomallei Subunit PotF Protein Vaccine YH, ZX VIOLIN Vaccine ID: 862 A Burkholderia pseudomallei vaccine preparation that results in the generation of a B. pseudomallei Subunit PotF Protein Vaccine preparation of YF-Vax VIOLIN Vaccine ID: 346 YH, ZX A Yellow fever virus vaccine preparation that results in the generation of a YF-Vax preparation of Varivax VIOLIN Vaccine ID: 347 YH, ZX A Varicella-zoster virus vaccine preparation that results in the generation of a Varivax preparation of Zostavax YH, ZX VIOLIN Vaccine ID: 348 A Varicella-zoster virus vaccine preparation that results in the generation of a Zostavax preparation of Twinrix YH, ZX A Hepatitis A virus vaccine preparation that results in the generation of a Twinrix VIOLIN Vaccine ID: 349 preparation of Twinrix VIOLIN Vaccine ID: 350 YH, ZX A Hepatitis B virus vaccine preparation that results in the generation of a Twinrix preparation of P. yoelii MSP1 and MSP4/5 Proteins Subunit Vaccine A Plasmodium spp. vaccine preparation that results in the generation of a P. yoelii MSP1 and MSP4/5 Proteins Subunit Vaccine VIOLIN Vaccine ID: 984 YH, ZX preparation of P. falciparum MSP3 Protein Subunit Vaccine VIOLIN Vaccine ID: 985 YH, ZX A Plasmodium spp. vaccine preparation that results in the generation of a P. falciparum MSP3 Protein Subunit Vaccine preparation of TICE BCG YH, ZX A Cancer vaccine preparation that results in the generation of a TICE BCG VIOLIN Vaccine ID: 351 preparation of Tripedia YH, ZX A Corynebacterium diphtheriae vaccine preparation that results in the generation of a Tripedia VIOLIN Vaccine ID: 354 preparation of Infanrix YH, ZX A Corynebacterium diphtheriae vaccine preparation that results in the generation of a Infanrix VIOLIN Vaccine ID: 355 preparation of DAPTACEL A Corynebacterium diphtheriae vaccine preparation that results in the generation of a DAPTACEL YH, ZX VIOLIN Vaccine ID: 356 preparation of Pediarix YH, ZX VIOLIN Vaccine ID: 357 A Corynebacterium diphtheriae vaccine preparation that results in the generation of a Pediarix preparation of KINRIX VIOLIN Vaccine ID: 358 YH, ZX A Corynebacterium diphtheriae vaccine preparation that results in the generation of a KINRIX preparation of Pentacel VIOLIN Vaccine ID: 359 YH, ZX A Corynebacterium diphtheriae vaccine preparation that results in the generation of a Pentacel preparation of Infanrix YH, ZX A Clostridium tetani vaccine preparation that results in the generation of a Infanrix VIOLIN Vaccine ID: 361 preparation of Diphtheria & Tetanus Toxoids Adsorbed VIOLIN Vaccine ID: 362 A Clostridium tetani vaccine preparation that results in the generation of a Diphtheria & Tetanus Toxoids Adsorbed YH, ZX preparation of DAPTACEL VIOLIN Vaccine ID: 363 A Clostridium tetani vaccine preparation that results in the generation of a DAPTACEL YH, ZX preparation of Pediarix YH, ZX VIOLIN Vaccine ID: 364 A Clostridium tetani vaccine preparation that results in the generation of a Pediarix preparation of KINRIX A Clostridium tetani vaccine preparation that results in the generation of a KINRIX YH, ZX VIOLIN Vaccine ID: 365 preparation of Tripedia A Clostridium tetani vaccine preparation that results in the generation of a Tripedia VIOLIN Vaccine ID: 366 YH, ZX preparation of Pentacel YH, ZX VIOLIN Vaccine ID: 367 A Clostridium tetani vaccine preparation that results in the generation of a Pentacel preparation of COMVAX VIOLIN Vaccine ID: 368 A Haemophilus influenzae vaccine preparation that results in the generation of a COMVAX YH, ZX preparation of Lassa Virus Nucleoprotein Subunit Vaccine VIOLIN Vaccine ID: 1035 A Lassa Fever Virus vaccine preparation that results in the generation of a Lassa Virus Nucleoprotein Subunit Vaccine YH, ZX preparation of DECAVAC VIOLIN Vaccine ID: 369 YH, ZX A Corynebacterium diphtheriae vaccine preparation that results in the generation of a DECAVAC preparation of TENIVAC VIOLIN Vaccine ID: 370 YH, ZX A Corynebacterium diphtheriae vaccine preparation that results in the generation of a TENIVAC preparation of Adacel A Corynebacterium diphtheriae vaccine preparation that results in the generation of a Adacel VIOLIN Vaccine ID: 371 YH, ZX preparation of Boostrix YH, ZX VIOLIN Vaccine ID: 372 A Corynebacterium diphtheriae vaccine preparation that results in the generation of a Boostrix preparation of E. coli C4424 protein vaccine VIOLIN Vaccine ID: 923 A Escherichia coli vaccine preparation that results in the generation of a E. coli C4424 protein vaccine YH, ZX preparation of E. coli Hma protein vaccine A Escherichia coli vaccine preparation that results in the generation of a E. coli Hma protein vaccine VIOLIN Vaccine ID: 924 YH, ZX preparation of E. coli IreA protein vaccine VIOLIN Vaccine ID: 925 YH, ZX A Escherichia coli vaccine preparation that results in the generation of a E. coli IreA protein vaccine preparation of E. coli IutA protein vaccine A Escherichia coli vaccine preparation that results in the generation of a E. coli IutA protein vaccine VIOLIN Vaccine ID: 926 YH, ZX preparation of F. tularensis GroEL protein vaccine YH, ZX VIOLIN Vaccine ID: 928 A Francisella tularensis vaccine preparation that results in the generation of a F. tularensis GroEL protein vaccine preparation of F. tularensis DNA vaccine rLm/iglC VIOLIN Vaccine ID: 929 YH, ZX A Francisella tularensis vaccine preparation that results in the generation of a F. tularensis DNA vaccine rLm/iglC preparation of M-M-R II VIOLIN Vaccine ID: 374 A Mumps virus vaccine preparation that results in the generation of a M-M-R II YH, ZX preparation of E. tenella vaccine rBCG pMV361-Rho YH, ZX A Eimeria tenella vaccine preparation that results in the generation of a E. tenella vaccine rBCG pMV361-Rho VIOLIN Vaccine ID: 912 preparation of E. tenella DNA vaccine pcDNA-TA4-IL-2 YH, ZX A Eimeria tenella vaccine preparation that results in the generation of a E. tenella DNA vaccine pcDNA-TA4-IL-2 VIOLIN Vaccine ID: 913 preparation of E. histolytica Eh29 protein vaccine A Entamoeba histolytica vaccine preparation that results in the generation of a E. histolytica Eh29 protein vaccine YH, ZX VIOLIN Vaccine ID: 915 preparation of E. histolytica Gal/GalNAc lectin protein vaccine A Entamoeba histolytica vaccine preparation that results in the generation of a E. histolytica Gal/GalNAc lectin protein vaccine YH, ZX VIOLIN Vaccine ID: 916 preparation of M-M-R II YH, ZX A Rubella virus vaccine preparation that results in the generation of a M-M-R II VIOLIN Vaccine ID: 375 preparation of Dengue Vaccine using Vaccinia Virus expressing prM Protein VIOLIN Vaccine ID: 853 YH, ZX A Dengue Virus vaccine preparation that results in the generation of a Dengue Vaccine using Vaccinia Virus expressing prM Protein preparation of C. muridarum MOMP protein vaccine YH, ZX A Chlamydia muridarum vaccine preparation that results in the generation of a C. muridarum MOMP protein vaccine VIOLIN Vaccine ID: 854 preparation of Dengue DNA Vaccine encoding NS1 Protein VIOLIN Vaccine ID: 855 A Dengue Virus vaccine preparation that results in the generation of a Dengue DNA Vaccine encoding NS1 Protein YH, ZX preparation of Dengue Vaccine using Vaccinia Virus expressing M Protein YH, ZX VIOLIN Vaccine ID: 856 A Dengue Virus vaccine preparation that results in the generation of a Dengue Vaccine using Vaccinia Virus expressing M Protein preparation of C. muridarum PmpE/F-2 protein vaccine A Chlamydia muridarum vaccine preparation that results in the generation of a C. muridarum PmpE/F-2 protein vaccine VIOLIN Vaccine ID: 857 YH, ZX preparation of Dengue Subunit E Protein Vaccine VIOLIN Vaccine ID: 858 YH, ZX A Dengue Virus vaccine preparation that results in the generation of a Dengue Subunit E Protein Vaccine preparation of C. muridarum PmpG-1 protein vaccine A Chlamydia muridarum vaccine preparation that results in the generation of a C. muridarum PmpG-1 protein vaccine VIOLIN Vaccine ID: 859 YH, ZX preparation of ProQuad A Rubella virus vaccine preparation that results in the generation of a ProQuad VIOLIN Vaccine ID: 376 YH, ZX preparation of Canine distemper virus DNA vaccine encoding HA YH, ZX VIOLIN Vaccine ID: 847 A Canine distemper virus vaccine preparation that results in the generation of a Canine distemper virus DNA vaccine encoding HA preparation of C. posadasii Subunit PMP1 Protein Vaccine A Coccidioides spp. vaccine preparation that results in the generation of a C. posadasii Subunit PMP1 Protein Vaccine VIOLIN Vaccine ID: 848 YH, ZX preparation of C. posadasii DNA Vaccine encoding PRA Protein YH, ZX A Coccidioides spp. vaccine preparation that results in the generation of a C. posadasii DNA Vaccine encoding PRA Protein VIOLIN Vaccine ID: 849 preparation of Canine parvovirus DNA vaccine pGT36VP1 A Canine parvovirus vaccine preparation that results in the generation of a Canine parvovirus DNA vaccine pGT36VP1 VIOLIN Vaccine ID: 850 YH, ZX preparation of C. immitis Subunit URE Protein Vaccine A Coccidioides spp. vaccine preparation that results in the generation of a C. immitis Subunit URE Protein Vaccine YH, ZX VIOLIN Vaccine ID: 851 preparation of Canine parvovirus CPMV-PARVO1 protein vaccine A Canine parvovirus vaccine preparation that results in the generation of a Canine parvovirus CPMV-PARVO1 protein vaccine YH, ZX VIOLIN Vaccine ID: 852 preparation of ProQuad YH, ZX VIOLIN Vaccine ID: 377 A Mumps virus vaccine preparation that results in the generation of a ProQuad preparation of Ebola virus DNA vaccine encoding ZEBOV GP and SEBOV GP YH, ZX VIOLIN Vaccine ID: 901 A Ebola virus vaccine preparation that results in the generation of a Ebola virus DNA vaccine encoding ZEBOV GP and SEBOV GP preparation of S. flexneri Invaplex 24 Subunit Vaccine A Shigella vaccine preparation that results in the generation of a S. flexneri Invaplex 24 Subunit Vaccine YH, ZX VIOLIN Vaccine ID: 902 preparation of E. maxima Gam82 protein vaccine A Eimeria maxima vaccine preparation that results in the generation of a E. maxima Gam82 protein vaccine VIOLIN Vaccine ID: 903 YH, ZX preparation of ProQuad YH, ZX A Measles virus vaccine preparation that results in the generation of a ProQuad VIOLIN Vaccine ID: 378 preparation of S. flexneri Invaplex 50 Subunit Vaccine A Shigella vaccine preparation that results in the generation of a S. flexneri Invaplex 50 Subunit Vaccine YH, ZX VIOLIN Vaccine ID: 904 preparation of E. tenella DNA vaccine proIE A Eimeria tenella vaccine preparation that results in the generation of a E. tenella DNA vaccine proIE YH, ZX VIOLIN Vaccine ID: 905 preparation of E. tenella GX3262 protein vaccine A Eimeria tenella vaccine preparation that results in the generation of a E. tenella GX3262 protein vaccine YH, ZX VIOLIN Vaccine ID: 907 preparation of E. tenella DNA vaccine EtMIC2 YH, ZX VIOLIN Vaccine ID: 909 A Eimeria tenella vaccine preparation that results in the generation of a E. tenella DNA vaccine EtMIC2 preparation of E. tenella DNA vaccine rBCG pMV261-Rho VIOLIN Vaccine ID: 910 YH, ZX A Eimeria tenella vaccine preparation that results in the generation of a E. tenella DNA vaccine rBCG pMV261-Rho preparation of ProQuad A Varicella-zoster virus vaccine preparation that results in the generation of a ProQuad VIOLIN Vaccine ID: 379 YH, ZX preparation of Menactra YH, ZX VIOLIN Vaccine ID: 381 A Neisseria meningitidis vaccine preparation that results in the generation of a Menactra preparation of Adacel A Clostridium tetani vaccine preparation that results in the generation of a Adacel VIOLIN Vaccine ID: 383 YH, ZX preparation of TENIVAC A Clostridium tetani vaccine preparation that results in the generation of a TENIVAC VIOLIN Vaccine ID: 384 YH, ZX preparation of Boostrix YH, ZX A Clostridium tetani vaccine preparation that results in the generation of a Boostrix VIOLIN Vaccine ID: 385 preparation of Decavac VIOLIN Vaccine ID: 386 A Clostridium tetani vaccine preparation that results in the generation of a Decavac YH, ZX preparation of Porcilis-PCV2 A Porcine circovirus 2 vaccine preparation that results in the generation of a Porcilis-PCV2 VIOLIN Vaccine ID: 387 YH, ZX preparation of Suvaxyn PCV2 VIOLIN Vaccine ID: 388 YH, ZX A Porcine circovirus 2 vaccine preparation that results in the generation of a Suvaxyn PCV2 preparation of Suvaxyn Aujeszky A Pseudorabies virus vaccine preparation that results in the generation of a Suvaxyn Aujeszky VIOLIN Vaccine ID: 389 YH, ZX preparation of Porcilis Pesti YH, ZX VIOLIN Vaccine ID: 390 A Classical swine fever virus vaccine preparation that results in the generation of a Porcilis Pesti preparation of Bayovac CSF E2 A Classical swine fever virus vaccine preparation that results in the generation of a Bayovac CSF E2 VIOLIN Vaccine ID: 391 YH, ZX preparation of Bovilis IBR Marker YH, ZX A Bovine herpesvirus 1 vaccine preparation that results in the generation of a Bovilis IBR Marker VIOLIN Vaccine ID: 392 preparation of PROTEQ-FLU/Recombitek A Influenza virus vaccine preparation that results in the generation of a PROTEQ-FLU/Recombitek VIOLIN Vaccine ID: 393 YH, ZX preparation of PreveNile YH, ZX VIOLIN Vaccine ID: 394 A West Nile virus vaccine preparation that results in the generation of a PreveNile preparation of West Nile-Innovator DNA VIOLIN Vaccine ID: 395 YH, ZX A West Nile virus vaccine preparation that results in the generation of a West Nile-Innovator DNA preparation of RECOMBITEKEquine WNV VIOLIN Vaccine ID: 396 YH, ZX A West Nile virus vaccine preparation that results in the generation of a RECOMBITEKEquine WNV preparation of Vaxxitek HVT+IBD YH, ZX A Marek's; disease virus vaccine preparation that results in the generation of a Vaxxitek HVT+IBD VIOLIN Vaccine ID: 397 preparation of Newcastle disease virus vaccine by Dow AgroSciences VIOLIN Vaccine ID: 398 A Newcastle disease virus vaccine preparation that results in the generation of a Newcastle disease virus vaccine by Dow AgroSciences YH, ZX preparation of Vectormune FP-ND VIOLIN Vaccine ID: 399 A Newcastle disease virus vaccine preparation that results in the generation of a Vectormune FP-ND YH, ZX preparation of Poulvac FluFend I AI H5N3 RG YH, ZX A Influenza virus vaccine preparation that results in the generation of a Poulvac FluFend I AI H5N3 RG VIOLIN Vaccine ID: 401 preparation of Avian influenza virus (H5N1) and NDV vaccine by Intervet YH, ZX A Influenza virus vaccine preparation that results in the generation of a Avian influenza virus (H5N1) and NDV vaccine by Intervet VIOLIN Vaccine ID: 400 preparation of Trovac AI H5 YH, ZX VIOLIN Vaccine ID: 402 A Influenza virus vaccine preparation that results in the generation of a Trovac AI H5 preparation of Raboral YH, ZX A Rabies virus vaccine preparation that results in the generation of a Raboral VIOLIN Vaccine ID: 403 preparation of Purevax Feline Rabies A Rabies virus vaccine preparation that results in the generation of a Purevax Feline Rabies YH, ZX VIOLIN Vaccine ID: 404 preparation of EURIFEL FeLV A Feline leukemia virus vaccine preparation that results in the generation of a EURIFEL FeLV VIOLIN Vaccine ID: 405 YH, ZX preparation of RECOMBITEK Canine Parvo YH, ZX A Canine parvovirus vaccine preparation that results in the generation of a RECOMBITEK Canine Parvo VIOLIN Vaccine ID: 406 preparation of RECOMBITEK Corona MLV YH, ZX A Canine coronavirus vaccine preparation that results in the generation of a RECOMBITEK Corona MLV VIOLIN Vaccine ID: 407 preparation of RECOMBITEK rDistemper A Canine distemper virus vaccine preparation that results in the generation of a RECOMBITEK rDistemper VIOLIN Vaccine ID: 408 YH, ZX preparation of PUREVAXFerret Distemper A Canine distemper virus vaccine preparation that results in the generation of a PUREVAXFerret Distemper YH, ZX VIOLIN Vaccine ID: 409 preparation of Apex-IHN A Infectious Hematopoietic Necrosis Virus vaccine preparation that results in the generation of a Apex-IHN YH, ZX VIOLIN Vaccine ID: 410 preparation of Enterisol Ileitis A Lawsonia intracellularis vaccine preparation that results in the generation of a Enterisol Ileitis VIOLIN Vaccine ID: 411 YH, ZX preparation of Periovac VIOLIN Vaccine ID: 412 A Porphyromonas gulae vaccine preparation that results in the generation of a Periovac YH, ZX preparation of AquaVac ERM YH, ZX VIOLIN Vaccine ID: 413 A Yersinia ruckeri vaccine preparation that results in the generation of a AquaVac ERM preparation of AquaVac Furuvac YH, ZX VIOLIN Vaccine ID: 414 A Aeromonas salmonicida vaccine preparation that results in the generation of a AquaVac Furuvac preparation of AquaVac Vibrio YH, ZX VIOLIN Vaccine ID: 415 A Vibrio anguillarum (Listonella anguillarum) vaccine preparation that results in the generation of a AquaVac Vibrio preparation of Equilis StrepE YH, ZX A Streptococcus equi vaccine preparation that results in the generation of a Equilis StrepE VIOLIN Vaccine ID: 416 preparation of Ovilis Enzovax YH, ZX A Chlamydophila abortus vaccine preparation that results in the generation of a Ovilis Enzovax VIOLIN Vaccine ID: 417 preparation of Vaxsafe MS A Mycoplasma synoviae vaccine preparation that results in the generation of a Vaxsafe MS VIOLIN Vaccine ID: 418 YH, ZX preparation of Vaxsafe MG VIOLIN Vaccine ID: 419 YH, ZX A Mycoplasma gallisepticum vaccine preparation that results in the generation of a Vaxsafe MG preparation of Art Vax VIOLIN Vaccine ID: 420 A Bordetella avium vaccine preparation that results in the generation of a Art Vax YH, ZX preparation of PleuroStar APP VIOLIN Vaccine ID: 421 A Actinobacillus pleuropneumoniae vaccine preparation that results in the generation of a PleuroStar APP YH, ZX preparation of Porcilis APP YH, ZX A Actinobacillus pleuropneumoniae vaccine preparation that results in the generation of a Porcilis APP VIOLIN Vaccine ID: 422 preparation of Megan Vac1 A Salmonella spp. vaccine preparation that results in the generation of a Megan Vac1 VIOLIN Vaccine ID: 423 YH, ZX preparation of Coccivac, Immucox, Paracox, Advent, Nobilis Cox ATM YH, ZX A Eimeria spp. vaccine preparation that results in the generation of a Coccivac, Immucox, Paracox, Advent, Nobilis Cox ATM VIOLIN Vaccine ID: 424 preparation of Inovocox A Eimeria spp. vaccine preparation that results in the generation of a Inovocox VIOLIN Vaccine ID: 425 YH, ZX preparation of Ovilis Toxovax A Toxoplasma gondii vaccine preparation that results in the generation of a Ovilis Toxovax YH, ZX VIOLIN Vaccine ID: 429 preparation of Livacox YH, ZX A Eimeria tenella vaccine preparation that results in the generation of a Livacox VIOLIN Vaccine ID: 426 preparation of Theileria parva vaccine by Centre for Ticks and Tickborne Disease, Malawi YH, ZX VIOLIN Vaccine ID: 427 A Theileria parva vaccine preparation that results in the generation of a Theileria parva vaccine by Centre for Ticks and Tickborne Disease, Malawi preparation of Theileria annulata vaccine by Local veterinary institutes A Theileria annulata vaccine preparation that results in the generation of a Theileria annulata vaccine by Local veterinary institutes YH, ZX VIOLIN Vaccine ID: 428 preparation of Babesia bovis vaccine by Local veterinary institutes A Babesia bovis vaccine preparation that results in the generation of a Babesia bovis vaccine by Local veterinary institutes YH, ZX VIOLIN Vaccine ID: 430 preparation of Bovilis, Neoguard YH, ZX VIOLIN Vaccine ID: 431 A Neospora caninum vaccine preparation that results in the generation of a Bovilis, Neoguard preparation of Giardiavax YH, ZX VIOLIN Vaccine ID: 432 A Giardia duodenalis vaccine preparation that results in the generation of a Giardiavax preparation of Epm vaccine VIOLIN Vaccine ID: 433 YH, ZX A Sarcocystis neurona vaccine preparation that results in the generation of a Epm vaccine preparation of Pirodog and Nobivac Piro A Babesia canis vaccine preparation that results in the generation of a Pirodog and Nobivac Piro VIOLIN Vaccine ID: 434 YH, ZX preparation of Leishmune A Leishmania donovani vaccine preparation that results in the generation of a Leishmune YH, ZX VIOLIN Vaccine ID: 435 preparation of CoxAbic VIOLIN Vaccine ID: 436 YH, ZX A Eimeria maxima vaccine preparation that results in the generation of a CoxAbic preparation of Influenza A (H1N1) 2009 Monovalent Vaccine by CSL Limited VIOLIN Vaccine ID: 452 YH, ZX A Influenza virus vaccine preparation that results in the generation of a Influenza A (H1N1) 2009 Monovalent Vaccine by CSL Limited preparation of Influenza A (H1N1) 2009 Monovalent Vaccine by Novartis YH, ZX A Influenza virus vaccine preparation that results in the generation of a Influenza A (H1N1) 2009 Monovalent Vaccine by Novartis VIOLIN Vaccine ID: 453 preparation of Influenza A (H1N1) 2009 Monovalent Vaccine from Sanofi Pasteur VIOLIN Vaccine ID: 454 YH, ZX A Influenza virus vaccine preparation that results in the generation of a Influenza A (H1N1) 2009 Monovalent Vaccine from Sanofi Pasteur preparation of Influenza A (H1N1) 2009 Monovalent Vaccine from MedImmune LLC A Influenza virus vaccine preparation that results in the generation of a Influenza A (H1N1) 2009 Monovalent Vaccine from MedImmune LLC VIOLIN Vaccine ID: 456 YH, ZX preparation of H. pylori DNA vaccine encoding UreB YH, ZX A Helicobacter pylori vaccine preparation that results in the generation of a H. pylori DNA vaccine encoding UreB VIOLIN Vaccine ID: 960 preparation of M. tuberculosis DNA Vaccine APADNA priming and APAMVA boosting YH, ZX VIOLIN Vaccine ID: 961 A Mycobacterium tuberculosis vaccine preparation that results in the generation of a M. tuberculosis DNA Vaccine APADNA priming and APAMVA boosting preparation of H. pylori VacA protein vaccine YH, ZX VIOLIN Vaccine ID: 962 A Helicobacter pylori vaccine preparation that results in the generation of a H. pylori VacA protein vaccine preparation of Twinrix Junior A Hepatitis A virus vaccine preparation that results in the generation of a Twinrix Junior YH, ZX VIOLIN Vaccine ID: 638 preparation of Twinrix Junior VIOLIN Vaccine ID: 637 A Hepatitis B virus vaccine preparation that results in the generation of a Twinrix Junior YH, ZX preparation of Twinrix A Hepatitis A virus vaccine preparation that results in the generation of a Twinrix YH, ZX VIOLIN Vaccine ID: 636 preparation of Twinrix A Hepatitis B virus vaccine preparation that results in the generation of a Twinrix VIOLIN Vaccine ID: 635 YH, ZX preparation of Human papillomavirus DNA vaccine pNGVL4a-E6/opt YH, ZX A Human papillomavirus vaccine preparation that results in the generation of a Human papillomavirus DNA vaccine pNGVL4a-E6/opt VIOLIN Vaccine ID: 981 preparation of PCV2 DNA Vaccine encoding ORF2 Protein A Porcine circovirus 2 vaccine preparation that results in the generation of a PCV2 DNA Vaccine encoding ORF2 Protein YH, ZX VIOLIN Vaccine ID: 982 preparation of Tripacel VIOLIN Vaccine ID: 634 A Bordetella avium vaccine preparation that results in the generation of a Tripacel YH, ZX preparation of Tripacel YH, ZX A Clostridium tetani vaccine preparation that results in the generation of a Tripacel VIOLIN Vaccine ID: 633 preparation of Tripacel VIOLIN Vaccine ID: 632 A Corynebacterium diphtheriae vaccine preparation that results in the generation of a Tripacel YH, ZX preparation of Tetanus Toxoid Adsorbed VIOLIN Vaccine ID: 631 A Clostridium tetani vaccine preparation that results in the generation of a Tetanus Toxoid Adsorbed YH, ZX preparation of Td Polio Adsorbed A Poliovirus vaccine preparation that results in the generation of a Td Polio Adsorbed VIOLIN Vaccine ID: 630 YH, ZX preparation of Td Polio Adsorbed A Corynebacterium diphtheriae vaccine preparation that results in the generation of a Td Polio Adsorbed YH, ZX VIOLIN Vaccine ID: 629 preparation of Td Polio Adsorbed VIOLIN Vaccine ID: 628 YH, ZX A Clostridium tetani vaccine preparation that results in the generation of a Td Polio Adsorbed preparation of Td Adsorbed YH, ZX VIOLIN Vaccine ID: 627 A Clostridium tetani vaccine preparation that results in the generation of a Td Adsorbed preparation of Quadracel YH, ZX VIOLIN Vaccine ID: 626 A Poliovirus vaccine preparation that results in the generation of a Quadracel preparation of Quadracel A Bordetella avium vaccine preparation that results in the generation of a Quadracel YH, ZX VIOLIN Vaccine ID: 625 preparation of Quadracel VIOLIN Vaccine ID: 624 YH, ZX A Clostridium tetani vaccine preparation that results in the generation of a Quadracel preparation of Quadracel YH, ZX VIOLIN Vaccine ID: 623 A Corynebacterium diphtheriae vaccine preparation that results in the generation of a Quadracel preparation of Priorix-Tetra VIOLIN Vaccine ID: 622 A Varicella-zoster virus vaccine preparation that results in the generation of a Priorix-Tetra YH, ZX preparation of Priorix-Tetra VIOLIN Vaccine ID: 620 YH, ZX A Mumps virus vaccine preparation that results in the generation of a Priorix-Tetra preparation of Priorix-Tetra VIOLIN Vaccine ID: 621 YH, ZX A Rubella virus vaccine preparation that results in the generation of a Priorix-Tetra preparation of C. jejuni FspA1 protein vaccine VIOLIN Vaccine ID: 841 A Campylobacter jejuni vaccine preparation that results in the generation of a C. jejuni FspA1 protein vaccine YH, ZX preparation of SARS Subunit Spike Protein Vaccine YH, ZX A SARS-CoV vaccine preparation that results in the generation of a SARS Subunit Spike Protein Vaccine VIOLIN Vaccine ID: 842 preparation of C. jejuni FspA2 protein vaccine YH, ZX VIOLIN Vaccine ID: 843 A Campylobacter jejuni vaccine preparation that results in the generation of a C. jejuni FspA2 protein vaccine preparation of C. jejuni DNA vaccine pcDNA3.1(+)-peblA YH, ZX A Campylobacter jejuni vaccine preparation that results in the generation of a C. jejuni DNA vaccine pcDNA3.1(+)-peblA VIOLIN Vaccine ID: 844 preparation of Canine distemper virus DNA vaccine encoding F and HA A Canine distemper virus vaccine preparation that results in the generation of a Canine distemper virus DNA vaccine encoding F and HA YH, ZX VIOLIN Vaccine ID: 845 preparation of C. posadasii Subunit GEL1 Protein Vaccine A Coccidioides spp. vaccine preparation that results in the generation of a C. posadasii Subunit GEL1 Protein Vaccine VIOLIN Vaccine ID: 846 YH, ZX preparation of Priorix-Tetra A Measles virus vaccine preparation that results in the generation of a Priorix-Tetra VIOLIN Vaccine ID: 619 YH, ZX preparation of Priorix A Mumps virus vaccine preparation that results in the generation of a Priorix YH, ZX VIOLIN Vaccine ID: 617 preparation of Priorix VIOLIN Vaccine ID: 618 A Rubella virus vaccine preparation that results in the generation of a Priorix YH, ZX preparation of T. brucei DNA Vaccine encoding TSA protein VIOLIN Vaccine ID: 836 YH, ZX A Trypanosoma brucei vaccine preparation that results in the generation of a T. brucei DNA Vaccine encoding TSA protein preparation of T. brucei Subunit p15 Protein Vaccine A Trypanosoma brucei vaccine preparation that results in the generation of a T. brucei Subunit p15 Protein Vaccine VIOLIN Vaccine ID: 837 YH, ZX preparation of C. jejuni MBP-FlaA protein vaccine VIOLIN Vaccine ID: 838 YH, ZX A Campylobacter jejuni vaccine preparation that results in the generation of a C. jejuni MBP-FlaA protein vaccine preparation of T. parva Subunit p67 Protein Vaccine YH, ZX A Theileria parva vaccine preparation that results in the generation of a T. parva Subunit p67 Protein Vaccine VIOLIN Vaccine ID: 839 preparation of C. jejuni FlaC protein vaccine VIOLIN Vaccine ID: 840 YH, ZX A Campylobacter jejuni vaccine preparation that results in the generation of a C. jejuni FlaC protein vaccine preparation of Pneumo 23 A Streptococcus pneumoniae vaccine preparation that results in the generation of a Pneumo 23 YH, ZX VIOLIN Vaccine ID: 615 preparation of Mutacol VIOLIN Vaccine ID: 780 A Vibrio cholerae vaccine preparation that results in the generation of a Mutacol YH, ZX preparation of B. pertussis FhaB and 69 kDa OMP protein vaccine A Bordetella pertussis vaccine preparation that results in the generation of a B. pertussis FhaB and 69 kDa OMP protein vaccine YH, ZX VIOLIN Vaccine ID: 805 preparation of Priorix VIOLIN Vaccine ID: 616 A Measles virus vaccine preparation that results in the generation of a Priorix YH, ZX preparation of H. influenzae Hap protein vaccine A Haemophilus influenzae vaccine preparation that results in the generation of a H. influenzae Hap protein vaccine VIOLIN Vaccine ID: 936 YH, ZX preparation of Pentacel YH, ZX A Haemophilus influenzae vaccine preparation that results in the generation of a Pentacel VIOLIN Vaccine ID: 614 preparation of Pentacel YH, ZX A Poliovirus vaccine preparation that results in the generation of a Pentacel VIOLIN Vaccine ID: 613 preparation of Pentacel YH, ZX VIOLIN Vaccine ID: 612 A Bordetella avium vaccine preparation that results in the generation of a Pentacel preparation of Pediarix VIOLIN Vaccine ID: 611 YH, ZX A Poliovirus vaccine preparation that results in the generation of a Pediarix preparation of Pediarix VIOLIN Vaccine ID: 610 A Hepatitis B virus vaccine preparation that results in the generation of a Pediarix YH, ZX preparation of Pediarix A Bordetella avium vaccine preparation that results in the generation of a Pediarix YH, ZX VIOLIN Vaccine ID: 609 preparation of Pediacel A Haemophilus influenzae vaccine preparation that results in the generation of a Pediacel YH, ZX VIOLIN Vaccine ID: 608 preparation of Japanese encephalitis virus DNA vaccine encoding NS1 (pUSK-NS1) A Japanese encephalitis virus vaccine preparation that results in the generation of a Japanese encephalitis virus DNA vaccine encoding NS1 (pUSK-NS1) YH, ZX VIOLIN Vaccine ID: 1033 preparation of Japanese encephalitis virus DNA vaccine pUJENS3 VIOLIN Vaccine ID: 1034 A Japanese encephalitis virus vaccine preparation that results in the generation of a Japanese encephalitis virus DNA vaccine pUJENS3 YH, ZX preparation of Pediacel YH, ZX A Poliovirus vaccine preparation that results in the generation of a Pediacel VIOLIN Vaccine ID: 607 preparation of Pediacel A Bordetella avium vaccine preparation that results in the generation of a Pediacel VIOLIN Vaccine ID: 606 YH, ZX preparation of Pediacel YH, ZX A Clostridium tetani vaccine preparation that results in the generation of a Pediacel VIOLIN Vaccine ID: 605 preparation of Pediacel VIOLIN Vaccine ID: 604 YH, ZX A Corynebacterium diphtheriae vaccine preparation that results in the generation of a Pediacel preparation of Mutacol YH, ZX VIOLIN Vaccine ID: 602 A Vibrio anguillarum (Listonella anguillarum) vaccine preparation that results in the generation of a Mutacol preparation of Neisvac-C A Neisseria meningitidis vaccine preparation that results in the generation of a Neisvac-C VIOLIN Vaccine ID: 603 YH, ZX preparation of M-M-R II YH, ZX A Measles virus vaccine preparation that results in the generation of a M-M-R II VIOLIN Vaccine ID: 601 preparation of Menjugate YH, ZX VIOLIN Vaccine ID: 600 A Neisseria meningitidis vaccine preparation that results in the generation of a Menjugate preparation of C. parvum DNA vaccine encoding CP15/60 YH, ZX A Cryptosporidium parvum vaccine preparation that results in the generation of a C. parvum DNA vaccine encoding CP15/60 VIOLIN Vaccine ID: 900 preparation of Meningitec A Neisseria meningitidis vaccine preparation that results in the generation of a Meningitec VIOLIN Vaccine ID: 598 YH, ZX preparation of Y. enterocolititica Subunit V Antigen Protein Vaccine A Yersinia enterocolitica vaccine preparation that results in the generation of a Y. enterocolititica Subunit V Antigen Protein Vaccine VIOLIN Vaccine ID: 896 YH, ZX preparation of C. botulinum FHc protein vaccine VIOLIN Vaccine ID: 897 YH, ZX A Clostridium botulinum vaccine preparation that results in the generation of a C. botulinum FHc protein vaccine preparation of WEEV DNA Vaccine encoding 6K-E1 Protein VIOLIN Vaccine ID: 898 A Western equine encephalomyelitis virus vaccine preparation that results in the generation of a WEEV DNA Vaccine encoding 6K-E1 Protein YH, ZX preparation of WEEV Subunit E2 Protein Vaccine VIOLIN Vaccine ID: 899 YH, ZX A Western equine encephalomyelitis virus vaccine preparation that results in the generation of a WEEV Subunit E2 Protein Vaccine preparation of Meningococcal Polysaccharide Vaccine, Groups A & C, Menomune A/C A Neisseria meningitidis vaccine preparation that results in the generation of a Meningococcal Polysaccharide Vaccine, Groups A & C, Menomune A/C YH, ZX VIOLIN Vaccine ID: 599 preparation of Cancer Subunit GV1001 Protein Vaccine YH, ZX A Cancer vaccine preparation that results in the generation of a Cancer Subunit GV1001 Protein Vaccine VIOLIN Vaccine ID: 891 preparation of Classical swine fever virus vaccine VAC-E2 YH, ZX VIOLIN Vaccine ID: 892 A Classical swine fever virus vaccine preparation that results in the generation of a Classical swine fever virus vaccine VAC-E2 preparation of Classical swine fever virus E1 protein vaccine A Classical swine fever virus vaccine preparation that results in the generation of a Classical swine fever virus E1 protein vaccine VIOLIN Vaccine ID: 893 YH, ZX preparation of Cancer Subunit DC (Tat-CEA) vaccine A Cancer vaccine preparation that results in the generation of a Cancer Subunit DC (Tat-CEA) vaccine VIOLIN Vaccine ID: 894 YH, ZX preparation of C. botulinum DNA vaccine pSCARSBHc VIOLIN Vaccine ID: 895 A Clostridium botulinum vaccine preparation that results in the generation of a C. botulinum DNA vaccine pSCARSBHc YH, ZX preparation of Influvac A Influenza virus vaccine preparation that results in the generation of a Influvac YH, ZX VIOLIN Vaccine ID: 597 preparation of Dobrava-Belgrade virus S nucleocapsid protein vaccine A Hantavirus vaccine preparation that results in the generation of a Dobrava-Belgrade virus S nucleocapsid protein vaccine VIOLIN Vaccine ID: 954 YH, ZX preparation of H. pylori catalase protein vaccine YH, ZX A Helicobacter pylori vaccine preparation that results in the generation of a H. pylori catalase protein vaccine VIOLIN Vaccine ID: 955 preparation of H. pylori NAP protein vaccine VIOLIN Vaccine ID: 958 YH, ZX A Helicobacter pylori vaccine preparation that results in the generation of a H. pylori NAP protein vaccine preparation of M. gallisepticum TM-1 Protein Subunit Vaccine VIOLIN Vaccine ID: 959 YH, ZX A Mycoplasma gallisepticum vaccine preparation that results in the generation of a M. gallisepticum TM-1 Protein Subunit Vaccine preparation of Infanrix -IPV/Hib YH, ZX A Haemophilus influenzae vaccine preparation that results in the generation of a Infanrix -IPV/Hib VIOLIN Vaccine ID: 596 preparation of Japanese encephalitis virus vaccine BV-G-E A Japanese encephalitis virus vaccine preparation that results in the generation of a Japanese encephalitis virus vaccine BV-G-E YH, ZX VIOLIN Vaccine ID: 1027 preparation of Infanrix -IPV/Hib A Poliovirus vaccine preparation that results in the generation of a Infanrix -IPV/Hib YH, ZX VIOLIN Vaccine ID: 595 preparation of T. annulata Subunit SPAG-1 Protein Vaccine A Theileria annulata vaccine preparation that results in the generation of a T. annulata Subunit SPAG-1 Protein Vaccine YH, ZX VIOLIN Vaccine ID: 873 preparation of C. abortus DNA vaccine encoding DnaK VIOLIN Vaccine ID: 874 YH, ZX A Chlamydophila abortus vaccine preparation that results in the generation of a C. abortus DNA vaccine encoding DnaK preparation of C. abortus DNA vaccine encoding DnaX VIOLIN Vaccine ID: 875 A Chlamydophila abortus vaccine preparation that results in the generation of a C. abortus DNA vaccine encoding DnaX YH, ZX preparation of C. abortus DNA vaccine encoding GatA/GatB A Chlamydophila abortus vaccine preparation that results in the generation of a C. abortus DNA vaccine encoding GatA/GatB YH, ZX VIOLIN Vaccine ID: 876 preparation of Infanrix -IPV/Hib YH, ZX VIOLIN Vaccine ID: 594 A Bordetella avium vaccine preparation that results in the generation of a Infanrix -IPV/Hib preparation of Infanrix -IPV/Hib YH, ZX A Clostridium tetani vaccine preparation that results in the generation of a Infanrix -IPV/Hib VIOLIN Vaccine ID: 593 preparation of Infanrix -IPV/Hib A Corynebacterium diphtheriae vaccine preparation that results in the generation of a Infanrix -IPV/Hib VIOLIN Vaccine ID: 592 YH, ZX preparation of Infanrix-IPV A Poliovirus vaccine preparation that results in the generation of a Infanrix-IPV YH, ZX VIOLIN Vaccine ID: 591 preparation of T. gondii Subunit Rop2-Hsp83 Fusion Protein Vaccine A Toxoplasma gondii vaccine preparation that results in the generation of a T. gondii Subunit Rop2-Hsp83 Fusion Protein Vaccine YH, ZX VIOLIN Vaccine ID: 866 preparation of C. muridarum DNA vaccine encoding TC0757 VIOLIN Vaccine ID: 867 A Chlamydia muridarum vaccine preparation that results in the generation of a C. muridarum DNA vaccine encoding TC0757 YH, ZX preparation of T. gondii DNA vaccine pcDNA3-MIC3 A Toxoplasma gondii vaccine preparation that results in the generation of a T. gondii DNA vaccine pcDNA3-MIC3 VIOLIN Vaccine ID: 868 YH, ZX preparation of C. muridarum DNA vaccine encoding TC0767/768 VIOLIN Vaccine ID: 869 YH, ZX A Chlamydia muridarum vaccine preparation that results in the generation of a C. muridarum DNA vaccine encoding TC0767/768 preparation of T. gondii DNA Vaccine encoding SAG1 Protein YH, ZX A Toxoplasma gondii vaccine preparation that results in the generation of a T. gondii DNA Vaccine encoding SAG1 Protein VIOLIN Vaccine ID: 870 preparation of C. abortus DNA vaccine encoding CAB049 A Chlamydophila abortus vaccine preparation that results in the generation of a C. abortus DNA vaccine encoding CAB049 YH, ZX VIOLIN Vaccine ID: 871 preparation of C. abortus DNA vaccine encoding CAB613 A Chlamydophila abortus vaccine preparation that results in the generation of a C. abortus DNA vaccine encoding CAB613 VIOLIN Vaccine ID: 872 YH, ZX preparation of Infanrix-IPV A Bordetella avium vaccine preparation that results in the generation of a Infanrix-IPV VIOLIN Vaccine ID: 590 YH, ZX preparation of Infanrix-IPV A Clostridium tetani vaccine preparation that results in the generation of a Infanrix-IPV VIOLIN Vaccine ID: 589 YH, ZX preparation of Infanrix-IPV A Corynebacterium diphtheriae vaccine preparation that results in the generation of a Infanrix-IPV YH, ZX VIOLIN Vaccine ID: 588 preparation of Infanrix/Hib A Haemophilus influenzae vaccine preparation that results in the generation of a Infanrix/Hib YH, ZX VIOLIN Vaccine ID: 587 preparation of Infleunza virus DNA vaccine encoding NP from Influenza A virus (A/chicken/Henan/12/2004(H5N1)) A Influenza virus vaccine preparation that results in the generation of a Infleunza virus DNA vaccine encoding NP from Influenza A virus (A/chicken/Henan/12/2004(H5N1)) YH, ZX VIOLIN Vaccine ID: 1023 preparation of Influenza virus DNA vaccine encoding NP from Influenza A virus (A/chicken/Hubei/489/2004(H5N1)) YH, ZX A Influenza virus vaccine preparation that results in the generation of a Influenza virus DNA vaccine encoding NP from Influenza A virus (A/chicken/Hubei/489/2004(H5N1)) VIOLIN Vaccine ID: 1024 preparation of L. donovani DNA Vaccine KMP-11 Protein YH, ZX A Leishmania donovani vaccine preparation that results in the generation of a L. donovani DNA Vaccine KMP-11 Protein VIOLIN Vaccine ID: 1025 preparation of Influenza virus NP protein vaccine (Influenza A virus (A/nt/60/1968(H3N2))) YH, ZX A Influenza virus vaccine preparation that results in the generation of a Influenza virus NP protein vaccine (Influenza A virus (A/nt/60/1968(H3N2))) VIOLIN Vaccine ID: 1026 preparation of Infanrix/Hib A Bordetella avium vaccine preparation that results in the generation of a Infanrix/Hib VIOLIN Vaccine ID: 586 YH, ZX preparation of Infanrix/Hib VIOLIN Vaccine ID: 585 A Clostridium tetani vaccine preparation that results in the generation of a Infanrix/Hib YH, ZX preparation of Infanrix/Hib VIOLIN Vaccine ID: 584 A Corynebacterium diphtheriae vaccine preparation that results in the generation of a Infanrix/Hib YH, ZX preparation of Infanrix-hexa YH, ZX VIOLIN Vaccine ID: 583 A Haemophilus influenzae vaccine preparation that results in the generation of a Infanrix-hexa preparation of L. donovani gp63 Protein Subunit Vaccine YH, ZX A Leishmania donovani vaccine preparation that results in the generation of a L. donovani gp63 Protein Subunit Vaccine VIOLIN Vaccine ID: 1022 preparation of Infanrix-hexa YH, ZX A Poliovirus vaccine preparation that results in the generation of a Infanrix-hexa VIOLIN Vaccine ID: 582 preparation of C. muridarum DNA vaccine encoding TC0439 A Chlamydia muridarum vaccine preparation that results in the generation of a C. muridarum DNA vaccine encoding TC0439 VIOLIN Vaccine ID: 864 YH, ZX preparation of C. muridarum DNA vaccine encoding TC0512 VIOLIN Vaccine ID: 865 YH, ZX A Chlamydia muridarum vaccine preparation that results in the generation of a C. muridarum DNA vaccine encoding TC0512 preparation of Infanrix-hexa VIOLIN Vaccine ID: 581 YH, ZX A Hepatitis B virus vaccine preparation that results in the generation of a Infanrix-hexa preparation of Measles Virus Vaccine VVN A Measles virus vaccine preparation that results in the generation of a Measles Virus Vaccine VVN VIOLIN Vaccine ID: 978 YH, ZX preparation of Measles Virus Vaccine VVP A Measles virus vaccine preparation that results in the generation of a Measles Virus Vaccine VVP VIOLIN Vaccine ID: 979 YH, ZX preparation of Measles Virus Vaccine VVM A Measles virus vaccine preparation that results in the generation of a Measles Virus Vaccine VVM VIOLIN Vaccine ID: 980 YH, ZX preparation of Infanrix-hexa A Bordetella avium vaccine preparation that results in the generation of a Infanrix-hexa VIOLIN Vaccine ID: 580 YH, ZX preparation of Infanrix-hexa YH, ZX A Clostridium tetani vaccine preparation that results in the generation of a Infanrix-hexa VIOLIN Vaccine ID: 579 preparation of Infanrix-hexa VIOLIN Vaccine ID: 578 YH, ZX A Corynebacterium diphtheriae vaccine preparation that results in the generation of a Infanrix-hexa preparation of Infanrix VIOLIN Vaccine ID: 577 YH, ZX A Bordetella avium vaccine preparation that results in the generation of a Infanrix preparation of Infanrix YH, ZX A Clostridium tetani vaccine preparation that results in the generation of a Infanrix VIOLIN Vaccine ID: 576 preparation of Infanrix VIOLIN Vaccine ID: 575 YH, ZX A Corynebacterium diphtheriae vaccine preparation that results in the generation of a Infanrix preparation of Inactived Poliomyelitis Vaccine IPV A Poliovirus vaccine preparation that results in the generation of a Inactived Poliomyelitis Vaccine IPV YH, ZX VIOLIN Vaccine ID: 574 preparation of B. pseudomallei DNA vaccine encoding Flagellin Protein YH, ZX VIOLIN Vaccine ID: 863 A Burkholderia pseudomallei vaccine preparation that results in the generation of a B. pseudomallei DNA vaccine encoding Flagellin Protein preparation of Imovax Polio YH, ZX A Poliovirus vaccine preparation that results in the generation of a Imovax Polio VIOLIN Vaccine ID: 573 preparation of Hiberix YH, ZX VIOLIN Vaccine ID: 572 A Haemophilus influenzae vaccine preparation that results in the generation of a Hiberix preparation of L. donovani ORFF Protein Subunit Vaccine VIOLIN Vaccine ID: 1017 A Leishmania donovani vaccine preparation that results in the generation of a L. donovani ORFF Protein Subunit Vaccine YH, ZX preparation of Influenza virus DNA vaccine encoding NA from Influenza B virus (B/Ibaraki/2/85) A Influenza virus vaccine preparation that results in the generation of a Influenza virus DNA vaccine encoding NA from Influenza B virus (B/Ibaraki/2/85) VIOLIN Vaccine ID: 1018 YH, ZX preparation of Influenza virus DNA vaccine encoding NA from Influenza A virus (A/chicken/Henan/12/2004(H5N1)) A Influenza virus vaccine preparation that results in the generation of a Influenza virus DNA vaccine encoding NA from Influenza A virus (A/chicken/Henan/12/2004(H5N1)) VIOLIN Vaccine ID: 1019 YH, ZX preparation of L. donovani DNA Vaccine encoding NH36 Protein VIOLIN Vaccine ID: 1020 YH, ZX A Leishmania donovani vaccine preparation that results in the generation of a L. donovani DNA Vaccine encoding NH36 Protein preparation of Fluviral S/F VIOLIN Vaccine ID: 571 A Influenza virus vaccine preparation that results in the generation of a Fluviral S/F YH, ZX preparation of Sin Nombre virus DNA vaccine encoding SNVsSgp1 (NP) YH, ZX VIOLIN Vaccine ID: 945 A Hantavirus vaccine preparation that results in the generation of a Sin Nombre virus DNA vaccine encoding SNVsSgp1 (NP) preparation of Epaxal YH, ZX VIOLIN Vaccine ID: 570 A Hepatitis A virus vaccine preparation that results in the generation of a Epaxal preparation of Eolarix A Rubella virus vaccine preparation that results in the generation of a Eolarix YH, ZX VIOLIN Vaccine ID: 569 preparation of S. equi Subunit EAG, FNZ and SFS Protein Vaccine YH, ZX VIOLIN Vaccine ID: 832 A Streptococcus equi vaccine preparation that results in the generation of a S. equi Subunit EAG, FNZ and SFS Protein Vaccine preparation of C. jejuni DNA vaccine pcDNA3.1(+)-cadF A Campylobacter jejuni vaccine preparation that results in the generation of a C. jejuni DNA vaccine pcDNA3.1(+)-cadF VIOLIN Vaccine ID: 833 YH, ZX preparation of S. equi Subunit CNE Protein Vaccine VIOLIN Vaccine ID: 834 YH, ZX A Streptococcus equi vaccine preparation that results in the generation of a S. equi Subunit CNE Protein Vaccine preparation of Eolarix VIOLIN Vaccine ID: 568 YH, ZX A Measles virus vaccine preparation that results in the generation of a Eolarix preparation of F. tularensis DNA vaccine pTUL4-15 YH, ZX VIOLIN Vaccine ID: 930 A Francisella tularensis vaccine preparation that results in the generation of a F. tularensis DNA vaccine pTUL4-15 preparation of Plasmodium berghei CS Protein Subunit Vaccine VIOLIN Vaccine ID: 931 A Plasmodium spp. vaccine preparation that results in the generation of a Plasmodium berghei CS Protein Subunit Vaccine YH, ZX preparation of G. duodenalis DNA vaccine encoding CWP2 YH, ZX A Giardia duodenalis vaccine preparation that results in the generation of a G. duodenalis DNA vaccine encoding CWP2 VIOLIN Vaccine ID: 932 preparation of H. influenzae D15 protein vaccine VIOLIN Vaccine ID: 933 YH, ZX A Haemophilus influenzae vaccine preparation that results in the generation of a H. influenzae D15 protein vaccine preparation of Newcastle Disease Virus HN Glycoprotein Subunit Vaccine A Newcastle disease virus vaccine preparation that results in the generation of a Newcastle Disease Virus HN Glycoprotein Subunit Vaccine YH, ZX VIOLIN Vaccine ID: 934 preparation of Dukoral VIOLIN Vaccine ID: 567 A Escherichia coli vaccine preparation that results in the generation of a Dukoral YH, ZX preparation of Dukoral A Vibrio anguillarum (Listonella anguillarum) vaccine preparation that results in the generation of a Dukoral YH, ZX VIOLIN Vaccine ID: 566 preparation of DT Polio Adsorbed VIOLIN Vaccine ID: 565 A Poliovirus vaccine preparation that results in the generation of a DT Polio Adsorbed YH, ZX preparation of DT Polio Adsorbed YH, ZX VIOLIN Vaccine ID: 564 A Clostridium tetani vaccine preparation that results in the generation of a DT Polio Adsorbed preparation of DT Polio Adsorbed YH, ZX VIOLIN Vaccine ID: 563 A Corynebacterium diphtheriae vaccine preparation that results in the generation of a DT Polio Adsorbed preparation of Boostrix VIOLIN Vaccine ID: 562 A Bordetella avium vaccine preparation that results in the generation of a Boostrix YH, ZX preparation of BCG Vaccine (Freeze-Dried) VIOLIN Vaccine ID: 561 A Bacillus anthracis vaccine preparation that results in the generation of a BCG Vaccine (Freeze-Dried) YH, ZX preparation of Avaxim - Pediatric VIOLIN Vaccine ID: 560 A Hepatitis A virus vaccine preparation that results in the generation of a Avaxim - Pediatric YH, ZX preparation of Avaxim VIOLIN Vaccine ID: 559 YH, ZX A Hepatitis A virus vaccine preparation that results in the generation of a Avaxim preparation of Adacel YH, ZX A Bordetella avium vaccine preparation that results in the generation of a Adacel VIOLIN Vaccine ID: 558 preparation of Actacel A Haemophilus influenzae vaccine preparation that results in the generation of a Actacel YH, ZX VIOLIN Vaccine ID: 557 preparation of Actacel VIOLIN Vaccine ID: 556 A Bordetella avium vaccine preparation that results in the generation of a Actacel YH, ZX preparation of Actacel VIOLIN Vaccine ID: 555 YH, ZX A Clostridium tetani vaccine preparation that results in the generation of a Actacel preparation of Actacel VIOLIN Vaccine ID: 554 A Corynebacterium diphtheriae vaccine preparation that results in the generation of a Actacel YH, ZX preparation of Typherix VIOLIN Vaccine ID: 639 YH, ZX A Salmonella spp. vaccine preparation that results in the generation of a Typherix preparation of Varilrix VIOLIN Vaccine ID: 640 A Varicella-zoster virus vaccine preparation that results in the generation of a Varilrix YH, ZX preparation of Varivax III YH, ZX A Varicella-zoster virus vaccine preparation that results in the generation of a Varivax III VIOLIN Vaccine ID: 641 preparation of Vaxigrip VIOLIN Vaccine ID: 642 YH, ZX A Influenza virus vaccine preparation that results in the generation of a Vaxigrip preparation of ViVaxim A Salmonella spp. vaccine preparation that results in the generation of a ViVaxim YH, ZX VIOLIN Vaccine ID: 643 preparation of Rabies DNA Vaccine encoding Rabies virus Glycoprotein YH, ZX VIOLIN Vaccine ID: 816 A Rabies virus vaccine preparation that results in the generation of a Rabies DNA Vaccine encoding Rabies virus Glycoprotein preparation of Bovine herpesvirus 1 DNA vaccine tgD-VP22 VIOLIN Vaccine ID: 817 A Bovine herpesvirus 1 vaccine preparation that results in the generation of a Bovine herpesvirus 1 DNA vaccine tgD-VP22 YH, ZX preparation of Rabies vaccine rVac-N YH, ZX A Rabies virus vaccine preparation that results in the generation of a Rabies vaccine rVac-N VIOLIN Vaccine ID: 818 preparation of ViVaxim YH, ZX VIOLIN Vaccine ID: 644 A Hepatitis A virus vaccine preparation that results in the generation of a ViVaxim preparation of Vivotif L A Salmonella spp. vaccine preparation that results in the generation of a Vivotif L YH, ZX VIOLIN Vaccine ID: 645 preparation of Bovine herpesvirus 1 DNA vaccine pRSV-gC VIOLIN Vaccine ID: 815 YH, ZX A Bovine herpesvirus 1 vaccine preparation that results in the generation of a Bovine herpesvirus 1 DNA vaccine pRSV-gC preparation of Vivotif A Salmonella spp. vaccine preparation that results in the generation of a Vivotif VIOLIN Vaccine ID: 646 YH, ZX preparation of Ixiaro A Japanese encephalitis virus vaccine preparation that results in the generation of a Ixiaro YH, ZX VIOLIN Vaccine ID: 741 preparation of Cervarix YH, ZX A Human papillomavirus vaccine preparation that results in the generation of a Cervarix VIOLIN Vaccine ID: 740 preparation of FSME-IMMUN YH, ZX A Tick-borne Encephalitis Virus (TBEV) vaccine preparation that results in the generation of a FSME-IMMUN VIOLIN Vaccine ID: 742 preparation of Megan Egg A Salmonella spp. vaccine preparation that results in the generation of a Megan Egg VIOLIN Vaccine ID: 752 YH, ZX preparation of Agriflu YH, ZX VIOLIN Vaccine ID: 753 A Influenza virus vaccine preparation that results in the generation of a Agriflu preparation of Andes virus vaccine using adenovirus viral vector expressing ANDV NP A Hantavirus vaccine preparation that results in the generation of a Andes virus vaccine using adenovirus viral vector expressing ANDV NP YH, ZX VIOLIN Vaccine ID: 943 preparation of Fluzone High-Dose YH, ZX VIOLIN Vaccine ID: 754 A Influenza virus vaccine preparation that results in the generation of a Fluzone High-Dose preparation of H. influenzae Omp26 protein vaccine YH, ZX VIOLIN Vaccine ID: 938 A Haemophilus influenzae vaccine preparation that results in the generation of a H. influenzae Omp26 protein vaccine preparation of N. caninum NcMIC1 Protein Subunit Vaccine VIOLIN Vaccine ID: 939 YH, ZX A Neospora caninum vaccine preparation that results in the generation of a N. caninum NcMIC1 Protein Subunit Vaccine preparation of N. caninum NcMAG1 Protein Subunit Vaccine A Neospora caninum vaccine preparation that results in the generation of a N. caninum NcMAG1 Protein Subunit Vaccine VIOLIN Vaccine ID: 941 YH, ZX preparation of N. caninum NcDG2 Protein Subunit Vaccine A Neospora caninum vaccine preparation that results in the generation of a N. caninum NcDG2 Protein Subunit Vaccine VIOLIN Vaccine ID: 942 YH, ZX Leishmania amazonensis vaccine A vaccine that protects against Leishmania amazonensis. YH, ZX Leishmania amazonensis Leishmania infantum vaccine Leishmania infantum A vaccine that protects against Leishmania infantum. YH, ZX Cryptosporidium parvum vaccine A vaccine that protects against Cryptosporidium parvum. Cryptosporidium parvum YH, ZX Bovine Leukemia virus vaccine YH, ZX A vaccine that protects against Bovine Leukemia virus. Bovine Leukemia virus Marek's disease virus vaccine YH, ZX A vaccine that protects against Marek's; disease virus. Marek's; disease virus Marburg Virus vaccine YH, ZX Marburg Virus A vaccine that protects against Marburg Virus. Plasmodium spp. vaccine YH, ZX A vaccine that protects against Plasmodium spp.. Plasmodium spp. Infectious Hematopoietic Necrosis Virus vaccine YH, ZX Infectious Hematopoietic Necrosis Virus A vaccine that protects against Infectious Hematopoietic Necrosis Virus. Rift Valley Fever virus vaccine A vaccine that protects against Rift Valley Fever virus. YH, ZX Rift Valley Fever virus Hantavirus vaccine A vaccine that protects against Hantavirus. Hantavirus YH, ZX Herpes simplex virus type 1 and 2 vaccine A vaccine that protects against Herpes simplex virus type 1 and 2. YH, ZX Herpes simplex virus type 1 and 2 Nipah virus vaccine YH, ZX A vaccine that protects against Nipah virus. Nipah virus Hendra virus vaccine YH, ZX Hendra virus A vaccine that protects against Hendra virus. Entamoeba histolytica vaccine YH, ZX A vaccine that protects against Entamoeba histolytica. Entamoeba histolytica Chlamydophila pneumoniae vaccine A vaccine that protects against Chlamydophila pneumoniae. Chlamydophila pneumoniae YH, ZX Chlamydophila psittaci vaccine A vaccine that protects against Chlamydophila psittaci. YH, ZX Chlamydophila psittaci Burkholderia pseudomallei vaccine YH, ZX A vaccine that protects against Burkholderia pseudomallei. Burkholderia pseudomallei Chlamydia muridarum vaccine A vaccine that protects against Chlamydia muridarum. YH, ZX Chlamydia muridarum Lassa Fever Virus vaccine YH, ZX A vaccine that protects against Lassa Fever Virus. Lassa Fever Virus Canine distemper virus vaccine Canine distemper virus A vaccine that protects against Canine distemper virus. YH, ZX Coccidioides spp. vaccine Coccidioides spp. YH, ZX A vaccine that protects against Coccidioides spp.. Canine parvovirus vaccine Canine parvovirus YH, ZX A vaccine that protects against Canine parvovirus. Helicobacter pylori vaccine A vaccine that protects against Helicobacter pylori. YH, ZX Helicobacter pylori Campylobacter jejuni vaccine YH, ZX A vaccine that protects against Campylobacter jejuni. Campylobacter jejuni SARS-CoV vaccine A vaccine that protects against SARS-CoV. SARS-CoV YH, ZX Trypanosoma brucei vaccine A vaccine that protects against Trypanosoma brucei. Trypanosoma brucei YH, ZX Haemophilus influenzae vaccine Haemophilus influenzae YH, ZX A vaccine that protects against Haemophilus influenzae. Yersinia enterocolitica vaccine Yersinia enterocolitica A vaccine that protects against Yersinia enterocolitica. YH, ZX Clostridium botulinum vaccine Clostridium botulinum YH, ZX A vaccine that protects against Clostridium botulinum . Western equine encephalomyelitis virus vaccine Western equine encephalomyelitis virus YH, ZX A vaccine that protects against Western equine encephalomyelitis virus. Tick-borne Encephalitis Virus (TBEV) vaccine YH, ZX A vaccine that protects against Tick-borne Encephalitis Virus (TBEV). Tick-borne Encephalitis Virus (TBEV) Bacillus anthracis vaccine preparation YH, ZX A bacterial vaccine preparation that results in the generation of a Bacillus anthracis vaccine VIOLIN Pathogen ID: 7 Bordetella pertussis vaccine preparation VIOLIN Pathogen ID: 109 YH, ZX A bacterial vaccine preparation that results in the generation of a Bordetella pertussis vaccine Corynebacterium diphtheriae vaccine preparation VIOLIN Pathogen ID: 62 A bacterial vaccine preparation that results in the generation of a Corynebacterium diphtheriae vaccine YH, ZX Brucella vaccine preparation A bacterial vaccine preparation that results in the generation of a Brucella vaccine VIOLIN Pathogen ID: 8 YH, ZX Mycobacterium tuberculosis vaccine preparation VIOLIN Pathogen ID: 29 YH, ZX A bacterial vaccine preparation that results in the generation of a Mycobacterium tuberculosis vaccine Yersinia pestis vaccine preparation A bacterial vaccine preparation that results in the generation of a Yersinia pestis vaccine YH, ZX VIOLIN Pathogen ID: 11 Japanese encephalitis virus vaccine preparation A viral vaccine preparation that results in the generation of a Japanese encephalitis virus vaccine YH, ZX VIOLIN Pathogen ID: 51 Francisella tularensis vaccine preparation YH, ZX VIOLIN Pathogen ID: 12 A bacterial vaccine preparation that results in the generation of a Francisella tularensis vaccine Ebola virus vaccine preparation YH, ZX VIOLIN Pathogen ID: 13 A viral vaccine preparation that results in the generation of a Ebola virus vaccine Variola virus vaccine preparation VIOLIN Pathogen ID: 18 YH, ZX A viral vaccine preparation that results in the generation of a Variola virus vaccine Escherichia coli vaccine preparation VIOLIN Pathogen ID: 25 A bacterial vaccine preparation that results in the generation of a Escherichia coli vaccine YH, ZX Neisseria meningitidis vaccine preparation YH, ZX A bacterial vaccine preparation that results in the generation of a Neisseria meningitidis vaccine VIOLIN Pathogen ID: 46 Human Immunodeficiency Virus vaccine preparation A viral vaccine preparation that results in the generation of a Human Immunodeficiency Virus vaccine VIOLIN Pathogen ID: 26 YH, ZX Haemophilus influenzae vaccine preparation YH, ZX A bacterial vaccine preparation that results in the generation of a Haemophilus influenzae vaccine VIOLIN Pathogen ID: 31 Leishmania amazonensis vaccine preparation VIOLIN Pathogen ID: 117 A parasite vaccine preparation that results in the generation of a Leishmania amazonensis vaccine YH, ZX Leishmania infantum vaccine preparation A parasite vaccine preparation that results in the generation of a Leishmania infantum vaccine YH, ZX VIOLIN Pathogen ID: 116 Plasmodium spp. vaccine preparation YH, ZX VIOLIN Pathogen ID: 30 A parasite vaccine preparation that results in the generation of a Plasmodium spp. vaccine Shigella vaccine preparation A bacterial vaccine preparation that results in the generation of a Shigella vaccine YH, ZX VIOLIN Pathogen ID: 43 Actinobacillus pleuropneumoniae vaccine preparation A bacterial vaccine preparation that results in the generation of a Actinobacillus pleuropneumoniae vaccine YH, ZX VIOLIN Pathogen ID: 86 Vibrio cholerae vaccine preparation YH, ZX A bacterial vaccine preparation that results in the generation of a Vibrio cholerae vaccine VIOLIN Pathogen ID: 102 Cryptosporidium parvum vaccine preparation A parasite vaccine preparation that results in the generation of a Cryptosporidium parvum vaccine VIOLIN Pathogen ID: 123 YH, ZX Cancer vaccine preparation VIOLIN Pathogen ID: 99 A vaccine preparation that results in the generation of a Cancer vaccine YH, ZX Allergy vaccine preparation VIOLIN Pathogen ID: 114 YH, ZX A vaccine preparation that results in the generation of a Allergy vaccine Babesia bovis vaccine preparation YH, ZX A parasite vaccine preparation that results in the generation of a Babesia bovis vaccine VIOLIN Pathogen ID: 92 Salmonella spp. vaccine preparation VIOLIN Pathogen ID: 42 A bacterial vaccine preparation that results in the generation of a Salmonella spp. vaccine YH, ZX Bovine Leukemia virus vaccine preparation A viral vaccine preparation that results in the generation of a Bovine Leukemia virus vaccine VIOLIN Pathogen ID: 101 YH, ZX Bovine herpesvirus 1 vaccine preparation YH, ZX VIOLIN Pathogen ID: 67 A viral vaccine preparation that results in the generation of a Bovine herpesvirus 1 vaccine Aeromonas salmonicida vaccine preparation A bacterial vaccine preparation that results in the generation of a Aeromonas salmonicida vaccine VIOLIN Pathogen ID: 79 YH, ZX Rickettsia spp vaccine preparation VIOLIN Pathogen ID: 108 YH, ZX A bacterial vaccine preparation that results in the generation of a Rickettsia spp vaccine Clostridium tetani vaccine preparation YH, ZX VIOLIN Pathogen ID: 41 A bacterial vaccine preparation that results in the generation of a Clostridium tetani vaccine Streptococcus pneumoniae vaccine preparation YH, ZX A bacterial vaccine preparation that results in the generation of a Streptococcus pneumoniae vaccine VIOLIN Pathogen ID: 47 Hepatitis A virus vaccine preparation A viral vaccine preparation that results in the generation of a Hepatitis A virus vaccine YH, ZX VIOLIN Pathogen ID: 48 Hepatitis B virus vaccine preparation YH, ZX A viral vaccine preparation that results in the generation of a Hepatitis B virus vaccine VIOLIN Pathogen ID: 49 Marek's disease virus vaccine preparation VIOLIN Pathogen ID: 69 A viral vaccine preparation that results in the generation of a Marek's disease virus vaccine YH, ZX Marburg Virus vaccine preparation A viral vaccine preparation that results in the generation of a Marburg Virus vaccine YH, ZX VIOLIN Pathogen ID: 28 Human papillomavirus vaccine preparation A viral vaccine preparation that results in the generation of a Human papillomavirus vaccine VIOLIN Pathogen ID: 54 YH, ZX Infectious Hematopoietic Necrosis Virus vaccine preparation A viral vaccine preparation that results in the generation of a Infectious Hematopoietic Necrosis Virus vaccine VIOLIN Pathogen ID: 75 YH, ZX Rift Valley Fever virus vaccine preparation VIOLIN Pathogen ID: 128 A viral vaccine preparation that results in the generation of a Rift Valley Fever virus vaccine YH, ZX Influenza virus vaccine preparation YH, ZX A viral vaccine preparation that results in the generation of a Influenza virus vaccine VIOLIN Pathogen ID: 50 Hantavirus vaccine preparation A viral vaccine preparation that results in the generation of a Hantavirus vaccine VIOLIN Pathogen ID: 27 YH, ZX Herpes simplex virus type 1 and 2 vaccine preparation VIOLIN Pathogen ID: 100 YH, ZX A viral vaccine preparation that results in the generation of a Herpes simplex virus type 1 and 2 vaccine Nipah virus vaccine preparation A viral vaccine preparation that results in the generation of a Nipah virus vaccine YH, ZX VIOLIN Pathogen ID: 127 Hendra virus vaccine preparation YH, ZX A viral vaccine preparation that results in the generation of a Hendra virus vaccine VIOLIN Pathogen ID: 125 Measles virus vaccine preparation VIOLIN Pathogen ID: 52 YH, ZX A viral vaccine preparation that results in the generation of a Measles virus vaccine Mumps virus vaccine preparation YH, ZX A viral vaccine preparation that results in the generation of a Mumps virus vaccine VIOLIN Pathogen ID: 53 Entamoeba histolytica vaccine preparation A parasite vaccine preparation that results in the generation of a Entamoeba histolytica vaccine VIOLIN Pathogen ID: 131 YH, ZX Poliovirus vaccine preparation VIOLIN Pathogen ID: 55 YH, ZX A viral vaccine preparation that results in the generation of a Poliovirus vaccine Chlamydophila pneumoniae vaccine preparation YH, ZX A bacterial vaccine preparation that results in the generation of a Chlamydophila pneumoniae vaccine VIOLIN Pathogen ID: 112 Chlamydophila psittaci vaccine preparation YH, ZX VIOLIN Pathogen ID: 120 A bacterial vaccine preparation that results in the generation of a Chlamydophila psittaci vaccine Classical swine fever virus vaccine preparation A viral vaccine preparation that results in the generation of a Classical swine fever virus vaccine YH, ZX VIOLIN Pathogen ID: 66 Chlamydophila abortus vaccine preparation VIOLIN Pathogen ID: 82 A bacterial vaccine preparation that results in the generation of a Chlamydophila abortus vaccine YH, ZX Rabies virus vaccine preparation A viral vaccine preparation that results in the generation of a Rabies virus vaccine YH, ZX VIOLIN Pathogen ID: 56 Rotavirus vaccine preparation VIOLIN Pathogen ID: 57 YH, ZX A viral vaccine preparation that results in the generation of a Rotavirus vaccine Rubella virus vaccine preparation YH, ZX A viral vaccine preparation that results in the generation of a Rubella virus vaccine VIOLIN Pathogen ID: 58 Burkholderia pseudomallei vaccine preparation YH, ZX VIOLIN Pathogen ID: 121 A bacterial vaccine preparation that results in the generation of a Burkholderia pseudomallei vaccine Chlamydia muridarum vaccine preparation A bacterial vaccine preparation that results in the generation of a Chlamydia muridarum vaccine VIOLIN Pathogen ID: 113 YH, ZX Yellow fever virus vaccine preparation A viral vaccine preparation that results in the generation of a Yellow fever virus vaccine YH, ZX VIOLIN Pathogen ID: 59 Varicella-zoster virus vaccine preparation VIOLIN Pathogen ID: 60 A viral vaccine preparation that results in the generation of a Varicella-zoster virus vaccine YH, ZX Lassa Fever Virus vaccine preparation VIOLIN Pathogen ID: 17 A viral vaccine preparation that results in the generation of a Lassa Fever Virus vaccine YH, ZX Eimeria tenella vaccine preparation A parasite vaccine preparation that results in the generation of a Eimeria tenella vaccine VIOLIN Pathogen ID: 88 YH, ZX Dengue Virus vaccine preparation A viral vaccine preparation that results in the generation of a Dengue Virus vaccine YH, ZX VIOLIN Pathogen ID: 126 Canine distemper virus vaccine preparation A viral vaccine preparation that results in the generation of a Canine distemper virus vaccine VIOLIN Pathogen ID: 74 YH, ZX Coccidioides spp. vaccine preparation A fungal vaccine preparation that results in the generation of a Coccidioides spp. vaccine YH, ZX VIOLIN Pathogen ID: 132 Canine parvovirus vaccine preparation A viral vaccine preparation that results in the generation of a Canine parvovirus vaccine YH, ZX VIOLIN Pathogen ID: 72 Eimeria maxima vaccine preparation VIOLIN Pathogen ID: 98 A parasite vaccine preparation that results in the generation of a Eimeria maxima vaccine YH, ZX Porcine circovirus 2 vaccine preparation YH, ZX VIOLIN Pathogen ID: 64 A viral vaccine preparation that results in the generation of a Porcine circovirus 2 vaccine Pseudorabies virus vaccine preparation YH, ZX VIOLIN Pathogen ID: 65 A viral vaccine preparation that results in the generation of a Pseudorabies virus vaccine West Nile virus vaccine preparation YH, ZX A viral vaccine preparation that results in the generation of a West Nile virus vaccine VIOLIN Pathogen ID: 68 Newcastle disease virus vaccine preparation VIOLIN Pathogen ID: 70 A viral vaccine preparation that results in the generation of a Newcastle disease virus vaccine YH, ZX Feline leukemia virus vaccine preparation VIOLIN Pathogen ID: 71 A viral vaccine preparation that results in the generation of a Feline leukemia virus vaccine YH, ZX Canine coronavirus vaccine preparation A viral vaccine preparation that results in the generation of a Canine coronavirus vaccine VIOLIN Pathogen ID: 73 YH, ZX Lawsonia intracellularis vaccine preparation YH, ZX A bacterial vaccine preparation that results in the generation of a Lawsonia intracellularis vaccine VIOLIN Pathogen ID: 76 Porphyromonas gulae vaccine preparation A bacterial vaccine preparation that results in the generation of a Porphyromonas gulae vaccine YH, ZX VIOLIN Pathogen ID: 77 Yersinia ruckeri vaccine preparation A bacterial vaccine preparation that results in the generation of a Yersinia ruckeri vaccine YH, ZX VIOLIN Pathogen ID: 78 Vibrio anguillarum (Listonella anguillarum) vaccine preparation A bacterial vaccine preparation that results in the generation of a Vibrio anguillarum (Listonella anguillarum) vaccine YH, ZX VIOLIN Pathogen ID: 80 Streptococcus equi vaccine preparation YH, ZX VIOLIN Pathogen ID: 81 A bacterial vaccine preparation that results in the generation of a Streptococcus equi vaccine Mycoplasma synoviae vaccine preparation YH, ZX A bacterial vaccine preparation that results in the generation of a Mycoplasma synoviae vaccine VIOLIN Pathogen ID: 83 Mycoplasma gallisepticum vaccine preparation VIOLIN Pathogen ID: 84 A bacterial vaccine preparation that results in the generation of a Mycoplasma gallisepticum vaccine YH, ZX Bordetella avium vaccine preparation A bacterial vaccine preparation that results in the generation of a Bordetella avium vaccine VIOLIN Pathogen ID: 85 YH, ZX Eimeria spp. vaccine preparation A parasite vaccine preparation that results in the generation of a Eimeria spp. vaccine VIOLIN Pathogen ID: 87 YH, ZX Toxoplasma gondii vaccine preparation A parasite vaccine preparation that results in the generation of a Toxoplasma gondii vaccine YH, ZX VIOLIN Pathogen ID: 91 Theileria parva vaccine preparation A parasite vaccine preparation that results in the generation of a Theileria parva vaccine VIOLIN Pathogen ID: 89 YH, ZX Theileria annulata vaccine preparation YH, ZX VIOLIN Pathogen ID: 90 A parasite vaccine preparation that results in the generation of a Theileria annulata vaccine Neospora caninum vaccine preparation A parasite vaccine preparation that results in the generation of a Neospora caninum vaccine VIOLIN Pathogen ID: 93 YH, ZX Giardia duodenalis vaccine preparation A parasite vaccine preparation that results in the generation of a Giardia duodenalis vaccine VIOLIN Pathogen ID: 94 YH, ZX Sarcocystis neurona vaccine preparation YH, ZX VIOLIN Pathogen ID: 95 A parasite vaccine preparation that results in the generation of a Sarcocystis neurona vaccine Babesia canis vaccine preparation YH, ZX VIOLIN Pathogen ID: 96 A parasite vaccine preparation that results in the generation of a Babesia canis vaccine Leishmania donovani vaccine preparation A parasite vaccine preparation that results in the generation of a Leishmania donovani vaccine YH, ZX VIOLIN Pathogen ID: 97 Helicobacter pylori vaccine preparation A bacterial vaccine preparation that results in the generation of a Helicobacter pylori vaccine YH, ZX VIOLIN Pathogen ID: 134 Campylobacter jejuni vaccine preparation VIOLIN Pathogen ID: 24 A bacterial vaccine preparation that results in the generation of a Campylobacter jejuni vaccine YH, ZX SARS-CoV vaccine preparation VIOLIN Pathogen ID: 129 A viral vaccine preparation that results in the generation of a SARS-CoV vaccine YH, ZX Trypanosoma brucei vaccine preparation YH, ZX VIOLIN Pathogen ID: 133 A parasite vaccine preparation that results in the generation of a Trypanosoma brucei vaccine Yersinia enterocolitica vaccine preparation YH, ZX VIOLIN Pathogen ID: 130 A bacterial vaccine preparation that results in the generation of a Yersinia enterocolitica vaccine Clostridium botulinum vaccine preparation YH, ZX A bacterial vaccine preparation that results in the generation of a Clostridium botulinum vaccine VIOLIN Pathogen ID: 14 Western equine encephalomyelitis virus vaccine preparation VIOLIN Pathogen ID: 122 A viral vaccine preparation that results in the generation of a Western equine encephalomyelitis virus vaccine YH, ZX Tick-borne Encephalitis Virus (TBEV) vaccine preparation VIOLIN Pathogen ID: 106 YH, ZX A viral vaccine preparation that results in the generation of a Tick-borne Encephalitis Virus (TBEV) vaccine AE: CSF protein increased AE: CSF protein increased is an abnormal cerebrospinal fluid production that results in and increase in blood level CSF protein SS, YH AE: CSF test abnormal AE: CSF test abnormal is a lab test abnormal that results in abnormal result in the Cerebrospinal fluid (CSF) collection test to look at the fluid that surrounds the brain and spinal cord. WEB: www.nlm.nih.gov/medlineplus/ency/article/003428.htm This should be inferred as a "AE: lab test abnormal". SS, YH AE: Henoch-Schonlein purpura allergic purpura, anaphylactoid purpura, vascular purpura SS, YH WEB: http://en.wikipedia.org/wiki/Henoch-Schonlein_purpura AE: Henoch-Schonlein purpura is purpura that is a systemic vasculitis (inflammation of blood vessels) characterized by deposition of immune complexes containing the antibody IgA in the skin and kidney. This results from some allergic response, AE: abasia WEB: http://en.wikipedia.org/wiki/Abasia SS, YH AE: abasia is a movement disorder that results in and inability to walk due to impaired muscle coordination AE: abdominal pain upper SS, YH AE: abdominal pain upper is an abdominal pain that results in an upper stomach ache AE: ageusia WEB: http://en.wikipedia.org/wiki/Ageusia AE: ageusia is an abnormal behavior AE that results in loss of taste functions of the tongue, particularly the inability to detect sweetness, sourness, bitterness, saltiness, and umami (the taste of monosodium glutamate). SS, YH AE: alanine aminotransferase increased SS, YH AE: alanine aminotransferase increased is a lab test abnormal that results in an increase in blood level alanine aminotransferase AE: anosmia AE: anosmia is an abnormal behavior AE that results in a lack of functioning olfaction , an inability to perceive odors WEB: http://en.wikipedia.org/wiki/Olfaction SS, YH AE: anxiety SS, YH AE: anxiety is an abnormal behavior AE that results in a psychological and physiological state characterized by cognitive, somatic, emotional, and behavioral components.[2] These components combine to create an unpleasant feeling that is typically associated with uneasiness, fear, or worry WEB: http://en.wikipedia.org/wiki/Anxiety AE: aspartate aminotransferase increased SS, YH AE: aspartate aminotransferase increased is a lab test abnormal that results in an increase in blood level aspartate aminotransferase AE: balance disorder SS, YH WEB: http://en.wikipedia.org/wiki/Balance_disorder AE: balance disorder is an abnormal behavior AE that results in a disturbance that causes an individual to feel unsteady, giddy, woozy, or have a sensation of movement, spinning, or floating AE: blister WEB: http://en.wikipedia.org/wiki/Blister AE: blister is a skin adverse event that results in a small pocket of fluid within the upper layers of the skin SS, YH AE: cellulitis AE: cellulitis is a diffuse inflammation of connective tissue with severe inflammation of dermal and subcutaneous layers of the skin SS, YH WEB: http://en.wikipedia.org/wiki/Cellulitis AE: cold sweat WEB: http://en.wikipedia.org/wiki/Cold_sweat AE: cold sweat is an abnormal behavior AE that results in a type of perspiration usually associated with anxiety or fear SS, YH AE: convulsion AE: convulsion is a muscle adverse event that results in a medical condition where body muscles contract and relax rapidly and repeatedly, resulting in an uncontrolled shaking of the body WEB: http://en.wikipedia.org/wiki/Convulsion SS, YH AE: difficulty in walking AE: difficulty in walking is a movement disorder that results in inability to walk properly SS, YH AE: dysgeusia WEB: http://en.wikipedia.org/wiki/Dysgeusia AE: dysgeusia is an abnormal behavior AE that results in distortion of the sense of taste SS, YH AE: dyskinesia AE: dyskinesia is a movement disorder which consists of effects including diminished voluntary movements and the presence of involuntary movements SS, YH WEB: http://en.wikipedia.org/wiki/Dyskinesia AE: dyspnoea AE: dyspnea SS, YH AE: dyspnoea is an abnormal respiration debilitating symptom that is the experience of unpleasant or uncomfortable respiratory sensations, shortness of breath, air hunger WEB: http://en.wikipedia.org/wiki/Dyspnoea AE: electromyogram abnormal SS, YH AE: electromyogram abnormal is a lab test abnormal that results in abnormal activity in skeletal muscles evaluted and measured by electromyography WEB: http://en.wikipedia.org/wiki/Electromyography AE: eye irritation WEB: http://www.freemd.com/eye-irritation/ AE: eye irritation is an eye disorder that results in mild eye redness, itching, or tearing SS, YH AE: eye pruritus SS, YH AE: eye pruritus is a pruritus (an unpleasant sensation that evokes the desire or reflex to scratch) at the eye area AE: glomerulonephritis SS, YH WEB: http://en.wikipedia.org/wiki/Glomerulonephritis AE: glomerular nephritis AE: glomerulonephritis is a kidney disorder that results in a renal disease that is characterized by inflammation of the glomeruli, or small blood vessels in the kidneys. AE: kidney disorder SS, YH AE: kidney disorder is an adverse event that results in disease or disorder that affects the functions of the kidneys. AE: haematocrit decreased SS, YH AE: hematocrit decreased AE: haematocrit decreased is a lab test abnormal that results in decrease in the proportion of blood volume that is occupied by red blood cells WEB: http://en.wikipedia.org/wiki/Hematocrit AE: haemoglobin decreased AE: haemoglobin decreased is a lab test abnormal that results in a decrease in blood level hemoglobin SS, YH AE: hemoglobin decreased AE: hypoaesthesia WEB:http://medguides.medicines.org.uk/document.aspx?name=hypoaesthesia AE: hypoesthesia SS, YH AE: hypoaesthesia is a sensory capability AE that skin loses some of its sensitivity to pain or touch AE: hypoaesthesia oral AE: hypoesthesia oral SS, YH WEB: http://en.wikipedia.org/wiki/Hypoesthesia AE: hypoaesthesia oral is a nervous system AE that results in a reduced sense of touch or sensation, or a partial loss of sensitivity to sensory stimuli in the oral area AE: influenza AE: influenza is a respiratory system AE that results in an infectious disease caused by RNA viruses of the family Orthomyxoviridae (the influenza viruses), that affects birds and mammals SS, YH WEB: http://en.wikipedia.org/wiki/Influenza AE: influenza like illness WEB: http://en.wikipedia.org/wiki/Influenza-like_illness SS, YH acute respiratory infection, ARI, flu-like syndrome AE: influenza like illness is a respiratory system AE that results in a medical diagnosis of possible influenza or other illness causing a set of common symptoms AE: injected limb mobility decreased SS, YH AE: injected limb mobility decreased is a mobility decreased that occurs in the limb in which injection is administered AE: mobility decreased SS, YH AE: mobility decreased is a nervous system AE that results in difficulty in movement leading to less ability to move part(s) of body AE: injection-site haematoma SS, YH http://en.wikipedia.org/wiki/Hematoma AE: injection-site haematoma is an injection-site AE that results in a collection of blood outside the blood vessels at the physical area of injection AE: injection-site hematoma AE: injection-site induration SS, YH AE: injection-site induration is an injection-site AE that results in hardening or thickening of tissue at the physical injection site WEB: http://wordnetweb.princeton.edu/perl/webwn?s=induration AE: injection-site pruritus SS, YH WEB: http://en.wikipedia.org/wiki/Itch AE: injection-site pruritus is an injection-site AE that results in an unpleasant sensation that evokes the desire or reflex to scratch at the physical area of injection AE: injection-site rash AE: injection-site rash is a rash that results in a change of the skin which affects its color, appearance or texture at the physical injection site SS, YH WEB: http://en.wikipedia.org/wiki/Rash AE: injection-site warmth SS, YH AE: injection-site warmth is an injection-site AE that results in feeling of warmth at the physical injection site AE: joint swelling WEB: http://www.nlm.nih.gov/medlineplus/ency/article/003262.htm AE: joint swelling is a joint disorder that results in a buildup of fluid in the soft tissue surrounding the joint SS, YH AE: lacrimation increased WEB: http://www.medterms.com/script/main/art.asp?articlekey=6199 SS, YH AE: lacrimation increased is a crying abnormal that results in an increase in production, secretion, and shedding of tears AE: lip swelling AE: lip swelling is an edema (swelling) that results in enlargement or protuberance in the lip WEB: http://en.wikipedia.org/wiki/Swelling_%28medical%29 SS, YH AE: lymphadenopathy AE: lymphadenopathy is an immune system disorder that results in swollen/enlarged lymph nodes SS, YH WEB: http://en.wikipedia.org/wiki/Lymphadenopathy AE: muscular weakness WEB: http://en.wikipedia.org/wiki/Muscular_weakness SS, YH AE: muscular weakness is a muscle adverse event that results in lack of muscle strength AE: musculoskeletal stiffness AE: musculoskeletal stiffness is a sensory capability AE that results in a sensation of stiffness in muscles and skeleton SS, YH AE: nasal congestion WEB: http://en.wikipedia.org/wiki/Nasal_congestion SS, YH AE: nasal congestion is a respiratory system AE that results in a blockage of the nasal passages usually due to membranes lining the nose becoming swollen from inflamed blood vessels AE: nasopharyngitis WEB: http://en.wikipedia.org/wiki/Nasopharyngitis AE: common cold AE: nasopharyngitis is a respiratory system inflammation that results in common cold, a contagious, viral infectious disease of the upper respiratory system SS, YH AE: neuropathy peripheral WEB: http://www.ninds.nih.gov/disorders/peripheralneuropathy/detail_peripheralneuropathy.htm AE: neuropathy peripheral is an AE: neuropathy that results in a damage to the peripheral nervous system, the vast communication network that transmits information from the brain and the spinal cord (the central nervous system) to every other part of the body SS, YH AE: ocular hyperaemia WEB: http://www.med.miami.edu/news/view.asp?id=259 AE: ocular hyperaemia is an eye disorder that results in severe redness and irritation of the eyes SS, YH AE: ocular hyperemia AE: oropharyngeal pain WEB: http://en.wikipedia.org/wiki/Oropharyngeal_airway SS, YH AE: oropharyngeal pain is a pain in oral airway AE: otitis media AE: otitis media is an ear disorder that results in inflammation of the middle ear, or middle ear infection WEB: http://en.wikipedia.org/wiki/Otitis_media SS, YH AE: pericarditis AE: pericarditis is a cardiovascular disorder that results in a condition in which the sac-like covering around the heart (pericardium) becomes inflamed SS, YH WEB: http://www.nlm.nih.gov/medlineplus/ency/article/000182.htm AE: pharyngeal edema WEB: http://www.ncbi.nlm.nih.gov/mesh/68004487?ordinalpos=1&itool=EntrezSystem2.PEntrez.Mesh.Mesh_ResultsPanel.Mesh_RVDocSum SS, YH AE: pharyngeal oedema AE: pharyngeal edema is an edema that results in an bbnormal fluid accumulation in TISSUES or body cavities in pharynx (throat swelling). AE: pharyngitis SS, YH AE: pharyngitis is a digestive system AE that results in an inflammation of the throat or pharynx WEB: http://en.wikipedia.org/wiki/Pharyngitis AE: pharyngolaryngeal pain WEB: http://www.wordinfo.info/words/index/info/view_unit/1631/ AE: pharyngolaryngeal pain is a pain in sinus and throat SS, YH AE: rash macular WEB: http://medical-dictionary.thefreedictionary.com/macular+rash AE: rash macular is a rash that results in a skin eruption in which the lesions are flat and less than 1 cm in diameter SS, YH AE: rash papular AE: rash papular is a skin adverse event that results in a change of the skin which affects its color, appearance or texture to a form similar to a papule WEB: http://en.wikipedia.org/wiki/Rash SS, YH AE: respiratory distress WEB: http://en.wikipedia.org/wiki/Acute_respiratory_distress_syndrome AE: respiratory distress is a respiratory system AE that results in a severe lung disease caused by a variety of direct and indirect issues. It is characterized by inflammation of the lung parenchyma leading to impaired gas exchange with concomitant systemic release of inflammatory mediators causing inflammation, hypoxemia and frequently resulting in multiple organ failure. SS, YH AE: respiratory tract congestion SS, YH AE: respiratory tract congestion is a respiratory system AE that results in congestion in respiratory tract AE: retching SS, YH WEB: http://en.wikipedia.org/wiki/Retching AE: retching is a gustatory system AE that results in a process in the human body where gastric (and sometimes duodenal) contents are forced into the esophagus, but do not enter the pharynx AE: rhinitis SS, YH AE: rhinitis is a respiratory system inflammation that is characterized by runny nose,irritation and inflammation of some internal areas of the nose runny nose WEB: http://en.wikipedia.org/wiki/Rhinitis AE: rhinorrhoea AE: rhinorrhoea is a respiratory system AE that results in runny nose, an unusually significant amount of nasal fluid SS, YH AE: rhinorrhea WEB: http://en.wikipedia.org/wiki/Rhinorrhoea AE: shoulder pain SS, YH WEB: http://www.nlm.nih.gov/medlineplus/ency/article/003171.htm AE: shoulder pain is a pain iin or around the shoulder joint AE: sinus congestion SS, YH WEB: http://en.wikipedia.org/wiki/Sinus_%28anatomy%29, http://en.wikipedia.org/wiki/Nasal_congestion AE: sinus congestion is a respiratory system AE that results in blockage of the air cavities in the cranial bones or nasal passages usually due to membranes lining the nose becoming swollen from inflamed blood vessels AE: sneezing sternutation AE: sneezing is an adverse event that results in sternutation, a semi-autonomous, convulsive expulsion of air from the lungs through the nose and mouth, usually caused by foreign particles irritating the nasal mucosa WEB: http://en.wikipedia.org/wiki/Sneezing SS, YH AE: tachycardia SS, YH AE: tachycardia is an increased heart rate that exceeds the normal range for a resting heartrate (heartrate in an inactive or sleeping individual) WEB: http://en.wikipedia.org/wiki/Tachycardia AE: tendonitis AE: tendonitis is a tendon disorder that results in an inflammation of a tendon AE: tendinitis SS, YH WEB: http://en.wikipedia.org/wiki/Tendinitis AE: throat tightness AE: throat tightness is a sensory capability AE that results in a sensation of tightness in the throat AE: upper respiratory tract infection WEB: http://en.wikipedia.org/wiki/Upper_respiratory_tract_infection AE: upper respiratory tract infection is a respiratory system AE that results in illnesses caused by an acute infection which involves the upper respiratory tract: nose, sinuses, pharynx or larynx URI, URTI SS, YH AE: varicella AE: varicella is an AE: infect viral that results in an acute contagious diseased caused by herpes varicella zoster virus; causes a rash of vesicles on the face and body. WEB: http://wordnetweb.princeton.edu/perl/webwn?s=varicella SS, YH AE: chicken pox Staphylococcus aureus protein YH, ZX Streptococcus agalactiae protein YH, ZX Streptococcus pyogenes protein YH, ZX Treponema pallidum protein YH, ZX YopH from Y. pestis strain: CO92, biovar: Orientalis Protegen ID: 51; NCBI Gene GI: 1172712; NCBI Protein GI: 16082755; NCBI Protein Accession: NP_395201; NCBITaxon: 214092 YH, ZX OprF Protegen ID: 843; NCBI Gene GI: 878442; NCBI Protein GI: 15596974; NCBI Protein Accession: NP_250468; NCBITaxon: 208964 The oprF gene was cloned into plasmid vector pVR1020, and the plasmid vaccines were delivered to mice by biolistic (gene gun) intradermal inoculation. Following the initial immunization and two consecutive boosts, each at 2-week intervals, protection was demonstrated in a mouse model of chronic pulmonary infection by P. aeruginosa. Eight days postchallenge, both lungs were removed and examined. A significant reduction in the presence of severe macroscopic lesions, as well as in the number of bacteria present in the lungs, was seen [PubMed: 11292786]. YH, ZX PcrV YH, ZX Burned Pseudomonas aeruginosa-infected mice immunized against PcrV, a type III virulence system translocating protein, showed significantly enhanced survival compared to controls [PubMed: 11500471]. Protegen ID: 844; NCBI Gene GI: 882997; NCBI Protein GI: 15596903; NCBI Protein Accession: NP_250397; NCBITaxon: 208964 OprI Protegen ID: 845; NCBI Gene GI: 879851; NCBI Protein GI: 15598049; NCBI Protein Accession: NP_251543; NCBITaxon: 208964 Recombinant OprI protein was used to immunize mice, and was found to be protective against a challenge with a four- to fivefold 50% lethal dose of P. aeruginosa [PubMed: 2114360]. YH, ZX AY243312 YH, ZX Protegen ID: 68; NCBI Nucleotide GI: 29692106 Ag85B from M. tuberculosis H37Rv YH, ZX Protegen ID: 118; NCBI Gene GI: 885785; NCBI Protein GI: 15609023; NCBI Protein Accession: NC_000962.2; NCBITaxon: 1773 In mice, a primary vaccination with Ag85B-encoding plasmid DNA (DNA-85B) was protective against Mycobacterium tuberculosis (MTB) infection and associated with Ag85B-specific CD4+ T cells producing IFN-gamma and controlling intramacrophagic MTB growth [PubMed: 17250590]. znuA YH, ZX Protegen ID: 228; NCBI Gene GI: 3341411; NCBI Protein GI: 62317941; NCBI Protein Accession: YP_223794; NCBITaxon: 262698 FbpD YH, ZX Protegen ID: 814; NCBI Gene GI: 7562680; NCBI Protein GI: 224992215; NCBI Protein Accession: YP_002646905; NCBITaxon: 561275 Intravenous vaccination with recombinant bacteria carrying expression plasmid for MPB/MPT51 in BALB/c mice elicited significant protective responses, comparable to those evoked by a live Mycobacterium bovis BCG vaccine [PubMed: 15039321]. MPT64 DNA vaccines encoding secreted proteins Ag85B and MPT64 protect mice from the tuberculosis H37Rv strain [PubMed: 15498274]. *Note* MPT64 in combination with Ag85B was protective, DNA vaccine of just MPT64 was mildly protective in mice. Protegen ID: 815; NCBI Gene GI: 885925; NCBI Protein GI: 15609117; NCBI Protein Accession: NP_216496; NCBITaxon: 83332 YH, ZX ESAT-6 Protegen ID: 816; NCBI Gene GI: 886209; NCBI Protein GI: 57117165; NCBI Protein Accession: YP_178023; NCBITaxon: 83332 YH, ZX In a prophylactic vaccine model, immunization with the Mycobacterium tuberculosis protein ESAT-6 with LANAC adjuvant elicited significant protective immunity against aerosol challenge with virulent M. tuberculosis [PubMed: 16751377]. KatG DNA vaccines encoding KatG antigen fused to TPA signal sequences evoked a significant protective response in mice aerogenically challenged with low doses of Mycobacterium tuberculosis Erdman 17 to 21 days after the final immunization [PubMed: 10456931]. YH, ZX Protegen ID: 817; NCBI Gene GI: 885638; NCBI Protein GI: 15609045; NCBI Protein Accession: NP_216424; NCBITaxon: 83332 PstS3 Mice vaccinated with PstS-3 DNA demonstrated significant and sustained reduction in bacterial CFU numbers in spleen and lungs for 3 mo after M. tuberculosis challenge, as compared with CFU counts in mice vaccinated with control DNA [PubMed: 9916741]. Protegen ID: 818; NCBI Gene GI: 885366; NCBI Protein GI: 57116798; NCBI Protein Accession: YP_177768; NCBITaxon: 83332 YH, ZX PE20 Protegen ID: 819; NCBI Gene GI: 885537; NCBI Protein GI: 57116919; NCBI Protein Accession: YP_177843; NCBITaxon: 83332 YH, ZX A selection of previously identified protective Mycobacterium tuberculosis DNA vaccines were re-formulated as proteins and administered with a Th1-inducing adjuvant to help stimulate the relevant immune responses necessary for protection. One candidate (Rv1806-1807) induced protection in the guinea pig aerosol infection model 30 days post-challenge on the basis of reducing the bacterial burden of M. tuberculosis in the lungs [PubMed: 16520093]. PPE31 A selection of previously identified protective Mycobacterium tuberculosis DNA vaccines were re-formulated as proteins and administered with a Th1-inducing adjuvant to help stimulate the relevant immune responses necessary for protection. One candidate (Rv1806-1807) induced protection in the guinea pig aerosol infection model 30 days post-challenge on the basis of reducing the bacterial burden of M. tuberculosis in the lungs [PubMed: 16520093]. YH, ZX Protegen ID: 820; NCBI Gene GI: 885072; NCBI Protein GI: 57116920; NCBI Protein Accession: YP_177653; NCBITaxon: 83332 HBHA Protegen ID: 821; NCBI Gene GI: 5211814; NCBI Protein GI: 148660242; NCBI Protein Accession: YP_001281765; NCBITaxon: 25177 YH, ZX Purified preparations of HBHA were emulsified in a dimethyldioctadecylammonium bromide-monophosphoryl lipid A adjuvant and tested for the ability to reduce M. tuberculosis infection in the mouse aerosol challenge model for tuberculosis. The HBHA-containing vaccine gave a approximately 0.7-log reduction in CFU in both mouse lungs and spleens compared to adjuvant controls 28 days following challenge [PubMed: 15557600]. PPE14 YH, ZX Protegen ID: 822; NCBI Gene GI: 885069; NCBI Protein GI: 57116795; NCBI Protein Accession: YP_177765; NCBITaxon: 83332 immunization with the soluble recombinant rMTB41 protein plus adjuvant, a regimen known to generate primarily CD4+ T cells, resulted in induction of protection comparable to BCG in two well-established animal models of tuberculosis (mice and guinea pigs) [PubMed: 15917115]. Gap GAPDH (Gap) associated with murine IL-12 gene in a DNA vaccine formulation partially protected mice against experimental infection [PubMed: 12171297]. YH, ZX Protegen ID: 823; NCBI Gene GI: 3340207; NCBI Protein GI: 62290600; NCBI Protein Accession: YP_222393; NCBITaxon: 262698 HtrA YH, ZX rHtrA was found to be very immunogenic and partially protective in both the passive infant rat model of bacteremia and the active chinchilla model of otitis media [PubMed: 9488373]. Protegen ID: 824; NCBI Protein GI: 2935168; NCBITaxon: 727 HspA Orogastric immunization of mice with recombinant H. pylori HspA proteins protected 80% of animals from a challenge dose of 10^4 Helicobacter felis bacteria [PubMed: 7604021]. Protegen ID: 825; NCBI Protein GI: 712830; NCBITaxon: 210 YH, ZX HspB YH, ZX Protegen ID: 826; NCBI Protein GI: 712831; NCBITaxon: 210 Orogastric immunization of mice with recombinant H. pylori HspB proteins protected 70% of animals from a challenge dose of 10^4 Helicobacter felis bacteria [PubMed: 7604021]. GltA Mice were immunised with the citrate synthase protein by intra-Peyer's patch immunisation. Pre-immunisation with the citrate synthase protein led to a 84-91% reduction in H. pylori infection compared to unimmunised controls [PubMed: 10378424]. YH, ZX Protegen ID: 827; NCBI Protein GI: 2493711; NCBITaxon: 210 TbpA Protegen ID: 833; NCBI Protein GI: 8926211; NCBITaxon: 487 Recombinant TbpA protein was used in a mouse intraperitoneal-infection model to determine their ability to protect against meningococcal infection and to induce cross-reactive and bactericidal antibodies. TbpA was found to afford protection against meningococcal challenge when administered as the sole immunogen [PubMed: 11179327]. YH, ZX LSA-3 YH, ZX Protegen ID: 834; NCBI Gene GI: 812783; NCBI Protein GI: 124801463; NCBI Protein Accession: XP_001349701; NCBITaxon: 36329 In chimpanzees (Pan troglodytes), the primates most closely related to humans and that share a similar susceptibility to P. falciparum liver-stage infection, immunization with LSA-3 induced protection against successive heterologous challenges with large numbers of P. falciparum sporozoites [PubMed: 11062538]. eba-175 YH, ZX Protegen ID: 835; NCBI Gene GI: 2654998; NCBI Protein GI: 296004911; NCBI Protein Accession: XP_001349207; NCBITaxon: 36329 1 of 3 Monkeys vaccinated with EBA-175 was protected from challenge of parasitized erythrocytes [PubMed: 11471569]. phpA-79 Protegen ID: 836; NCBI Protein GI: 13447096; NCBITaxon: 32630 YH, ZX Immunization with rPhpA-79 protein adjuvanted with monophosphoryl lipid A (for subcutaneous immunization) or a mutant cholera toxin, CT-E29H (for intranasal immunization), protected CBA/N mice against death and bacteremia, as well as reduced nasopharyngeal colonization, following intranasal challenge with a heterologous pneumococcal strain [PubMed: 11349048]. OspA Mice immunized with recombinant OspA protein were protected from challenge with Borrelia burgdorferi [PubMed: 8168958]. Protegen ID: 838; NCBI Gene GI: 1194357; NCBI Protein GI: 11496927; NCBI Protein Accession: NP_045688; NCBITaxon: 224326 YH, ZX OspB Mice immunized with recombinant OspB protein were protected from challenge with Borrelia burgdorferi [PubMed: 8168958]. YH, ZX Protegen ID: 839; NCBI Gene GI: 1194340; NCBI Protein GI: 11496910; NCBI Protein Accession: NP_045689; NCBITaxon: 224326 OspC YH, ZX Protegen ID: 840; NCBI Gene GI: 1194415; NCBI Protein GI: 11497024; NCBI Protein Accession: NP_047005; NCBITaxon: 224326 Mice immunized with recombinant OspC protein were protected from challenge with Borrelia burgdorferi [PubMed: 8168958]. DbpA YH, ZX Protegen ID: 841; NCBI Gene GI: 8319341; NCBI Protein GI: 256041910; NCBI Protein Accession: YP_003110629; NCBITaxon: 521009 Mice immunized with recombinant DbpA protein are protected against challenge with Borrelia burgdorferi [PubMed: 11035759]. Hly YH, ZX Protegen ID: 842; NCBI Gene GI: 987033; NCBI Protein GI: 16802248; NCBI Protein Accession: NP_463733; NCBITaxon: 169963 In an attempt to generate a subunit vaccine in this experimental disease model, eukaryotic plasmid DNA expression vectors containing genes encoding either the wild-type or modified forms of recombinant listeriolysin O (hly) were generated and used for genetic vaccination of naive mice. Results of these studies indicate that the intramuscular immunization of mice with specifically designed plasmid DNA constructs encoding recombinant forms of listeriolysin O (hly) stimulates peptide-specific CD8+ immune T cells that exhibit in vitro cytotoxic activity. More importantly, such immunization can provide protective immunity against a subsequent challenge with viable L. monocytogenes [PubMed: 10384131]. CNA Protegen ID: 846; NCBI Nucleotide GI: 387879; NCBI Protein GI: 387880; NCBI Protein Accession: AAA20874.1; NCBITaxon: 1280 YH, ZX Mice were immunized with a recombinant fragment of CNA protein, and were then challenged with the S. aureus clinical isolate strain Phillips. At 14 d after inoculation, mortality in the collagen adhesin-vaccinated group was only 13%, compared with 87% in the control antigen immunized group [PubMed: 9637697]. ClfA Protegen ID: 847; NCBI Gene GI: 5330438; NCBI Protein GI: 151220968; NCBI Protein Accession: YP_001331790; NCBITaxon: 426430 Mice immunized with recombinant ClfA and challenged with S. aureus developed less-severe arthritis than did mice immunized with a control antigen [PubMed: 11740733]. YH, ZX MecA YH, ZX Protegen ID: 848; NCBI Gene GI: 2861157; NCBI Protein GI: 49482291; NCBI Protein Accession: YP_039515; NCBITaxon: 282458 An internal region from the transpeptidase domain from the PBP2a (encoded by mecA) was cloned into a mammalian expression vector, to be used as DNA vaccine in a Murine model. After three sets of DNA vaccination, the immune response represented by antibodies against a fragment of PBP2a was evaluated by enzyme linked immunosorbent assay (ELISA), showing a significant antibody response. The antibacterial effect of the DNA vaccine was evaluated by intraperitoneal immunization and challenge with a sublethal dose of MRSA for 7 days in mice. After the challenge, the number of bacteria from kidneys from immunized and non-immunized mice were determined. Kidneys from immunized mice had 1000 times less on bacteria than the positive controls (non-immunized mice) [PubMed: 12744903]. FnbA YH, ZX Protegen ID: 849; NCBI Protein GI: 120457; NCBITaxon: 93061 Mice were immunized with fusion proteins encompassing the fibronectin-binding domain of a staphylococcal fibronectin-binding protein (FnBP-A). Vaccination of mice with recombinant FnBP resulted in significant protection against challenge with S. aureus [PubMed: 7975852]. BPS YH, ZX Immunization of mice with recombinant BPS protein by the subcutaneous route produced an efficient antigen-specific response, and immunized animals survived challenge with a lethal dose of a virulent strain [PubMed: 11796614]. Protegen ID: 850; NCBI Protein GI: 5327234; NCBITaxon: 1311 SfbI Intranasal immunization of mice with either SfbI alone or coupled to cholera toxin B subunit (CTB) triggered efficient SfbI-specific humoral (mainly IgG) and lung mucosal (14% of total IgA) responses. SfbI-vaccinated animals showed 80% and 90% protection against homologous and heterologous challenge, respectively [PubMed: 10068585]. Protegen ID: 851; NCBI Nucleotide GI: 511149; NCBI Protein GI: 511150; NCBI Protein Accession: CAA48133.1; NCBITaxon: 1314 YH, ZX FBP54 Mice subcutaneously or orally immunized with FBP54 survived significantly longer following the challenge with S. pyogenes than did nonimmunized mice [PubMed: 11159987]. Protegen ID: 852; NCBI Nucleotide GI: 496254; NCBITaxon: 1314 YH, ZX FbaA Protegen ID: 853; NCBI Protein GI: 14915682; NCBITaxon: 1314 Mice immunized with FbpA were protected from challenge with group A streptococcus [PubMed: 19254483]. YH, ZX Emm1 Protegen ID: 854; NCBI Nucleotide GI: 311757; NCBI Protein GI: 311758; NCBI Protein Accession: CAA44062.1; NCBITaxon: 1314 Mice were intranasally immunized with diphtheria toxoid (DT) conjugated polypeptides encompassing a conformational-constrained B cell epitope of the M1 protein (J8). Vaccinated mice were challenged 10 days after the last boost by the intranasal route. Animals had 60% protection against challenge [PubMed: 16828529]. YH, ZX Sib35 YH, ZX Immunization with Sib 35 enhanced survival rates in mice challenged with a GAS strain, while exhibiting no toxicity in hosts [PubMed: 15990202]. Protegen ID: 855; NCBI Protein GI: 90567992; NCBITaxon: 342023 GlpQ Protegen ID: 856; NCBI Gene GI: 2611763; NCBI Protein GI: 15639249; NCBI Protein Accession: NP_218698; NCBITaxon: 243276 Immunization with the recombinant GlpQ significantly protected rabbits from subsequent T. pallidum challenge, altering lesion development at the sites of challenge [PubMed: 9826352]. YH, ZX TmpB Treponema pallidum-susceptible guinea pigs of strain C4D were immunized with recombinant T. pallidum antigen TmpB. Guinea pigs receiving TmpB antigen demonstrated protection expressed by the development of significantly (P less than 0.01) smaller, atypical lesions of significantly (P less than 0.01) shorter duration and devoid of or containing fewer T. pallidum organisms than lesions in the remaining immunized and control animals [PubMed: 1937794]. YH, ZX Protegen ID: 857; NCBI Gene GI: 2611387; NCBI Protein GI: 15639756; NCBI Protein Accession: NP_219206; NCBITaxon: 243276 Tp92 Protegen ID: 858; NCBI Protein GI: 159158965; NCBITaxon: 243276 YH, ZX Immunization with recombinant Tp92 partially protected rabbits from subsequent T. pallidum challenge [PubMed: 10762571]. Sip Protegen ID: 859; NCBI Gene GI: 3685788; NCBI Protein GI: 76788047; NCBI Protein Accession: YP_328758; NCBITaxon: 205921 Immunization with the recombinant Sip protein efficiently protected CD-1 mice against deadly challenges with six GBS strains of serotypes Ia/c, Ib, II/R, III, V, and VI [PubMed: 10992461]. YH, ZX Rib YH, ZX Protegen ID: 860; NCBI Protein GI: 1620648; NCBITaxon: 1311 Vaccination of mice with the Rib protein protected against two strains of capsular type III and two strains of type II, and vaccination with the alpha protein protected against one strain of type II and one strain of type Ib [PubMed: 8751893]. p60 YH, ZX Protegen ID: 862; NCBI Protein GI: 215422507; NCBITaxon: 1639 Mice immunized with p60 encapsulated in liposomes launched a strong CTL response and were protected against a subsequent challenge with L. monocytogenes [PubMed: 18433404]. NucA Protegen ID: 863; NCBI Protein GI: 4929317; NCBITaxon: 727 Mouse antiserum directed against the recombinant NucA protein was reactive on Western immunoblots and whole-cell ELISA with all H. influenzae strains tested including Eagan and was bactericidal for two heterologous strains tested. The antiserum also resulted in a log reduction in bacteremia, in an infant-rat protection study with H. influenzae type b as the challenge strain [PubMed: 10768940]. YH, ZX OmpP1 YH, ZX Protegen ID: 864; NCBI Protein GI: 9716645; NCBITaxon: 727 When chinchillas were immunized with recombinant P1 (rP1) obtained from one of these isolates (BCH-3), all animals developed antibodies specific for rP1. Immunized animals were protected against disease when challenged with BCH-3, but not with an ompP1 mutant of BCH-3 or a strain (BCH-2) possessing a heterologous P1 (91% identity). We conclude that (i) while P1 induces protection against NTHI-mediated otitis media, development of a polyvalent vaccine reflecting the variability of P1 would be necessary to construct an efficacious vaccine [PubMed: 10899849]. PstS1 Protegen ID: 865; NCBI Gene GI: 885724; NCBI Protein GI: 57116801; NCBI Protein Accession: YP_177770; NCBITaxon: 83332 Vaccination with the recombinant PstS-1 antigen and cholera toxin significantly protected against the challenge given 10 days later, but only marginally after 12 weeks [PubMed: 10869767]. YH, ZX DnaK Protegen ID: 866; NCBI Gene GI: 885946; NCBI Protein GI: 15607491; NCBI Protein Accession: NP_214864; NCBITaxon: 83332 YH, ZX In an ex vivo transfection approach with a retroviral vector a single antigen (hsp70) could evoke strong protection in mice [PubMed: 9234527]. MPT83 Protegen ID: 867; NCBI Gene GI: 887155; NCBI Protein GI: 15610010; NCBI Protein Accession: NP_217389; NCBITaxon: 83332 A single DNA vaccine encoding the MPT-83 tuberculosis antigens evoked partial protection against an aerogenic challenge with M. tuberculosis Erdman in the mouse model of pulmonary tuberculosis [PubMed: 10715531]. YH, ZX AE: paraesthesia oral http://www.answers.com/topic/oral-paresthesia AE: paresthesia oral paraesthesia oral is a paresthesia that results in a numbness or tingling that occurs in the mucosa or tissues of the oral cavity. SS, YH